PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"30190953","Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial","Rimassa L, Porta C, Borbath I, Daniele B, Finn RS, Raoul JL, Schwartz LH, He AR, Trojan J, Peck-Radosavljevic M, Abbadessa G, Goldberg T, Santoro A, Bruix J.","Hepat Oncol. 2014 Apr;1(2):181-188. doi: 10.2217/hep.14.3. Epub 2014 Jan 29.","Rimassa L","Hepat Oncol","2014","2018/09/08","PMC6095177","","10.2217/hep.14.3"
"28943627","Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma","Lee JJX, Chan JJ, Choo SP.","Diseases. 2015 Oct 28;3(4):306-324. doi: 10.3390/diseases3040306.","Lee JJX","Diseases","2015","2017/09/26","PMC5548260","","10.3390/diseases3040306"
"28154679","First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study","Aitelhaj M, Lkhoyaali S, Rais G, Boutayeb S, Errihani H.","Pan Afr Med J. 2016 Aug 24;24:324. doi: 10.11604/pamj.2016.24.324.4058. eCollection 2016.","Aitelhaj M","Pan Afr Med J","2016","2017/02/04","PMC5267845","","10.11604/pamj.2016.24.324.4058"
"28404110","Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial","Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W.","Lancet Gastroenterol Hepatol. 2016 Sep;1(1):36-44. doi: 10.1016/S2468-1253(16)30002-4. Epub 2016 Jun 16.","Waked I","Lancet Gastroenterol Hepatol","2016","2017/04/14","","","10.1016/S2468-1253(16)30002-4"
"28072706","A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea","Lee HS, Chung MJ, Park JY, Bang S, Park SW, Kim HG, Noh MH, Lee SH, Kim YT, Kim HJ, Kim CD, Lee DK, Cho KB, Cho CM, Moon JH, Kim DU, Kang DH, Cheon YK, Choi HS, Kim TH, Kim JK, Moon J, Shin HJ, Song SY; Korean Society of Gastrointestinal Cancer.","Medicine (Baltimore). 2017 Jan;96(1):e5702. doi: 10.1097/MD.0000000000005702.","Lee HS","Medicine (Baltimore)","2017","2017/01/11","PMC5228666","","10.1097/MD.0000000000005702"
"28072765","Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group","Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, Priou F, Tazi Y, Floquet A, Selle F, Berton-Rigaud D, Lesoin A, Kalbacher E, Lortholary A, Favier L, Treilleux I, Ray-Coquard I.","Br J Cancer. 2017 Jan;116(3):303-309. doi: 10.1038/bjc.2016.430. Epub 2017 Jan 10.","Heudel PE","Br J Cancer","2017","2017/01/11","PMC5294485","","10.1038/bjc.2016.430"
"28147363","Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials","Kudo M.","Oncology. 2017;92 Suppl 1:50-62. doi: 10.1159/000451016. Epub 2017 Feb 2.","Kudo M","Oncology","2017","2017/02/02","","","10.1159/000451016"
"28177438","Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine","Husseini F, Delord JP, Fournel-Federico C, Guitton J, Erbs P, Homerin M, Halluard C, Jemming C, Orange C, Limacher JM, Kurtz JE.","Ann Oncol. 2017 Jan 1;28(1):169-174. doi: 10.1093/annonc/mdw440.","Husseini F","Ann Oncol","2017","2017/02/09","","","10.1093/annonc/mdw440"
"28480218","Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease","Gharib AM, Han MAT, Meissner EG, Kleiner DE, Zhao X, McLaughlin M, Matthews L, Rizvi B, Abd-Elmoniem KZ, Sinkus R, Levy E, Koh C, Myers RP, Subramanian GM, Kottilil S, Heller T, Kovacs JA, Morse CG.","Biomed Res Int. 2017;2017:2067479. doi: 10.1155/2017/2067479. Epub 2017 Apr 5.","Gharib AM","Biomed Res Int","2017","2017/05/09","PMC5396439","","10.1155/2017/2067479"
"28508838","Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003","Kusano M, Honda M, Okabayashi K, Akimaru K, Kino S, Tsuji Y, Watanabe M, Suzuki S, Yoshikawa T, Sakamoto J, Oba K, Saji S.","J Cancer Res Ther. 2017 Jan-Mar;13(1):84-90. doi: 10.4103/0973-1482.184524.","Kusano M","J Cancer Res Ther","2017","2017/05/17","","","10.4103/0973-1482.184524"
"29037107","First-in-Man Evaluation of (124)I-PGN650: A PET Tracer for Detecting Phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment","Laforest R, Dehdashti F, Liu Y, Frye J, Frye S, Luehmann H, Sultan D, Shan JS, Freimark BD, Siegel BA.","Mol Imaging. 2017 Jan-Dec;16:1536012117733349. doi: 10.1177/1536012117733349.","Laforest R","Mol Imaging","2017","2017/10/18","PMC5648081","","10.1177/1536012117733349"
"29040994","Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience","Ueshima K, Nishida N, Kudo M.","Dig Dis. 2017;35(6):611-617. doi: 10.1159/000480257. Epub 2017 Oct 17.","Ueshima K","Dig Dis","2017","2017/10/18","","","10.1159/000480257"
"29283332","Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma","Akhtar B, Muhammad F, Sharif A, Akhtar MF, Majeed W.","Crit Rev Eukaryot Gene Expr. 2017;27(4):373-385. doi: 10.1615/CritRevEukaryotGeneExpr.2017021006.","Akhtar B","Crit Rev Eukaryot Gene Expr","2017","2017/12/29","","","10.1615/CritRevEukaryotGeneExpr.2017021006"
"28086942","External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26","Herrmann E, Naehrig D, Sassowsky M, Bigler M, Buijsen J, Ciernik I, Zwahlen D, Pellanda AF, Meister A, Brauchli P, Berardi S, Kuettel E, Dufour JF, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).","Radiat Oncol. 2017 Jan 13;12(1):12. doi: 10.1186/s13014-016-0745-0.","Herrmann E","Radiat Oncol","2017","2017/01/15","PMC5237353","","10.1186/s13014-016-0745-0"
"28058445","Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study","Sarantopoulos J, Mita AC, He A, Wade JL, Hsueh CT, Morris JC, Lockhart AC, Quinn DI, Hwang J, Mier J, Zhang W, Wack C, Yin J, Clot PF, Rixe O.","Cancer Chemother Pharmacol. 2017 Feb;79(2):339-351. doi: 10.1007/s00280-016-3210-8. Epub 2017 Jan 5.","Sarantopoulos J","Cancer Chemother Pharmacol","2017","2017/01/07","PMC5306058","","10.1007/s00280-016-3210-8"
"28088688","Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study","Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, Voest EE; Hepatica study group.","Neoplasia. 2017 Feb;19(2):93-99. doi: 10.1016/j.neo.2016.08.010. Epub 2017 Jan 12.","Snoeren N","Neoplasia","2017","2017/01/16","PMC5237801","","10.1016/j.neo.2016.08.010"
"28120036","Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)","Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, Wan P, Shao YY, Lin ZZ, Frenette C, O'Neil B, Schwartz L, Smith-Jones PM, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen YC, Agajanov T, Boisserie F, Di Laurenzio L, Lee R, Larson SM, Cheng AL, Carrasquilo JA.","Cancer Chemother Pharmacol. 2017 Feb;79(2):421-429. doi: 10.1007/s00280-017-3241-9. Epub 2017 Jan 24.","Abou-Alfa GK","Cancer Chemother Pharmacol","2017","2017/01/26","PMC5548107","NIHMS887016","10.1007/s00280-017-3241-9"
"28166812","Efficacy of high-intensity focused ultrasound-assisted hepatic resection (HIFU-AR) on blood loss reduction in patients with liver metastases requiring hepatectomy: study protocol for a randomized controlled trial","Dupré A, Pérol D, Blanc E, Peyrat P, Basso V, Chen Y, Vincenot J, Kocot A, Melodelima D, Rivoire M.","Trials. 2017 Feb 6;18(1):57. doi: 10.1186/s13063-017-1801-2.","Dupré A","Trials","2017","2017/02/08","PMC5294714","","10.1186/s13063-017-1801-2"
"28174906","Efficacy and Safety of Praziquantel Against Light Infections of Opisthorchis viverrini: A Randomized Parallel Single-Blind Dose-Ranging Trial","Sayasone S, Meister I, Andrews JR, Odermatt P, Vonghachack Y, Xayavong S, Senggnam K, Phongluxa K, Hattendorf J, Bogoch II, Keiser J.","Clin Infect Dis. 2017 Feb 15;64(4):451-458. doi: 10.1093/cid/ciw785.","Sayasone S","Clin Infect Dis","2017","2017/02/09","","","10.1093/cid/ciw785"
"28087069","Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial","van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW.","Lancet. 2017 Feb 18;389(10070):709-717. doi: 10.1016/S0140-6736(16)31715-9. Epub 2017 Jan 11.","van der Ree MH","Lancet","2017","2017/01/15","","","10.1016/S0140-6736(16)31715-9"
"28045619","Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials","Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P.","J Clin Oncol. 2017 Feb 20;35(6):622-628. doi: 10.1200/JCO.2016.69.5197. Epub 2017 Jan 3.","Jackson R","J Clin Oncol","2017","2017/01/04","","","10.1200/JCO.2016.69.5197"
"28176241","Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials","Franco P, Arcadipane F, Strignano P, Spadi R, Trino E, Martini S, Iorio GC, Satolli MA, Airoldi M, Romagnoli R, Camandona M, Ricardi U.","Med Oncol. 2017 Mar;34(3):40. doi: 10.1007/s12032-017-0898-1. Epub 2017 Feb 7.","Franco P","Med Oncol","2017","2017/02/09","","","10.1007/s12032-017-0898-1"
"28247011","Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer","Mittapalli RK, Nuthalapati S, Shepherd SP, Xiong H.","Cancer Chemother Pharmacol. 2017 Mar;79(3):587-594. doi: 10.1007/s00280-017-3262-4. Epub 2017 Feb 28.","Mittapalli RK","Cancer Chemother Pharmacol","2017","2017/03/02","","","10.1007/s00280-017-3262-4"
"28286921","Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract","Cives M, Strosberg J.","Curr Treat Options Oncol. 2017 Mar;18(3):14. doi: 10.1007/s11864-017-0461-5.","Cives M","Curr Treat Options Oncol","2017","2017/03/14","","","10.1007/s11864-017-0461-5"
"28314319","Multicenter Phase II Clinical Trial of Genexol-PM® with Gemcitabine in Advanced Biliary Tract Cancer","Kim JY, Do YR, Song HS, Cho YY, Ryoo HM, Bae SH, Kim JG, Chae YS, Kang BW, Baek JH, Kim MK, Lee KH, Park K.","Anticancer Res. 2017 Mar;37(3):1467-1473. doi: 10.21873/anticanres.11471.","Kim JY","Anticancer Res","2017","2017/03/19","","","10.21873/anticanres.11471"
"28426123","Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study","Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, Lee Y, Van Cutsem E.","Ann Oncol. 2017 Mar 1;28(3):528-534. doi: 10.1093/annonc/mdw651.","Kelley RK","Ann Oncol","2017","2017/04/21","PMC5391701","","10.1093/annonc/mdw651"
"28122204","To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes","Dou Y, Hynynen K, Allen C.","J Control Release. 2017 Mar 10;249:63-73. doi: 10.1016/j.jconrel.2017.01.025. Epub 2017 Jan 22.","Dou Y","J Control Release","2017","2017/01/26","","","10.1016/j.jconrel.2017.01.025"
"28153734","High-throughput screening for Survivin and Borealin interaction inhibitors in hepatocellular carcinoma","Yue L, Li L, Li D, Yang Z, Han S, Chen M, Lan S, Xu X, Hui L.","Biochem Biophys Res Commun. 2017 Mar 11;484(3):642-647. doi: 10.1016/j.bbrc.2017.01.160. Epub 2017 Jan 31.","Yue L","Biochem Biophys Res Commun","2017","2017/02/04","","","10.1016/j.bbrc.2017.01.160"
"28314990","An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism","Wang K, Stark FS, Schlothauer T, Lahr A, Cosson V, Zhi J, Habben K, Tessier J, Schick E, Staack RF, Krieter O.","Cancer Chemother Pharmacol. 2017 Apr;79(4):661-671. doi: 10.1007/s00280-017-3242-8. Epub 2017 Mar 17.","Wang K","Cancer Chemother Pharmacol","2017","2017/03/19","","","10.1007/s00280-017-3242-8"
"28333016","Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma","Velec M, Haddad CR, Craig T, Wang L, Lindsay P, Brierley J, Brade A, Ringash J, Wong R, Kim J, Dawson LA.","Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):939-946. doi: 10.1016/j.ijrobp.2017.01.221. Epub 2017 Feb 1.","Velec M","Int J Radiat Oncol Biol Phys","2017","2017/03/24","","","10.1016/j.ijrobp.2017.01.221"
"28443252","Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L","Tarakanovskaya MG, Chinburen J, Batchuluun P, Munkhzaya C, Purevsuren G, Dandii D, Hulan T, Oyungerel D, Kutsyna GA, Reid AA, Borisova V, Bain AI, Jirathitikal V, Bourinbaiar AS.","J Hepatocell Carcinoma. 2017 Apr 12;4:59-69. doi: 10.2147/JHC.S122507. eCollection 2017.","Tarakanovskaya MG","J Hepatocell Carcinoma","2017","2017/04/27","PMC5396941","","10.2147/JHC.S122507"
"28412761","Preoperative Assessment of Hepatocellular Carcinoma with Split-Bolus Combined Phase Contrast-Enhanced Computed Tomography","Jiang J, Wang K, Xu Y, Liu J, Luo J, Tao X, Wang X.","Med Sci Monit. 2017 Apr 16;23:1834-1841. doi: 10.12659/msm.904129.","Jiang J","Med Sci Monit","2017","2017/04/17","PMC5402837","","10.12659/msm.904129"
"28420329","Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial","Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Han K, Nam CM, Park SH, Lee KH.","BMC Cancer. 2017 Apr 18;17(1):279. doi: 10.1186/s12885-017-3267-8.","Park JH","BMC Cancer","2017","2017/04/20","PMC5395905","","10.1186/s12885-017-3267-8"
"28272913","Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma","Ishizaki M, Kaibori M, Matsui K, Ikeda H, Yoshida K, Okazaki K, Kariya S, Tanigawa N, Nakatake R, Matsushima H, Sakaguchi T, Kon M.","Cancer Invest. 2017 Apr 21;35(4):271-276. doi: 10.1080/07357907.2017.1289382. Epub 2017 Mar 8.","Ishizaki M","Cancer Invest","2017","2017/03/09","","","10.1080/07357907.2017.1289382"
"28083690","The (68)Ga/(177)Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV(max) values and absorbed dose estimates","Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I.","Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12.","Scarpa L","Eur J Nucl Med Mol Imaging","2017","2017/01/14","","","10.1007/s00259-016-3609-9"
"28188748","Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma","Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, Ozawa T, Kishi H, Kitahara M, Yamashita T, Arai K, Terashima T, Iida N, Fushimi K, Muraguchi A, Kaneko S.","Gastroenterology. 2017 May;152(6):1395-1406.e10. doi: 10.1053/j.gastro.2017.02.001. Epub 2017 Feb 7.","Nakagawa H","Gastroenterology","2017","2017/02/12","","","10.1053/j.gastro.2017.02.001"
"28202227","Phase I trial of radiation therapy and sorafenib in unresectable liver metastases","Goody RB, Brade AM, Wang L, Craig T, Brierley J, Dinniwell R, Wong RKS, Cho C, Kim J, Kassam Z, Ringash J, Knox JJ, Dawson LA.","Radiother Oncol. 2017 May;123(2):234-239. doi: 10.1016/j.radonc.2017.01.018. Epub 2017 Feb 13.","Goody RB","Radiother Oncol","2017","2017/02/17","","","10.1016/j.radonc.2017.01.018"
"28266163","Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan","Kondo S, Hosoi H, Itahashi K, Hashimoto J.","Cancer Sci. 2017 May;108(5):995-999. doi: 10.1111/cas.13223. Epub 2017 May 16.","Kondo S","Cancer Sci","2017","2017/03/08","PMC5448621","","10.1111/cas.13223"
"28292641","Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours","Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T.","Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11.","Lepage C","Dig Liver Dis","2017","2017/03/16","","","10.1016/j.dld.2017.02.004"
"28301826","A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study","Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, Bournaud-Salinas C, Wemeau JL, Gimbert A, Picat MQ, Pedenon D, Digue L, Daste A, Catargi B, Delord JP.","Eur J Cancer. 2017 May;76:110-117. doi: 10.1016/j.ejca.2017.01.029. Epub 2017 Mar 20.","Ravaud A","Eur J Cancer","2017","2017/03/17","","","10.1016/j.ejca.2017.01.029"
"28341759","A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma","Uldrick TS, Gonçalves PH, Wyvill KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudek MA, Figg WD, Yarchoan R.","Oncologist. 2017 May;22(5):505-e49. doi: 10.1634/theoncologist.2016-0486. Epub 2017 Mar 24.","Uldrick TS","Oncologist","2017","2017/03/26","PMC5423501","","10.1634/theoncologist.2016-0486"
"28360015","Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial","Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS.","Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.","Twelves C","Eur J Cancer","2017","2017/04/01","","","10.1016/j.ejca.2017.02.011"
"28389316","Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial","García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, González Del Alba A, Castellano D, Gallardo E, Anido U, García Del Muro X, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J.","Lancet Oncol. 2017 May;18(5):672-681a. doi: 10.1016/S1470-2045(17)30242-5. Epub 2017 Apr 4.","García-Donas J","Lancet Oncol","2017","2017/04/09","","","10.1016/S1470-2045(17)30242-5"
"28411193","Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC","Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A.","Cancer Immunol Res. 2017 May;5(5):417-424. doi: 10.1158/2326-6066.CIR-16-0325. Epub 2017 Apr 14.","Tumeh PC","Cancer Immunol Res","2017","2017/04/16","PMC5749922","NIHMS918737","10.1158/2326-6066.CIR-16-0325"
"28444112","Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study","Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, Grob JJ, Koralek DO, Rooney I, Hsu JJ, McKenna EF, McArthur GA.","Ann Oncol. 2017 May 1;28(5):1137-1144. doi: 10.1093/annonc/mdx040.","Dréno B","Ann Oncol","2017","2017/04/27","","","10.1093/annonc/mdx040"
"28715649","Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature","Mamdani H, Wu H, O'Neil BH, Sehdev A.","Discov Med. 2017 May;23(128):331-336.","Mamdani H","Discov Med","2017","2017/07/18","","",""
"28186961","Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study","Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N.","Oncotarget. 2017 May 23;8(21):35326-35338. doi: 10.18632/oncotarget.15108.","Azad NS","Oncotarget","2017","2017/02/11","PMC5471058","","10.18632/oncotarget.15108"
"28102465","Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?","Fountzilas C, Stuart S, Hernandez B, Bowhay-Carnes E, Michalek J, Sarantopoulos J, Karnad A, Patel S, Weitman S, Mahalingam D.","Invest New Drugs. 2017 Jun;35(3):386-391. doi: 10.1007/s10637-017-0425-4. Epub 2017 Jan 19.","Fountzilas C","Invest New Drugs","2017","2017/01/20","PMC11025657","NIHMS1982205","10.1007/s10637-017-0425-4"
"28102887","Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)","Kim Y, Lee SJ, Lee JY, Lee SH, Sun JM, Park K, An HJ, Cho JY, Kang EJ, Lee HY, Kim J, Keam B, Kim HR, Lee KE, Choi MY, Lee KH, Ahn MJ.","Cancer. 2017 Jun 1;123(11):1958-1964. doi: 10.1002/cncr.30537. Epub 2017 Jan 19.","Kim Y","Cancer","2017","2017/01/20","","","10.1002/cncr.30537"
"28131794","Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM.","J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26.","Lencioni R","J Hepatol","2017","2017/01/30","","","10.1016/j.jhep.2017.01.012"
"28198177","Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena","Ferri J, Dockx Y, Vonghia L, Papadimitriou K, Rasschaert M, Francque S, Peeters M, Rolfo C.","Minerva Chir. 2017 Jun;72(3):206-218. doi: 10.23736/S0026-4733.17.07311-4. Epub 2017 Feb 14.","Ferri J","Minerva Chir","2017","2017/02/16","","","10.23736/S0026-4733.17.07311-4"
"28237539","Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer","Yoshino T, Uetake H, Tsuchihara K, Shitara K, Yamazaki K, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Yamanaka K, Iwasaki K, Soeda J, Hihara M, Yamanaka T, Ochiai A, Muro K.","Clin Colorectal Cancer. 2017 Jun;16(2):158-163. doi: 10.1016/j.clcc.2017.01.001. Epub 2017 Jan 24.","Yoshino T","Clin Colorectal Cancer","2017","2017/02/27","","","10.1016/j.clcc.2017.01.001"
"28251667","A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects","Krauwinkel W, Noukens J, van Dijk J, Popa S, Ouatas T, de Vries M, Phung D, Gibbons J, Mordenti J, Mateva L.","J Clin Pharm Ther. 2017 Jun;42(3):268-275. doi: 10.1111/jcpt.12503. Epub 2017 Mar 1.","Krauwinkel W","J Clin Pharm Ther","2017","2017/03/03","","","10.1111/jcpt.12503"
"28334948","A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma","Ikeda M, Okusaka T, Sato Y, Furuse J, Mitsunaga S, Ueno H, Morizane C, Inaba Y, Kobayashi T, Arai Y.","Jpn J Clin Oncol. 2017 Jun 1;47(6):512-519. doi: 10.1093/jjco/hyx038.","Ikeda M","Jpn J Clin Oncol","2017","2017/03/24","","","10.1093/jjco/hyx038"
"28357727","A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies","Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai P, Morris JC.","Target Oncol. 2017 Jun;12(3):323-332. doi: 10.1007/s11523-017-0482-9.","Wise-Draper TM","Target Oncol","2017","2017/03/31","PMC5447332","","10.1007/s11523-017-0482-9"
"28495639","Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial","Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B.","Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. Epub 2017 May 8.","Alistar A","Lancet Oncol","2017","2017/05/13","PMC5635818","NIHMS885686","10.1016/S1470-2045(17)30314-5"
"28497756","S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial","Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M, Okusaka T.","Lancet Gastroenterol Hepatol. 2017 Jun;2(6):407-417. doi: 10.1016/S2468-1253(17)30072-9. Epub 2017 Apr 6.","Kudo M","Lancet Gastroenterol Hepatol","2017","2017/05/13","","","10.1016/S2468-1253(17)30072-9"
"28625628","Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial","Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, Knegjens J, Hatton M, van Dam I, van der Leest A, Reymen B, Stigt J, Haslett K, Tripathi D, Smit EF, Senan S.","Lung Cancer. 2017 Jun;108:150-153. doi: 10.1016/j.lungcan.2017.03.007. Epub 2017 Mar 21.","Slotman BJ","Lung Cancer","2017","2017/06/20","","","10.1016/j.lungcan.2017.03.007"
"28548587","Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial","Lu W, Jin XL, Yang C, Du P, Jiang FQ, Ma JP, Yang J, Xie P, Zhang Z.","Cancer Biol Ther. 2017 Jun 3;18(6):433-438. doi: 10.1080/15384047.2017.1323589. Epub 2017 May 26.","Lu W","Cancer Biol Ther","2017","2017/05/27","PMC5536939","","10.1080/15384047.2017.1323589"
"28638797","Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review","Araujo RLC, Herman P, Riechelmann RP.","World J Clin Oncol. 2017 Jun 10;8(3):266-272. doi: 10.5306/wjco.v8.i3.266.","Araujo RLC","World J Clin Oncol","2017","2017/06/23","PMC5465017","","10.5306/wjco.v8.i3.266"
"28645287","Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial","Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S.","Health Qual Life Outcomes. 2017 Jun 23;15(1):130. doi: 10.1186/s12955-017-0704-y.","Devlin N","Health Qual Life Outcomes","2017","2017/06/25","PMC5481866","","10.1186/s12955-017-0704-y"
"28434648","Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial","El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I.","Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.","El-Khoueiry AB","Lancet","2017","2017/04/25","PMC7539326","NIHMS1623792","10.1016/S0140-6736(17)31046-2"
"28159938","Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study","Xu JM, Wang Y, Chen YL, Jia R, Li J, Gong JF, Li J, Qi C, Hua Y, Tan CR, Wang J, Li K, Sai Y, Zhou F, Ren YX, Qing WG, Jia H, Su WG, Shen L.","Oncotarget. 2017 Jun 27;8(26):42076-42086. doi: 10.18632/oncotarget.14942.","Xu JM","Oncotarget","2017","2017/02/05","PMC5522050","","10.18632/oncotarget.14942"
"28066978","mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib","Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ.","Liver Int. 2017 Jul;37(7):1047-1055. doi: 10.1111/liv.13359. Epub 2017 Feb 2.","Meyer T","Liver Int","2017","2017/01/10","","","10.1111/liv.13359"
"28240635","Comparison of the Timing of Hepatic Arterial Phase and Image Quality Using Test-Bolus and Bolus-Tracking Techniques in Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Hepatic Dynamic Magnetic Resonance Imaging","Iyama Y, Nakaura T, Yokoyama K, Kidoh M, Utsunomiya D, Oda S, Namimoto T, Yamashita Y.","J Comput Assist Tomogr. 2017 Jul/Aug;41(4):638-643. doi: 10.1097/RCT.0000000000000583.","Iyama Y","J Comput Assist Tomogr","2017","2017/02/28","PMC5516670","","10.1097/RCT.0000000000000583"
"28284916","Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study","Detry O, Vandermeulen M, Delbouille MH, Somja J, Bletard N, Briquet A, Lechanteur C, Giet O, Baudoux E, Hannon M, Baron F, Beguin Y.","J Hepatol. 2017 Jul;67(1):47-55. doi: 10.1016/j.jhep.2017.03.001. Epub 2017 Mar 9.","Detry O","J Hepatol","2017","2017/03/13","","","10.1016/j.jhep.2017.03.001"
"28419193","A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)","Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera MB, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh AJM, Pujol E, Perez-Gracia JL, González Larriba JL, Collado R, Los M, Maciá S, De Wit R; SOGUG and DUOS.","Ann Oncol. 2017 Jul 1;28(7):1517-1522. doi: 10.1093/annonc/mdx186.","Bellmunt J","Ann Oncol","2017","2017/04/19","","","10.1093/annonc/mdx186"
"28431480","Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study","Young RJ, Litière S, Lia M, Hogendoorn PCW, Fisher C, Mechtersheimer G, Daugaard S, Sciot R, Collin F, Messiou C, Grünwald V, Gronchi A, van der Graaf W, Wardelmann E, Judson I.","Acta Oncol. 2017 Jul;56(7):1013-1020. doi: 10.1080/0284186X.2017.1315173. Epub 2017 Apr 21.","Young RJ","Acta Oncol","2017","2017/04/23","","","10.1080/0284186X.2017.1315173"
"28510787","A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas","Kumthekar P, Grimm S, Chandler J, Mehta M, Marymont M, Levy R, Muro K, Helenowski I, McCarthy K, Fountas L, Raizer J.","J Neurooncol. 2017 Jul;133(3):589-594. doi: 10.1007/s11060-017-2469-x. Epub 2017 May 16.","Kumthekar P","J Neurooncol","2017","2017/05/17","","","10.1007/s11060-017-2469-x"
"28535298","Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study","Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG.","Clin Infect Dis. 2017 Jul 1;65(1):13-19. doi: 10.1093/cid/cix289.","Feld JJ","Clin Infect Dis","2017","2017/05/24","","","10.1093/cid/cix289"
"28580808","Regorafenib for the treatment of unresectable hepatocellular carcinoma","Rimassa L, Pressiani T, Personeni N, Santoro A.","Expert Rev Anticancer Ther. 2017 Jul;17(7):567-576. doi: 10.1080/14737140.2017.1338955. Epub 2017 Jun 9.","Rimassa L","Expert Rev Anticancer Ther","2017","2017/06/06","","","10.1080/14737140.2017.1338955"
"28592620","Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma","Abou-Alfa GK, Blanc JF, Miles S, Ganten T, Trojan J, Cebon J, Liem AK, Lipton L, Gupta C, Wu B, Bass M, Hollywood E, Ma J, Bradley M, Litten J, Saltz LB.","Oncologist. 2017 Jul;22(7):780-e65. doi: 10.1634/theoncologist.2017-0058. Epub 2017 Jun 7.","Abou-Alfa GK","Oncologist","2017","2017/06/09","PMC5507650","","10.1634/theoncologist.2017-0058"
"29123959","Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma","Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, Endo I, Nakatsura T.","Oncoimmunology. 2017 Jul 11;6(10):e1346764. doi: 10.1080/2162402X.2017.1346764. eCollection 2017.","Tsuchiya N","Oncoimmunology","2017","2017/11/11","PMC5665076","","10.1080/2162402X.2017.1346764"
"28724419","Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014)","Passalacqua R, Lazzarelli S, Donini M, Montironi R, Tambaro R, De Giorgi U, Pignata S, Palumbo R, Ceresoli GL, Del Conte G, Tonini G, Morelli F, Nolè F, Panni S, Rondini E, Guida A, Zucali PA, Doni L, Iezzi E, Caminiti C.","BMC Cancer. 2017 Jul 19;17(1):493. doi: 10.1186/s12885-017-3466-3.","Passalacqua R","BMC Cancer","2017","2017/07/21","PMC5517798","","10.1186/s12885-017-3466-3"
"28280091","Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer","Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S.","Clin Cancer Res. 2017 Aug 1;23(15):4146-4154. doi: 10.1158/1078-0432.CCR-16-3138. Epub 2017 Mar 9.","Parseghian CM","Clin Cancer Res","2017","2017/03/11","PMC5540760","NIHMS859928","10.1158/1078-0432.CCR-16-3138"
"28298546","(64)Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer","Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS.","Clin Cancer Res. 2017 Aug 1;23(15):4190-4202. doi: 10.1158/1078-0432.CCR-16-3193. Epub 2017 Mar 15.","Lee H","Clin Cancer Res","2017","2017/03/17","PMC6790129","NIHMS1540409","10.1158/1078-0432.CCR-16-3193"
"28451811","Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan","de Leede EM, Burgmans MC, Meijer TS, Martini CH, Tijl FGJ, Vuyk J, van Erkel AR, van der Velde CJH, Kapiteijn E, Vahrmeijer AL.","Cardiovasc Intervent Radiol. 2017 Aug;40(8):1196-1205. doi: 10.1007/s00270-017-1630-4. Epub 2017 Apr 27.","de Leede EM","Cardiovasc Intervent Radiol","2017","2017/04/29","PMC5554291","","10.1007/s00270-017-1630-4"
"28528917","Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial","Dinkic C, Eichbaum M, Schmidt M, Grischke EM, Gebauer G, Fricke HC, Lenz F, Wallwiener M, Marme F, Schneeweiss A, Sohn C, Rom J.","Gynecol Oncol. 2017 Aug;146(2):279-284. doi: 10.1016/j.ygyno.2017.05.013. Epub 2017 May 19.","Dinkic C","Gynecol Oncol","2017","2017/05/23","","","10.1016/j.ygyno.2017.05.013"
"28591675","Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study","Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.","Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4.","Chau I","Eur J Cancer","2017","2017/06/08","","","10.1016/j.ejca.2017.05.001"
"28633089","First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)","Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).","Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19.","Carrato A","Eur J Cancer","2017","2017/06/21","","","10.1016/j.ejca.2017.04.024"
"28648803","Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.","Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23.","Meyer T","Lancet Gastroenterol Hepatol","2017","2017/06/27","","","10.1016/S2468-1253(17)30156-5"
"28685225","Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma","Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC.","Endocrine. 2017 Aug;57(2):220-225. doi: 10.1007/s12020-017-1359-5. Epub 2017 Jul 6.","Jasim S","Endocrine","2017","2017/07/08","","","10.1007/s12020-017-1359-5"
"28687420","Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI.","Lancet Haematol. 2017 Aug;4(8):e387-e398. doi: 10.1016/S2352-3026(17)30103-5. Epub 2017 Jul 4.","Kantarjian HM","Lancet Haematol","2017","2017/07/09","","","10.1016/S2352-3026(17)30103-5"
"28764740","Variation of stemness markers expression in tumor nodules from synchronous multi-focal hepatocellular carcinoma - an immunohistochemical study","Lo RC, Leung CO, Chok KS, Ng IO.","Diagn Pathol. 2017 Aug 1;12(1):56. doi: 10.1186/s13000-017-0649-9.","Lo RC","Diagn Pathol","2017","2017/08/03","PMC5539743","","10.1186/s13000-017-0649-9"
"29036035","The treatment path in hepatocellular carcinoma","El-Serag HB, Zhu AX, Johnson MS.","Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 9(8):1-20.","El-Serag HB","Clin Adv Hematol Oncol","2017","2017/10/17","","",""
"28839440","Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma","Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR.","World J Gastroenterol. 2017 Aug 7;23(29):5395-5404. doi: 10.3748/wjg.v23.i29.5395.","Shen J","World J Gastroenterol","2017","2017/08/26","PMC5550789","","10.3748/wjg.v23.i29.5395"
"28465443","Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma","Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF.","Clin Cancer Res. 2017 Aug 15;23(16):4633-4641. doi: 10.1158/1078-0432.CCR-16-3171. Epub 2017 May 2.","Duffy AG","Clin Cancer Res","2017","2017/05/04","PMC6640149","NIHMS873576","10.1158/1078-0432.CCR-16-3171"
"28903369","Toxicology and efficacy of tumor-targeting Salmonella typhimurium A1-R compared to VNP 20009 in a syngeneic mouse tumor model in immunocompetent mice","Zhang Y, Cao W, Toneri M, Zhang N, Kiyuna T, Murakami T, Nelson SD, Dry SM, Li Y, Li S, Wang X, Ma H, Singh AS, Eilber FC, Hoffman RM, Zhao M.","Oncotarget. 2017 May 3;8(33):54616-54628. doi: 10.18632/oncotarget.17605. eCollection 2017 Aug 15.","Zhang Y","Oncotarget","2017","2017/09/15","PMC5589608","","10.18632/oncotarget.17605"
"28630120","Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis","Machlus KR, Wu SK, Vijey P, Soussou TS, Liu ZJ, Shacham E, Unger TJ, Kashyap T, Klebanov B, Sola-Visner M, Crochiere M, Italiano JE Jr, Landesman Y.","Blood. 2017 Aug 31;130(9):1132-1143. doi: 10.1182/blood-2016-11-752840. Epub 2017 Jun 19.","Machlus KR","Blood","2017","2017/06/21","PMC5580272","","10.1182/blood-2016-11-752840"
"28376151","Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial","Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Folprecht G, Van Cutsem E, Ducreux M, Nordlinger B; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG).","J Natl Cancer Inst. 2017 Sep 1;109(9):djx015. doi: 10.1093/jnci/djx015.","Ruers T","J Natl Cancer Inst","2017","2017/04/05","PMC5408999","","10.1093/jnci/djx015"
"28448662","Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial","Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD.","JAMA Oncol. 2017 Sep 1;3(9):1237-1244. doi: 10.1001/jamaoncol.2017.0515.","Al-Batran SE","JAMA Oncol","2017","2017/04/28","PMC5824287","","10.1001/jamaoncol.2017.0515"
"28529147","norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group.","J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18.","Fickert P","J Hepatol","2017","2017/05/23","","","10.1016/j.jhep.2017.05.009"
"28560600","Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study","Bisschop C, van Dijk TH, Beukema JC, Jansen RLH, Gelderblom H, de Jong KP, Rutten HJT, van de Velde CJH, Wiggers T, Havenga K, Hospers GAP.","Ann Surg Oncol. 2017 Sep;24(9):2632-2638. doi: 10.1245/s10434-017-5897-0. Epub 2017 May 30.","Bisschop C","Ann Surg Oncol","2017","2017/06/01","PMC5539276","","10.1245/s10434-017-5897-0"
"28573606","A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma","Sho T, Nakanishi M, Morikawa K, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Nakai M, Suda G, Ogawa K, Chuma M, Meguro T, Nakamura M, Nagasaka A, Horimoto H, Yamamoto Y, Sakamoto N.","Drugs R D. 2017 Sep;17(3):381-388. doi: 10.1007/s40268-017-0187-7.","Sho T","Drugs R D","2017","2017/06/03","PMC5629128","","10.1007/s40268-017-0187-7"
"28624576","Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis","Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, Brunt EM, Kleiner DE, Doo E, Van Natta ML, Lavine JE, Neuschwander-Tetri BA, Sanyal A, Loomba R, Sirlin CB; NASH Clinical Research Network.","Gastroenterology. 2017 Sep;153(3):753-761. doi: 10.1053/j.gastro.2017.06.005. Epub 2017 Jun 15.","Middleton MS","Gastroenterology","2017","2017/06/19","PMC5695870","NIHMS885201","10.1053/j.gastro.2017.06.005"
"28728751","A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study","Chan JK, Deng W, Higgins RV, Tewari KS, Bonebrake AJ, Hicks M, Gaillard S, Ramirez PT, Chafe W, Monk BJ, Aghajanian C.","Gynecol Oncol. 2017 Sep;146(3):554-559. doi: 10.1016/j.ygyno.2017.05.033. Epub 2017 Jul 18.","Chan JK","Gynecol Oncol","2017","2017/07/22","PMC5728988","NIHMS923638","10.1016/j.ygyno.2017.05.033"
"28781171","First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials","Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators; van Hazel G, Sharma RA.","Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3.","Wasan HS","Lancet Oncol","2017","2017/08/08","PMC5593813","","10.1016/S1470-2045(17)30457-6"
"28784312","Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial","Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE.","Lancet Oncol. 2017 Sep;18(9):1249-1260. doi: 10.1016/S1470-2045(17)30447-3. Epub 2017 Aug 4.","Alderson D","Lancet Oncol","2017","2017/08/09","PMC5585417","","10.1016/S1470-2045(17)30447-3"
"28801995","INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial","Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee SJ, Bedrick E, Du R, Lee FC.","Cancer Med. 2017 Sep;6(9):2042-2051. doi: 10.1002/cam4.1138. Epub 2017 Aug 11.","Patt YZ","Cancer Med","2017","2017/08/13","PMC5603839","","10.1002/cam4.1138"
"28844410","Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial","Kimura K, Ikoma A, Shibakawa M, Shimoda S, Harada K, Saio M, Imamura J, Osawa Y, Kimura M, Nishikawa K, Okusaka T, Morita S, Inoue K, Kanto T, Todaka K, Nakanishi Y, Kohara M, Mizokami M.","EBioMedicine. 2017 Sep;23:79-87. doi: 10.1016/j.ebiom.2017.08.016. Epub 2017 Aug 19.","Kimura K","EBioMedicine","2017","2017/08/29","PMC5605374","","10.1016/j.ebiom.2017.08.016"
"28864693","Ablation with irreversible electroporation in patients with advanced perihilar cholangiocarcinoma (ALPACA): a multicentre phase I/II feasibility study protocol","Coelen RJS, Vogel JA, Vroomen LGPH, Roos E, Busch ORC, van Delden OM, Delft FV, Heger M, van Hooft JE, Kazemier G, Klümpen HJ, van Lienden KP, Rauws EAJ, Scheffer HJ, Verheul HM, Vries J, Wilmink JW, Zonderhuis BM, Besselink MG, van Gulik TM, Meijerink MR.","BMJ Open. 2017 Sep 1;7(9):e015810. doi: 10.1136/bmjopen-2016-015810.","Coelen RJS","BMJ Open","2017","2017/09/03","PMC5588990","","10.1136/bmjopen-2016-015810"
"28910150","Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma","Cahan B, Leong L, Wagman L, Yamauchi D, Shibata S, Wilzcynski S, Williams LE, Yazaki P, Colcher D, Frankel P, Wu A, Raubitschek A, Shively J, Wong JYC.","Cancer Biother Radiopharm. 2017 Sep;32(7):258-265. doi: 10.1089/cbr.2017.2223.","Cahan B","Cancer Biother Radiopharm","2017","2017/09/15","PMC5646801","","10.1089/cbr.2017.2223"
"28954285","Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype","Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX.","J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx031.","Hong TS","J Natl Cancer Inst","2017","2017/09/28","","","10.1093/jnci/djx031"
"28682681","De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET","Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA.","J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.","Harbeck N","J Clin Oncol","2017","2017/07/07","","","10.1200/JCO.2016.71.9815"
"28817753","Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study","Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.","JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.","Powles T","JAMA Oncol","2017","2017/08/18","PMC5824288","","10.1001/jamaoncol.2017.2411"
"28931010","Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial","Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T.","PLoS One. 2017 Sep 20;12(9):e0183288. doi: 10.1371/journal.pone.0183288. eCollection 2017.","Lambert A","PLoS One","2017","2017/09/21","PMC5606928","","10.1371/journal.pone.0183288"
"28344102","Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial","Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung D, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS.","Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. doi: 10.1016/j.clgc.2017.02.007. Epub 2017 Mar 3.","Alumkal JJ","Clin Genitourin Cancer","2017","2017/03/28","","","10.1016/j.clgc.2017.02.007"
"28735109","Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study","Barritt AS 4th, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Powell M, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal A.","Contemp Clin Trials. 2017 Oct;61:33-38. doi: 10.1016/j.cct.2017.07.015. Epub 2017 Jul 19.","Barritt AS 4th","Contemp Clin Trials","2017","2017/07/24","","","10.1016/j.cct.2017.07.015"
"28765194","Effect of Green Tea Supplements on Liver Enzyme Elevation: Results from a Randomized Intervention Study in the United States","Yu Z, Samavat H, Dostal AM, Wang R, Torkelson CJ, Yang CS, Butler LM, Kensler TW, Wu AH, Kurzer MS, Yuan JM.","Cancer Prev Res (Phila). 2017 Oct;10(10):571-579. doi: 10.1158/1940-6207.CAPR-17-0160. Epub 2017 Aug 1.","Yu Z","Cancer Prev Res (Phila)","2017","2017/08/03","PMC9257888","NIHMS897788","10.1158/1940-6207.CAPR-17-0160"
"28771889","Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma","Maruyama D, Nagai H, Maeda Y, Nakane T, Shimoyama T, Nakazato T, Sakai R, Ishikawa T, Izutsu K, Ueda R, Tobinai K.","Cancer Sci. 2017 Oct;108(10):2061-2068. doi: 10.1111/cas.13340. Epub 2017 Sep 4.","Maruyama D","Cancer Sci","2017","2017/08/04","PMC5623731","","10.1111/cas.13340"
"28798986","A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers","Escudier B, Faivre S, Van Cutsem E, Germann N, Pouget JC, Plummer R, Vergote I, Thistlethwaite F, Bjarnason GA, Jones R, Mackay H, Edeline J, Fartoux L, Hirte H, Oza A.","Target Oncol. 2017 Oct;12(5):655-661. doi: 10.1007/s11523-017-0525-2.","Escudier B","Target Oncol","2017","2017/08/12","","","10.1007/s11523-017-0525-2"
"28870611","Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.","Lancet Oncol. 2017 Oct;18(10):1386-1396. doi: 10.1016/S1470-2045(17)30621-6. Epub 2017 Sep 1.","van Zandwijk N","Lancet Oncol","2017","2017/09/06","","","10.1016/S1470-2045(17)30621-6"
"28871989","Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases","McPartlin A, Swaminath A, Wang R, Pintilie M, Brierley J, Kim J, Ringash J, Wong R, Dinniwell R, Craig T, Dawson LA.","Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):388-395. doi: 10.1016/j.ijrobp.2017.04.010. Epub 2017 Apr 13.","McPartlin A","Int J Radiat Oncol Biol Phys","2017","2017/09/06","","","10.1016/j.ijrobp.2017.04.010"
"28893090","An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma","Raoul JL, Gilabert M, Adhoute X, Edeline J.","Expert Opin Pharmacother. 2017 Oct;18(14):1467-1476. doi: 10.1080/14656566.2017.1378346. Epub 2017 Sep 14.","Raoul JL","Expert Opin Pharmacother","2017","2017/09/13","","","10.1080/14656566.2017.1378346"
"28803710","Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial","Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, Berry-Kravis E, Davidson CD, Bianconi S, Keener LA, Rao R, Soldatos A, Sidhu R, Walters KA, Xu X, Thurm A, Solomon B, Pavan WJ, Machielse BN, Kao M, Silber SA, McKew JC, Brewer CC, Vite CH, Walkley SU, Austin CP, Porter FD.","Lancet. 2017 Oct 14;390(10104):1758-1768. doi: 10.1016/S0140-6736(17)31465-4. Epub 2017 Aug 10.","Ory DS","Lancet","2017","2017/08/15","PMC6176479","NIHMS1507972","10.1016/S0140-6736(17)31465-4"
"28640364","A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma","Chan SL, Yeo W, Mo F, Chan AWH, Koh J, Li L, Hui EP, Chong CCN, Lai PBS, Mok TSK, Yu SCH.","Cancer. 2017 Oct 15;123(20):3977-3985. doi: 10.1002/cncr.30825. Epub 2017 Jun 22.","Chan SL","Cancer","2017","2017/06/23","","","10.1002/cncr.30825"
"28662297","Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials","Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, Kobashi G, Ebner DK, Okada NN, Makishima H, Miyazaki M, Kamada T, Tsujii H; Liver Cancer Working Group.","Cancer. 2017 Oct 15;123(20):3955-3965. doi: 10.1002/cncr.30816. Epub 2017 Jun 29.","Kasuya G","Cancer","2017","2017/06/30","PMC5655922","","10.1002/cncr.30816"
"28822576","Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.","Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.","Schachter J","Lancet","2017","2017/08/21","","","10.1016/S0140-6736(17)31601-X"
"29061175","Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study","He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP, Shi M.","Chin J Cancer. 2017 Oct 23;36(1):83. doi: 10.1186/s40880-017-0251-2.","He MK","Chin J Cancer","2017","2017/10/25","PMC5654007","","10.1186/s40880-017-0251-2"
"28536862","Mechanisms of hepatotoxicity associated with the monocyclic β-lactam antibiotic BAL30072","Paech F, Messner S, Spickermann J, Wind M, Schmitt-Hoffmann AH, Witschi AT, Howell BA, Church RJ, Woodhead J, Engelhardt M, Krähenbühl S, Maurer M.","Arch Toxicol. 2017 Nov;91(11):3647-3662. doi: 10.1007/s00204-017-1994-x. Epub 2017 May 23.","Paech F","Arch Toxicol","2017","2017/05/25","","","10.1007/s00204-017-1994-x"
"28687477","Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies","Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J.","J Hepatol. 2017 Nov;67(5):999-1008. doi: 10.1016/j.jhep.2017.06.026. Epub 2017 Jul 4.","Bruix J","J Hepatol","2017","2017/07/09","","","10.1016/j.jhep.2017.06.026"
"28758319","Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres","Wang EA, Stein JP, Bellavia RJ, Broadwell SR.","Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30.","Wang EA","Int J Clin Pract","2017","2017/08/01","","","10.1111/ijcp.12972"
"28849688","A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[(18)F]fluoro-2-deoxy-d-galactose","Fode MM, Bak-Fredslund K, Petersen JB, Worm E, Sørensen M, Høyer M.","Acta Oncol. 2017 Nov;56(11):1614-1620. doi: 10.1080/0284186X.2017.1366051. Epub 2017 Aug 29.","Fode MM","Acta Oncol","2017","2017/08/30","","","10.1080/0284186X.2017.1366051"
"28923573","Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)","Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart MJ, Von Minckwitz G, Baselga J, Loi S.","Eur J Cancer. 2017 Nov;85:133-145. doi: 10.1016/j.ejca.2017.08.020. Epub 2017 Sep 17.","Loibl S","Eur J Cancer","2017","2017/09/20","PMC5640494","NIHMS907517","10.1016/j.ejca.2017.08.020"
"28958502","Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS.","Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.","Wu YL","Lancet Oncol","2017","2017/09/30","","","10.1016/S1470-2045(17)30608-3"
"29059128","The 2017 Transplantation Awards: Recognizing a Landmark Clinical Trial and a Basic Science Discovery With Far-Reaching Implications","Grey ST, Issa F.","Transplantation. 2017 Nov;101(11):2655-2656. doi: 10.1097/TP.0000000000001949.","Grey ST","Transplantation","2017","2017/10/24","","","10.1097/TP.0000000000001949"
"29059635","Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours","Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI.","Eur J Cancer. 2017 Nov;86:296-304. doi: 10.1016/j.ejca.2017.09.011. Epub 2017 Oct 20.","Schöffski P","Eur J Cancer","2017","2017/10/24","","","10.1016/j.ejca.2017.09.011"
"30657405","Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm","Dercle L, Lu L, Lichtenstein P, Yang H, Wang D, Zhu J, Wu F, Piessevaux H, Schwartz LH, Zhao B.","JCO Clin Cancer Inform. 2017 Nov;1:1-8. doi: 10.1200/CCI.17.00108.","Dercle L","JCO Clin Cancer Inform","2017","2019/01/19","PMC6874047","","10.1200/CCI.17.00108"
"29098441","Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial","Walter I, Schulz U, Vogelhuber M, Wiedmann K, Endlicher E, Klebl F, Andreesen R, Herr W, Ghibelli L, Hackl C, Wiest R, Reichle A.","Med Oncol. 2017 Nov 2;34(12):192. doi: 10.1007/s12032-017-1040-0.","Walter I","Med Oncol","2017","2017/11/04","PMC5668342","","10.1007/s12032-017-1040-0"
"29115938","Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma","Shiba S, Abe T, Shibuya K, Katoh H, Koyama Y, Shimada H, Kakizaki S, Shirabe K, Kuwano H, Ohno T, Nakano T.","BMC Cancer. 2017 Nov 7;17(1):721. doi: 10.1186/s12885-017-3724-4.","Shiba S","BMC Cancer","2017","2017/11/09","PMC5678597","","10.1186/s12885-017-3724-4"
"28549676","Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma","Solms A, Reinecke I, Fiala-Buskies S, Keunecke A, Drenth HJ, Bruix J, Meinhardt G, Cleton A, Ploeger B.","Eur J Pharm Sci. 2017 Nov 15;109S:S149-S153. doi: 10.1016/j.ejps.2017.05.050. Epub 2017 May 23.","Solms A","Eur J Pharm Sci","2017","2017/05/28","","","10.1016/j.ejps.2017.05.050"
"28262413","CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma","Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators.","Eur Urol. 2017 Dec;72(6):962-971. doi: 10.1016/j.eururo.2017.02.010. Epub 2017 Mar 3.","Escudier B","Eur Urol","2017","2017/03/07","","","10.1016/j.eururo.2017.02.010"
"28947470","Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor","Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW.","Antimicrob Agents Chemother. 2017 Nov 22;61(12):e00813-17. doi: 10.1128/AAC.00813-17. Print 2017 Dec.","Caro L","Antimicrob Agents Chemother","2017","2017/09/27","PMC5700330","","10.1128/AAC.00813-17"
"28950298","Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","Necchi A, Joseph RW, Loriot Y, Hoffman-Censits J, Perez-Gracia JL, Petrylak DP, Derleth CL, Tayama D, Zhu Q, Ding B, Kaiser C, Rosenberg JE.","Ann Oncol. 2017 Dec 1;28(12):3044-3050. doi: 10.1093/annonc/mdx518.","Necchi A","Ann Oncol","2017","2017/09/27","PMC5834063","","10.1093/annonc/mdx518"
"29050954","The TRENDY multi-center randomized trial on hepatocellular carcinoma - Trial QA including automated treatment planning and benchmark-case results","Habraken SJM, Sharfo AWM, Buijsen J, Verbakel WFAR, Haasbeek CJA, Öllers MC, Westerveld H, van Wieringen N, Reerink O, Seravalli E, Braam PM, Wendling M, Lacornerie T, Mirabel X, Weytjens R, Depuydt L, Tanadini-Lang S, Riesterer O, Haustermans K, Depuydt T, Dwarkasing RS, Willemssen FEJA, Heijmen BJM, Méndez Romero A.","Radiother Oncol. 2017 Dec;125(3):507-513. doi: 10.1016/j.radonc.2017.09.007. Epub 2017 Oct 16.","Habraken SJM","Radiother Oncol","2017","2017/10/21","","","10.1016/j.radonc.2017.09.007"
"29076951","Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study","Schinzari G, Rossi E, Cassano A, Dadduzio V, Quirino M, Pagliara M, Blasi MA, Barone C.","Melanoma Res. 2017 Dec;27(6):591-595. doi: 10.1097/CMR.0000000000000401.","Schinzari G","Melanoma Res","2017","2017/10/28","","","10.1097/CMR.0000000000000401"
"29087397","Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients","Nguyen MH, Trinh H, Do S, Nguyen T, Nguyen P, Henry L.","Am J Gastroenterol. 2017 Dec;112(12):1824-1831. doi: 10.1038/ajg.2017.399. Epub 2017 Oct 31.","Nguyen MH","Am J Gastroenterol","2017","2017/11/01","","","10.1038/ajg.2017.399"
"29102858","Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial","Climent MÁ, Pérez-Valderrama B, Mellado B, Fernández Parra EM, Fernández Calvo O, Ochoa de Olza M, Muinelo Romay L, Anido U, Domenech M, Hernando Polo S, Arranz Arija JÁ, Caballero C, Juan Fita MJ, Castellano D.","Eur J Cancer. 2017 Dec;87:30-37. doi: 10.1016/j.ejca.2017.09.028. Epub 2017 Nov 2.","Climent MÁ","Eur J Cancer","2017","2017/11/06","","","10.1016/j.ejca.2017.09.028"
"29103871","Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N.","Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2.","Bang YJ","Lancet Oncol","2017","2017/11/07","","","10.1016/S1470-2045(17)30682-4"
"29107679","Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group.","Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.","Vilgrain V","Lancet Oncol","2017","2017/11/07","","","10.1016/S1470-2045(17)30683-6"
"29299370","Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus","Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA.","J Gastrointest Oncol. 2017 Dec;8(6):1079-1099. doi: 10.21037/jgo.2017.09.10.","Kennedy A","J Gastrointest Oncol","2017","2018/01/05","PMC5750172","","10.21037/jgo.2017.09.10"
"29229898","A Multicenter Phase III Study to Evaluate the Efficacy and Safety of Hepabulin, a New Hepatitis B Immunoglobulin, in Liver Transplantation Recipients with Hepatitis B","Choi HJ, Kim DG, Kim SI, Wang HJ, Joh JW, Suh KS, Kim SH.","Ann Transplant. 2017 Dec 12;22:740-748. doi: 10.12659/aot.905898.","Choi HJ","Ann Transplant","2017","2017/12/13","PMC6248297","","10.12659/aot.905898"
"29299154","Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis","Soukupova J, Bertran E, Peñuelas-Haro I, Urdiroz-Urricelqui U, Borgman M, Kohlhof H, Fabregat I.","Oncotarget. 2017 Nov 30;8(66):110367-110379. doi: 10.18632/oncotarget.22775. eCollection 2017 Dec 15.","Soukupova J","Oncotarget","2017","2018/01/05","PMC5746389","","10.18632/oncotarget.22775"
"28705916","Biodistribution and Dosimetry of (18)F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies","Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S.","J Nucl Med. 2018 Jan;59(1):147-153. doi: 10.2967/jnumed.117.193169. Epub 2017 Jul 13.","Pandit-Taskar N","J Nucl Med","2018","2017/07/15","PMC5750519","","10.2967/jnumed.117.193169"
"28707600","A New Potent NS5A Inhibitor in the Management of Hepatitis C Virus: Ravidasvir","Hafez E, Elbaz T, El Kassas M, Esmat G.","Curr Drug Discov Technol. 2018;15(1):24-31. doi: 10.2174/1570163814666170713104435.","Hafez E","Curr Drug Discov Technol","2018","2017/07/15","","","10.2174/1570163814666170713104435"
"28796864","Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial","Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, Parikh ND, Welling TH, Normolle D, Ten Haken RK, Lawrence TS.","JAMA Oncol. 2018 Jan 1;4(1):40-47. doi: 10.1001/jamaoncol.2017.2303.","Feng M","JAMA Oncol","2018","2017/08/11","PMC5766368","NIHMS911063","10.1001/jamaoncol.2017.2303"
"28943046","Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial","Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, Alongi F, Del Conte A, Militello L, Muraro E, Martorelli D, Spazzapan S, Berretta M.","Radiother Oncol. 2018 Jan;126(1):177-180. doi: 10.1016/j.radonc.2017.08.032. Epub 2017 Sep 21.","Trovo M","Radiother Oncol","2018","2017/09/26","","","10.1016/j.radonc.2017.08.032"
"28953134","National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery","Jones NL, Chen L, Chatterjee S, Tergas AI, Burke WM, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD.","Int J Gynecol Cancer. 2018 Jan;28(1):19-25. doi: 10.1097/IGC.0000000000001132.","Jones NL","Int J Gynecol Cancer","2018","2017/09/28","PMC5734991","NIHMS899038","10.1097/IGC.0000000000001132"
"28967554","Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results","Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.","Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.","Motzer RJ","Eur Urol","2018","2017/10/03","PMC6684251","NIHMS1535781","10.1016/j.eururo.2017.09.008"
"28988687","Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y.","Lancet Gastroenterol Hepatol. 2018 Jan;3(1):37-46. doi: 10.1016/S2468-1253(17)30290-X. Epub 2017 Oct 4.","Kudo M","Lancet Gastroenterol Hepatol","2018","2017/10/10","","","10.1016/S2468-1253(17)30290-X"
"29018051","Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions","Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, Chiou YY, Huang GT, Cai J, Abdullah BJJ, Lee JS, Lee JY, Choi JY, Gopez-Cervantes J, Sherman M, Finn RS, Omata M, O'Neal M, Makris L, Borys N, Poon R, Lencioni R.","Clin Cancer Res. 2018 Jan 1;24(1):73-83. doi: 10.1158/1078-0432.CCR-16-2433. Epub 2017 Oct 10.","Tak WY","Clin Cancer Res","2018","2017/10/12","","","10.1158/1078-0432.CCR-16-2433"
"29054986","Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors","Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D.","Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20.","Lam ET","Mol Cancer Ther","2018","2017/10/22","PMC5752572","NIHMS912462","10.1158/1535-7163.MCT-17-0330"
"29061504","Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial","Das K, Taguri M, Imamura H, Sugimoto N, Nishikawa K, Yoshida K, Tan P, Tsuburaya A.","Cancer Lett. 2018 Jan 1;412:208-215. doi: 10.1016/j.canlet.2017.10.011. Epub 2017 Oct 20.","Das K","Cancer Lett","2018","2017/10/25","","","10.1016/j.canlet.2017.10.011"
"29064750","The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival","Abramson RG, Lakomkin N, Hainline A, Kang H, Hutson MS, Arteaga CL.","AJR Am J Roentgenol. 2018 Jan;210(1):W1-W7. doi: 10.2214/AJR.17.18249. Epub 2017 Oct 24.","Abramson RG","AJR Am J Roentgenol","2018","2017/10/25","","","10.2214/AJR.17.18249"
"29119292","Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis","Schmid U, Liesenfeld KH, Fleury A, Dallinger C, Freiwald M.","Cancer Chemother Pharmacol. 2018 Jan;81(1):89-101. doi: 10.1007/s00280-017-3452-0. Epub 2017 Nov 8.","Schmid U","Cancer Chemother Pharmacol","2018","2017/11/10","PMC5754397","","10.1007/s00280-017-3452-0"
"29127060","Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial","Newsome PN, Fox R, King AL, Barton D, Than NN, Moore J, Corbett C, Townsend S, Thomas J, Guo K, Hull D, Beard HA, Thompson J, Atkinson A, Bienek C, McGowan N, Guha N, Campbell J, Hollyman D, Stocken D, Yap C, Forbes SJ.","Lancet Gastroenterol Hepatol. 2018 Jan;3(1):25-36. doi: 10.1016/S2468-1253(17)30326-6. Epub 2017 Nov 7.","Newsome PN","Lancet Gastroenterol Hepatol","2018","2017/11/12","PMC5738975","","10.1016/S2468-1253(17)30326-6"
"29158365","Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer","Araujo-Mino EP, Patt YZ, Murray-Krezan C, Hanson JA, Bansal P, Liem BJ, Rajput A, Fekrazad MH, Heywood G, Lee FC.","Oncologist. 2018 Jan;23(1):2-e5. doi: 10.1634/theoncologist.2017-0474. Epub 2017 Nov 20.","Araujo-Mino EP","Oncologist","2018","2017/11/22","PMC5759821","","10.1634/theoncologist.2017-0474"
"29167924","Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment","Nikanjam M, Capparelli EV, Lancet JE, Louie A, Schiller G.","Cancer Chemother Pharmacol. 2018 Jan;81(1):171-178. doi: 10.1007/s00280-017-3484-5. Epub 2017 Nov 22.","Nikanjam M","Cancer Chemother Pharmacol","2018","2017/11/24","PMC5756117","NIHMS922408","10.1007/s00280-017-3484-5"
"29188322","Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects","Gerisch M, Hafner FT, Lang D, Radtke M, Diefenbach K, Cleton A, Lettieri J.","Cancer Chemother Pharmacol. 2018 Jan;81(1):195-206. doi: 10.1007/s00280-017-3480-9. Epub 2017 Nov 29.","Gerisch M","Cancer Chemother Pharmacol","2018","2017/12/01","PMC5754413","","10.1007/s00280-017-3480-9"
"29462253","Overview of current systemic management of EGFR-mutant NSCLC","Hsu WH, Yang JC, Mok TS, Loong HH.","Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9. doi: 10.1093/annonc/mdx702.","Hsu WH","Ann Oncol","2018","2018/02/21","","","10.1093/annonc/mdx702"
"29539626","Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients","Zarrabi K, Wu S.","Oncology. 2018;94(5):259-273. doi: 10.1159/000486679. Epub 2018 Mar 14.","Zarrabi K","Oncology","2018","2018/03/15","","","10.1159/000486679"
"29569657","Regorafenib for the treatment of hepatocellular carcinoma","Tovoli F, Granito A, De Lorenzo S, Bolondi L.","Drugs Today (Barc). 2018 Jan;54(1):5-13. doi: 10.1358/dot.2018.54.1.2736667.","Tovoli F","Drugs Today (Barc)","2018","2018/03/24","","","10.1358/dot.2018.54.1.2736667"
"29705792","Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies","Moehler M, Göpfert K, Lenz HJ.","Oncol Res Treat. 2018;41(5):313-315. doi: 10.1159/000489047. Epub 2018 Apr 26.","Moehler M","Oncol Res Treat","2018","2018/04/30","PMC7493693","NIHMS1623826","10.1159/000489047"
"29970651","Conversion chemotherapy with capecitabine and oxaliplatin for colorectal cancer with potentially resectable liver metastases: A phase II, open-label, single-arm study","Li Y, Li GX, Chu ZH, Hao CY, Jiang ZW, Chen HQ, Lin JJ, Li DC, Hu B, Wang XS, Lin F.","J Cancer Res Ther. 2018;14(4):772-779. doi: 10.4103/jcrt.JCRT_738_17.","Li Y","J Cancer Res Ther","2018","2018/07/05","","","10.4103/jcrt.JCRT_738_17"
"30032643","Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers","Suyama K, Iwase H.","Cancer Control. 2018 Jan-Dec;25(1):1073274818789361. doi: 10.1177/1073274818789361.","Suyama K","Cancer Control","2018","2018/07/24","PMC6056795","","10.1177/1073274818789361"
"30041178","Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports","Giordano G, Febbraro A, Quaquarini E, Turletti A, Pedersini R, Raffaele M, Villa F, Rossello R; The Italian Eribulin Working Group.","Oncology. 2018;94 Suppl 1(Suppl 1):34-44. doi: 10.1159/000489067. Epub 2018 Jul 24.","Giordano G","Oncology","2018","2018/07/25","PMC6193749","","10.1159/000489067"
"30352542","Stereotactic Radiotherapy for Oligometastases in Lymph Nodes-A Review","Matsushita H, Jingu K, Umezawa R, Yamamoto T, Ishikawa Y, Takahashi N, Katagiri Y, Kadoya N.","Technol Cancer Res Treat. 2018 Jan 1;17:1533033818803597. doi: 10.1177/1533033818803597.","Matsushita H","Technol Cancer Res Treat","2018","2018/10/25","PMC6201169","","10.1177/1533033818803597"
"30472978","Development, Characterization, and Pharmacokinetic Evaluation of a CRV431 Loaded Self-Microemulsifying Drug Delivery System","Trepanier DJ, Ure DR, Foster RT.","J Pharm Pharm Sci. 2018;21(1s):335s-348s. doi: 10.18433/jpps30245.","Trepanier DJ","J Pharm Pharm Sci","2018","2018/11/27","","","10.18433/jpps30245"
"29325521","Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study","Siebenhüner AR, Seifert H, Bachmann H, Seifert B, Winder T, Feilchenfeldt J, Breitenstein S, Clavien PA, Stupp R, Knuth A, Pestalozzi B, Samaras P.","BMC Cancer. 2018 Jan 11;18(1):72. doi: 10.1186/s12885-017-3967-0.","Siebenhüner AR","BMC Cancer","2018","2018/01/13","PMC5765636","","10.1186/s12885-017-3967-0"
"29329568","Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization","Xing M, Kokabi N, Camacho JC, Kim HS.","BMC Cancer. 2018 Jan 12;18(1):75. doi: 10.1186/s12885-017-3921-1.","Xing M","BMC Cancer","2018","2018/01/14","PMC5766991","","10.1186/s12885-017-3921-1"
"29336009","Gefitinib for advanced non-small cell lung cancer","Sim EH, Yang IA, Wood-Baker R, Bowman RV, Fong KM.","Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD006847. doi: 10.1002/14651858.CD006847.pub2.","Sim EH","Cochrane Database Syst Rev","2018","2018/01/17","PMC6491254","","10.1002/14651858.CD006847.pub2"
"29196412","A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.","Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.","Stein EM","Blood","2018","2017/12/03","PMC5813721","","10.1182/blood-2017-06-789800"
"29487723","A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209","Eigl BJ, Chi K, Tu D, Hotte SJ, Winquist E, Booth CM, Canil C, Potvin K, Gregg R, North S, Zulfiqar M, Ellard S, Ruether JD, Le L, Kakumanu AS, Salim M, Allan AL, Feilotter H, Theis A, Seymour L.","Oncotarget. 2018 Jan 17;9(8):8155-8164. doi: 10.18632/oncotarget.24263. eCollection 2018 Jan 30.","Eigl BJ","Oncotarget","2018","2018/03/01","PMC5814290","","10.18632/oncotarget.24263"
"28766016","Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial","Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Miriplatin TACE Study Group.","J Gastroenterol. 2018 Feb;53(2):281-290. doi: 10.1007/s00535-017-1374-6. Epub 2017 Aug 1.","Ikeda M","J Gastroenterol","2018","2017/08/03","PMC5846877","","10.1007/s00535-017-1374-6"
"28859185","Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial","Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H.","JAMA Oncol. 2018 Feb 1;4(2):230-234. doi: 10.1001/jamaoncol.2017.2380.","Jabbour E","JAMA Oncol","2018","2017/09/01","PMC5838597","","10.1001/jamaoncol.2017.2380"
"28906589","Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial","Chen HH, Lin JK, Chen JB, Chuang CH, Liu MC, Wang JY, Changchien CR.","Asia Pac J Clin Oncol. 2018 Feb;14(1):61-68. doi: 10.1111/ajco.12692. Epub 2017 Sep 14.","Chen HH","Asia Pac J Clin Oncol","2018","2017/09/15","","","10.1111/ajco.12692"
"29080924","Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials","Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, Geissler M, Koukakis R, Demonty G, Peeters M.","J Cancer Res Clin Oncol. 2018 Feb;144(2):321-335. doi: 10.1007/s00432-017-2534-z. Epub 2017 Oct 28.","Taieb J","J Cancer Res Clin Oncol","2018","2017/10/30","PMC5794806","","10.1007/s00432-017-2534-z"
"29183960","Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program","Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators.","Oncologist. 2018 Feb;23(2):193-202. doi: 10.1634/theoncologist.2017-0413. Epub 2017 Nov 28.","Sartor O","Oncologist","2018","2017/11/30","PMC5813754","","10.1634/theoncologist.2017-0413"
"29253194","Chemotherapy for hepatocellular carcinoma: current status and future perspectives","Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J.","Jpn J Clin Oncol. 2018 Feb 1;48(2):103-114. doi: 10.1093/jjco/hyx180.","Ikeda M","Jpn J Clin Oncol","2018","2017/12/19","","","10.1093/jjco/hyx180"
"29258812","Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study","Walter T, Malka D, Hentic O, Lombard-Bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz JE, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec JY, Lepage C.","Dig Liver Dis. 2018 Feb;50(2):195-198. doi: 10.1016/j.dld.2017.11.020. Epub 2017 Dec 6.","Walter T","Dig Liver Dis","2018","2017/12/21","","","10.1016/j.dld.2017.11.020"
"29535817","Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab","Chen G, Chen YC, Reis B, Belousov A, Jukofsky L, Rossin C, Muehlig A, Xu C, Essioux L, Ohtomo T, Di Laurenzio L, Puig O, Lee R.","Oncotarget. 2018 Jan 2;9(12):10436-10444. doi: 10.18632/oncotarget.23830. eCollection 2018 Feb 13.","Chen G","Oncotarget","2018","2018/03/15","PMC5828203","","10.18632/oncotarget.23830"
"29268948","Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A.","Lancet. 2018 Feb 24;391(10122):748-757. doi: 10.1016/S0140-6736(17)33297-X. Epub 2017 Dec 18.","Powles T","Lancet","2018","2017/12/23","","","10.1016/S0140-6736(17)33297-X"
"29028128","Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease","Middleton MS, Van Natta ML, Heba ER, Alazraki A, Trout AT, Masand P, Brunt EM, Kleiner DE, Doo E, Tonascia J, Lavine JE, Shen W, Hamilton G, Schwimmer JB, Sirlin CB; NASH Clinical Research Network.","Hepatology. 2018 Mar;67(3):858-872. doi: 10.1002/hep.29596. Epub 2018 Jan 26.","Middleton MS","Hepatology","2018","2017/10/14","PMC6211296","NIHMS913346","10.1002/hep.29596"
"29047142","Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial","Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V.","Int J Cancer. 2018 Mar 1;142(5):1047-1055. doi: 10.1002/ijc.31114. Epub 2017 Nov 7.","Holch JW","Int J Cancer","2018","2017/10/20","","","10.1002/ijc.31114"
"29106740","Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment","Marzin K, Kretschmar G, Luedtke D, Kraemer S, Kuelzer R, Schlenker-Herceg R, Schmid U, Schnell D, Dallinger C.","J Clin Pharmacol. 2018 Mar;58(3):357-363. doi: 10.1002/jcph.1025. Epub 2017 Nov 6.","Marzin K","J Clin Pharmacol","2018","2017/11/07","PMC5836871","","10.1002/jcph.1025"
"29277446","Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, Green O, Michalski J, Mutic S, Parikh P, Olsen J.","Radiother Oncol. 2018 Mar;126(3):519-526. doi: 10.1016/j.radonc.2017.11.032. Epub 2017 Dec 23.","Henke L","Radiother Oncol","2018","2017/12/27","","","10.1016/j.radonc.2017.11.032"
"29330194","Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R.","Endocr Relat Cancer. 2018 Mar;25(3):309-322. doi: 10.1530/ERC-17-0455. Epub 2018 Jan 12.","Pavel M","Endocr Relat Cancer","2018","2018/01/14","PMC5811631","","10.1530/ERC-17-0455"
"29352572","Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies","Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP.","Gynecol Oncol. 2018 Mar;148(3):507-514. doi: 10.1016/j.ygyno.2017.12.029. Epub 2018 Jan 17.","Gray HJ","Gynecol Oncol","2018","2018/01/21","","","10.1016/j.ygyno.2017.12.029"
"29392450","A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies","Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ.","Cancer Chemother Pharmacol. 2018 Mar;81(3):587-596. doi: 10.1007/s00280-018-3533-8. Epub 2018 Feb 1.","Deeken JF","Cancer Chemother Pharmacol","2018","2018/02/03","","","10.1007/s00280-018-3533-8"
"29395863","Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN.","Lancet Oncol. 2018 Mar;19(3):347-355. doi: 10.1016/S1470-2045(18)30062-7. Epub 2018 Jan 26.","Giaccone G","Lancet Oncol","2018","2018/02/04","PMC10683856","NIHMS1893447","10.1016/S1470-2045(18)30062-7"
"29402752","Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK)","Michel P, Boige V, Andre T, Aparicio T, Bachet JB, Dahan L, Guimbaud R, Lepage C, Manfredi S, Tougeron D, Taieb J, Selves J, Le Malicot K, Di Fiore F, Maillard E.","Dig Liver Dis. 2018 Mar;50(3):305-307. doi: 10.1016/j.dld.2017.12.023. Epub 2017 Dec 30.","Michel P","Dig Liver Dis","2018","2018/02/07","","","10.1016/j.dld.2017.12.023"
"29407583","Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses","Burke PW, Aldoss I, Lunning MA, Devlin SM, Tallman MS, Pullarkat V, Mohrbacher AM, Douer D.","Leuk Res. 2018 Mar;66:49-56. doi: 10.1016/j.leukres.2017.12.013. Epub 2018 Jan 3.","Burke PW","Leuk Res","2018","2018/02/07","","","10.1016/j.leukres.2017.12.013"
"29506478","A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma","Lee DW, Lee KH, Kim HJ, Kim TY, Kim JS, Han SW, Oh DY, Kim JH, Im SA, Kim TY.","BMC Cancer. 2018 Mar 5;18(1):252. doi: 10.1186/s12885-018-4039-9.","Lee DW","BMC Cancer","2018","2018/03/07","PMC5838934","","10.1186/s12885-018-4039-9"
"29381690","Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)","Sun JM, Lee KH, Kim BS, Kim HG, Min YJ, Yi SY, Yun HJ, Jung SH, Lee SH, Ahn JS, Park K, Ahn MJ.","Br J Cancer. 2018 Mar 6;118(5):648-653. doi: 10.1038/bjc.2017.465. Epub 2018 Jan 30.","Sun JM","Br J Cancer","2018","2018/01/31","PMC5846070","","10.1038/bjc.2017.465"
"29515114","Momelotinib therapy for myelofibrosis: a 7-year follow-up","Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Gangat N, Pardanani A.","Blood Cancer J. 2018 Mar 7;8(3):29. doi: 10.1038/s41408-018-0067-6.","Tefferi A","Blood Cancer J","2018","2018/03/09","PMC5841331","","10.1038/s41408-018-0067-6"
"29536211","Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations","Parasrampuria DA, Benet LZ, Sharma A.","AAPS J. 2018 Mar 13;20(3):46. doi: 10.1208/s12248-018-0204-y.","Parasrampuria DA","AAPS J","2018","2018/03/15","","","10.1208/s12248-018-0204-y"
"29433850","Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL.","Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.","Kudo M","Lancet","2018","2018/02/14","","","10.1016/S0140-6736(18)30207-1"
"28916623","Efficacy of Radioembolization with (166)Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study","Prince JF, van den Bosch MAAJ, Nijsen JFW, Smits MLJ, van den Hoven AF, Nikolakopoulos S, Wessels FJ, Bruijnen RCG, Braat MNGJA, Zonnenberg BA, Lam MGEH.","J Nucl Med. 2018 Apr;59(4):582-588. doi: 10.2967/jnumed.117.197194. Epub 2017 Sep 15.","Prince JF","J Nucl Med","2018","2017/09/17","","","10.2967/jnumed.117.197194"
"28986512","Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of (68)Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer","Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, Murphy D, Mitchell C, Siva S, Hicks RJ, Young JD, Blower PJ, Mullen GE.","J Nucl Med. 2018 Apr;59(4):625-631. doi: 10.2967/jnumed.117.199554. Epub 2017 Oct 6.","Hofman MS","J Nucl Med","2018","2017/10/08","PMC7116766","EMS115487","10.2967/jnumed.117.199554"
"28990424","An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria","Serrano-Mendioroz I, Sampedro A, Alegre M, Enríquez de Salamanca R, Berraondo P, Fontanellas A.","Hum Gene Ther. 2018 Apr;29(4):480-491. doi: 10.1089/hum.2017.056. Epub 2018 Jan 2.","Serrano-Mendioroz I","Hum Gene Ther","2018","2017/10/10","","","10.1089/hum.2017.056"
"29138342","Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes","Iñarrairaegui M, Melero I, Sangro B.","Clin Cancer Res. 2018 Apr 1;24(7):1518-1524. doi: 10.1158/1078-0432.CCR-17-0289. Epub 2017 Nov 14.","Iñarrairaegui M","Clin Cancer Res","2018","2017/11/16","","","10.1158/1078-0432.CCR-17-0289"
"29211833","A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, Matsuki T, Miura K, Kawakita D, Hirai H, Hoshino E, Kamata S, Saotome T.","Ann Oncol. 2018 Apr 1;29(4):979-984. doi: 10.1093/annonc/mdx771.","Fushimi C","Ann Oncol","2018","2017/12/07","PMC5913639","","10.1093/annonc/mdx771"
"29408986","Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases","Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G Jr, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crinò L.","Ann Oncol. 2018 Apr 1;29(4):959-965. doi: 10.1093/annonc/mdy041.","Vokes EE","Ann Oncol","2018","2018/02/07","","","10.1093/annonc/mdy041"
"29409778","Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)","Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C.","Dig Liver Dis. 2018 Apr;50(4):408-410. doi: 10.1016/j.dld.2018.01.119. Epub 2018 Mar 1.","Zaanan A","Dig Liver Dis","2018","2018/02/08","","","10.1016/j.dld.2018.01.119"
"29468454","Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC)","Nakayama T, Sagara Y, Takashima T, Matsunami N, Masuda N, Miyoshi Y, Taguchi T, Aono T, Ito T, Kagimura T, Noguchi S.","Cancer Chemother Pharmacol. 2018 Apr;81(4):755-762. doi: 10.1007/s00280-018-3544-5. Epub 2018 Feb 21.","Nakayama T","Cancer Chemother Pharmacol","2018","2018/02/23","PMC5854715","","10.1007/s00280-018-3544-5"
"29468455","Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer","El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T, El-Rayes BF.","Cancer Chemother Pharmacol. 2018 Apr;81(4):659-670. doi: 10.1007/s00280-018-3517-8. Epub 2018 Feb 21.","El-Khoueiry AB","Cancer Chemother Pharmacol","2018","2018/02/23","PMC7539325","NIHMS1623791","10.1007/s00280-018-3517-8"
"29473963","HEPATOFLUO: A prospective monocentric study assessing the benefits of indocyanine green (ICG) fluorescence for hepatic surgery","Peyrat P, Blanc E, Guillermet S, Chen Y, Ferlay C, Perol D, Basso V, Rivoire M, Dupré A.","J Surg Oncol. 2018 Apr;117(5):922-927. doi: 10.1002/jso.25011. Epub 2018 Feb 23.","Peyrat P","J Surg Oncol","2018","2018/02/24","","","10.1002/jso.25011"
"29474553","A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class","Suzuki E, Kaneko S, Okusaka T, Ikeda M, Yamaguchi K, Sugimoto R, Aramaki T, Asagi A, Yasui K, Sano K, Hosokawa A, Kato N, Ishii H, Sato T, Furuse J.","Jpn J Clin Oncol. 2018 Apr 1;48(4):317-321. doi: 10.1093/jjco/hyy010.","Suzuki E","Jpn J Clin Oncol","2018","2018/02/24","","","10.1093/jjco/hyy010"
"29534618","Investigational CD33-targeted therapeutics for acute myeloid leukemia","Walter RB.","Expert Opin Investig Drugs. 2018 Apr;27(4):339-348. doi: 10.1080/13543784.2018.1452911. Epub 2018 Mar 15.","Walter RB","Expert Opin Investig Drugs","2018","2018/03/15","","","10.1080/13543784.2018.1452911"
"29058097","Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm","Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A.","Gastric Cancer. 2018 May;21(3):429-438. doi: 10.1007/s10120-017-0773-y. Epub 2017 Oct 20.","Sawaki A","Gastric Cancer","2018","2017/10/24","PMC5906488","","10.1007/s10120-017-0773-y"
"29271486","No augmentation of indoleamine 2,3-dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients","Bigenzahn S, Juergens B, Mahr B, Pratschke J, Koenigsrainer A, Becker T, Fuchs D, Brandacher G, Kainz A, Muehlbacher F, Wekerle T.","Clin Exp Immunol. 2018 May;192(2):233-241. doi: 10.1111/cei.13093. Epub 2018 Feb 2.","Bigenzahn S","Clin Exp Immunol","2018","2017/12/23","PMC5904696","","10.1111/cei.13093"
"29327075","Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis","He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M.","Cardiovasc Intervent Radiol. 2018 May;41(5):734-743. doi: 10.1007/s00270-017-1874-z. Epub 2018 Jan 11.","He MK","Cardiovasc Intervent Radiol","2018","2018/01/13","","","10.1007/s00270-017-1874-z"
"29331343","Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial","Zhu HD, Guo JH, Huang M, Ji JS, Xu H, Lu J, Li HL, Wang WH, Li YL, Ni CF, Shi HB, Xiao EH, Lv WF, Sun JH, Xu K, Han GH, Du LA, Ren WX, Li MQ, Mao AW, Xiang H, Zhang KX, Min J, Zhu GY, Su C, Chen L, Teng GJ.","J Hepatol. 2018 May;68(5):970-977. doi: 10.1016/j.jhep.2017.12.028. Epub 2018 Jan 10.","Zhu HD","J Hepatol","2018","2018/01/15","","","10.1016/j.jhep.2017.12.028"
"29420221","Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study","Wang Z, Ren Z, Chen Y, Hu J, Yang G, Yu L, Yang X, Huang A, Zhang X, Zhou S, Sun H, Wang Y, Ge N, Xu X, Tang Z, Lau W, Fan J, Wang J, Zhou J.","Clin Cancer Res. 2018 May 1;24(9):2074-2081. doi: 10.1158/1078-0432.CCR-17-2899. Epub 2018 Feb 2.","Wang Z","Clin Cancer Res","2018","2018/02/09","","","10.1158/1078-0432.CCR-17-2899"
"29451701","Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases","Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, Chen Z, Brutcher E, Renfroe M, El-Rayes BF.","Cancer. 2018 May 1;124(9):1992-2000. doi: 10.1002/cncr.31192. Epub 2018 Feb 16.","Kim HS","Cancer","2018","2018/02/17","","","10.1002/cncr.31192"
"29455421","Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study","Abdel-Rahman O.","J Cancer Res Clin Oncol. 2018 May;144(5):901-908. doi: 10.1007/s00432-018-2610-z. Epub 2018 Feb 17.","Abdel-Rahman O","J Cancer Res Clin Oncol","2018","2018/02/19","","","10.1007/s00432-018-2610-z"
"29462473","Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)","Convertino M, Church TR, Olsen GW, Liu Y, Doyle E, Elcombe CR, Barnett AL, Samuel LM, MacPherson IR, Evans TRJ.","Toxicol Sci. 2018 May 1;163(1):293-306. doi: 10.1093/toxsci/kfy035.","Convertino M","Toxicol Sci","2018","2018/02/21","PMC5920327","","10.1093/toxsci/kfy035"
"29478735","Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States","Pal SK, Hoffman-Censits J, Zheng H, Kaiser C, Tayama D, Bellmunt J.","Eur Urol. 2018 May;73(5):800-806. doi: 10.1016/j.eururo.2018.02.010. Epub 2018 Feb 22.","Pal SK","Eur Urol","2018","2018/02/27","","","10.1016/j.eururo.2018.02.010"
"29503247","Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial","Vietti Violi N, Duran R, Guiu B, Cercueil JP, Aubé C, Digklia A, Pache I, Deltenre P, Knebel JF, Denys A.","Lancet Gastroenterol Hepatol. 2018 May;3(5):317-325. doi: 10.1016/S2468-1253(18)30029-3. Epub 2018 Mar 2.","Vietti Violi N","Lancet Gastroenterol Hepatol","2018","2018/03/06","","","10.1016/S2468-1253(18)30029-3"
"29520435","A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma","El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR.","Cancer Chemother Pharmacol. 2018 May;81(5):957-963. doi: 10.1007/s00280-018-3553-4. Epub 2018 Mar 8.","El-Khoueiry AB","Cancer Chemother Pharmacol","2018","2018/03/10","PMC6330274","NIHMS999548","10.1007/s00280-018-3553-4"
"29563636","A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma","Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T.","Br J Cancer. 2018 May;118(9):1162-1168. doi: 10.1038/s41416-018-0051-8. Epub 2018 Mar 22.","Palmer DH","Br J Cancer","2018","2018/03/23","PMC5943284","","10.1038/s41416-018-0051-8"
"29576417","TACE plus external beam radiotherapy in liver cancer","Das M.","Lancet Oncol. 2018 May;19(5):e231. doi: 10.1016/S1470-2045(18)30218-3. Epub 2018 Mar 23.","Das M","Lancet Oncol","2018","2018/03/27","","","10.1016/S1470-2045(18)30218-3"
"29625879","Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.","Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.","Rimassa L","Lancet Oncol","2018","2018/04/08","","","10.1016/S1470-2045(18)30146-3"
"29650363","Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial","Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators.","Lancet Oncol. 2018 May;19(5):616-628. doi: 10.1016/S1470-2045(18)30132-3. Epub 2018 Apr 9.","Cats A","Lancet Oncol","2018","2018/04/14","","","10.1016/S1470-2045(18)30132-3"
"29887782","The Role of Normothermic Perfusion in Liver Transplantation (TRaNsIT Study): A Systematic Review of Preliminary Studies","Jayant K, Reccia I, Virdis F, Shapiro AMJ.","HPB Surg. 2018 May 17;2018:6360423. doi: 10.1155/2018/6360423. eCollection 2018.","Jayant K","HPB Surg","2018","2018/06/12","PMC5985064","","10.1155/2018/6360423"
"29843754","Immune checkpoint therapy in liver cancer","Xu F, Jin T, Zhu Y, Dai C.","J Exp Clin Cancer Res. 2018 May 29;37(1):110. doi: 10.1186/s13046-018-0777-4.","Xu F","J Exp Clin Cancer Res","2018","2018/05/31","PMC5975687","","10.1186/s13046-018-0777-4"
"28058527","Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure","Sato Y, Inaba Y, Ura T, Nishiofuku H, Yamaura H, Kato M, Takahari D, Tanaka T, Muro K.","J Gastrointest Cancer. 2018 Jun;49(2):132-137. doi: 10.1007/s12029-016-9915-4.","Sato Y","J Gastrointest Cancer","2018","2017/01/07","","","10.1007/s12029-016-9915-4"
"28871342","A systematic review of publications on charged particle therapy for hepatocellular carcinoma","Igaki H, Mizumoto M, Okumura T, Hasegawa K, Kokudo N, Sakurai H.","Int J Clin Oncol. 2018 Jun;23(3):423-433. doi: 10.1007/s10147-017-1190-2. Epub 2017 Sep 4.","Igaki H","Int J Clin Oncol","2018","2017/09/06","","","10.1007/s10147-017-1190-2"
"29025985","Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study","Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, Reubi JC, Rivier JEF, Maecke HR, Fani M, Wild D.","J Nucl Med. 2018 Jun;59(6):909-914. doi: 10.2967/jnumed.117.199737. Epub 2017 Oct 12.","Nicolas GP","J Nucl Med","2018","2017/10/14","","","10.2967/jnumed.117.199737"
"29177975","Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial","Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M.","Invest New Drugs. 2018 Jun;36(3):476-486. doi: 10.1007/s10637-017-0546-9. Epub 2017 Nov 27.","Calvo E","Invest New Drugs","2018","2017/11/28","","","10.1007/s10637-017-0546-9"
"29191855","Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study","Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D.","J Nucl Med. 2018 Jun;59(6):915-921. doi: 10.2967/jnumed.117.199760. Epub 2017 Nov 30.","Nicolas GP","J Nucl Med","2018","2017/12/02","","","10.2967/jnumed.117.199760"
"29237235","Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study","Jeng LB, Lee SG, Soin AS, Lee WC, Suh KS, Joo DJ, Uemoto S, Joh J, Yoshizumi T, Yang HR, Song GW, Lopez P, Kochuparampil J, Sips C, Kaneko S, Levy G.","Am J Transplant. 2018 Jun;18(6):1435-1446. doi: 10.1111/ajt.14623. Epub 2018 Jan 25.","Jeng LB","Am J Transplant","2018","2017/12/14","","","10.1111/ajt.14623"
"29345044","Pre-clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK-063","Tohyama K, Sudo M, Morohashi A, Kato S, Takahashi J, Tagawa Y.","Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):577-587. doi: 10.1111/bcpt.12964. Epub 2018 Feb 26.","Tohyama K","Basic Clin Pharmacol Toxicol","2018","2018/01/19","","","10.1111/bcpt.12964"
"29427728","Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial","Guiu B, Jouve JL, Schmitt A, Minello A, Bonnetain F, Cassinotto C, Piron L, Cercueil JP, Loffroy R, Latournerie M, Wendremaire M, Lepage C, Boulin M.","J Hepatol. 2018 Jun;68(6):1163-1171. doi: 10.1016/j.jhep.2018.01.022. Epub 2018 Feb 8.","Guiu B","J Hepatol","2018","2018/02/11","","","10.1016/j.jhep.2018.01.022"
"29430582","The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases","Jacobs BAW, Snoeren N, Samim M, Rosing H, de Vries N, Deenen MJ, Beijnen JH, Schellens JHM, Koopman M, van Hillegersberg R.","Eur J Clin Pharmacol. 2018 Jun;74(6):737-744. doi: 10.1007/s00228-018-2426-4. Epub 2018 Feb 11.","Jacobs BAW","Eur J Clin Pharmacol","2018","2018/02/13","","","10.1007/s00228-018-2426-4"
"29631810","Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial","Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group.","Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.","Kudo M","Lancet Gastroenterol Hepatol","2018","2018/04/11","","","10.1016/S2468-1253(18)30078-5"
"29659672","Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma","Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT.","Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101.","Abou-Alfa GK","Ann Oncol","2018","2018/04/17","","","10.1093/annonc/mdy101"
"29669701","Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial","Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A.","Lancet Respir Med. 2018 Jun;6(6):431-441. doi: 10.1016/S2213-2600(18)30116-4. Epub 2018 Apr 15.","Schöffski P","Lancet Respir Med","2018","2018/04/20","","","10.1016/S2213-2600(18)30116-4"
"29741103","Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?","Sacco JJ, Kalirai H, Kenyani J, Figueiredo CR, Coulson JM, Coupland SE.","Future Oncol. 2018 Jun;14(14):1335-1338. doi: 10.2217/fon-2018-0116. Epub 2018 May 9.","Sacco JJ","Future Oncol","2018","2018/05/10","","","10.2217/fon-2018-0116"
"29752332","Prolonged duration of response in lenvatinib responders with thyroid cancer","Gianoukakis AG, Dutcus CE, Batty N, Guo M, Baig M.","Endocr Relat Cancer. 2018 Jun;25(6):699-704. doi: 10.1530/ERC-18-0049.","Gianoukakis AG","Endocr Relat Cancer","2018","2018/05/13","PMC5958278","","10.1530/ERC-18-0049"
"29792572","GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics","Springer AD, Dowdy SF.","Nucleic Acid Ther. 2018 Jun;28(3):109-118. doi: 10.1089/nat.2018.0736. Epub 2018 May 24.","Springer AD","Nucleic Acid Ther","2018","2018/05/25","PMC5994659","","10.1089/nat.2018.0736"
"29807383","[Hepatocellular Carcinoma: New multimodal therapy concepts]","Schultheiß M, Bettinger D, Fichtner-Feigl S, Thimme R.","Dtsch Med Wochenschr. 2018 Jun;143(11):815-819. doi: 10.1055/s-0043-124158. Epub 2018 May 28.","Schultheiß M","Dtsch Med Wochenschr","2018","2018/05/29","","","10.1055/s-0043-124158"
"29913090","Oral chemotherapy for the treatment of hepatocellular carcinoma","Yamamoto S, Kondo S.","Expert Opin Pharmacother. 2018 Jun;19(9):993-1001. doi: 10.1080/14656566.2018.1479398. Epub 2018 Jun 18.","Yamamoto S","Expert Opin Pharmacother","2018","2018/06/19","","","10.1080/14656566.2018.1479398"
"29866075","Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial","Hatooka M, Kawaoka T, Aikata H, Inagaki Y, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Awai K, Masaki K, Waki K, Kohno H, Kohno H, Moriya T, Nagaoki Y, Tamura T, Amano H, Katamura Y, Chayama K.","BMC Cancer. 2018 Jun 4;18(1):633. doi: 10.1186/s12885-018-4519-y.","Hatooka M","BMC Cancer","2018","2018/06/06","PMC5987491","","10.1186/s12885-018-4519-y"
"29884132","A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients","Giraudet AL, Cassier PA, Iwao-Fukukawa C, Garin G, Badel JN, Kryza D, Chabaud S, Gilles-Afchain L, Clapisson G, Desuzinges C, Sarrut D, Halty A, Italiano A, Mori M, Tsunoda T, Katagiri T, Nakamura Y, Alberti L, Cropet C, Baconnier S, Berge-Montamat S, Pérol D, Blay JY.","BMC Cancer. 2018 Jun 8;18(1):646. doi: 10.1186/s12885-018-4544-x.","Giraudet AL","BMC Cancer","2018","2018/06/10","PMC5994021","","10.1186/s12885-018-4544-x"
"29863955","Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group.","N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.","Socinski MA","N Engl J Med","2018","2018/06/05","","","10.1056/NEJMoa1716948"
"29902988","Additional hepatic (166)Ho-radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)","Braat AJAT, Kwekkeboom DJ, Kam BLR, Teunissen JJM, de Herder WW, Dreijerink KMA, van Rooij R, Krijger GC, de Jong HWAM, van den Bosch MAAJ, Lam MGEH.","BMC Gastroenterol. 2018 Jun 15;18(1):84. doi: 10.1186/s12876-018-0817-8.","Braat AJAT","BMC Gastroenterol","2018","2018/06/16","PMC6003090","","10.1186/s12876-018-0817-8"
"29924955","Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss","Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA.","N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109.","Brock PR","N Engl J Med","2018","2018/06/21","PMC6117111","NIHMS980032","10.1056/NEJMoa1801109"
"29222911","Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K.","Hepatology. 2018 Jul;68(1):361-371. doi: 10.1002/hep.29724.","Younossi ZM","Hepatology","2018","2017/12/10","PMC6508084","NIHMS1027524","10.1002/hep.29724"
"29470615","Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients","Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A.","Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1233-1241. doi: 10.1007/s00259-018-3964-9. Epub 2018 Feb 22.","Stokke C","Eur J Nucl Med Mol Imaging","2018","2018/02/23","PMC5953993","","10.1007/s00259-018-3964-9"
"29498924","SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma","Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group.","J Clin Oncol. 2018 Jul 1;36(19):1913-1921. doi: 10.1200/JCO.2017.76.0892. Epub 2018 Mar 2.","Chow PKH","J Clin Oncol","2018","2018/03/03","","","10.1200/JCO.2017.76.0892"
"29505843","The role of molecular enrichment on future therapies in hepatocellular carcinoma","Nault JC, Galle PR, Marquardt JU.","J Hepatol. 2018 Jul;69(1):237-247. doi: 10.1016/j.jhep.2018.02.016. Epub 2018 Mar 2.","Nault JC","J Hepatol","2018","2018/03/06","","","10.1016/j.jhep.2018.02.016"
"29567081","Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial","Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH.","Gastroenterology. 2018 Jul;155(1):29-32. doi: 10.1053/j.gastro.2018.03.029. Epub 2018 Mar 20.","Beatty GL","Gastroenterology","2018","2018/03/24","PMC6035088","NIHMS952785","10.1053/j.gastro.2018.03.029"
"29675772","Phase I/II Study of Radiofrequency Ablation for Painful Bone Metastases: Japan Interventional Radiology in Oncology Study Group 0208","Tanigawa N, Arai Y, Yamakado K, Aramaki T, Inaba Y, Kanazawa S, Matsui O, Miyazaki M, Kodama Y, Anai H, Hamanaka A.","Cardiovasc Intervent Radiol. 2018 Jul;41(7):1043-1048. doi: 10.1007/s00270-018-1944-x. Epub 2018 Apr 12.","Tanigawa N","Cardiovasc Intervent Radiol","2018","2018/04/21","","","10.1007/s00270-018-1944-x"
"29700205","Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer","Cotogno PM, Ranasinghe LK, Ledet EM, Lewis BE, Sartor O.","Oncologist. 2018 Jul;23(7):791-797. doi: 10.1634/theoncologist.2017-0564. Epub 2018 Apr 26.","Cotogno PM","Oncologist","2018","2018/04/28","PMC6058331","","10.1634/theoncologist.2017-0564"
"29714501","Automatic spectral imaging protocol and iterative reconstruction for radiation dose reduction in typical hepatic hemangioma computed tomography with reduced iodine load: a preliminary study","Li W, Li A, Wang B, Niu X, Cao X, Wang X, Shi H.","Br J Radiol. 2018 Jul;91(1087):20170978. doi: 10.1259/bjr.20170978. Epub 2018 May 17.","Li W","Br J Radiol","2018","2018/05/02","PMC6221781","","10.1259/bjr.20170978"
"29718092","Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.","Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155.","Hortobagyi GN","Ann Oncol","2018","2018/05/03","","","10.1093/annonc/mdy155"
"29720733","Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial","Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.","Leukemia. 2018 Jul;32(7):1621-1630. doi: 10.1038/s41375-018-0129-6. Epub 2018 Apr 17.","Paschka P","Leukemia","2018","2018/05/04","","","10.1038/s41375-018-0129-6"
"29743140","A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis","Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA.","Gynecol Oncol. 2018 Jul;150(1):23-30. doi: 10.1016/j.ygyno.2018.05.001. Epub 2018 May 6.","Tempfer CB","Gynecol Oncol","2018","2018/05/11","","","10.1016/j.ygyno.2018.05.001"
"29752139","Intraprocedural Parenchymal Blood Volume Is a Predictor of Treatment Response for Chemoembolization in Hepatocellular Carcinoma: Results of a Prospective Study","de Korompay N, Alshammari M, Klass D, Chou FY, Chung J, Ho S, Liu DM.","J Vasc Interv Radiol. 2018 Jul;29(7):928-935. doi: 10.1016/j.jvir.2018.01.783. Epub 2018 May 8.","de Korompay N","J Vasc Interv Radiol","2018","2018/05/13","","","10.1016/j.jvir.2018.01.783"
"29762149","Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer","Polastro L, El Hachem G, Hendlisz A.","Curr Opin Oncol. 2018 Jul;30(4):269-275. doi: 10.1097/CCO.0000000000000455.","Polastro L","Curr Opin Oncol","2018","2018/05/16","","","10.1097/CCO.0000000000000455"
"29783126","Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond","Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR.","Cancer Treat Rev. 2018 Jul;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. Epub 2018 May 26.","Raoul JL","Cancer Treat Rev","2018","2018/05/22","","","10.1016/j.ctrv.2018.05.006"
"29808014","Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study","Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX.","Br J Cancer. 2018 Jul;119(1):19-26. doi: 10.1038/s41416-018-0103-0. Epub 2018 May 29.","Chau I","Br J Cancer","2018","2018/05/30","PMC6035236","","10.1038/s41416-018-0103-0"
"29875066","Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators.","Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.","Zhu AX","Lancet Oncol","2018","2018/06/08","","","10.1016/S1470-2045(18)30351-6"
"29884593","Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, Shao ZH, Ren HY, Hu JD, Xu KL, Wang JW, Song YP, Fang MY, Li J, Yan XY, Huang XJ.","Lancet Oncol. 2018 Jul;19(7):871-879. doi: 10.1016/S1470-2045(18)30295-X. Epub 2018 Jun 5.","Zhu HH","Lancet Oncol","2018","2018/06/10","","","10.1016/S1470-2045(18)30295-X"
"29943375","Regorafenib: A Review in Metastatic Colorectal Cancer","Dhillon S.","Drugs. 2018 Jul;78(11):1133-1144. doi: 10.1007/s40265-018-0938-y.","Dhillon S","Drugs","2018","2018/06/27","","","10.1007/s40265-018-0938-y"
"29972759","Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK.","N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.","Abou-Alfa GK","N Engl J Med","2018","2018/07/05","PMC7523244","NIHMS1623777","10.1056/NEJMoa1717002"
"29990497","Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer","Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzulli A, Trusolino L, Siena S, Marsoni S, Bardelli A.","Cancer Cell. 2018 Jul 9;34(1):148-162.e7. doi: 10.1016/j.ccell.2018.06.004.","Siravegna G","Cancer Cell","2018","2018/07/11","","","10.1016/j.ccell.2018.06.004"
"29346573","The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia","Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S.","J Natl Cancer Inst. 2018 Aug 1;110(8):888-894. doi: 10.1093/jnci/djx288.","Overman MJ","J Natl Cancer Inst","2018","2018/01/19","","","10.1093/jnci/djx288"
"29398432","Dual-phase Cone-beam CT-based Navigation Imaging Significantly Enhances Tumor Detectability and Aids Superselective Transarterial Chemoembolization of Liver Cancer","Yao X, Yan D, Jiang X, Li X, Zeng H, Liu D, Li H.","Acad Radiol. 2018 Aug;25(8):1031-1037. doi: 10.1016/j.acra.2017.12.022. Epub 2018 Feb 15.","Yao X","Acad Radiol","2018","2018/02/06","","","10.1016/j.acra.2017.12.022"
"29440181","A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER(+)/HER2(-) Advanced Breast Cancer","Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, Klinowska T, Lindemann JPO, Morgan SR, Schiavon G, Weir HM, Im SA.","Clin Cancer Res. 2018 Aug 1;24(15):3510-3518. doi: 10.1158/1078-0432.CCR-17-3102. Epub 2018 Feb 13.","Hamilton EP","Clin Cancer Res","2018","2018/02/15","","","10.1158/1078-0432.CCR-17-3102"
"29462005","Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial","Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, Oh DY, Chie EK, Lee JM, Heo JS, Park JO, Lim DH, Kim SH, Park SJ, Lee WJ, Koh YH, Park JS, Yoon DS, Lee IJ, Choi SH.","Ann Surg. 2018 Aug;268(2):215-222. doi: 10.1097/SLA.0000000000002705.","Jang JY","Ann Surg","2018","2018/02/21","","","10.1097/SLA.0000000000002705"
"29704513","Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial","Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J.","J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.","Finn RS","J Hepatol","2018","2018/04/29","","","10.1016/j.jhep.2018.04.010"
"29900755","Exploring the role of oncolytic viruses in hepatobiliary cancers","Tenneti P, Borad MJ, Babiker HM.","Immunotherapy. 2018 Aug;10(11):971-986. doi: 10.2217/imt-2018-0048. Epub 2018 Jun 14.","Tenneti P","Immunotherapy","2018","2018/06/15","","","10.2217/imt-2018-0048"
"29905898","Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors","Weekes CD, Rosen LS, Capasso A, Wong KM, Ye W, Anderson M, McCall B, Fredrickson J, Wakshull E, Eppler S, Shon-Nguyen Q, Desai R, Huseni M, Hegde PS, Pourmohamad T, Rhee I, Bessudo A.","Cancer Chemother Pharmacol. 2018 Aug;82(2):339-351. doi: 10.1007/s00280-018-3622-8. Epub 2018 Jun 15.","Weekes CD","Cancer Chemother Pharmacol","2018","2018/06/16","","","10.1007/s00280-018-3622-8"
"29934260","Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study","Sato Y, Nishiofuku H, Yasumoto T, Nakatsuka A, Matsuo K, Kodama Y, Okubo H, Abo D, Takaki H, Inaba Y, Yamakado K.","J Vasc Interv Radiol. 2018 Aug;29(8):1061-1067. doi: 10.1016/j.jvir.2018.03.020. Epub 2018 Jun 20.","Sato Y","J Vasc Interv Radiol","2018","2018/06/24","","","10.1016/j.jvir.2018.03.020"
"29983345","Refametinib in RAS-mutated hepatocellular cancer","Das M.","Lancet Oncol. 2018 Aug;19(8):e389. doi: 10.1016/S1470-2045(18)30505-9. Epub 2018 Jul 5.","Das M","Lancet Oncol","2018","2018/07/10","","","10.1016/S1470-2045(18)30505-9"
"29988111","Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer","Knödler M, Körfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F.","Br J Cancer. 2018 Aug;119(3):296-302. doi: 10.1038/s41416-018-0150-6. Epub 2018 Jul 10.","Knödler M","Br J Cancer","2018","2018/07/11","PMC6070920","","10.1038/s41416-018-0150-6"
"30001990","Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial","Lyon PC, Gray MD, Mannaris C, Folkes LK, Stratford M, Campo L, Chung DYF, Scott S, Anderson M, Goldin R, Carlisle R, Wu F, Middleton MR, Gleeson FV, Coussios CC.","Lancet Oncol. 2018 Aug;19(8):1027-1039. doi: 10.1016/S1470-2045(18)30332-2. Epub 2018 Jul 11.","Lyon PC","Lancet Oncol","2018","2018/07/14","PMC6073884","","10.1016/S1470-2045(18)30332-2"
"30042075","Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial","He MK, Zou RH, Wei W, Shen JX, Zhao M, Zhang YF, Lin XJ, Zhang YJ, Guo RP, Shi M.","J Vasc Interv Radiol. 2018 Aug;29(8):1068-1077.e2. doi: 10.1016/j.jvir.2018.03.027. Epub 2018 Jul 2.","He MK","J Vasc Interv Radiol","2018","2018/07/26","","","10.1016/j.jvir.2018.03.027"
"30175147","Contrast-Enhanced Ultrasound in Residual Tumor of Hepatocellular Carcinoma following Transarterial Chemoembolization: Is It Helpful for Tumor Response?","Jiang T, Zhao Q, Huang M, Sun J, Tian G.","Biomed Res Int. 2018 Aug 2;2018:8632069. doi: 10.1155/2018/8632069. eCollection 2018.","Jiang T","Biomed Res Int","2018","2018/09/04","PMC6098931","","10.1155/2018/8632069"
"30081865","Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973)","Goéré D, Pignon JP, Gelli M, Elias D, Benhaim L, Deschamps F, Caramella C, Boige V, Ducreux M, de Baere T, Malka D.","BMC Cancer. 2018 Aug 6;18(1):787. doi: 10.1186/s12885-018-4697-7.","Goéré D","BMC Cancer","2018","2018/08/08","PMC6080555","","10.1186/s12885-018-4697-7"
"30159302","The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma","Abdel-Rahman O, Cheung WY.","Can J Gastroenterol Hepatol. 2018 Aug 7;2018:4763832. doi: 10.1155/2018/4763832. eCollection 2018.","Abdel-Rahman O","Can J Gastroenterol Hepatol","2018","2018/08/31","PMC6106970","","10.1155/2018/4763832"
"29716923","Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab","Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K.","Clin Cancer Res. 2018 Aug 15;24(16):3857-3866. doi: 10.1158/1078-0432.CCR-17-3451. Epub 2018 May 1.","Higgs BW","Clin Cancer Res","2018","2018/05/03","","","10.1158/1078-0432.CCR-17-3451"
"30111304","Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial","Puijk RS, Ruarus AH, Vroomen LGPH, van Tilborg AAJM, Scheffer HJ, Nielsen K, de Jong MC, de Vries JJJ, Zonderhuis BM, Eker HH, Kazemier G, Verheul H, van der Meijs BB, van Dam L, Sorgedrager N, Coupé VMH, van den Tol PMP, Meijerink MR; COLLISION Trial Group.","BMC Cancer. 2018 Aug 15;18(1):821. doi: 10.1186/s12885-018-4716-8.","Puijk RS","BMC Cancer","2018","2018/08/17","PMC6094448","","10.1186/s12885-018-4716-8"
"30111528","Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial","Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Kulik L, Master F, Salem R.","JMIR Res Protoc. 2018 Aug 15;7(8):e11234. doi: 10.2196/11234.","Chauhan N","JMIR Res Protoc","2018","2018/08/17","PMC6115595","","10.2196/11234"
"30139340","Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT)","Mohkam K, Rayar M, Adam JP, Muscari F, Rode A, Merle P, Pradat P, Bauler S, Delfour I, Chiche L, Ducerf C, Boudjema K, Lesurtel M, Laurent C, Mabrut JY.","BMC Cancer. 2018 Aug 23;18(1):844. doi: 10.1186/s12885-018-4667-0.","Mohkam K","BMC Cancer","2018","2018/08/25","PMC6108122","","10.1186/s12885-018-4667-0"
"29802888","Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC","Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N.","J Thorac Oncol. 2018 Sep;13(9):1363-1372. doi: 10.1016/j.jtho.2018.05.015. Epub 2018 May 23.","Gettinger S","J Thorac Oncol","2018","2018/05/27","","","10.1016/j.jtho.2018.05.015"
"29806062","Hepatocellular Carcinoma: Review of Targeted and Immune Therapies","da Motta Girardi D, Correa TS, Crosara Teixeira M, Dos Santos Fernandes G.","J Gastrointest Cancer. 2018 Sep;49(3):227-236. doi: 10.1007/s12029-018-0121-4.","da Motta Girardi D","J Gastrointest Cancer","2018","2018/05/29","","","10.1007/s12029-018-0121-4"
"29848570","Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases","McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK.","Clin Cancer Res. 2018 Sep 1;24(17):4081-4088. doi: 10.1158/1078-0432.CCR-17-3577. Epub 2018 May 30.","McKay RR","Clin Cancer Res","2018","2018/06/01","PMC6688176","NIHMS1535687","10.1158/1078-0432.CCR-17-3577"
"29850984","Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy","Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, Cristofanilli M, Gradishar WJ.","Breast Cancer Res Treat. 2018 Sep;171(2):371-381. doi: 10.1007/s10549-018-4792-0. Epub 2018 May 30.","Jain S","Breast Cancer Res Treat","2018","2018/06/01","","","10.1007/s10549-018-4792-0"
"29936065","Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group","Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.","Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.","Goey KKH","Eur J Cancer","2018","2018/06/25","","","10.1016/j.ejca.2018.05.010"
"29951694","A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat","Peer CJ, Hall OM, Sissung TM, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.","Cancer Chemother Pharmacol. 2018 Sep;82(3):565-570. doi: 10.1007/s00280-018-3631-7. Epub 2018 Jun 27.","Peer CJ","Cancer Chemother Pharmacol","2018","2018/06/29","PMC6410699","NIHMS1008777","10.1007/s00280-018-3631-7"
"29971467","A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies","Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK.","Cancer Chemother Pharmacol. 2018 Sep;82(3):429-440. doi: 10.1007/s00280-018-3635-3. Epub 2018 Jul 3.","Harding JJ","Cancer Chemother Pharmacol","2018","2018/07/05","PMC6850802","NIHMS1050078","10.1007/s00280-018-3635-3"
"30010751","Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study","Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G.","Ann Oncol. 2018 Sep 1;29(9):1955-1963. doi: 10.1093/annonc/mdy241.","Van Cutsem E","Ann Oncol","2018","2018/07/17","PMC6158765","","10.1093/annonc/mdy241"
"30044042","MicroRNA-194 protects against chronic hepatitis B-related liver damage by promoting hepatocyte growth via ACVR2B","Gao X, Zhao P, Hu J, Zhu H, Zhang J, Zhou Z, Zhao J, Tang F.","J Cell Mol Med. 2018 Sep;22(9):4534-4544. doi: 10.1111/jcmm.13714. Epub 2018 Jul 25.","Gao X","J Cell Mol Med","2018","2018/07/26","PMC6111826","","10.1111/jcmm.13714"
"30249900","A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32)","Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S.","J Cancer Res Ther. 2018 Sep;14(Supplement):S761-S766. doi: 10.4103/0973-1482.179188.","Kusano M","J Cancer Res Ther","2018","2018/09/26","","","10.4103/0973-1482.179188"
"30049811","CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL.","Blood. 2018 Sep 6;132(10):1013-1021. doi: 10.1182/blood-2018-01-827246. Epub 2018 Jul 26.","Straus DJ","Blood","2018","2018/07/28","PMC6128083","","10.1182/blood-2018-01-827246"
"30283461","Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report","Kjeldsen JW, Iversen TZ, Engell-Noerregaard L, Mellemgaard A, Andersen MH, Svane IM.","Front Immunol. 2018 Sep 19;9:2145. doi: 10.3389/fimmu.2018.02145. eCollection 2018.","Kjeldsen JW","Front Immunol","2018","2018/10/05","PMC6157336","","10.3389/fimmu.2018.02145"
"30199249","Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N(2)-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N(8)-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722)","Woodward HL, Innocenti P, Cheung KJ, Hayes A, Roberts J, Henley AT, Faisal A, Mak GW, Box G, Westwood IM, Cronin N, Carter M, Valenti M, De Haven Brandon A, O'Fee L, Saville H, Schmitt J, Burke R, Broccatelli F, van Montfort RLM, Raynaud FI, Eccles SA, Linardopoulos S, Blagg J, Hoelder S.","J Med Chem. 2018 Sep 27;61(18):8226-8240. doi: 10.1021/acs.jmedchem.8b00690. Epub 2018 Sep 10.","Woodward HL","J Med Chem","2018","2018/09/11","PMC6166229","","10.1021/acs.jmedchem.8b00690"
"30271080","Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?","Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A.","World J Gastroenterol. 2018 Sep 28;24(36):4152-4163. doi: 10.3748/wjg.v24.i36.4152.","Marisi G","World J Gastroenterol","2018","2018/10/02","PMC6158485","","10.3748/wjg.v24.i36.4152"
"29334610","Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)","Choi YJ, Kim HS, Park SH, Kim BS, Kim KH, Lee HJ, Song HS, Shin DY, Lee HY, Kim HG, Lee KH, Lee JL, Park KH.","Cancer Res Treat. 2018 Oct;50(4):1252-1259. doi: 10.4143/crt.2017.438. Epub 2018 Jan 2.","Choi YJ","Cancer Res Treat","2018","2018/01/16","PMC6192917","","10.4143/crt.2017.438"
"29950351","Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma","Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM.","Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. doi: 10.1158/1078-0432.CCR-17-3588. Epub 2018 Jun 27.","Lim HY","Clin Cancer Res","2018","2018/06/29","","","10.1158/1078-0432.CCR-17-3588"
"30019318","Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study","Udar N, Lofton-Day C, Dong J, Vavrek D, Jung AS, Meier K, Iyer A, Slaughter R, Gutekunst K, Bach BA, Peeters M, Douillard JY.","J Cancer Res Clin Oncol. 2018 Oct;144(10):2001-2010. doi: 10.1007/s00432-018-2688-3. Epub 2018 Jul 17.","Udar N","J Cancer Res Clin Oncol","2018","2018/07/19","PMC6153611","","10.1007/s00432-018-2688-3"
"30398482","An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib","Ielasi L, Sansone V, Granito A, Benevento F, De Lorenzo S, Tovoli F.","Drugs Today (Barc). 2018 Oct;54(10):615-627. doi: 10.1358/dot.2018.54.10.2880176.","Ielasi L","Drugs Today (Barc)","2018","2018/11/07","","","10.1358/dot.2018.54.10.2880176"
"30291297","A new pharmacokinetic model for (90)Y-ibritumomab tiuxetan based on 3-dimensional dosimetry","Morschhauser F, Dekyndt B, Baillet C, Barthélémy C, Malek E, Fulcrand J, Bigot P, Huglo D, Décaudin B, Simon N, Odou P.","Sci Rep. 2018 Oct 5;8(1):14860. doi: 10.1038/s41598-018-33160-0.","Morschhauser F","Sci Rep","2018","2018/10/07","PMC6173718","","10.1038/s41598-018-33160-0"
"30305149","Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety","Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, Lin XJ, Xu L, Shi M, Zheng L, Chen MS, Guo RP.","Cancer Commun (Lond). 2018 Oct 10;38(1):61. doi: 10.1186/s40880-018-0331-y.","Wei W","Cancer Commun (Lond)","2018","2018/10/12","PMC6235393","","10.1186/s40880-018-0331-y"
"30310047","Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study","Lee EC, Kim SH, Park SJ.","Ann Transplant. 2018 Oct 12;23:713-720. doi: 10.12659/AOT.910618.","Lee EC","Ann Transplant","2018","2018/10/13","PMC6248274","","10.12659/AOT.910618"
"29736851","Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases","Winter KS, Hofmann FO, Thierfelder KM, Holch JW, Hesse N, Baumann AB, Modest DP, Stintzing S, Heinemann V, Ricke J, Sommer WH, D'Anastasi M.","Eur Radiol. 2018 Nov;28(11):4839-4848. doi: 10.1007/s00330-018-5424-0. Epub 2018 May 7.","Winter KS","Eur Radiol","2018","2018/05/09","","","10.1007/s00330-018-5424-0"
"29802174","Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial","Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZJ, Cai JQ, Ding YT, Li LQ, Zhang YB, Zheng QC, Xu GL, Li B, Zhou WP, Cai SW, Wang XY, Wen H, Peng XY, Zhang XW, Dai CL, Bie P, Xing BC, Fu ZR, Liu LX, Mu Y, Zhang L, Zhang QS, Jiang B, Qian HX, Wang YJ, Liu JF, Qin XH, Li Q, Yin P, Zhang ZW, Chen XP.","Gut. 2018 Nov;67(11):2006-2016. doi: 10.1136/gutjnl-2018-315983. Epub 2018 May 25.","Chen Q","Gut","2018","2018/05/27","","","10.1136/gutjnl-2018-315983"
"30033575","Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study","Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B.","Am J Hematol. 2018 Nov;93(11):1311-1317. doi: 10.1002/ajh.25228. Epub 2018 Aug 31.","Flinn IW","Am J Hematol","2018","2018/07/24","PMC6220789","","10.1002/ajh.25228"
"30128737","Increased Tim-3(+) T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients","Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, Mori M, Satoh T, Doki Y, Wada H.","Cancer Immunol Immunother. 2018 Nov;67(11):1673-1683. doi: 10.1007/s00262-018-2225-x. Epub 2018 Aug 20.","Kato R","Cancer Immunol Immunother","2018","2018/08/22","PMC11028199","","10.1007/s00262-018-2225-x"
"30182147","A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement","Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM.","Cancer Chemother Pharmacol. 2018 Nov;82(5):877-885. doi: 10.1007/s00280-018-3680-y. Epub 2018 Sep 4.","Fountzilas E","Cancer Chemother Pharmacol","2018","2018/09/06","","","10.1007/s00280-018-3680-y"
"30196427","First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs","Giuliani J, Bonetti A.","Int J Colorectal Dis. 2018 Nov;33(11):1505-1516. doi: 10.1007/s00384-018-3158-8. Epub 2018 Sep 8.","Giuliani J","Int J Colorectal Dis","2018","2018/09/10","","","10.1007/s00384-018-3158-8"
"30343254","FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial","Bachet JB, Lucidarme O, Levache CB, Barbier E, Raoul JL, Lecomte T, Desauw C, Brocard F, Pernot S, Breysacher G, Lagasse JP, Di Fiore F, Etienne PL, Dupuis OJM, Aleba A, Lepage C, Taieb J; for FFCD 1102 investigators.","Eur J Cancer. 2018 Nov;104:108-116. doi: 10.1016/j.ejca.2018.09.006. Epub 2018 Oct 18.","Bachet JB","Eur J Cancer","2018","2018/10/22","","","10.1016/j.ejca.2018.09.006"
"30361170","Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD.","Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22.","Hodi FS","Lancet Oncol","2018","2018/10/27","","","10.1016/S1470-2045(18)30700-9"
"30486767","Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer","Spindler KG, Demuth C, Sorensen BS, Johansen JS, Nielsen D, Pallisgaard N, Hoegdall E, Pfeiffer P, Vittrup Jensen B.","Tumour Biol. 2018 Nov;40(11):1010428318811207. doi: 10.1177/1010428318811207.","Spindler KG","Tumour Biol","2018","2018/11/30","","","10.1177/1010428318811207"
"30453910","Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)","von Bubnoff N, Ihorst G, Grishina O, Röthling N, Bertz H, Duyster J, Finke J, Zeiser R.","BMC Cancer. 2018 Nov 19;18(1):1132. doi: 10.1186/s12885-018-5045-7.","von Bubnoff N","BMC Cancer","2018","2018/11/21","PMC6245867","","10.1186/s12885-018-5045-7"
"30166329","Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma","Kobe C, Goergen H, Baues C, Kuhnert G, Voltin CA, Zijlstra J, Hoekstra O, Mettler J, Drzezga A, Engert A, Borchmann P, Dietlein M.","Blood. 2018 Nov 22;132(21):2273-2279. doi: 10.1182/blood-2018-05-852129. Epub 2018 Aug 30.","Kobe C","Blood","2018","2018/09/01","","","10.1182/blood-2018-05-852129"
"30477560","Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up","Scorsetti M, Comito T, Clerici E, Franzese C, Tozzi A, Iftode C, Di Brina L, Navarria P, Mancosu P, Reggiori G, Fogliata A, Tomatis S, Torzilli G, Cozzi L.","Radiat Oncol. 2018 Nov 26;13(1):234. doi: 10.1186/s13014-018-1185-9.","Scorsetti M","Radiat Oncol","2018","2018/11/28","PMC6258482","","10.1186/s13014-018-1185-9"
"30345906","Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators.","N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.","Schmid P","N Engl J Med","2018","2018/10/23","","","10.1056/NEJMoa1809615"
"29882070","CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial","Froelich MF, Heinemann V, Sommer WH, Holch JW, Schoeppe F, Hesse N, Baumann AB, Kunz WG, Reiser MF, Ricke J, D'Anastasi M, Stintzing S, Modest DP, Kazmierczak PM, Hofmann FO.","Eur Radiol. 2018 Dec;28(12):5284-5292. doi: 10.1007/s00330-018-5454-7. Epub 2018 Jun 7.","Froelich MF","Eur Radiol","2018","2018/06/09","","","10.1007/s00330-018-5454-7"
"29980490","AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer","Pentheroudakis G, Kotoula V, Koliou GA, Karavasilis V, Samantas E, Aravantinos G, Kalogeropoulou L, Souglakos I, Kentepozidis N, Koumakis G, Sgouros J, Zarkavelis G, Efstratiou I, Laschos K, Petraki C, Tikas I, Poulios C, Voutsina A, Goudopoulou A, Bafaloukos D, Vrettou E, Kalogera-Fountzila A, Pectasides D, Fountzilas G.","Clin Colorectal Cancer. 2018 Dec;17(4):e631-e637. doi: 10.1016/j.clcc.2018.06.003. Epub 2018 Jun 15.","Pentheroudakis G","Clin Colorectal Cancer","2018","2018/07/08","","","10.1016/j.clcc.2018.06.003"
"30072278","Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer","Lee JJ, Chu E.","Clin Colorectal Cancer. 2018 Dec;17(4):258-273. doi: 10.1016/j.clcc.2018.06.004. Epub 2018 Jun 21.","Lee JJ","Clin Colorectal Cancer","2018","2018/08/04","PMC6612427","NIHMS1013443","10.1016/j.clcc.2018.06.004"
"30144431","Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis","Moreau R, Elkrief L, Bureau C, Perarnau JM, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d'Alteroche L, Di Martino V, Ripault MP, Pauwels A, Grangé JD, Carbonell N, Bronowicki JP, Payancé A, Rautou PE, Valla D, Gault N, Lebrec D; NORFLOCIR Trial Investigators.","Gastroenterology. 2018 Dec;155(6):1816-1827.e9. doi: 10.1053/j.gastro.2018.08.026. Epub 2018 Aug 23.","Moreau R","Gastroenterology","2018","2018/08/26","","","10.1053/j.gastro.2018.08.026"
"30145148","Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial","Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, Reinacher-Schick A.","Clin Colorectal Cancer. 2018 Dec;17(4):e733-e739. doi: 10.1016/j.clcc.2018.07.007. Epub 2018 Jul 25.","Noepel-Duennebacke S","Clin Colorectal Cancer","2018","2018/08/27","","","10.1016/j.clcc.2018.07.007"
"30178032","Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial","Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, Munshi HG, Benson AB 3rd, O'Dwyer PJ.","JAMA Oncol. 2018 Dec 1;4(12):1707-1712. doi: 10.1001/jamaoncol.2018.3277.","Sahai V","JAMA Oncol","2018","2018/09/05","PMC6440720","","10.1001/jamaoncol.2018.3277"
"30198057","Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients","Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, Hidaka H, Yeon JE, Mizukoshi E, Morimoto M, Lee MA, Yasui K, Kawaguchi Y, Heo J, Morita S, Kim TY, Furuse J, Katayama K, Aramaki T, Hara R, Kimura T, Nakamura O, Kudo M.","Invest New Drugs. 2018 Dec;36(6):1072-1084. doi: 10.1007/s10637-018-0658-x. Epub 2018 Sep 10.","Tak WY","Invest New Drugs","2018","2018/09/11","","","10.1007/s10637-018-0658-x"
"30211813","Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma","Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS.","Melanoma Res. 2018 Dec;28(6):605-610. doi: 10.1097/CMR.0000000000000509.","Shah S","Melanoma Res","2018","2018/09/14","","","10.1097/CMR.0000000000000509"
"30217745","Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma","Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, Ursic-Bedoya J, Pageaux GP, Mariano-Goulart D, Aho S, Guiu B.","J Vasc Interv Radiol. 2018 Dec;29(12):1662-1670.e4. doi: 10.1016/j.jvir.2018.07.006. Epub 2018 Sep 11.","Allimant C","J Vasc Interv Radiol","2018","2018/09/16","","","10.1016/j.jvir.2018.07.006"
"30228027","Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States","Cho SK, Hay JW, Barzi A.","Clin Colorectal Cancer. 2018 Dec;17(4):e751-e761. doi: 10.1016/j.clcc.2018.08.003. Epub 2018 Aug 24.","Cho SK","Clin Colorectal Cancer","2018","2018/09/20","","","10.1016/j.clcc.2018.08.003"
"30264918","Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease","Michelson AD, Smolensky Koganov E, Forde EE, Carmichael SL, Frelinger AL 3rd.","J Thromb Haemost. 2018 Dec;16(12):2515-2519. doi: 10.1111/jth.14295. Epub 2018 Oct 15.","Michelson AD","J Thromb Haemost","2018","2018/09/29","","","10.1111/jth.14295"
"30278776","Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations","Moyer GC, Bannow BS, Thornburg C, Rosovsky R, Wang TF, Woller S, Thornhill D, Kreuziger LB.","Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):209S-216S. doi: 10.1177/1076029618804080. Epub 2018 Oct 2.","Moyer GC","Clin Appl Thromb Hemost","2018","2018/10/04","PMC6714851","","10.1177/1076029618804080"
"30304963","Nivolumab for the treatment of hepatocellular carcinoma","Finkelmeier F, Waidmann O, Trojan J.","Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22.","Finkelmeier F","Expert Rev Anticancer Ther","2018","2018/10/12","","","10.1080/14737140.2018.1535315"
"30337148","Irinotecan-Eluting 75-150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study","Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, Georgiades C.","J Vasc Interv Radiol. 2018 Dec;29(12):1646-1653.e5. doi: 10.1016/j.jvir.2018.08.010. Epub 2018 Oct 15.","Fereydooni A","J Vasc Interv Radiol","2018","2018/10/20","","","10.1016/j.jvir.2018.08.010"
"30394521","A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315)","Geller JI, Fox E, Turpin BK, Goldstein SL, Liu X, Minard CG, Kudgus RA, Reid JM, Berg SL, Weigel BJ.","Cancer. 2018 Dec 1;124(23):4548-4555. doi: 10.1002/cncr.31725. Epub 2018 Nov 5.","Geller JI","Cancer","2018","2018/11/06","PMC6289772","NIHMS983574","10.1002/cncr.31725"
"30447539","Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study","Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, Takatsuka S, Koga H, Wada N, Minami H, Hatsumichi M, Asada S, Namba Y, Yamazaki N.","Eur J Cancer. 2018 Dec;105:114-126. doi: 10.1016/j.ejca.2018.09.025. Epub 2018 Nov 15.","Namikawa K","Eur J Cancer","2018","2018/11/18","","","10.1016/j.ejca.2018.09.025"
"30463680","Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study","Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, Gebski VJ, Desai J, Segelov E.","Clin Colorectal Cancer. 2018 Dec;17(4):313-319. doi: 10.1016/j.clcc.2018.06.002. Epub 2018 Jun 8.","Shapiro JD","Clin Colorectal Cancer","2018","2018/11/23","","","10.1016/j.clcc.2018.06.002"
"30527191","A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations","Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, Kuwako T, Naruse I, Nemoto K, Uchino J, Morozumi N, Ishihara S, Minato K, Hisada T.","Lung Cancer. 2018 Dec;126:41-47. doi: 10.1016/j.lungcan.2018.10.014. Epub 2018 Oct 13.","Imai H","Lung Cancer","2018","2018/12/12","","","10.1016/j.lungcan.2018.10.014"
"30595804","Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer","Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S; Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer.","World J Gastrointest Oncol. 2018 Dec 15;10(12):505-515. doi: 10.4251/wjgo.v10.i12.505.","Chung MJ","World J Gastrointest Oncol","2018","2019/01/01","PMC6304301","","10.4251/wjgo.v10.i12.505"
"30131387","Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma","Blakeley JO, Grossman SA, Chi AS, Mikkelsen T, Rosenfeld MR, Ahluwalia MS, Nabors LB, Eichler A, Ribas IG, Desideri S, Ye X; Adult Brain Tumor Consortium.","Clin Cancer Res. 2019 Jan 1;25(1):73-79. doi: 10.1158/1078-0432.CCR-18-0110. Epub 2018 Aug 21.","Blakeley JO","Clin Cancer Res","2019","2018/08/23","PMC6367923","NIHMS1504503","10.1158/1078-0432.CCR-18-0110"
"30131389","First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors","Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL.","Clin Cancer Res. 2019 Jan 1;25(1):99-109. doi: 10.1158/1078-0432.CCR-18-1512. Epub 2018 Aug 21.","Strauss J","Clin Cancer Res","2019","2018/08/23","PMC6320276","NIHMS1504509","10.1158/1078-0432.CCR-18-1512"
"30190369","A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma","Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX.","Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6.","Goyal L","Clin Cancer Res","2019","2018/09/08","PMC6320284","NIHMS1506046","10.1158/1078-0432.CCR-18-0847"
"30203225","Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial","Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, Yatsuhashi H, Takikawa Y, Kanda T, Sakamoto M, Tamori A, Mita E, Chayama K, Zhang G, De-Oertel S, Dvory-Sobol H, Matsuda T, Stamm LM, Brainard DM, Tanaka Y, Kurosaki M.","J Gastroenterol. 2019 Jan;54(1):87-95. doi: 10.1007/s00535-018-1503-x. Epub 2018 Sep 10.","Takehara T","J Gastroenterol","2019","2018/09/12","PMC6314981","","10.1007/s00535-018-1503-x"
"30232224","A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers","Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.","Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.","Beltran H","Clin Cancer Res","2019","2018/09/21","PMC6320304","NIHMS1507722","10.1158/1078-0432.CCR-18-1912"
"30240280","Improving image quality with model-based iterative reconstruction at quarter of nominal dose in upper abdominal CT","Zhang X, Chen J, Yu N, Ren Z, Tian Q, Tian X, He T, Guo C.","Br J Radiol. 2019 Jan;92(1093):20180137. doi: 10.1259/bjr.20180137. Epub 2018 Sep 21.","Zhang X","Br J Radiol","2019","2018/09/22","PMC6435090","","10.1259/bjr.20180137"
"30368584","Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers","Rioux N, Kim A, Nix D, Bowser T, Warmuth M, Smith PG, Schindler J.","Cancer Chemother Pharmacol. 2019 Jan;83(1):91-96. doi: 10.1007/s00280-018-3708-3. Epub 2018 Oct 27.","Rioux N","Cancer Chemother Pharmacol","2019","2018/10/29","","","10.1007/s00280-018-3708-3"
"30417485","Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study","Makishima H, Yasuda S, Isozaki Y, Kasuya G, Okada N, Miyazaki M, Mohamad O, Matsufuji N, Yamada S, Tsuji H, Kamada T; Liver Cancer Working Group.","Cancer Sci. 2019 Jan;110(1):303-309. doi: 10.1111/cas.13872. Epub 2018 Dec 12.","Makishima H","Cancer Sci","2019","2018/11/13","PMC6317930","","10.1111/cas.13872"
"30477937","Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group.","Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3. Epub 2018 Nov 23.","Duffaud F","Lancet Oncol","2019","2018/11/28","","","10.1016/S1470-2045(18)30742-3"
"30579113","Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase","Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F.","Eur J Cancer. 2019 Jan;107:164-174. doi: 10.1016/j.ejca.2018.11.016. Epub 2018 Dec 19.","Schwartz S","Eur J Cancer","2019","2018/12/23","","","10.1016/j.ejca.2018.11.016"
"30852467","Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib","Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, Borghaei H, West J, Kirpalani P, Morris D, Lee C, Pecot CV, Zagar T, Stinchcombe T, Pennell N.","Cancer Treat Res Commun. 2019;19:100126. doi: 10.1016/j.ctarc.2019.100126. Epub 2019 Feb 26.","Weiss J","Cancer Treat Res Commun","2019","2019/03/11","","","10.1016/j.ctarc.2019.100126"
"30857437","Dose-Related Modulatory Effects of Polymeric Black Tea Polyphenols (PBPs) on Initiation and Promotion Events in B(a)P and NNK-Induced Lung Carcinogenesis","Hudlikar RR, Pai V, Kumar R, Thorat RA, Kannan S, Ingle AD, Maru GB, Mahimkar MB.","Nutr Cancer. 2019;71(3):508-523. doi: 10.1080/01635581.2019.1578389. Epub 2019 Mar 11.","Hudlikar RR","Nutr Cancer","2019","2019/03/13","","","10.1080/01635581.2019.1578389"
"30999314","Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer","Larsen FO, Jensen BV, Nørgaard HH, Hermann HK, Larsen PN, Markussen A, Hogdall E, Nielsen D.","Oncology. 2019;96(6):299-308. doi: 10.1159/000499314. Epub 2019 Apr 18.","Larsen FO","Oncology","2019","2019/04/19","","","10.1159/000499314"
"31092758","[Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma]","Watanabe T, Koyama N.","Nihon Yakurigaku Zasshi. 2019;153(5):242-248. doi: 10.1254/fpj.153.242.","Watanabe T","Nihon Yakurigaku Zasshi","2019","2019/05/17","","","10.1254/fpj.153.242"
"31266008","Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials","Tiu C, Loh Z, Gan CL, Gan H, John T, Hawkes E.","Oncology. 2019;97(5):270-276. doi: 10.1159/000501211. Epub 2019 Jul 2.","Tiu C","Oncology","2019","2019/07/03","","","10.1159/000501211"
"31327798","Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma","Yao X, Wang L, Gao J.","Biosci Trends. 2019;13(3):282-283. doi: 10.5582/bst.2019.01161.","Yao X","Biosci Trends","2019","2019/07/23","","","10.5582/bst.2019.01161"
"31532397","Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta","Deterding K, Wedemeyer H.","AIDS Rev. 2019;21(3):126-134. doi: 10.24875/AIDSRev.19000080.","Deterding K","AIDS Rev","2019","2019/09/19","","","10.24875/AIDSRev.19000080"
"30616534","Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study","Tomita Y, Uemura H, Oya M, Shinohara N, Habuchi T, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Rini BI.","BMC Cancer. 2019 Jan 7;19(1):17. doi: 10.1186/s12885-018-5224-6.","Tomita Y","BMC Cancer","2019","2019/01/09","PMC6322336","","10.1186/s12885-018-5224-6"
"30341058","Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K.","Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.","Kusumoto S","Blood","2019","2018/10/21","PMC6337873","","10.1182/blood-2018-04-848044"
"30625052","Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer","Mariette C, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, D'Journo XB, Brigand C, Perniceni T, Carrère N, Mabrut JY, Msika S, Peschaud F, Prudhomme M, Bonnetain F, Piessen G; Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group.","N Engl J Med. 2019 Jan 10;380(2):152-162. doi: 10.1056/NEJMoa1805101.","Mariette C","N Engl J Med","2019","2019/01/10","","","10.1056/NEJMoa1805101"
"30327302","PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial","Voss MH, Chen D, Reising A, Marker M, Shi J, Xu J, Ostrovnaya I, Seshan VE, Redzematovic A, Chen YB, Patel P, Han X, Hsieh JJ, Hakimi AA, Motzer RJ.","Clin Cancer Res. 2019 Jan 15;25(2):506-514. doi: 10.1158/1078-0432.CCR-18-1833. Epub 2018 Oct 16.","Voss MH","Clin Cancer Res","2019","2018/10/18","","","10.1158/1078-0432.CCR-18-1833"
"30348638","Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study","Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, Wang Y, Yi X, Hu Z, Zou J, Wang Q.","Clin Cancer Res. 2019 Jan 15;25(2):515-523. doi: 10.1158/1078-0432.CCR-18-2484. Epub 2018 Oct 22.","Xu J","Clin Cancer Res","2019","2018/10/24","","","10.1158/1078-0432.CCR-18-2484"
"30669763","[Application of adaptie statistical iterative reconstruction technology combined with low tube voltage in three phase enhanced low dose liver scanning]","Jia GS, Li JP, Hu HY, Zhao CL, Jiang HJ.","Zhonghua Yi Xue Za Zhi. 2019 Jan 15;99(3):198-203. doi: 10.3760/cma.j.issn.0376-2491.2019.03.009.","Jia GS","Zhonghua Yi Xue Za Zhi","2019","2019/01/24","","","10.3760/cma.j.issn.0376-2491.2019.03.009"
"30664496","TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial","Chauhan N, Mulcahy MF, Salem R, Benson Iii AB, Boucher E, Bukovcan J, Cosgrove D, Laframboise C, Lewandowski RJ, Master F, El-Rayes B, Strosberg JR, Sze DY, Sharma RA.","JMIR Res Protoc. 2019 Jan 17;8(1):e11545. doi: 10.2196/11545.","Chauhan N","JMIR Res Protoc","2019","2019/01/22","PMC6354199","","10.2196/11545"
"30690953","[New Systemic Therapies for Advanced Hepatocellular Carcinoma]","Kim DY.","Korean J Gastroenterol. 2019 Jan 25;73(1):10-15. doi: 10.4166/kjg.2019.73.1.10.","Kim DY","Korean J Gastroenterol","2019","2019/01/29","","","10.4166/kjg.2019.73.1.10"
"29781056","Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors","Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.","Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21.","Lockhart AC","Invest New Drugs","2019","2018/05/22","PMC6510847","","10.1007/s10637-018-0610-0"
"29995286","A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma","Ikeda M, Morimoto M, Tajimi M, Inoue K, Benhadji KA, Lahn MMF, Sakai D.","Invest New Drugs. 2019 Feb;37(1):118-126. doi: 10.1007/s10637-018-0636-3. Epub 2018 Jul 11.","Ikeda M","Invest New Drugs","2019","2018/07/12","PMC6510840","","10.1007/s10637-018-0636-3"
"30105510","A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation","Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, Ochiai T, Fukuhara T, Kano T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M.","J Gastroenterol. 2019 Feb;54(2):171-181. doi: 10.1007/s00535-018-1499-2. Epub 2018 Aug 13.","Tateishi R","J Gastroenterol","2019","2018/08/15","PMC6349796","","10.1007/s00535-018-1499-2"
"30190299","Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study","Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, André T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A.","Oncologist. 2019 Feb;24(2):185-192. doi: 10.1634/theoncologist.2018-0072. Epub 2018 Sep 6.","Van Cutsem E","Oncologist","2019","2018/09/08","PMC6369948","","10.1634/theoncologist.2018-0072"
"30347469","Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies","von Tresckow B, Sayehli C, Aulitzky WE, Goebeler ME, Schwab M, Braz E, Krauss B, Krauss R, Hermann F, Bartz R, Engert A.","Eur J Haematol. 2019 Feb;102(2):163-173. doi: 10.1111/ejh.13188. Epub 2019 Jan 7.","von Tresckow B","Eur J Haematol","2019","2018/10/23","","","10.1111/ejh.13188"
"30352941","A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma","Abou-Alfa GK, Miksad RA, Tejani MA, Williamson S, Gutierrez ME, Olowokure OO, Sharma MR, El Dika I, Sherman ML, Pandya SS.","Oncologist. 2019 Feb;24(2):161-e70. doi: 10.1634/theoncologist.2018-0654. Epub 2018 Oct 23.","Abou-Alfa GK","Oncologist","2019","2018/10/25","PMC6369956","","10.1634/theoncologist.2018-0654"
"30406361","Phase I/IIa PET imaging study with (89)zirconium labeled anti-PSMA minibody for urological malignancies","Joraku A, Hatano K, Kawai K, Kandori S, Kojima T, Fukumitsu N, Isobe T, Mori Y, Sakata M, Hara T, Nasu K, Minami M, Iizumi Y, Nishiyama H.","Ann Nucl Med. 2019 Feb;33(2):119-127. doi: 10.1007/s12149-018-1312-6. Epub 2018 Nov 7.","Joraku A","Ann Nucl Med","2019","2018/11/09","","","10.1007/s12149-018-1312-6"
"30425003","Results of a Prospective Phase 2 Pilot Trial of (177)Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression","Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, Epstein R, Blanksby A, Horvath L, Guminski A, Mahon K, Gedye C, Yin C, Stricker P, Joshua AM.","Clin Genitourin Cancer. 2019 Feb;17(1):15-22. doi: 10.1016/j.clgc.2018.09.014. Epub 2018 Sep 27.","Emmett L","Clin Genitourin Cancer","2019","2018/11/15","","","10.1016/j.clgc.2018.09.014"
"30446785","A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors","Toyoda M, Watanabe K, Amagasaki T, Natsume K, Takeuchi H, Quadt C, Shirao K, Minami H.","Cancer Chemother Pharmacol. 2019 Feb;83(2):289-299. doi: 10.1007/s00280-018-3725-2. Epub 2018 Nov 16.","Toyoda M","Cancer Chemother Pharmacol","2019","2018/11/18","PMC6394493","","10.1007/s00280-018-3725-2"
"30449052","Transient liver toxicity as a result of the oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer","Miyake M, Nakai Y, Hori S, Morizawa Y, Hirao Y, Fujimoto K.","Int J Urol. 2019 Feb;26(2):315-317. doi: 10.1111/iju.13856. Epub 2018 Nov 18.","Miyake M","Int J Urol","2019","2018/11/19","","","10.1111/iju.13856"
"30455077","Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial","Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP, McVerry BJ, Ortiz LA, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD.","Lancet Respir Med. 2019 Feb;7(2):154-162. doi: 10.1016/S2213-2600(18)30418-1. Epub 2018 Nov 16.","Matthay MA","Lancet Respir Med","2019","2018/11/21","PMC7597675","NIHMS1639177","10.1016/S2213-2600(18)30418-1"
"30467591","Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(®)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors","Quartino AL, Li H, Kirschbrown WP, Mangat R, Wada DR, Garg A, Jin JY, Lum B.","Cancer Chemother Pharmacol. 2019 Feb;83(2):329-340. doi: 10.1007/s00280-018-3728-z. Epub 2018 Nov 22.","Quartino AL","Cancer Chemother Pharmacol","2019","2018/11/24","PMC6394489","","10.1007/s00280-018-3728-z"
"30488303","Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial","Mohnike K, Steffen IG, Seidensticker M, Hass P, Damm R, Peters N, Seidensticker R, Schütte K, Arend J, Bornschein J, Streitparth T, Wybranski C, Wieners G, Stübs P, Malfertheiner P, Pech M, Ricke J.","Cardiovasc Intervent Radiol. 2019 Feb;42(2):239-249. doi: 10.1007/s00270-018-2127-5. Epub 2018 Nov 28.","Mohnike K","Cardiovasc Intervent Radiol","2019","2018/11/30","","","10.1007/s00270-018-2127-5"
"30544058","Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer","Lindgaard SC, Brinch CM, Jensen BK, Nørgaard HH, Hermann KL, Theile S, Larsen FO, Jensen BV, Michelsen H, Nelausen KM, Holm VH, Ekblad L, Soerensen PG, Nielsen DL.","Breast. 2019 Feb;43:113-119. doi: 10.1016/j.breast.2018.12.002. Epub 2018 Dec 5.","Lindgaard SC","Breast","2019","2018/12/14","","","10.1016/j.breast.2018.12.002"
"30581069","Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study","Phelip JM, Edeline J, Blanc JF, Barbier E, Michel P, Bourgeois V, Neuzillet C, Malka D, Manfredi S, Desrame J; PRODIGE 38 Investigators.","Dig Liver Dis. 2019 Feb;51(2):318-320. doi: 10.1016/j.dld.2018.11.018. Epub 2018 Nov 28.","Phelip JM","Dig Liver Dis","2019","2018/12/25","","","10.1016/j.dld.2018.11.018"
"30592991","A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer","Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA.","Eur J Cancer. 2019 Feb;108:17-24. doi: 10.1016/j.ejca.2018.11.017. Epub 2018 Dec 25.","Bang YJ","Eur J Cancer","2019","2018/12/29","","","10.1016/j.ejca.2018.11.017"
"30648632","The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial","Bjarnason GA, Knox JJ, Kollmannsberger CK, Soulieres D, Ernst DS, Zalewski P, Canil CM, Winquist E, Hotte SJ, North SA, Heng DYC, Macfarlane RJ, Venner PM, Kapoor A, Hansen AR, Eigl BJ, Czaykowski P, Boyd B, Wang L, Basappa NS.","Eur J Cancer. 2019 Feb;108:69-77. doi: 10.1016/j.ejca.2018.12.006. Epub 2019 Jan 14.","Bjarnason GA","Eur J Cancer","2019","2019/01/17","","","10.1016/j.ejca.2018.12.006"
"30649748","Safety and Tolerability of c-MET Inhibitors in Cancer","Puccini A, Marín-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz HJ, Loupakis F, Battaglin F.","Drug Saf. 2019 Feb;42(2):211-233. doi: 10.1007/s40264-018-0780-x.","Puccini A","Drug Saf","2019","2019/01/17","PMC7491978","NIHMS1623870","10.1007/s40264-018-0780-x"
"30654298","NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT.","Eur J Cancer. 2019 Feb;108:78-87. doi: 10.1016/j.ejca.2018.12.007. Epub 2019 Jan 14.","Wang-Gillam A","Eur J Cancer","2019","2019/01/18","","","10.1016/j.ejca.2018.12.007"
"30658732","Endpoints and patient stratification in clinical trials for alcoholic hepatitis","Mathurin P, Thursz M.","J Hepatol. 2019 Feb;70(2):314-318. doi: 10.1016/j.jhep.2018.11.005.","Mathurin P","J Hepatol","2019","2019/01/20","","","10.1016/j.jhep.2018.11.005"
"30665869","Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.","Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.","Zhu AX","Lancet Oncol","2019","2019/01/23","","","10.1016/S1470-2045(18)30937-9"
"30767164","Cabozantinib: A Review in Advanced Hepatocellular Carcinoma","Deeks ED.","Target Oncol. 2019 Feb;14(1):107-113. doi: 10.1007/s11523-019-00622-y.","Deeks ED","Target Oncol","2019","2019/02/16","","","10.1007/s11523-019-00622-y"
"30819826","Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges","Liu X, Qin S.","Oncologist. 2019 Feb;24(Suppl 1):S3-S10. doi: 10.1634/theoncologist.2019-IO-S1-s01.","Liu X","Oncologist","2019","2019/03/02","PMC6394775","","10.1634/theoncologist.2019-IO-S1-s01"
"30668363","Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2)","von Hagens C, Walter-Sack I, Goeckenjan M, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Munzinger J, Edler L, Efferth T, Schneeweiss A, Strowitzki T.","Phytomedicine. 2019 Feb 15;54:140-148. doi: 10.1016/j.phymed.2018.09.178. Epub 2018 Sep 17.","von Hagens C","Phytomedicine","2019","2019/01/23","","","10.1016/j.phymed.2018.09.178"
"30809080","Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond","Kudo M.","World J Gastroenterol. 2019 Feb 21;25(7):789-807. doi: 10.3748/wjg.v25.i7.789.","Kudo M","World J Gastroenterol","2019","2019/02/28","PMC6385008","","10.3748/wjg.v25.i7.789"
"30813956","CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation","Shan QY, Hu HT, Feng ST, Peng ZP, Chen SL, Zhou Q, Li X, Xie XY, Lu MD, Wang W, Kuang M.","Cancer Imaging. 2019 Feb 27;19(1):11. doi: 10.1186/s40644-019-0197-5.","Shan QY","Cancer Imaging","2019","2019/03/01","PMC6391838","","10.1186/s40644-019-0197-5"
"30166639","Consuming glucose-sweetened, not fructose-sweetened, beverages increases fasting insulin in healthy humans","Kuzma JN, Cromer G, Hagman DK, Breymeyer KL, Roth CL, Foster-Schubert KE, Holte SE, Weigle DS, Kratz M.","Eur J Clin Nutr. 2019 Mar;73(3):487-490. doi: 10.1038/s41430-018-0297-5. Epub 2018 Aug 30.","Kuzma JN","Eur J Clin Nutr","2019","2018/09/01","PMC6395516","NIHMS1503646","10.1038/s41430-018-0297-5"
"30168613","Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation","Kisiel JB, Dukek BA, V S R Kanipakam R, Ghoz HM, Yab TC, Berger CK, Taylor WR, Foote PH, Giama NH, Onyirioha K, Abdallah MA, Burger KN, Slettedahl SW, Mahoney DW, Smyrk TC, Lewis JT, Giakoumopoulos M, Allawi HT, Lidgard GP, Roberts LR, Ahlquist DA.","Hepatology. 2019 Mar;69(3):1180-1192. doi: 10.1002/hep.30244. Epub 2019 Feb 5.","Kisiel JB","Hepatology","2019","2018/09/01","PMC6429916","NIHMS1008886","10.1002/hep.30244"
"30315941","Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial","Reshef R, Ganetsky A, Acosta EP, Blauser R, Crisalli L, McGraw J, Frey NV, Hexner EO, Hoxie JA, Loren AW, Luger SM, Mangan J, Stadtmauer EA, Mick R, Vonderheide RH, Porter DL.","Biol Blood Marrow Transplant. 2019 Mar;25(3):515-521. doi: 10.1016/j.bbmt.2018.09.034. Epub 2018 Oct 10.","Reshef R","Biol Blood Marrow Transplant","2019","2018/10/14","PMC6445759","NIHMS1509336","10.1016/j.bbmt.2018.09.034"
"30421537","Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis","Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, Kwo PY, Weiland O, Villa E, Heo J, Gane E, Ryder SD, Welzel TM, Ruane PJ, Agarwal K, Ng TI, Xue Z, Lovell SS, Krishnan P, Kopecky-Bromberg S, Trinh R, Mensa FJ, Wyles DL.","J Viral Hepat. 2019 Mar;26(3):337-349. doi: 10.1111/jvh.13038. Epub 2018 Dec 11.","Flamm S","J Viral Hepat","2019","2018/11/14","PMC7379735","","10.1111/jvh.13038"
"30428505","Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies","Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE Jr, Pinchasik DE, Tsimberidou AM.","Br J Clin Pharmacol. 2019 Mar;85(3):530-539. doi: 10.1111/bcp.13817. Epub 2018 Dec 25.","Ou Y","Br J Clin Pharmacol","2019","2018/11/15","PMC6379218","","10.1111/bcp.13817"
"30445597","A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers","Choi J, Lee EJ, Yang SH, Im YR, Seong J.","J Radiat Res. 2019 Mar 1;60(2):242-248. doi: 10.1093/jrr/rry092.","Choi J","J Radiat Res","2019","2018/11/17","PMC6430247","","10.1093/jrr/rry092"
"30503296","Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma","Kim JW, Kim DY, Han KH, Seong J.","Dig Liver Dis. 2019 Mar;51(3):445-451. doi: 10.1016/j.dld.2018.11.004. Epub 2018 Nov 17.","Kim JW","Dig Liver Dis","2019","2018/12/04","","","10.1016/j.dld.2018.11.004"
"30529597","Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation","Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A.","J Thorac Oncol. 2019 Mar;14(3):553-559. doi: 10.1016/j.jtho.2018.11.028. Epub 2018 Dec 4.","Yang JC","J Thorac Oncol","2019","2018/12/12","","","10.1016/j.jtho.2018.11.028"
"30558859","Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases","Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V.","Clin Colorectal Cancer. 2019 Mar;18(1):34-43.e6. doi: 10.1016/j.clcc.2018.11.004. Epub 2018 Nov 24.","Pietrantonio F","Clin Colorectal Cancer","2019","2018/12/19","","","10.1016/j.clcc.2018.11.004"
"30559073","Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10","Kienle DL, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder RC, Koeberle D, Horber D, Bastian S, Kueng M, Saletti P, Helbling D, Baertschi D, Lugli A, Bernhard J, Andrieu C, von Moos R.","J Geriatr Oncol. 2019 Mar;10(2):304-310. doi: 10.1016/j.jgo.2018.11.011. Epub 2018 Dec 14.","Kienle DL","J Geriatr Oncol","2019","2018/12/19","","","10.1016/j.jgo.2018.11.011"
"30644314","Ramucirumab and its use in the treatment of hepatocellular carcinoma","Turkes F, Chau I.","Future Oncol. 2019 Mar;15(9):979-988. doi: 10.2217/fon-2018-0822. Epub 2019 Jan 15.","Turkes F","Future Oncol","2019","2019/01/16","","","10.2217/fon-2018-0822"
"30731276","Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort","Segal NH, Ou SI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR, Weiss J, Schöffski P, Antonia SJ, Massard C, Zandberg DP, Khleif SN, Xiao F, Rebelatto MC, Steele KE, Robbins PB, Angra N, Song X, Abdullah S, Butler M.","Eur J Cancer. 2019 Mar;109:154-161. doi: 10.1016/j.ejca.2018.12.029. Epub 2019 Feb 4.","Segal NH","Eur J Cancer","2019","2019/02/08","","","10.1016/j.ejca.2018.12.029"
"30735919","Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial","Cremolini C, Marmorino F, Bergamo F, Aprile G, Salvatore L, Masi G, Dell'Aquila E, Antoniotti C, Murgioni S, Allegrini G, Borelli B, Gemma D, Casagrande M, Granetto C, Delfanti S, Di Donato S, Schirripa M, Sensi E, Tonini G, Lonardi S, Fontanini G, Boni L, Falcone A.","Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.","Cremolini C","Eur J Cancer","2019","2019/02/09","","","10.1016/j.ejca.2018.12.028"
"30738780","Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C.","Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.","Smith M","Lancet Oncol","2019","2019/02/11","","","10.1016/S1470-2045(18)30860-X"
"30837503","Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer","Li Y, Zhao Y, Gong C, Xie Y, Hu X, Zhang J, Wang L, Zhang S, Cao J, Tao Z, Wang B.","Sci Rep. 2019 Mar 5;9(1):3563. doi: 10.1038/s41598-019-39314-y.","Li Y","Sci Rep","2019","2019/03/07","PMC6400896","","10.1038/s41598-019-39314-y"
"30842276","MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF","Pradhan AK, Bhoopathi P, Talukdar S, Scheunemann D, Sarkar D, Cavenee WK, Das SK, Emdad L, Fisher PB.","Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5687-5692. doi: 10.1073/pnas.1819869116. Epub 2019 Mar 6.","Pradhan AK","Proc Natl Acad Sci U S A","2019","2019/03/08","PMC6431152","","10.1073/pnas.1819869116"
"30922248","First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers","Fan Y, Li S, Ding X, Yue J, Jiang J, Zhao H, Hao R, Qiu W, Liu K, Li Y, Wang S, Zheng L, Ye B, Meng K, Xu B.","BMC Cancer. 2019 Mar 28;19(1):279. doi: 10.1186/s12885-019-5471-1.","Fan Y","BMC Cancer","2019","2019/03/30","PMC6437929","","10.1186/s12885-019-5471-1"
"30922256","Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies","He L, Deng H, Lei J, Yi F, Li J, Fan X, Wei Y, Xu J, Zhang W.","BMC Cancer. 2019 Mar 28;19(1):276. doi: 10.1186/s12885-019-5487-6.","He L","BMC Cancer","2019","2019/03/30","PMC6437948","","10.1186/s12885-019-5487-6"
"30922261","Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial","Chen LC, Chiou WY, Lin HY, Lee MS, Lo YC, Huang LW, Chang CM, Hung TH, Lin CW, Tseng KC, Liu DW, Hsu FC, Hung SK.","BMC Cancer. 2019 Mar 28;19(1):275. doi: 10.1186/s12885-019-5461-3.","Chen LC","BMC Cancer","2019","2019/03/30","PMC6437913","","10.1186/s12885-019-5461-3"
"30922327","Case-control Indian buffet process identifies biomarkers of response to Codrituzumab","Pradier MF, Reis B, Jukofsky L, Milletti F, Ohtomo T, Perez-Cruz F, Puig O.","BMC Cancer. 2019 Mar 28;19(1):278. doi: 10.1186/s12885-019-5472-0.","Pradier MF","BMC Cancer","2019","2019/03/30","PMC6438135","","10.1186/s12885-019-5472-0"
"29898591","Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma","Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY.","Cancer Res Treat. 2019 Apr;51(2):510-518. doi: 10.4143/crt.2018.226. Epub 2018 Jun 13.","Yoo C","Cancer Res Treat","2019","2018/06/15","PMC6473286","","10.4143/crt.2018.226"
"30171497","A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors","Jazieh K, Molina J, Allred J, Yin J, Reid J, Goetz M, Lim VS, Kaufmann SH, Adjei A.","Invest New Drugs. 2019 Apr;37(2):307-314. doi: 10.1007/s10637-018-0662-1. Epub 2018 Aug 31.","Jazieh K","Invest New Drugs","2019","2018/09/02","PMC9594493","NIHMS1505538","10.1007/s10637-018-0662-1"
"30399420","Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease","Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, Masereeuw R, Netea MG, Levine JE, Morales G, Ferrara JL, Blijlevens NMA, van Oosterhout YVJM, Stelljes M, van der Velden WJFM.","Biol Blood Marrow Transplant. 2019 Apr;25(4):712-719. doi: 10.1016/j.bbmt.2018.10.020. Epub 2018 Nov 3.","Groth C","Biol Blood Marrow Transplant","2019","2018/11/07","PMC6595479","NIHMS1036469","10.1016/j.bbmt.2018.10.020"
"30411217","A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer","Saito K, Isayama H, Nakai Y, Takahara N, Ishigaki K, Takeda T, Hakuta R, Saito T, Uchino R, Kishikawa T, Hamada T, Mizuno S, Sasaki T, Kogure H, Matsubara S, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K.","Invest New Drugs. 2019 Apr;37(2):338-344. doi: 10.1007/s10637-018-0691-9. Epub 2018 Nov 9.","Saito K","Invest New Drugs","2019","2018/11/10","","","10.1007/s10637-018-0691-9"
"30529387","Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial","Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J.","J Hepatol. 2019 Apr;70(4):684-691. doi: 10.1016/j.jhep.2018.11.029. Epub 2018 Dec 6.","Park JW","J Hepatol","2019","2018/12/12","","","10.1016/j.jhep.2018.11.029"
"30644817","Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial","Gray MD, Lyon PC, Mannaris C, Folkes LK, Stratford M, Campo L, Chung DYF, Scott S, Anderson M, Goldin R, Carlisle R, Wu F, Middleton MR, Gleeson FV, Coussios CC.","Radiology. 2019 Apr;291(1):232-238. doi: 10.1148/radiol.2018181445. Epub 2019 Jan 15.","Gray MD","Radiology","2019","2019/01/16","","","10.1148/radiol.2018181445"
"30725360","Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia","Hatsumi N, Miyawaki S, Yamauchi T, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M, Machida S, Nishii K, Honda S, Ohnishi K, Naoe T; Japan Adult Leukemia Study Group (JALSG).","Int J Hematol. 2019 Apr;109(4):418-425. doi: 10.1007/s12185-019-02606-0. Epub 2019 Feb 6.","Hatsumi N","Int J Hematol","2019","2019/02/07","","","10.1007/s12185-019-02606-0"
"30824408","O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET)","Lemelin A, Barritault M, Hervieu V, Payen L, Péron J, Couvelard A, Cros J, Scoazec JY, Bin S, Villeneuve L, Lombard-Bohas C, Walter T; MGMT-NET investigators.","Dig Liver Dis. 2019 Apr;51(4):595-599. doi: 10.1016/j.dld.2019.02.001. Epub 2019 Feb 14.","Lemelin A","Dig Liver Dis","2019","2019/03/03","","","10.1016/j.dld.2019.02.001"
"30830522","Design and Endpoints of Clinical Trials, Current and Future","Sherman M.","Dig Dis Sci. 2019 Apr;64(4):1050-1057. doi: 10.1007/s10620-019-05541-6.","Sherman M","Dig Dis Sci","2019","2019/03/05","","","10.1007/s10620-019-05541-6"
"30926081","An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study","Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G.","Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.","Savona MR","Lancet Haematol","2019","2019/03/31","","","10.1016/S2352-3026(19)30030-4"
"30944458","Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial","Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V.","Br J Cancer. 2019 Apr;120(9):896-902. doi: 10.1038/s41416-019-0443-4. Epub 2019 Apr 4.","Assenat E","Br J Cancer","2019","2019/04/05","PMC6734663","","10.1038/s41416-019-0443-4"
"30957065","Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver","Dueland S, Line PD, Hagness M, Foss A, Andersen MH.","BJS Open. 2018 Oct 25;3(2):180-185. doi: 10.1002/bjs5.50116. eCollection 2019 Apr.","Dueland S","BJS Open","2018","2019/04/09","PMC6433324","","10.1002/bjs5.50116"
"30953467","Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial","Buisman FE, Homs MYV, Grünhagen DJ, Filipe WF, Bennink RJ, Besselink MGH, Borel Rinkes IHM, Bruijnen RCG, Cercek A, D'Angelica MI, van Delden OM, Donswijk ML, van Doorn L, Doornebosch PG, Emmering J, Erdmann JI, IJzerman NS, Grootscholten C, Hagendoorn J, Kemeny NE, Kingham TP, Klompenhouwer EG, Kok NFM, Koolen S, Kuhlmann KFD, Kuiper MC, Lam MGE, Mathijssen RHJ, Moelker A, Oomen-de Hoop E, Punt CJA, Te Riele WW, Roodhart JML, Swijnenburg RJ, Prevoo W, Tanis PJ, Vermaas M, Versleijen MWJ, Veuger FP, Weterman MJ, Verhoef C, Groot Koerkamp B.","BMC Cancer. 2019 Apr 5;19(1):327. doi: 10.1186/s12885-019-5515-6.","Buisman FE","BMC Cancer","2019","2019/04/07","PMC6451273","","10.1186/s12885-019-5515-6"
"31057324","Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer","Wang T, Lu R, Lai S, Schiller JH, Zhou FL, Ci B, Wang S, Gao X, Yao B, Gerber DE, Johnson DH, Xiao G, Xie Y.","Cancer Inform. 2019 Apr 5;18:1176935119837547. doi: 10.1177/1176935119837547. eCollection 2019.","Wang T","Cancer Inform","2019","2019/05/07","PMC6452590","","10.1177/1176935119837547"
"30232616","Intraoperative confocal laser endomicroscopy for real-time in vivo tissue characterization during surgical procedures","Fuks D, Pierangelo A, Validire P, Lefevre M, Benali A, Trebuchet G, Criton A, Gayet B.","Surg Endosc. 2019 May;33(5):1544-1552. doi: 10.1007/s00464-018-6442-3. Epub 2018 Sep 19.","Fuks D","Surg Endosc","2019","2018/09/21","","","10.1007/s00464-018-6442-3"
"30393375","Phase I trial of intravenous Ad5CRT in patients with liver metastasis of gastrointestinal cancers","Lee SJ, Shin SP, Lee SH, Kang JW, Kook MC, Kim IH, Kim HK.","Cancer Gene Ther. 2019 May;26(5-6):174-178. doi: 10.1038/s41417-018-0055-9. Epub 2018 Nov 5.","Lee SJ","Cancer Gene Ther","2019","2018/11/06","","","10.1038/s41417-018-0055-9"
"30612267","mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival","Yasuno M, Uetake H, Ishiguro M, Mizunuma N, Komori T, Miyata G, Shiomi A, Kagimura T, Sugihara K.","Int J Clin Oncol. 2019 May;24(5):516-525. doi: 10.1007/s10147-018-01393-8. Epub 2019 Jan 5.","Yasuno M","Int J Clin Oncol","2019","2019/01/07","PMC6469677","","10.1007/s10147-018-01393-8"
"30617039","Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial","Vernieri C, Signorelli D, Galli G, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Rizzo AM, Corsetto PA, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC.","Clin Lung Cancer. 2019 May;20(3):e413-e417. doi: 10.1016/j.cllc.2018.12.011. Epub 2018 Dec 19.","Vernieri C","Clin Lung Cancer","2019","2019/01/09","","","10.1016/j.cllc.2018.12.011"
"30716200","Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors","Schweitzer N, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, Manns MP, Vogel A.","Liver Int. 2019 May;39(5):914-923. doi: 10.1111/liv.14063. Epub 2019 Mar 18.","Schweitzer N","Liver Int","2019","2019/02/05","","","10.1111/liv.14063"
"30738047","Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma","Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J.","Gastroenterology. 2019 May;156(6):1731-1741. doi: 10.1053/j.gastro.2019.01.261. Epub 2019 Feb 6.","Teufel M","Gastroenterology","2019","2019/02/10","","","10.1053/j.gastro.2019.01.261"
"30783901","End-points for drug treatment in NASH","Adams LA.","Hepatol Int. 2019 May;13(3):253-258. doi: 10.1007/s12072-019-09935-6. Epub 2019 Feb 19.","Adams LA","Hepatol Int","2019","2019/02/21","","","10.1007/s12072-019-09935-6"
"30852136","Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial","Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LØ, Ryg J, Osterlund P, Berglund Å, Qvortrup C, Glimelius B, Sorbye H, Pfeiffer P.","Lancet Gastroenterol Hepatol. 2019 May;4(5):376-388. doi: 10.1016/S2468-1253(19)30041-X. Epub 2019 Mar 7.","Winther SB","Lancet Gastroenterol Hepatol","2019","2019/03/11","","","10.1016/S2468-1253(19)30041-X"
"30872388","Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment","Grande E, Harvey RD, You B, Batlle JF, Galbraith H, Sarantopoulos J, Ramalingam SS, Mann H, So K, Johnson M, Vishwanathan K.","J Pharmacol Exp Ther. 2019 May;369(2):291-299. doi: 10.1124/jpet.118.255919. Epub 2019 Mar 14.","Grande E","J Pharmacol Exp Ther","2019","2019/03/16","PMC11046734","","10.1124/jpet.118.255919"
"30905200","Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials","Matos I, Noguerido A, Ros J, Mulet N, Argilés G, Elez É, Tabernero J.","Expert Opin Investig Drugs. 2019 May;28(5):463-471. doi: 10.1080/13543784.2019.1599860. Epub 2019 Apr 20.","Matos I","Expert Opin Investig Drugs","2019","2019/03/26","","","10.1080/13543784.2019.1599860"
"30922733","Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans JTR, Stocken D, Praseedom R, Ma YT, Davidson B, Neoptolemos JP, Iveson T, Raftery J, Zhu S, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater J; BILCAP study group.","Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25.","Primrose JN","Lancet Oncol","2019","2019/03/30","","","10.1016/S1470-2045(18)30915-X"
"30922878","Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group.","Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.","Reck M","Lancet Respir Med","2019","2019/03/30","","","10.1016/S2213-2600(19)30084-0"
"30948276","Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM.","Lancet Oncol. 2019 May;20(5):649-662. doi: 10.1016/S1470-2045(18)30935-5. Epub 2019 Apr 1.","Davies A","Lancet Oncol","2019","2019/04/06","PMC6494978","","10.1016/S1470-2045(18)30935-5"
"30954183","Selective Internal Radiation Therapy in the Multidisciplinary Management of Liver Metastases From Colorectal Carcinoma","Tchelebi L, Sharma NK.","Semin Nucl Med. 2019 May;49(3):182-188. doi: 10.1053/j.semnuclmed.2019.01.002. Epub 2019 Feb 14.","Tchelebi L","Semin Nucl Med","2019","2019/04/08","","","10.1053/j.semnuclmed.2019.01.002"
"30973373","Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors","Shah HA, Fischer JH, Venepalli NK, Danciu OC, Christian S, Russell MJ, Liu LC, Zacny JP, Dudek AZ.","Am J Clin Oncol. 2019 May;42(5):413-420. doi: 10.1097/COC.0000000000000543.","Shah HA","Am J Clin Oncol","2019","2019/04/12","","","10.1097/COC.0000000000000543"
"30975630","Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial","Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL.","Lancet Oncol. 2019 May;20(5):719-727. doi: 10.1016/S1470-2045(18)30895-7. Epub 2019 Apr 8.","Katzenstein HM","Lancet Oncol","2019","2019/04/13","PMC6499702","NIHMS1025719","10.1016/S1470-2045(18)30895-7"
"31005216","Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial)","Kondo K, Matsusaka S, Ishihara S, Horie H, Uehara K, Oguchi M, Murafushi K, Ueno M, Mizunuma N, Shimbo T, Kato D, Okuda J, Hashiguchi Y, Nakazawa M, Sunami E, Kawai K, Yamashita H, Okada T, Ishikawa Y, Fujii M, Nakajima T.","Radiother Oncol. 2019 May;134:199-203. doi: 10.1016/j.radonc.2019.02.006. Epub 2019 Feb 26.","Kondo K","Radiother Oncol","2019","2019/04/22","","","10.1016/j.radonc.2019.02.006"
"31131841","Lenvatinib mesylate to treat hepatocellular carcinoma","Ielasi L, Tovoli F, Piscaglia F.","Drugs Today (Barc). 2019 May;55(5):305-313. doi: 10.1358/dot.2019.55.5.2969817.","Ielasi L","Drugs Today (Barc)","2019","2019/05/28","","","10.1358/dot.2019.55.5.2969817"
"31053989","Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)","Hidaka H, Izumi N, Aramaki T, Ikeda M, Inaba Y, Imanaka K, Okusaka T, Kanazawa S, Kaneko S, Kora S, Saito H, Furuse J, Matsui O, Yamashita T, Yokosuka O, Morita S, Arioka H, Kudo M, Arai Y.","Med Oncol. 2019 May 3;36(6):52. doi: 10.1007/s12032-019-1272-2.","Hidaka H","Med Oncol","2019","2019/05/05","","","10.1007/s12032-019-1272-2"
"30951590","Fostamatinib for the treatment of immune thrombocytopenia in adults","Moore DC, Gebru T, Muslimani A.","Am J Health Syst Pharm. 2019 May 17;76(11):789-794. doi: 10.1093/ajhp/zxz052.","Moore DC","Am J Health Syst Pharm","2019","2019/04/06","","","10.1093/ajhp/zxz052"
"31142037","Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial","Bidard FC, Kiavue N, Ychou M, Cabel L, Stern MH, Madic J, Saliou A, Rampanou A, Decraene C, Bouché O, Rivoire M, Ghiringhelli F, Francois E, Guimbaud R, Mineur L, Khemissa-Akouz F, Mazard T, Moussata D, Proudhon C, Pierga JY, Stanbury T, Thézenas S, Mariani P.","Cells. 2019 May 28;8(6):516. doi: 10.3390/cells8060516.","Bidard FC","Cells","2019","2019/05/31","PMC6627974","","10.3390/cells8060516"
"30108162","Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial","Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM.","Gut. 2019 Jun;68(6):1065-1075. doi: 10.1136/gutjnl-2018-316408. Epub 2018 Aug 14.","Pinyol R","Gut","2019","2018/08/16","PMC6580745","","10.1136/gutjnl-2018-316408"
"30302599","Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer","Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S.","Invest New Drugs. 2019 Jun;37(3):482-489. doi: 10.1007/s10637-018-0645-2. Epub 2018 Oct 10.","Weldon Gilcrease G","Invest New Drugs","2019","2018/10/11","","","10.1007/s10637-018-0645-2"
"30598500","An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma","El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK.","Oncologist. 2019 Jun;24(6):747-e218. doi: 10.1634/theoncologist.2018-0838. Epub 2018 Dec 31.","El Dika I","Oncologist","2019","2019/01/02","PMC6656521","","10.1634/theoncologist.2018-0838"
"30628113","Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment","Saif MW, Rosen L, Rudek MA, Sun W, Shepard DR, Becerra C, Yamashita F, Bebeau P, Winkler R.","Br J Clin Pharmacol. 2019 Jun;85(6):1239-1246. doi: 10.1111/bcp.13856. Epub 2019 Mar 28.","Saif MW","Br J Clin Pharmacol","2019","2019/01/11","PMC6533429","","10.1111/bcp.13856"
"30767147","Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial","Meijer TS, Burgmans MC, Fiocco M, de Geus-Oei LF, Kapiteijn E, de Leede EM, Martini CH, van der Meer RW, Tijl FGJ, Vahrmeijer AL.","Cardiovasc Intervent Radiol. 2019 Jun;42(6):841-852. doi: 10.1007/s00270-019-02177-x. Epub 2019 Feb 14.","Meijer TS","Cardiovasc Intervent Radiol","2019","2019/02/16","PMC6502784","","10.1007/s00270-019-02177-x"
"30790149","Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma","Akiyama N, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Uto T, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Suda T.","Invest New Drugs. 2019 Jun;37(3):531-537. doi: 10.1007/s10637-019-00747-x. Epub 2019 Feb 21.","Akiyama N","Invest New Drugs","2019","2019/02/22","","","10.1007/s10637-019-00747-x"
"30848403","Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial","Inoue K, Ninomiya J, Saito T, Okubo K, Nakakuma T, Yamada H, Kimizuka K, Higuchi T; SBCCSG-36 investigators.","Invest New Drugs. 2019 Jun;37(3):538-547. doi: 10.1007/s10637-019-00755-x. Epub 2019 Mar 8.","Inoue K","Invest New Drugs","2019","2019/03/09","PMC6538821","","10.1007/s10637-019-00755-x"
"30915497","First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma","Massard C, Soria JC, Krauss J, Gordon M, Lockhart AC, Rasmussen E, Upreti VV, Patel S, Ngarmchamnanrith G, Henary H.","Cancer Chemother Pharmacol. 2019 Jun;83(6):1057-1063. doi: 10.1007/s00280-019-03796-4. Epub 2019 Mar 26.","Massard C","Cancer Chemother Pharmacol","2019","2019/03/28","","","10.1007/s00280-019-03796-4"
"30929823","Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer","Secord AA, McCollum M, Davidson BA, Broadwater G, Squatrito R, Havrilesky LJ, Gabel AC, Starr MD, Brady JC, Nixon AB, Duska LR.","Gynecol Oncol. 2019 Jun;153(3):555-561. doi: 10.1016/j.ygyno.2019.03.246. Epub 2019 Mar 28.","Secord AA","Gynecol Oncol","2019","2019/04/02","","","10.1016/j.ygyno.2019.03.246"
"30943423","Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival","Llovet JM, Montal R, Villanueva A.","J Hepatol. 2019 Jun;70(6):1262-1277. doi: 10.1016/j.jhep.2019.01.028. Epub 2019 Mar 31.","Llovet JM","J Hepatol","2019","2019/04/04","","","10.1016/j.jhep.2019.01.028"
"30954567","Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial","Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators.","Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4.","Merle P","Lancet Gastroenterol Hepatol","2019","2019/04/08","","","10.1016/S2468-1253(19)30040-8"
"30969136","RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX.","Future Oncol. 2019 Jun;15(16):1811-1822. doi: 10.2217/fon-2019-0097. Epub 2019 Apr 10.","Qin S","Future Oncol","2019","2019/04/11","","","10.2217/fon-2019-0097"
"31003911","Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators.","Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16.","Eng C","Lancet Oncol","2019","2019/04/21","","","10.1016/S1470-2045(19)30027-0"
"31036468","Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X.","Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27.","Jiang Z","Lancet Oncol","2019","2019/05/01","","","10.1016/S1470-2045(19)30164-0"
"31038408","Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial","Guiu B, Chevallier P, Assenat E, Barbier E, Merle P, Bouvier A, Dumortier J, Nguyen-Khac E, Gugenheim J, Rode A, Oberti F, Valette PJ, Yzet T, Chevallier O, Barbare JC, Latournerie M, Boulin M.","Radiology. 2019 Jun;291(3):801-808. doi: 10.1148/radiol.2019182399. Epub 2019 Apr 30.","Guiu B","Radiology","2019","2019/05/01","","","10.1148/radiol.2019182399"
"31059588","Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302","Teply BA, Qiu F, Antonarakis ES, Carducci MA, Denmeade SR.","Prostate. 2019 Jun;79(8):929-933. doi: 10.1002/pros.23798.","Teply BA","Prostate","2019","2019/05/07","","","10.1002/pros.23798"
"31072748","Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial","Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B.","Clin Genitourin Cancer. 2019 Jun;17(3):e689-e703. doi: 10.1016/j.clgc.2019.03.017. Epub 2019 Apr 1.","Bracarda S","Clin Genitourin Cancer","2019","2019/05/11","","","10.1016/j.clgc.2019.03.017"
"31109691","Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis","Liao W, Huang J, Wu Q, Zhu G, Wang X, Wen F, Zhang P, Zhang N, Li Q.","Oral Oncol. 2019 Jun;93:15-20. doi: 10.1016/j.oraloncology.2019.04.003. Epub 2019 Apr 9.","Liao W","Oral Oncol","2019","2019/05/22","","","10.1016/j.oraloncology.2019.04.003"
"31119644","Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities","Manka P, Zeller A, Syn WK.","Drugs. 2019 Jun;79(9):903-927. doi: 10.1007/s40265-019-01126-9.","Manka P","Drugs","2019","2019/05/24","","","10.1007/s40265-019-01126-9"
"31149341","A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH)","Povsic M, Oliver L, Jiandani NR, Perry R, Bottomley J.","Pharmacol Res Perspect. 2019 May 27;7(3):e00485. doi: 10.1002/prp2.485. eCollection 2019 Jun.","Povsic M","Pharmacol Res Perspect","2019","2019/06/01","PMC6536401","","10.1002/prp2.485"
"31171879","Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH Jr, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O.","Nat Med. 2019 Jun;25(6):936-940. doi: 10.1038/s41591-019-0476-5. Epub 2019 Jun 6.","Ribas A","Nat Med","2019","2019/06/08","PMC8562134","NIHMS1751954","10.1038/s41591-019-0476-5"
"31200357","Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma","Soto-Perez-de-Celis E, Aguiar PN, Cordón ML, Chavarri-Guerra Y, Lopes GL.","J Natl Compr Canc Netw. 2019 Jun 1;17(6):669-675. doi: 10.6004/jnccn.2018.7275.","Soto-Perez-de-Celis E","J Natl Compr Canc Netw","2019","2019/06/15","","","10.6004/jnccn.2018.7275"
"31203498","MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer","Matikas A, Souglakos J, Katsaounis P, Kotsakis A, Kouroupakis P, Pantazopoulos N, Kentepozidis N, Nikolaidi A, Messaritakis I, Tzovara I, Hatzidaki D, Prinarakis E, Georgoulias V.","Target Oncol. 2019 Jun;14(3):285-293. doi: 10.1007/s11523-019-00647-3.","Matikas A","Target Oncol","2019","2019/06/17","","","10.1007/s11523-019-00647-3"
"31293976","A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?","Al-Shafa F, Arifin AJ, Rodrigues GB, Palma DA, Louie AV.","Front Oncol. 2019 Jun 21;9:543. doi: 10.3389/fonc.2019.00543. eCollection 2019.","Al-Shafa F","Front Oncol","2019","2019/07/12","PMC6598429","","10.3389/fonc.2019.00543"
"31261712","Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam","Liem NT, Van Phong N, Kien NT, Anh BV, Huyen TL, Thao CT, Tu ND, Hiep DT, Hoai Thu DT, Nhung HTM.","Int J Mol Sci. 2019 Jun 28;20(13):3166. doi: 10.3390/ijms20133166.","Liem NT","Int J Mol Sci","2019","2019/07/03","PMC6651639","","10.3390/ijms20133166"
"28440086","DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer","Di Noia V, Basso M, Marsico V, Cerchiaro E, Rossi S, D'Argento E, Strippoli A, Schinzari G, Iezzi R, Cassano A, Barone C.","Future Oncol. 2019 Jul;15(20):2349-2360. doi: 10.2217/fon-2017-0025. Epub 2017 Apr 25.","Di Noia V","Future Oncol","2019","2017/04/26","","","10.2217/fon-2017-0025"
"30477287","A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients","Kim Y, Kim TW, Han SW, Ahn JB, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK.","Cancer Res Treat. 2019 Jul;51(3):1128-1134. doi: 10.4143/crt.2018.379. Epub 2018 Nov 21.","Kim Y","Cancer Res Treat","2019","2018/11/28","PMC6639242","","10.4143/crt.2018.379"
"30552157","Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)","Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS, Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J.","Oncologist. 2019 Jul;24(7):921-932. doi: 10.1634/theoncologist.2018-0344. Epub 2018 Dec 14.","Hurwitz HI","Oncologist","2019","2018/12/16","PMC6656450","","10.1634/theoncologist.2018-0344"
"30715571","Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with (188)Re-SSS Lipiodol radioembolization","Delaunay K, Edeline J, Rolland Y, Lepareur N, Laffont S, Palard X, Bouvry C, Le Sourd S, Pracht M, Ardisson V, Noiret N, Bellissant É, Garin E.","Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1506-1517. doi: 10.1007/s00259-019-04277-9. Epub 2019 Feb 4.","Delaunay K","Eur J Nucl Med Mol Imaging","2019","2019/02/05","","","10.1007/s00259-019-04277-9"
"30825666","NRG Oncology/RTOG 0438: A Phase 1 Trial of Highly Conformal Radiation Therapy for Liver Metastases","Dawson LA, Winter KA, Katz AW, Schell MC, Brierley J, Chen Y, Kopek N, Crane CH, Willett CG.","Pract Radiat Oncol. 2019 Jul-Aug;9(4):e386-e393. doi: 10.1016/j.prro.2019.02.013. Epub 2019 Feb 27.","Dawson LA","Pract Radiat Oncol","2019","2019/03/03","PMC6592755","NIHMS1526805","10.1016/j.prro.2019.02.013"
"30851442","Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study","Cho BC, Obermannova R, Bearz A, McKeage M, Kim DW, Batra U, Borra G, Orlov S, Kim SW, Geater SL, Postmus PE, Laurie SA, Park K, Yang CT, Ardizzoni A, Bettini AC, de Castro G Jr, Kiertsman F, Chen Z, Lau YY, Viraswami-Appanna K, Passos VQ, Dziadziuszko R.","J Thorac Oncol. 2019 Jul;14(7):1255-1265. doi: 10.1016/j.jtho.2019.03.002. Epub 2019 Mar 7.","Cho BC","J Thorac Oncol","2019","2019/03/10","","","10.1016/j.jtho.2019.03.002"
"30877190","A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer","Chen X, Qiu T, Zhu Y, Sun J, Li P, Wang B, Lin P, Cai X, Han X, Zhao F, Shu Y, Chang L, Jiang H, Gu Y.","Oncologist. 2019 Jul;24(7):883-e407. doi: 10.1634/theoncologist.2019-0164. Epub 2019 Mar 15.","Chen X","Oncologist","2019","2019/03/17","PMC6656475","","10.1634/theoncologist.2019-0164"
"30879929","Contrast-enhanced intra-operative ultrasound as a clinical decision making tool during surgery for colorectal liver metastases: The ULIIS study","Desolneux G, Isambert M, Mathoulin-Pelissier S, Dupré A, Rivoire M, Cattena V, Palussière J, Dinart D, Bellera C, Evrard S.","Eur J Surg Oncol. 2019 Jul;45(7):1212-1218. doi: 10.1016/j.ejso.2019.03.002. Epub 2019 Mar 10.","Desolneux G","Eur J Surg Oncol","2019","2019/03/19","","","10.1016/j.ejso.2019.03.002"
"30952642","Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer","Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Tuvy Y, Berger MF, Tang L, Kelsen DP, Schattner M, Ilson DH, Capanu M, Solit DB, Schultz N, Janjigian YY.","Clin Cancer Res. 2019 Jul 1;25(13):3811-3817. doi: 10.1158/1078-0432.CCR-18-3789. Epub 2019 Apr 5.","Won E","Clin Cancer Res","2019","2019/04/07","PMC6606369","NIHMS1526176","10.1158/1078-0432.CCR-18-3789"
"31046124","Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy","Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG.","Ann Oncol. 2019 Jul 1;30(7):1088-1095. doi: 10.1093/annonc/mdz139.","Hamfjord J","Ann Oncol","2019","2019/05/03","","","10.1093/annonc/mdz139"
"31070690","Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial","He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, Le Y, Zhou Z, Zhao M, Guo Y, Guo R, Chen M, Shi M.","JAMA Oncol. 2019 Jul 1;5(7):953-960. doi: 10.1001/jamaoncol.2019.0250.","He M","JAMA Oncol","2019","2019/05/10","PMC6512278","","10.1001/jamaoncol.2019.0250"
"31122901","Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F.","Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.","West H","Lancet Oncol","2019","2019/05/25","","","10.1016/S1470-2045(19)30167-6"
"31160251","Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU.","Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31.","Rozeman EA","Lancet Oncol","2019","2019/06/05","","","10.1016/S1470-2045(19)30151-2"
"31204849","Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib","Personeni N, Pressiani T, Rimassa L.","Future Oncol. 2019 Jul;15(21):2449-2462. doi: 10.2217/fon-2019-0026. Epub 2019 Jun 17.","Personeni N","Future Oncol","2019","2019/06/18","","","10.2217/fon-2019-0026"
"31249394","Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma","Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW.","Br J Cancer. 2019 Jul;121(3):218-221. doi: 10.1038/s41416-019-0506-6. Epub 2019 Jun 28.","Evans TRJ","Br J Cancer","2019","2019/06/29","PMC6738107","","10.1038/s41416-019-0506-6"
"31285591","Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)","Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, Nagasaka T, Hatano E, Ojima H, Manaka D, Kusumoto T, Katayose Y, Fujiwara T, Yoshida K, Unno M, Hyodo I, Tomita N, Sugihara K, Maehara Y.","Br J Cancer. 2019 Jul;121(3):222-229. doi: 10.1038/s41416-019-0518-2. Epub 2019 Jul 9.","Oki E","Br J Cancer","2019","2019/07/10","PMC6738101","","10.1038/s41416-019-0518-2"
"31295152","A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma","Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G.","Clin Transl Gastroenterol. 2019 Jul;10(7):e00056. doi: 10.14309/ctg.0000000000000056.","Kelley RK","Clin Transl Gastroenterol","2019","2019/07/12","PMC6708671","","10.14309/ctg.0000000000000056"
"31112475","Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study","Barrington SF, Phillips EH, Counsell N, Hancock B, Pettengell R, Johnson P, Townsend W, Culligan D, Popova B, Clifton-Hadley L, McMillan A, Hoskin P, O'Doherty MJ, Illidge T, Radford J.","J Clin Oncol. 2019 Jul 10;37(20):1732-1741. doi: 10.1200/JCO.18.01799. Epub 2019 May 21.","Barrington SF","J Clin Oncol","2019","2019/05/22","PMC6638600","","10.1200/JCO.18.01799"
"31053600","Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial","Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Roussel M, Jaccard A, Pétillon MO, Belhadj-Merzoug K, Lepeu G, Chrétien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Attal M, Moreau P, Avet-Loiseau H, Hulin C, Facon T.","Clin Cancer Res. 2019 Jul 15;25(14):4224-4230. doi: 10.1158/1078-0432.CCR-18-3642. Epub 2019 May 3.","Leleu X","Clin Cancer Res","2019","2019/05/05","","","10.1158/1078-0432.CCR-18-3642"
"31331370","Systemic chemotherapy plus cetuximab after complete surgery in the treatment of isolated colorectal peritoneal carcinoma: COCHISE phase II clinical trial","Evrard S, Desolneux G, Bellera C, Esnaud T, Bécouarn Y, Collet D, Chafai N, Marchal F, Cany L, Lermite E, Rivoire M, Mathoulin-Pélissier S.","BMC Res Notes. 2019 Jul 22;12(1):450. doi: 10.1186/s13104-019-4476-9.","Evrard S","BMC Res Notes","2019","2019/07/24","PMC6647143","","10.1186/s13104-019-4476-9"
"31384311","Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives","Xu W, Liu K, Chen M, Sun JY, McCaughan GW, Lu XJ, Ji J.","Ther Adv Med Oncol. 2019 Jul 23;11:1758835919862692. doi: 10.1177/1758835919862692. eCollection 2019.","Xu W","Ther Adv Med Oncol","2019","2019/08/07","PMC6651675","","10.1177/1758835919862692"
"31340866","First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors","Shitara K, Ueha S, Shichino S, Aoki H, Ogiwara H, Nakatsura T, Suzuki T, Shimomura M, Yoshikawa T, Shoda K, Kitano S, Yamashita M, Nakayama T, Sato A, Kuroda S, Wakabayashi M, Nomura S, Yokochi S, Ito S, Matsushima K, Doi T.","J Immunother Cancer. 2019 Jul 24;7(1):195. doi: 10.1186/s40425-019-0677-y.","Shitara K","J Immunother Cancer","2019","2019/07/26","PMC6657210","","10.1186/s40425-019-0677-y"
"30666445","Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging","Chen S, Feng S, Wei J, Liu F, Li B, Li X, Hou Y, Gu D, Tang M, Xiao H, Jia Y, Peng S, Tian J, Kuang M.","Eur Radiol. 2019 Aug;29(8):4177-4187. doi: 10.1007/s00330-018-5986-x. Epub 2019 Jan 21.","Chen S","Eur Radiol","2019","2019/01/23","","","10.1007/s00330-018-5986-x"
"30710067","A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction","Gong J, Cho M, Gupta R, Synold TW, Frankel P, Ruel C, Fakih M, Chung V, Lim D, Chao J.","Oncologist. 2019 Aug;24(8):1137-1145. doi: 10.1634/theoncologist.2018-0336. Epub 2019 Feb 1.","Gong J","Oncologist","2019","2019/02/03","PMC6693729","","10.1634/theoncologist.2018-0336"
"30963691","Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma","Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, Giannelli G.","Liver Int. 2019 Aug;39(8):1468-1477. doi: 10.1111/liv.14113. Epub 2019 Jun 3.","Faivre S","Liver Int","2019","2019/04/10","","","10.1111/liv.14113"
"31065872","Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success","Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P, Elvevi A, Uguccioni M; NetworkER+.","Breast Cancer Res Treat. 2019 Aug;176(3):483-494. doi: 10.1007/s10549-019-05261-5. Epub 2019 May 7.","Cazzaniga ME","Breast Cancer Res Treat","2019","2019/05/09","PMC6586706","","10.1007/s10549-019-05261-5"
"31150059","Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivelä TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM.","Ann Oncol. 2019 Aug 1;30(8):1370-1380. doi: 10.1093/annonc/mdz176.","Khoja L","Ann Oncol","2019","2019/06/01","","","10.1093/annonc/mdz176"
"31175181","Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters","Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, Ley AM, Zhang M, Hong JA, Venzon D, Jackson JP, Brouwer KR, Grohar P, Glod J, Widemann BC, Heller T, Schrump DS, Figg WD.","Mol Pharmacol. 2019 Aug;96(2):158-167. doi: 10.1124/mol.118.114827. Epub 2019 Jun 7.","Sissung TM","Mol Pharmacol","2019","2019/06/09","PMC6608607","","10.1124/mol.118.114827"
"31207163","Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma","He M, Li Q, Shen J, Tan G, Li Q, Lai J, Wei W, Zhang Y, Zou R, Chen M, Guo R, Shi M.","Cancer Med. 2019 Aug;8(9):4200-4213. doi: 10.1002/cam4.2355. Epub 2019 Jun 17.","He M","Cancer Med","2019","2019/06/18","PMC6675716","","10.1002/cam4.2355"
"31221547","Prognostic factors in patients with stage II colon cancer: Role of E-selectin gene polymorphisms","Turpin A, Labreuche J, Fléjou JF, Andre T, de Gramont A, Hebbar M.","Dig Liver Dis. 2019 Aug;51(8):1198-1201. doi: 10.1016/j.dld.2019.05.019. Epub 2019 Jun 18.","Turpin A","Dig Liver Dis","2019","2019/06/22","","","10.1016/j.dld.2019.05.019"
"31253577","Hepatocellular carcinoma: Current situation and challenge","Li Z, Zhu JY.","Hepatobiliary Pancreat Dis Int. 2019 Aug;18(4):303-304. doi: 10.1016/j.hbpd.2019.05.013. Epub 2019 Jun 11.","Li Z","Hepatobiliary Pancreat Dis Int","2019","2019/06/30","","","10.1016/j.hbpd.2019.05.013"
"31276981","Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials","Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN; GEICAM Spanish Breast Cancer Group; GBG (German Breast Group); Alliance for Clinical Trials in Oncology (Alliance).","Eur J Cancer. 2019 Aug;117:91-98. doi: 10.1016/j.ejca.2019.06.002. Epub 2019 Jul 2.","Martín M","Eur J Cancer","2019","2019/07/06","PMC6718694","NIHMS1531846","10.1016/j.ejca.2019.06.002"
"31305287","Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma","Gordon SW, McGuire WP 3rd, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS.","Am J Clin Oncol. 2019 Aug;42(8):649-654. doi: 10.1097/COC.0000000000000567.","Gordon SW","Am J Clin Oncol","2019","2019/07/16","","","10.1097/COC.0000000000000567"
"31363167","A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients","Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Grávalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, López C, Alonso B, Ruiz de Mena I, Díaz-Rubio E, Tabernero J, Aranda E.","Br J Cancer. 2019 Aug;121(5):378-383. doi: 10.1038/s41416-019-0537-z. Epub 2019 Jul 31.","Elez E","Br J Cancer","2019","2019/08/01","PMC6738054","","10.1038/s41416-019-0537-z"
"31415377","Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments","Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Kumanogoh A, Kawase I, Oka Y, Azuma I, Morita S, Sugiyama H.","Medicine (Baltimore). 2019 Aug;98(33):e16771. doi: 10.1097/MD.0000000000016771.","Nishida S","Medicine (Baltimore)","2019","2019/08/16","PMC6831317","","10.1097/MD.0000000000016771"
"31412920","Magnetic resonance imaging of liver tumors using gadoxetic acid (Gd-EOB-DTPA) - pilot study","Borusewicz P, Stańczyk E, Kubiak K, Spużak J, Glińska-Suchocka K, Jankowski M, Sławuta P, Kubiak-Nowak D, Podgórski P.","BMC Vet Res. 2019 Aug 14;15(1):293. doi: 10.1186/s12917-019-2038-y.","Borusewicz P","BMC Vet Res","2019","2019/08/16","PMC6694506","","10.1186/s12917-019-2038-y"
"31464611","Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy","Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Shaib WL, Alese OB, Steuer CE, Wu C, Lawson DH, Kudchadkar R, Master VA, El-Rayes B, Ramalingam SS, Owonikoko TK, Harvey RD.","BMC Cancer. 2019 Aug 29;19(1):857. doi: 10.1186/s12885-019-6073-7.","Bilen MA","BMC Cancer","2019","2019/08/30","PMC6716879","","10.1186/s12885-019-6073-7"
"29797144","Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma","Rayan A, Abdel Fattah ON, Soliman A, Hasan HA, Zahran AM.","J Gastrointest Cancer. 2019 Sep;50(3):519-524. doi: 10.1007/s12029-018-0116-1.","Rayan A","J Gastrointest Cancer","2019","2018/05/26","","","10.1007/s12029-018-0116-1"
"30796165","Early Phase I Study of a (99m)Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer","Xing Y, Chand G, Liu C, Cook GJR, O'Doherty J, Zhao L, Wong NCL, Meszaros LK, Ting HH, Zhao J.","J Nucl Med. 2019 Sep;60(9):1213-1220. doi: 10.2967/jnumed.118.224170. Epub 2019 Feb 22.","Xing Y","J Nucl Med","2019","2019/02/24","PMC6735283","","10.2967/jnumed.118.224170"
"30920122","Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer","Grevel J, Jentsch G, Austin R, Prins NH, Lettieri J, Mitchell D, Huang F, Brose MS, Schlumberger M, Meinhardt G, Peña CEA, Ploeger BA.","Clin Transl Sci. 2019 Sep;12(5):459-469. doi: 10.1111/cts.12634. Epub 2019 Apr 12.","Grevel J","Clin Transl Sci","2019","2019/03/29","PMC6742948","","10.1111/cts.12634"
"30996008","A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases","Bi N, Ma Y, Xiao J, Zhang H, Xu Y, Tian Y, Li J, Zhang Y, Liu Q, Wang K, Deng L, Wang W, Chen X, Liu F, Zhao R, Yang S, Huang X, Yi J, Hu C, Li Y.","Oncologist. 2019 Sep;24(9):e914-e920. doi: 10.1634/theoncologist.2018-0702. Epub 2019 Apr 17.","Bi N","Oncologist","2019","2019/04/19","PMC6738306","","10.1634/theoncologist.2018-0702"
"31125576","Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma","Jouve JL, Lecomte T, Bouché O, Barbier E, Khemissa Akouz F, Riachi G, Nguyen Khac E, Ollivier-Hourmand I, Debette-Gratien M, Faroux R, Villing AL, Vergniol J, Ramee JF, Bronowicki JP, Seitz JF, Legoux JL, Denis J, Manfredi S, Phelip JM; PRODIGE-11 investigators/collaborators.","J Hepatol. 2019 Sep;71(3):516-522. doi: 10.1016/j.jhep.2019.04.021. Epub 2019 May 22.","Jouve JL","J Hepatol","2019","2019/05/25","","","10.1016/j.jhep.2019.04.021"
"31129279","Gadoxetate acid disodium-enhanced MRI: Multiple arterial phases using differential sub-sampling with cartesian ordering (DISCO) may achieve more optimal late arterial phases than the single arterial phase imaging","Wei Y, Deng L, Yuan Y, Huang Z, He X, Wei X, Yang H, Song B.","Magn Reson Imaging. 2019 Sep;61:116-123. doi: 10.1016/j.mri.2019.05.033. Epub 2019 May 23.","Wei Y","Magn Reson Imaging","2019","2019/05/27","","","10.1016/j.mri.2019.05.033"
"31142504","A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer","Harding JJ, Zhu AX, Bauer TM, Choueiri TK, Drilon A, Voss MH, Fuchs CS, Abou-Alfa GK, Wijayawardana SR, Wang XA, Moser BA, Uruñuela A, Wacheck V, Bendell JC.","Clin Cancer Res. 2019 Sep 1;25(17):5202-5211. doi: 10.1158/1078-0432.CCR-18-4010. Epub 2019 May 29.","Harding JJ","Clin Cancer Res","2019","2019/05/31","","","10.1158/1078-0432.CCR-18-4010"
"31176752","Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis","Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz CD, Kudo M.","J Hepatol. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7.","Yau T","J Hepatol","2019","2019/06/10","","","10.1016/j.jhep.2019.05.014"
"31203390","Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study","Pintova S, Dharmupari S, Moshier E, Zubizarreta N, Ang C, Holcombe RF.","Cancer Chemother Pharmacol. 2019 Sep;84(3):591-598. doi: 10.1007/s00280-019-03886-3. Epub 2019 Jun 15.","Pintova S","Cancer Chemother Pharmacol","2019","2019/06/17","","","10.1007/s00280-019-03886-3"
"31266752","GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study","Cheung KWK, Yoshida K, Cheeti S, Chen B, Morley R, Chan IT, Sahasranaman S, Liu L.","Drug Metab Dispos. 2019 Sep;47(9):966-973. doi: 10.1124/dmd.119.087924. Epub 2019 Jul 2.","Cheung KWK","Drug Metab Dispos","2019","2019/07/04","","","10.1124/dmd.119.087924"
"31273511","Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study","Ghiringhelli F, Vincent J, Bengrine L, Borg C, Jouve JL, Loffroy R, Guiu B, Blanc J, Bertaut A.","J Cancer Res Clin Oncol. 2019 Sep;145(9):2357-2363. doi: 10.1007/s00432-019-02970-8. Epub 2019 Jul 4.","Ghiringhelli F","J Cancer Res Clin Oncol","2019","2019/07/06","","","10.1007/s00432-019-02970-8"
"31559948","Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT","Nixon J, Brown S, Smith IL, McGinnis E, Vargas-Palacios A, Nelson EA, Brown J, Coleman S, Collier H, Fernandez C, Gilberts R, Henderson V, McCabe C, Muir D, Rutherford C, Stubbs N, Thorpe B, Wallner K, Walker K, Wilson L, Hulme C.","Health Technol Assess. 2019 Sep;23(52):1-176. doi: 10.3310/hta23520.","Nixon J","Health Technol Assess","2019","2019/09/28","PMC6790649","","10.3310/hta23520"
"31609293","Contrast Material Injection Protocol With the Dose Determined According to Lean Body Weight at Hepatic Dynamic Computed Tomography: Comparison Among Patients With Different Body Mass Indices","Matsumoto Y, Masuda T, Sato T, Arataki K, Nakamura Y, Tatsugami F, Awai K.","J Comput Assist Tomogr. 2019 Sep/Oct;43(5):736-740. doi: 10.1097/RCT.0000000000000909.","Matsumoto Y","J Comput Assist Tomogr","2019","2019/10/15","","","10.1097/RCT.0000000000000909"
"30623276","A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors","Doi T, Aramaki T, Yasui H, Muro K, Ikeda M, Okusaka T, Inaba Y, Nakai K, Ikezawa H, Nakajima R.","Invest New Drugs. 2019 Oct;37(5):1061-1074. doi: 10.1007/s10637-018-0713-7. Epub 2019 Jan 9.","Doi T","Invest New Drugs","2019","2019/01/10","PMC6736902","","10.1007/s10637-018-0713-7"
"31195062","Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, Foxton M, Rodriguez CF, Esteban R, Hyland R, Lu S, Kirby BJ, Meng A, Markova S, Dvory-Sobol H, Osinusi AO, Bruck R, Ampuero J, Ryder SD, Agarwal K, Fox R, Shaw D, Haider S, Willems B, Lurie Y, Calleja JL, Gane EJ.","J Hepatol. 2019 Oct;71(4):660-665. doi: 10.1016/j.jhep.2019.05.028. Epub 2019 Jun 11.","Borgia SM","J Hepatol","2019","2019/06/14","","","10.1016/j.jhep.2019.05.028"
"31220446","Safety and efficacy of a metal stent covered with a silicone membrane containing integrated silver particles in preventing biofilm and sludge formation in endoscopic drainage of malignant biliary obstruction: a phase 2 pilot study","Lee TH, Jung MK, Kim TK, Pack CG, Park YK, Kim SO, Park DH.","Gastrointest Endosc. 2019 Oct;90(4):663-672.e2. doi: 10.1016/j.gie.2019.06.007. Epub 2019 Jun 18.","Lee TH","Gastrointest Endosc","2019","2019/06/21","","","10.1016/j.gie.2019.06.007"
"31299242","Quality Assurance of Dose-Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal cancer","Boustani J, Rivin Del Campo E, Blanc J, Peiffert D, Benezery K, Pereira R, Rio E, Le Prisé E, Créhange G, Huguet F.","Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):329-337. doi: 10.1016/j.ijrobp.2019.06.2542. Epub 2019 Jul 9.","Boustani J","Int J Radiat Oncol Biol Phys","2019","2019/07/13","","","10.1016/j.ijrobp.2019.06.2542"
"31343665","Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab","Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M.","JAMA Oncol. 2019 Oct 1;5(10):1411-1420. doi: 10.1001/jamaoncol.2019.2187.","Topalian SL","JAMA Oncol","2019","2019/07/26","PMC6659167","","10.1001/jamaoncol.2019.2187"
"31371809","Insights into the success and failure of systemic therapy for hepatocellular carcinoma","Bruix J, da Fonseca LG, Reig M.","Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):617-630. doi: 10.1038/s41575-019-0179-x. Epub 2019 Aug 1.","Bruix J","Nat Rev Gastroenterol Hepatol","2019","2019/08/03","","","10.1038/s41575-019-0179-x"
"31429027","Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial","Mokdad AA, Zhu H, Beg MS, Arriaga Y, Dowell JE, Singal AG, Yopp AC.","Target Oncol. 2019 Oct;14(5):541-550. doi: 10.1007/s11523-019-00663-3.","Mokdad AA","Target Oncol","2019","2019/08/21","","","10.1007/s11523-019-00663-3"
"31453767","A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis","Gonsalves CF, Eschelman DJ, Adamo RD, Anne PR, Orloff MM, Terai M, Hage AN, Yi M, Chervoneva I, Sato T.","Radiology. 2019 Oct;293(1):223-231. doi: 10.1148/radiol.2019190199. Epub 2019 Aug 27.","Gonsalves CF","Radiology","2019","2019/08/28","PMC6776232","","10.1148/radiol.2019190199"
"31523058","Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study","Xu Y, Huang Z, Lu H, Yu X, Li Y, Li W, Chen J, Chen M, Gong L, Chen K, Qin J, Xu X, Jin Y, Zhao J, Shi X, Han N, Xie F, Zhang P, Xu W, Fan Y.","Br J Cancer. 2019 Oct;121(8):640-646. doi: 10.1038/s41416-019-0583-6. Epub 2019 Sep 16.","Xu Y","Br J Cancer","2019","2019/09/17","PMC6889407","","10.1038/s41416-019-0583-6"
"31588789","Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials","Cabibbo G, Cucchetti A, Cammà C, Casadei-Gardini A, Celsa C, Emanuele Maria Rizzo G, Johnson P, Ercolani G.","Future Oncol. 2019 Oct;15(29):3411-3422. doi: 10.2217/fon-2019-0287. Epub 2019 Oct 7.","Cabibbo G","Future Oncol","2019","2019/10/08","","","10.2217/fon-2019-0287"
"31603008","Cabozantinib for the treatment of hepatocellular carcinoma","Personeni N, Rimassa L, Pressiani T, Smiroldo V, Santoro A.","Expert Rev Anticancer Ther. 2019 Oct;19(10):847-855. doi: 10.1080/14737140.2019.1674141. Epub 2019 Oct 11.","Personeni N","Expert Rev Anticancer Ther","2019","2019/10/12","","","10.1080/14737140.2019.1674141"
"31599521","[Recent advances in managing hepatitis D]","Bonnemain CL, Cochand L, Portmann A, Béguelin C.","Rev Med Suisse. 2019 Oct 9;15(666):1802-1806.","Bonnemain CL","Rev Med Suisse","2019","2019/10/11","","",""
"31356140","Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy","Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP.","J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29.","Rosenberg JE","J Clin Oncol","2019","2019/07/30","PMC6784850","","10.1200/JCO.19.01140"
"31390274","Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653)","Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN Jr.","J Clin Oncol. 2019 Oct 10;37(29):2682-2688. doi: 10.1200/JCO.19.00861. Epub 2019 Aug 7.","Sadeghi S","J Clin Oncol","2019","2019/08/08","PMC7006847","","10.1200/JCO.19.00861"
"31251403","Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma","Feun LG, Li YY, Wu C, Wangpaichitr M, Jones PD, Richman SP, Madrazo B, Kwon D, Garcia-Buitrago M, Martin P, Hosein PJ, Savaraj N.","Cancer. 2019 Oct 15;125(20):3603-3614. doi: 10.1002/cncr.32339. Epub 2019 Jun 28.","Feun LG","Cancer","2019","2019/06/29","PMC7592647","NIHMS1630226","10.1002/cncr.32339"
"31615466","Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial","Kondo M, Morimoto M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Aikata H, Hatanaka T, Takizawa D, Matsunaga K, Okuse C, Suzuki M, Taguri M, Ishibashi T, Numata K, Maeda S, Tanaka K.","BMC Cancer. 2019 Oct 15;19(1):954. doi: 10.1186/s12885-019-6198-8.","Kondo M","BMC Cancer","2019","2019/10/17","PMC6794885","","10.1186/s12885-019-6198-8"
"31665578","Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ.","N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.","Perl AE","N Engl J Med","2019","2019/10/31","","","10.1056/NEJMoa1902688"
"30958892","A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors","Weekes C, Lockhart AC, Lee JJ, Sturm I, Cleton A, Huang F, Lenz HJ.","Int J Cancer. 2019 Nov 1;145(9):2450-2458. doi: 10.1002/ijc.32317. Epub 2019 Jun 14.","Weekes C","Int J Cancer","2019","2019/04/09","PMC6771657","","10.1002/ijc.32317"
"31034092","Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum","Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V; Liver Forum Case Definitions Working Group.","Hepatology. 2019 Nov;70(5):1841-1855. doi: 10.1002/hep.30672.","Cheung A","Hepatology","2019","2019/04/30","","","10.1002/hep.30672"
"31187515","Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma","Nguyen L, Chapel S, Tran BD, Lacy S.","J Clin Pharmacol. 2019 Nov;59(11):1551-1561. doi: 10.1002/jcph.1467. Epub 2019 Jun 11.","Nguyen L","J Clin Pharmacol","2019","2019/06/13","PMC6790584","","10.1002/jcph.1467"
"31209941","Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study","Smedman TM, Guren TK, Line PD, Dueland S.","Transpl Int. 2019 Nov;32(11):1144-1150. doi: 10.1111/tri.13471. Epub 2019 Jun 17.","Smedman TM","Transpl Int","2019","2019/06/19","","","10.1111/tri.13471"
"31227340","Safety of radiofrequency ablation in patients with locally advanced, unresectable pancreatic cancer: A phase II study","Fegrachi S, Walma MS, de Vries JJJ, van Santvoort HC, Besselink MG, von Asmuth EG, van Leeuwen MS, Borel Rinkes IH, Bruijnen RC, de Hingh IH, Klaase JM, Molenaar IQ, van Hillegersberg R.","Eur J Surg Oncol. 2019 Nov;45(11):2166-2172. doi: 10.1016/j.ejso.2019.06.008. Epub 2019 Jun 12.","Fegrachi S","Eur J Surg Oncol","2019","2019/06/23","","","10.1016/j.ejso.2019.06.008"
"31321482","Five-Years Outcome Analysis of 142 Consecutive Hepatocellular Carcinoma Patients Treated with Doxorubicin Eluting Microspheres 30-60 μm: Results from a Single-Centre Prospective Phase II Trial","Malagari K, Moschouris H, Kiakidis T, Harward S, Kelekis A, Vrakas S, Koundouras D, Filipiadis D, Glantzounis G, Emmanouil E, Chatziioannou A, Vergadis V, Elefsiniotis I, Koskinas J, Dourakis S, Kelekis N.","Cardiovasc Intervent Radiol. 2019 Nov;42(11):1551-1562. doi: 10.1007/s00270-019-02260-3. Epub 2019 Jul 18.","Malagari K","Cardiovasc Intervent Radiol","2019","2019/07/20","","","10.1007/s00270-019-02260-3"
"31332611","Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials","Hirose K, Oki E, Shimose T, Sakamoto S, Sasaki S, Jogo T, Hu Q, Tsuda Y, Ando K, Nakashima Y, Saeki H, Mori M.","Int J Clin Oncol. 2019 Nov;24(11):1397-1405. doi: 10.1007/s10147-019-01509-8. Epub 2019 Jul 22.","Hirose K","Int J Clin Oncol","2019","2019/07/24","","","10.1007/s10147-019-01509-8"
"31420468","A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)","Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, Villa D, Cabanero M, Tu D, Tsao M, Seymour L.","Oncologist. 2019 Nov;24(11):1439-1445. doi: 10.1634/theoncologist.2019-0321. Epub 2019 Aug 16.","Chia S","Oncologist","2019","2019/08/18","PMC6853090","","10.1634/theoncologist.2019-0321"
"31482223","Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma","Yamazaki K, Doi T, Ikeda M, Okusaka T, Schueler A, Watanabe M, Ohtsu A.","Cancer Chemother Pharmacol. 2019 Nov;84(5):1027-1037. doi: 10.1007/s00280-019-03924-0. Epub 2019 Sep 3.","Yamazaki K","Cancer Chemother Pharmacol","2019","2019/09/05","","","10.1007/s00280-019-03924-0"
"31482226","Population pharmacokinetics of siltuximab: impact of disease state","Nikanjam M, Yang J, Capparelli EV.","Cancer Chemother Pharmacol. 2019 Nov;84(5):993-1001. doi: 10.1007/s00280-019-03939-7. Epub 2019 Sep 3.","Nikanjam M","Cancer Chemother Pharmacol","2019","2019/09/05","PMC6800650","NIHMS1538986","10.1007/s00280-019-03939-7"
"31486832","Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial","Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP.","JAMA Oncol. 2019 Nov 1;5(11):1582-1588. doi: 10.1001/jamaoncol.2019.2792.","Abou-Alfa GK","JAMA Oncol","2019","2019/09/06","PMC6735405","","10.1001/jamaoncol.2019.2792"
"31498753","Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A.","J Clin Oncol. 2019 Nov 1;37(31):2835-2845. doi: 10.1200/JCO.19.00964. Epub 2019 Sep 10.","Fuchs M","J Clin Oncol","2019","2019/09/10","","","10.1200/JCO.19.00964"
"31542384","Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, Geer EB, Greenman Y, Witek P, Cohen F, Biller BMK.","Lancet Diabetes Endocrinol. 2019 Nov;7(11):855-865. doi: 10.1016/S2213-8587(19)30313-4. Epub 2019 Sep 18.","Fleseriu M","Lancet Diabetes Endocrinol","2019","2019/09/23","","","10.1016/S2213-8587(19)30313-4"
"31575503","Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial","Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnović Ž, Vasev N, Ma L, Richards DA, Wilks ST, Milenković D, Yang Z, Antal JM, Morris SR, O'Shaughnessy J.","Lancet Oncol. 2019 Nov;20(11):1587-1601. doi: 10.1016/S1470-2045(19)30616-3. Epub 2019 Sep 28.","Tan AR","Lancet Oncol","2019","2019/10/03","","","10.1016/S1470-2045(19)30616-3"
"31663777","A Phase I/Ib trial of Ad-REIC in liver cancer: study protocol","Oyama A, Shiraha H, Uchida D, Iwamuro M, Kato H, Takaki A, Ikeda F, Onishi H, Yasunaka T, Takeuchi Y, Wada N, Iwasaki Y, Sakata M, Okada H, Kumon H.","Future Oncol. 2019 Nov;15(31):3547-3554. doi: 10.2217/fon-2019-0115. Epub 2019 Oct 30.","Oyama A","Future Oncol","2019","2019/10/31","","","10.2217/fon-2019-0115"
"31799201","Systemic Treatment Options in Hepatocellular Carcinoma","Rimassa L, Pressiani T, Merle P.","Liver Cancer. 2019 Nov;8(6):427-446. doi: 10.1159/000499765. Epub 2019 May 29.","Rimassa L","Liver Cancer","2019","2019/12/05","PMC6883446","","10.1159/000499765"
"31799686","Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC)","Berretta M, Cobellis G, Franco R, Panarese I, Rinaldi B, Nasti G, Di Francia R, Rinaldi L.","Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):10139-10150. doi: 10.26355/eurrev_201911_19584.","Berretta M","Eur Rev Med Pharmacol Sci","2019","2019/12/05","","","10.26355/eurrev_201911_19584"
"31684985","Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma","Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu Z, Li Q, Luo M, Liang R, Ye J.","J Exp Clin Cancer Res. 2019 Nov 4;38(1):447. doi: 10.1186/s13046-019-1412-8.","Liu Z","J Exp Clin Cancer Res","2019","2019/11/06","PMC6827249","","10.1186/s13046-019-1412-8"
"31455681","A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors","Doi T, Muro K, Ishii H, Kato T, Tsushima T, Takenoyama M, Oizumi S, Gemmoto K, Suna H, Enokitani K, Kawakami T, Nishikawa H, Yamamoto N.","Clin Cancer Res. 2019 Nov 15;25(22):6614-6622. doi: 10.1158/1078-0432.CCR-19-1090. Epub 2019 Aug 27.","Doi T","Clin Cancer Res","2019","2019/08/29","","","10.1158/1078-0432.CCR-19-1090"
"30725388","Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials","Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA.","Invest New Drugs. 2019 Dec;37(6):1198-1206. doi: 10.1007/s10637-019-00736-0. Epub 2019 Feb 6.","Martini DJ","Invest New Drugs","2019","2019/02/07","PMC6684862","NIHMS1520941","10.1007/s10637-019-00736-0"
"30790152","Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations","Nishio M, Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T.","Invest New Drugs. 2019 Dec;37(6):1207-1217. doi: 10.1007/s10637-019-00732-4. Epub 2019 Feb 21.","Nishio M","Invest New Drugs","2019","2019/02/22","PMC6856039","","10.1007/s10637-019-00732-4"
"31409568","Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin","Celik H, Wakim P, Pritchard WF, Castro M, Leonard S, Karanian JW, Dewhirst MW, Lencioni R, Wood BJ.","J Vasc Interv Radiol. 2019 Dec;30(12):1908-1914. doi: 10.1016/j.jvir.2019.04.023. Epub 2019 Aug 10.","Celik H","J Vasc Interv Radiol","2019","2019/08/15","PMC6875689","NIHMS1528191","10.1016/j.jvir.2019.04.023"
"31421157","Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovič P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P.","J Hepatol. 2019 Dec;71(6):1164-1174. doi: 10.1016/j.jhep.2019.08.006. Epub 2019 Aug 14.","Ricke J","J Hepatol","2019","2019/08/18","","","10.1016/j.jhep.2019.08.006"
"31424576","Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial","Garlipp B, Gibbs P, Van Hazel GA, Jeyarajah R, Martin RCG, Bruns CJ, Lang H, Manas DM, Ettorre GM, Pardo F, Donckier V, Benckert C, van Gulik TM, Goéré D, Schoen M, Pratschke J, Bechstein WO, de la Cuesta AM, Adeyemi S, Ricke J, Seidensticker M.","Br J Surg. 2019 Dec;106(13):1837-1846. doi: 10.1002/bjs.11283. Epub 2019 Aug 19.","Garlipp B","Br J Surg","2019","2019/08/20","PMC6899564","","10.1002/bjs.11283"
"31481510","Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma","Cassaday RD, Press OW, Pagel JM, Rajendran JG, Gooley TA, Fisher DR, Holmberg LA, Miyaoka RS, Sandmaier BM, Green DJ, Gopal AK.","Clin Cancer Res. 2019 Dec 1;25(23):6932-6938. doi: 10.1158/1078-0432.CCR-19-1567. Epub 2019 Sep 3.","Cassaday RD","Clin Cancer Res","2019","2019/09/05","PMC6891166","NIHMS1538341","10.1158/1078-0432.CCR-19-1567"
"31490009","Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia","Flinn IW, Cherry MA, Maris MB, Matous JV, Berdeja JG, Patel M.","Am J Hematol. 2019 Dec;94(12):1325-1334. doi: 10.1002/ajh.25634. Epub 2019 Oct 4.","Flinn IW","Am J Hematol","2019","2019/09/07","","","10.1002/ajh.25634"
"31502668","Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial","Verguts J, Godin PA, De Vree B, Donnez O, Cosyns S, Luyckx M, Nisolle M.","Int J Gynaecol Obstet. 2019 Dec;147(3):339-343. doi: 10.1002/ijgo.12968. Epub 2019 Sep 30.","Verguts J","Int J Gynaecol Obstet","2019","2019/09/11","","","10.1002/ijgo.12968"
"31515083","Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials","Taieb J, Geissler M, Rivera F, Karthaus M, Wilson R, Loupakis F, Price T, Tracy M, Burdon P, Peeters M.","Clin Colorectal Cancer. 2019 Dec;18(4):245-256.e5. doi: 10.1016/j.clcc.2019.07.009. Epub 2019 Jul 29.","Taieb J","Clin Colorectal Cancer","2019","2019/09/14","","","10.1016/j.clcc.2019.07.009"
"31520695","Outcomes of Resectability Assessment of the Dutch Colorectal Cancer Group Liver Metastases Expert Panel","Huiskens J, Bolhuis K, Engelbrecht MR, De Jong KP, Kazemier G, Liem MS, Verhoef C, de Wilt JH, Punt CJ, van Gulik TM; Dutch Colorectal Cancer Group.","J Am Coll Surg. 2019 Dec;229(6):523-532.e2. doi: 10.1016/j.jamcollsurg.2019.08.1445. Epub 2019 Sep 11.","Huiskens J","J Am Coll Surg","2019","2019/09/15","","","10.1016/j.jamcollsurg.2019.08.1445"
"31522242","Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial","Luu T, Frankel P, Beumer JH, Lim D, Cristea M, Appleman LJ, Lenz HJ, Gandara DR, Kiesel BF, Piekarz RL, Newman EM.","Cancer Chemother Pharmacol. 2019 Dec;84(6):1201-1208. doi: 10.1007/s00280-019-03955-7. Epub 2019 Sep 14.","Luu T","Cancer Chemother Pharmacol","2019","2019/09/16","PMC6821594","NIHMS1539966","10.1007/s00280-019-03955-7"
"31571146","Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies","Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, Denner K, Bairlein M, von Bühler CJ, Wilkinson G, Gieschen H.","Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. doi: 10.1007/s13318-019-00577-5.","Zurth C","Eur J Drug Metab Pharmacokinet","2019","2019/10/02","PMC6828636","","10.1007/s13318-019-00577-5"
"31575541","First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma","Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.","Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1.","Kim RD","Cancer Discov","2019","2019/10/03","","","10.1158/2159-8290.CD-19-0555"
"31631570","A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis","Kreitz K, Ernst A, Schmidt R, Simon T, Fischer M, Volland R, Hero B, Berthold F.","Cancer Med. 2019 Dec;8(17):7236-7243. doi: 10.1002/cam4.2562. Epub 2019 Oct 20.","Kreitz K","Cancer Med","2019","2019/10/22","PMC6885891","","10.1002/cam4.2562"
"31637577","Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma","Nguyen L, Chapel S, Tran BD, Lacy S.","J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):577-589. doi: 10.1007/s10928-019-09659-y. Epub 2019 Oct 21.","Nguyen L","J Pharmacokinet Pharmacodyn","2019","2019/10/23","","","10.1007/s10928-019-09659-y"
"31641947","Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands","Buisman FE, Grünhagen DJ, Homs MYV, Grootscholten C, Filipe WF, Kemeny NE, Cercek A, D'Angelica MI, Donswijk ML, van Doorn L, Emmering J, Jarnagin WR, Kingham TP, Klompenhouwer EG, Kok NFM, Kuiper MC, Moelker A, Prevoo W, Versleijen MWJ, Verhoef C, Kuhlmann KFD, Groot Koerkamp B.","Ann Surg Oncol. 2019 Dec;26(13):4599-4607. doi: 10.1245/s10434-019-07973-w. Epub 2019 Oct 22.","Buisman FE","Ann Surg Oncol","2019","2019/10/24","PMC6863781","","10.1245/s10434-019-07973-w"
"31658994","Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses","Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS.","Cancer Immunol Res. 2019 Dec;7(12):1903-1909. doi: 10.1158/2326-6066.CIR-18-0793. Epub 2019 Oct 28.","Welsh JW","Cancer Immunol Res","2019","2019/10/30","PMC6891218","NIHMS1541562","10.1158/2326-6066.CIR-18-0793"
"31678771","Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study","Walter T, Lepage C, Coriat R, Barbier E, Cadiot G, Caroli-Bosc FX, Aparicio T, Bouhier-Leporrier K, Hentic-Dhome O, Gay F, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C, Di-Fiore F, Ghiringhelli F, Legoux JL, Guimbaud R, Baudin E, Lombard-Bohas C, de Baère T; FFCD 1104 investigators/investigators.","Eur J Cancer. 2019 Dec;123:92-100. doi: 10.1016/j.ejca.2019.09.021. Epub 2019 Oct 31.","Walter T","Eur J Cancer","2019","2019/11/04","","","10.1016/j.ejca.2019.09.021"
"31685491","A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardeshna KM, Solh M, Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA.","Clin Cancer Res. 2019 Dec 1;25(23):6986-6994. doi: 10.1158/1078-0432.CCR-19-0711. Epub 2019 Nov 4.","Kahl BS","Clin Cancer Res","2019","2019/11/06","","","10.1158/1078-0432.CCR-19-0711"
"31707181","Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial","Sharma A, Kalyan Mohanti B, Pal Chaudhary S, Sreenivas V, Kumar Sahoo R, Kumar Shukla N, Thulkar S, Pal S, Deo SV, Pathy S, Ranjan Dash N, Kumar S, Bhatnagar S, Kumar R, Mishra S, Sahni P, Iyer VK, Raina V.","Eur J Cancer. 2019 Dec;123:162-170. doi: 10.1016/j.ejca.2019.10.004. Epub 2019 Nov 14.","Sharma A","Eur J Cancer","2019","2019/11/11","","","10.1016/j.ejca.2019.10.004"
"31860408","Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial","Huillard O, Jouinot A, Tlemsani C, Brose MS, Arrondeau J, Meinhardt G, Fellous M, De Sanctis Y, Schlumberger M, Goldwasser F.","Thyroid. 2019 Dec;29(12):1820-1827. doi: 10.1089/thy.2018.0784.","Huillard O","Thyroid","2019","2019/12/21","PMC6918875","","10.1089/thy.2018.0784"
"31866800","Gadobutrol Precedes Gd-DTPA in Abdominal Contrast-Enhanced MRA and MRI: A Prospective, Multicenter, Intraindividual Study","Liu X, Li Z, Zhang W, Yang C, Diao Y, Duan T, Fu Y, Ren J, Bin S.","Contrast Media Mol Imaging. 2019 Dec 2;2019:9738464. doi: 10.1155/2019/9738464. eCollection 2019.","Liu X","Contrast Media Mol Imaging","2019","2019/12/24","PMC6914877","","10.1155/2019/9738464"
"31818843","Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1)","Wei M, Shi S, Hua J, Xu J, Yu X; Chinese Study Group for Pancreatic Cancer (CSPAC).","BMJ Open. 2019 Dec 8;9(12):e033452. doi: 10.1136/bmjopen-2019-033452.","Wei M","BMJ Open","2019","2019/12/11","PMC6924808","","10.1136/bmjopen-2019-033452"
"31609637","FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)","Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Ricke J, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Geissler M.","J Clin Oncol. 2019 Dec 10;37(35):3401-3411. doi: 10.1200/JCO.19.01340. Epub 2019 Oct 14.","Modest DP","J Clin Oncol","2019","2019/10/15","","","10.1200/JCO.19.01340"
"31831062","Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial","Treasure T, Farewell V, Macbeth F, Monson K, Williams NR, Brew-Graves C, Lees B, Grigg O, Fallowfield L; PulMiCC Trial Group.","Trials. 2019 Dec 12;20(1):718. doi: 10.1186/s13063-019-3837-y.","Treasure T","Trials","2019","2019/12/14","PMC6909580","","10.1186/s13063-019-3837-y"
"31471312","Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors","Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Pene Dumitrescu T, Wang X, Frey S, Carver J, Horner T, Oh C, Khaled A, Dhar A, Johnson PWM.","Clin Cancer Res. 2019 Dec 15;25(24):7331-7339. doi: 10.1158/1078-0432.CCR-18-4121. Epub 2019 Aug 30.","Yap TA","Clin Cancer Res","2019","2019/09/01","PMC7377921","NIHMS1606056","10.1158/1078-0432.CCR-18-4121"
"31908418","Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study","Wang L, Huang S, Li S, Li M, Shi J, Bai W, Wang Q, Zheng L, Liu Y.","Drug Des Devel Ther. 2019 Dec 19;13:4331-4340. doi: 10.2147/DDDT.S225613. eCollection 2019.","Wang L","Drug Des Devel Ther","2019","2020/01/08","PMC6930836","","10.2147/DDDT.S225613"
"31888672","Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine","Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R.","J Hematol Oncol. 2019 Dec 30;12(1):145. doi: 10.1186/s13045-019-0835-1.","Tsimberidou AM","J Hematol Oncol","2019","2020/01/01","PMC6937824","","10.1186/s13045-019-0835-1"
"31062483","Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study","Kim SS, Kim SH, Song KD, Choi SY, Heo NH.","J Magn Reson Imaging. 2020 Jan;51(1):70-80. doi: 10.1002/jmri.26768. Epub 2019 May 6.","Kim SS","J Magn Reson Imaging","2020","2019/05/08","","","10.1002/jmri.26768"
"31185468","A Prospective, Multi-Center Phase I Study of Postoperative Enoxaparin Treatment in Patients Undergoing Curative Hepatobiliary-Pancreatic Surgery for Malignancies","Eguchi H, Kawamoto K, Tsujie M, Yukawa M, Kubota M, Asaoka T, Takeda Y, Noda T, Shimizu J, Nagano H, Doki Y, Mori M.","Dig Surg. 2020;37(1):81-86. doi: 10.1159/000497451. Epub 2019 Jun 11.","Eguchi H","Dig Surg","2020","2019/06/12","","","10.1159/000497451"
"31396995","Novel sulfate tablet PBK-1701TC versus oral sulfate solution for colon cleansing: A randomized phase 3 trial","Yang HJ, Park DI, Park SK, Lee CK, Kim HJ, Oh SJ, Moon JR, Lee BJ, Koh JS, Kim HS, Park SY, Kim DH, Chun J, Kang EA, Kim J, Soh H, Eun CS, Kim YS, Jeen YT.","J Gastroenterol Hepatol. 2020 Jan;35(1):29-36. doi: 10.1111/jgh.14826. Epub 2019 Oct 7.","Yang HJ","J Gastroenterol Hepatol","2020","2019/08/10","","","10.1111/jgh.14826"
"31563412","Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial","Elbers JBW, Al-Mamgani A, Tesseslaar MET, van den Brekel MWM, Lange CAH, van der Wal JE, Verheij M, Zuur CL, de Boer JP.","Radiother Oncol. 2020 Jan;142:79-84. doi: 10.1016/j.radonc.2019.08.007. Epub 2019 Sep 26.","Elbers JBW","Radiother Oncol","2020","2019/09/30","","","10.1016/j.radonc.2019.08.007"
"31609741","Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019","Cantelmo AR, Dejos C, Kocher F, Hilbe W, Wolf D, Pircher A.","Curr Opin Oncol. 2020 Jan;32(1):44-53. doi: 10.1097/CCO.0000000000000591.","Cantelmo AR","Curr Opin Oncol","2020","2019/10/15","","","10.1097/CCO.0000000000000591"
"31670750","Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA Jr, Kemeny NE, Jarnagin WR.","JAMA Oncol. 2020 Jan 1;6(1):60-67. doi: 10.1001/jamaoncol.2019.3718.","Cercek A","JAMA Oncol","2020","2019/11/01","PMC6824231","","10.1001/jamaoncol.2019.3718"
"31675535","A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study","Ernani V, Jahan R, Smith LM, Marr AS, Kimbrough SE, Kos ME, Tijerina J, Pivovar S, Lakshmanan I, Ketcham M, Rauth S, Mallya K, Nasser MW, Jain M, Kessinger A, Batra SK, Ganti AK.","Cancer Treat Res Commun. 2020;22:100162. doi: 10.1016/j.ctarc.2019.100162. Epub 2019 Oct 7.","Ernani V","Cancer Treat Res Commun","2020","2019/11/02","PMC7315624","NIHMS1068846","10.1016/j.ctarc.2019.100162"
"31720835","REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H.","J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12.","Yamashita T","J Gastroenterol","2020","2019/11/14","PMC6942573","","10.1007/s00535-019-01642-1"
"31747082","Review article: new therapeutic interventions for advanced hepatocellular carcinoma","Bangaru S, Marrero JA, Singal AG.","Aliment Pharmacol Ther. 2020 Jan;51(1):78-89. doi: 10.1111/apt.15573. Epub 2019 Nov 20.","Bangaru S","Aliment Pharmacol Ther","2020","2019/11/21","","","10.1111/apt.15573"
"31760314","Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial","Hammel P, Fabienne P, Mineur L, Metges JP, Andre T, De La Fouchardiere C, Louvet C, El Hajbi F, Faroux R, Guimbaud R, Tougeron D, Bouche O, Lecomte T, Rebischung C, Tournigand C, Cros J, Kay R, Hamm A, Gupta A, Bachet JB, El Hariry I.","Eur J Cancer. 2020 Jan;124:91-101. doi: 10.1016/j.ejca.2019.10.020. Epub 2019 Nov 21.","Hammel P","Eur J Cancer","2020","2019/11/25","","","10.1016/j.ejca.2019.10.020"
"31768696","Multicenter phase II study of SOX plus trastuzumab for patients with HER2(+) metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B","Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M.","Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223. doi: 10.1007/s00280-019-03991-3. Epub 2019 Nov 25.","Yuki S","Cancer Chemother Pharmacol","2020","2019/11/27","","","10.1007/s00280-019-03991-3"
"31786121","Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators.","Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.","Schmid P","Lancet Oncol","2020","2019/12/02","","","10.1016/S1470-2045(19)30689-8"
"31830641","Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma","Vogel A, Saborowski A.","Cancer Treat Rev. 2020 Jan;82:101946. doi: 10.1016/j.ctrv.2019.101946. Epub 2019 Nov 29.","Vogel A","Cancer Treat Rev","2020","2019/12/13","","","10.1016/j.ctrv.2019.101946"
"31856081","Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial","Macarulla Mercadé T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A.","Pancreas. 2020 Jan;49(1):62-75. doi: 10.1097/MPA.0000000000001455.","Macarulla Mercadé T","Pancreas","2020","2019/12/20","PMC6946097","","10.1097/MPA.0000000000001455"
"32011488","Gastric and adrenal metastasis from breast cancer: Case report and review of literature","Tang T, Zhang L, Li C, Zhou T.","Medicine (Baltimore). 2020 Jan;99(3):e18812. doi: 10.1097/MD.0000000000018812.","Tang T","Medicine (Baltimore)","2020","2020/02/04","PMC7220226","","10.1097/MD.0000000000018812"
"31998643","High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma","Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A.","Front Oncol. 2020 Jan 10;9:1483. doi: 10.3389/fonc.2019.01483. eCollection 2019.","Silk AW","Front Oncol","2020","2020/01/31","PMC6965158","","10.3389/fonc.2019.01483"
"31940916","Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance","Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS.","Cancers (Basel). 2020 Jan 12;12(1):186. doi: 10.3390/cancers12010186.","Wu ZX","Cancers (Basel)","2020","2020/01/17","PMC7017082","","10.3390/cancers12010186"
"32089741","(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study","van Boxtel W, Lütje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, Nagarajah J, Gotthardt M, van Herpen CML.","Theranostics. 2020 Jan 12;10(5):2273-2283. doi: 10.7150/thno.38501. eCollection 2020.","van Boxtel W","Theranostics","2020","2020/02/25","PMC7019174","","10.7150/thno.38501"
"31747476","A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy","Jang WI, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, Cho EH, Choi CW, Kim KS, Hwang S, Kim JH, Chang AR, Park Y, Kim ES, Kim WC, Jo S, Park HJ.","Cancer. 2020 Jan 15;126(2):363-372. doi: 10.1002/cncr.32502. Epub 2019 Nov 20.","Jang WI","Cancer","2020","2019/11/21","","","10.1002/cncr.32502"
"31790344","Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators.","J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.","Finn RS","J Clin Oncol","2020","2019/12/03","","","10.1200/JCO.19.01307"
"30838483","A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study","Suenaga M, Wakatsuki T, Mashima T, Ogura M, Ichimura T, Shinozaki E, Nakayama I, Osumi H, Ota Y, Takahari D, Chin K, Seimiya H, Yamaguchi K.","Invest New Drugs. 2020 Feb;38(1):111-119. doi: 10.1007/s10637-019-00749-9. Epub 2019 Mar 6.","Suenaga M","Invest New Drugs","2020","2019/03/07","","","10.1007/s10637-019-00749-9"
"31151901","Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks","Ma J, Dercle L, Lichtenstein P, Wang D, Chen A, Zhu J, Piessevaux H, Zhao J, Schwartz LH, Lu L, Zhao B.","Acad Radiol. 2020 Feb;27(2):e10-e18. doi: 10.1016/j.acra.2019.02.024. Epub 2019 May 28.","Ma J","Acad Radiol","2020","2019/06/02","PMC9109713","NIHMS1530444","10.1016/j.acra.2019.02.024"
"31597496","S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial","Liao W, Huang J, Zhu G, Zhou J, Wen F, Zhang P, Zhou K, Wu Q, Wang X, Gou H, Li Q.","Expert Rev Pharmacoecon Outcomes Res. 2020 Feb;20(1):133-138. doi: 10.1080/14737167.2020.1677155. Epub 2019 Oct 10.","Liao W","Expert Rev Pharmacoecon Outcomes Res","2020","2019/10/11","","","10.1080/14737167.2020.1677155"
"31676575","Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis","Zhou J, Liu Y, Zhang Y, Li Q, Cao Y.","Cancer Res. 2020 Feb 1;80(3):591-601. doi: 10.1158/0008-5472.CAN-19-1940. Epub 2019 Nov 1.","Zhou J","Cancer Res","2020","2019/11/03","PMC7002273","NIHMS1541851","10.1158/0008-5472.CAN-19-1940"
"31778267","Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts","Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, Azaro A, Poon RTP, Hong D, Lin CC, Akimov M, Ghebremariam S, Zhao S, Giovannini M, Ma B.","Cancer Sci. 2020 Feb;111(2):536-547. doi: 10.1111/cas.14254. Epub 2019 Dec 30.","Bang YJ","Cancer Sci","2020","2019/11/29","PMC7004521","","10.1111/cas.14254"
"31891878","Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition","Boers J, Venema CM, de Vries EFJ, Glaudemans AWJM, Kwee TC, Schuuring E, Martens JWM, Elias SG, Hospers GAP, Schröder CP.","Eur J Cancer. 2020 Feb;126:11-20. doi: 10.1016/j.ejca.2019.10.024. Epub 2019 Dec 28.","Boers J","Eur J Cancer","2020","2020/01/01","","","10.1016/j.ejca.2019.10.024"
"32055698","Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting","Sho T, Suda G, Ogawa K, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Yokoo H, Kamiyama T, Taketomi A, Sakamoto N.","JGH Open. 2019 Jun 10;4(1):54-60. doi: 10.1002/jgh3.12209. eCollection 2020 Feb.","Sho T","JGH Open","2019","2020/02/15","PMC7008153","","10.1002/jgh3.12209"
"32060053","Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer","Shah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, Nelson V, Tsarwhas D, Cristofanilli M, Gradishar W.","J Immunother Cancer. 2020 Feb;8(1):e000173. doi: 10.1136/jitc-2019-000173.","Shah AN","J Immunother Cancer","2020","2020/02/16","PMC7057426","","10.1136/jitc-2019-000173"
"32012214","Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia","Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ.","Blood Adv. 2020 Feb 11;4(3):449-457. doi: 10.1182/bloodadvances.2019000767.","Jain N","Blood Adv","2020","2020/02/04","PMC7013258","","10.1182/bloodadvances.2019000767"
"32059704","Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial","Goetze TO, Bechstein WO, Bankstahl US, Keck T, Königsrainer A, Lang SA, Pauligk C, Piso P, Vogel A, Al-Batran SE.","BMC Cancer. 2020 Feb 14;20(1):122. doi: 10.1186/s12885-020-6610-4.","Goetze TO","BMC Cancer","2020","2020/02/16","PMC7023745","","10.1186/s12885-020-6610-4"
"32645197","Patient Reported Outcomes Show Newer Drug Combinations Maintain Quality of Life Longer Than Current Standard of Care Treatments","Wright KM.","Oncology (Williston Park). 2020 Feb 20;34(2):61-62.","Wright KM","Oncology (Williston Park)","2020","2020/07/10","","",""
"32135647","[Progress on clinical trials of cancer drugs in China, 2019]","Huang HY, Wu DW, Wang HX, Wang J, Fan Q, Wang SH, Bai Y, Yu Y, Fang Y, Sun C, Fang H, Bai H, Wang X, Liu ZY, Jiang M, Liu Z, Wang XH, Li HY, Li N, Cao C, Xu BH, Sun Y, He J.","Zhonghua Zhong Liu Za Zhi. 2020 Feb 23;42(2):127-132. doi: 10.3760/cma.j.issn.0253-3766.2020.02.008.","Huang HY","Zhonghua Zhong Liu Za Zhi","2020","2020/03/06","","","10.3760/cma.j.issn.0253-3766.2020.02.008"
"32074798","[Application of laparoscopic exploration combined with abdominal exfoliative cytology in the diagnosis and treatment of locally advanced gastric cancer]","Ding PA, Liu Y, Guo HH, Yang PG, Tian Y, Fan LQ, Tan BB, Li Y, Zhao Q.","Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Feb 25;23(2):170-176. doi: 10.3760/cma.j.issn.1671-0274.2020.02.013.","Ding PA","Zhonghua Wei Chang Wai Ke Za Zhi","2020","2020/02/20","","","10.3760/cma.j.issn.1671-0274.2020.02.013"
"31542380","EUS-guided confocal laser endomicroscopy: prediction of dysplasia in intraductal papillary mucinous neoplasms (with video)","Krishna SG, Hart PA, DeWitt JM, DiMaio CJ, Kongkam P, Napoleon B, Othman MO, Yew Tan DM, Strobel SG, Stanich PP, Patel A, Luthra AK, Chan MQ, Blaszczak AM, Lee D, El-Dika S, McCarthy ST, Walker JP, Arnold CA, Porter K, Conwell DL.","Gastrointest Endosc. 2020 Mar;91(3):551-563.e5. doi: 10.1016/j.gie.2019.09.014. Epub 2019 Sep 19.","Krishna SG","Gastrointest Endosc","2020","2019/09/23","","","10.1016/j.gie.2019.09.014"
"31626819","Perioperative omega-3 fatty acids fail to confer protection in liver surgery: Results of a multicentric, double-blind, randomized controlled trial","Linecker M, Botea F, Aristotele Raptis D, Nicolaescu D, Limani P, Alikhanov R, Kim P, Wirsching A, Kron P, Schneider MA, Tschuor C, Kambakamba P, Oberkofler C, De Oliveira ML, Bonvini J, Efanov M, Graf R, Petrowsky H, Khatkov I, Clavien PA, Popescu I.","J Hepatol. 2020 Mar;72(3):498-505. doi: 10.1016/j.jhep.2019.10.004. Epub 2019 Oct 15.","Linecker M","J Hepatol","2020","2019/10/19","","","10.1016/j.jhep.2019.10.004"
"31641948","Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial","Makhloufi S, Turpin A, El Amrani M, André T, Truant S, Bachet JB, Vernerey D, Hebbar M.","Ann Surg Oncol. 2020 Mar;27(3):877-885. doi: 10.1245/s10434-019-07976-7. Epub 2019 Oct 22.","Makhloufi S","Ann Surg Oncol","2020","2019/10/24","","","10.1245/s10434-019-07976-7"
"31899122","Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study","Randrian V, Adenis A, Desrame J, Barbier E, Di Fiore F, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Breysacher G, Roquin G, Louafi S, Lopez A, Louvet C, Borg C, Metges JP, Faroux R, Gaba L, Manfredi S, Tougeron D.","Dig Liver Dis. 2020 Mar;52(3):347-350. doi: 10.1016/j.dld.2019.11.014. Epub 2019 Dec 30.","Randrian V","Dig Liver Dis","2020","2020/01/04","","","10.1016/j.dld.2019.11.014"
"32014119","Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial","Bridgewater JA, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, Stanton L, Radford M, Corkhill A, Griffiths GO, Falk S, Valle JW, O'Reilly D, Siriwardena AK, Hornbuckle J, Rees M, Iveson TJ, Hickish T, Garden OJ, Cunningham D, Maughan TS, Primrose JN; New EPOC investigators.","Lancet Oncol. 2020 Mar;21(3):398-411. doi: 10.1016/S1470-2045(19)30798-3. Epub 2020 Jan 31.","Bridgewater JA","Lancet Oncol","2020","2020/02/05","PMC7052737","","10.1016/S1470-2045(19)30798-3"
"32037403","A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma","Fountzilas C, Gupta M, Lee S, Krishnamurthi S, Estfan B, Wang K, Attwood K, Wilton J, Bies R, Bshara W, Iyer R.","Br J Cancer. 2020 Mar;122(7):963-970. doi: 10.1038/s41416-020-0737-6. Epub 2020 Feb 10.","Fountzilas C","Br J Cancer","2020","2020/02/11","PMC7109127","","10.1038/s41416-020-0737-6"
"32182791","Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study","Koumarianou A, Pectasides D, Koliou GA, Dionysopoulos D, Kolomodi D, Poulios C, Skondra M, Sgouros J, Pentheroudakis G, Kaltsas G, Fountzilas G.","Biology (Basel). 2020 Mar 9;9(3):51. doi: 10.3390/biology9030051.","Koumarianou A","Biology (Basel)","2020","2020/03/19","PMC7150771","","10.3390/biology9030051"
"32168769","Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis","Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON.","Int J Mol Sci. 2020 Mar 11;21(6):1907. doi: 10.3390/ijms21061907.","Sumida Y","Int J Mol Sci","2020","2020/03/15","PMC7139365","","10.3390/ijms21061907"
"32210440","Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib","Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, Lahn MM, Raymond E, Benhadji KA, Faivre S.","PLoS One. 2020 Mar 25;15(3):e0222259. doi: 10.1371/journal.pone.0222259. eCollection 2020.","Giannelli G","PLoS One","2020","2020/03/27","PMC7094874","","10.1371/journal.pone.0222259"
"32219576","Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L","Herdman M, Kerr C, Pavesi M, Garside J, Lloyd A, Cubi-Molla P, Devlin N.","J Patient Rep Outcomes. 2020 Mar 27;4(1):22. doi: 10.1186/s41687-020-0185-3.","Herdman M","J Patient Rep Outcomes","2020","2020/03/29","PMC7099111","","10.1186/s41687-020-0185-3"
"31041575","A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies","Yamamoto N, Ryoo BY, Keam B, Kudo M, Lin CC, Kunieda F, Ball HA, Moran D, Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T.","Invest New Drugs. 2020 Apr;38(2):445-456. doi: 10.1007/s10637-019-00780-w. Epub 2019 Apr 30.","Yamamoto N","Invest New Drugs","2020","2019/05/02","","","10.1007/s10637-019-00780-w"
"31146645","Insights into resistance mechanism of hepatitis C virus nonstructural 3/4A protease mutant to boceprevir using umbrella sampling simulation study","Behmard E, Barzegari E.","J Biomol Struct Dyn. 2020 Apr;38(7):1938-1945. doi: 10.1080/07391102.2019.1621212. Epub 2019 May 31.","Behmard E","J Biomol Struct Dyn","2020","2019/06/01","","","10.1080/07391102.2019.1621212"
"31586002","First-in-Humans Imaging with (89)Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting","Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O'Donoghue JA, Ziolkowska M, Ruan S, Lyashchenko SK, Tsai F, Farwell M, Mitchell TC, Korn R, Le W, Lewis JS, Weber WA, Behera D, Wilson I, Gordon M, Wu AM, Wolchok JD.","J Nucl Med. 2020 Apr;61(4):512-519. doi: 10.2967/jnumed.119.229781. Epub 2019 Oct 4.","Pandit-Taskar N","J Nucl Med","2020","2019/10/06","PMC7198374","","10.2967/jnumed.119.229781"
"31715056","Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation","Sánchez-Fueyo A, Whitehouse G, Grageda N, Cramp ME, Lim TY, Romano M, Thirkell S, Lowe K, Fry L, Heward J, Kerr A, Ali J, Fisher C, Lewis G, Hope A, Kodela E, Lyne M, Farzaneh F, Kordasti S, Rebollo-Mesa I, Jose Lozano J, Safinia N, Heaton N, Lechler R, Martínez-Llordella M, Lombardi G.","Am J Transplant. 2020 Apr;20(4):1125-1136. doi: 10.1111/ajt.15700. Epub 2020 Feb 3.","Sánchez-Fueyo A","Am J Transplant","2020","2019/11/13","PMC7154724","","10.1111/ajt.15700"
"31873931","Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma","Smart AC, Goyal L, Horick N, Petkovska N, Zhu AX, Ferrone CR, Tanabe KK, Allen JN, Drapek LC, Qadan M, Murphy JE, Eyler CE, Ryan DP, Hong TS, Wo JY.","Ann Surg Oncol. 2020 Apr;27(4):1122-1129. doi: 10.1245/s10434-019-08142-9. Epub 2019 Dec 23.","Smart AC","Ann Surg Oncol","2020","2019/12/25","","","10.1245/s10434-019-08142-9"
"32031899","EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP.","J Clin Oncol. 2020 Apr 1;38(10):1041-1049. doi: 10.1200/JCO.19.02044. Epub 2020 Feb 7.","Rosenberg J","J Clin Oncol","2020","2020/02/08","PMC7106979","","10.1200/JCO.19.02044"
"32112737","Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study","Braat AJAT, Bruijnen RCG, van Rooij R, Braat MNGJA, Wessels FJ, van Leeuwaarde RS, van Treijen MJC, de Herder WW, Hofland J, Tesselaar MET, de Jong HWAM, Lam MGEH.","Lancet Oncol. 2020 Apr;21(4):561-570. doi: 10.1016/S1470-2045(20)30027-9. Epub 2020 Feb 26.","Braat AJAT","Lancet Oncol","2020","2020/03/01","","","10.1016/S1470-2045(20)30027-9"
"32112738","Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J.","Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26.","Qin S","Lancet Oncol","2020","2020/03/01","","","10.1016/S1470-2045(20)30011-5"
"32162844","Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors","Kim HK, Kang JW, Park YW, Kim JY, Kim M, Kim SJ, Kim SM, Ho Ryu K, Yoon S, Kim Y, Cho JY, Lee KS, Yun T, Kim K, Kwak MH, Kim TS, Chung J, Park JW.","Pharmacol Res Perspect. 2020 Apr;8(2):e00568. doi: 10.1002/prp2.568.","Kim HK","Pharmacol Res Perspect","2020","2020/03/13","PMC7066534","","10.1002/prp2.568"
"32198236","Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution","Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ.","Pharmacol Rev. 2020 Apr;72(2):486-526. doi: 10.1124/pr.119.018440.","Bharadwaj U","Pharmacol Rev","2020","2020/03/22","PMC7300325","","10.1124/pr.119.018440"
"32203980","Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial","Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G; TELESTO Study Investigators.","Ann Intern Med. 2020 Apr 21;172(8):513-522. doi: 10.7326/M19-0916. Epub 2020 Mar 24.","Angelucci E","Ann Intern Med","2020","2020/03/24","","","10.7326/M19-0916"
"31505228","A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease","Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, Waller EK, Burke E, Skerrett D, Shpall E, Martin PJ.","Biol Blood Marrow Transplant. 2020 May;26(5):835-844. doi: 10.1016/j.bbmt.2019.08.029. Epub 2019 Sep 7.","Kebriaei P","Biol Blood Marrow Transplant","2020","2019/09/11","PMC7060124","NIHMS1057685","10.1016/j.bbmt.2019.08.029"
"31870951","Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs","Paisant A, Vilgrain V, Riou J, Oberti F, Sutter O, Laurent V, Rodes A, Guiu B, Cassinotto C, Trillaud H, Bricault I, Michalak S, Bruno O, Ronot M, Aubé C.","J Hepatol. 2020 May;72(5):937-945. doi: 10.1016/j.jhep.2019.12.011. Epub 2019 Dec 21.","Paisant A","J Hepatol","2020","2019/12/25","","","10.1016/j.jhep.2019.12.011"
"31954087","Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials","Poordad F, Castro RE, Asatryan A, Aguilar H, Cacoub P, Dieterich D, Marinho RT, Carvalho A, Siddique A, Hu YB, Charafeddine M, Bondin M, Khan N, Cohen DE, Felizarta F.","J Viral Hepat. 2020 May;27(5):497-504. doi: 10.1111/jvh.13261. Epub 2020 Feb 17.","Poordad F","J Viral Hepat","2020","2020/01/19","","","10.1111/jvh.13261"
"32001057","Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial","Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, Bogart E, Le Deley MC, Steen V, Lacornerie T, Peiffert D, Mirabel X.","Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):116-125. doi: 10.1016/j.ijrobp.2019.12.004. Epub 2020 Jan 28.","Durand-Labrunie J","Int J Radiat Oncol Biol Phys","2020","2020/02/01","","","10.1016/j.ijrobp.2019.12.004"
"32052473","Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma","Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R.","Am J Hematol. 2020 May;95(5):510-520. doi: 10.1002/ajh.25757. Epub 2020 Feb 29.","Timmerman J","Am J Hematol","2020","2020/02/14","PMC7383599","","10.1002/ajh.25757"
"32052857","New Drugs for NASH and HIV Infection: Great Expectations for a Great Need","Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G; SHIVER Network.","Hepatology. 2020 May;71(5):1831-1844. doi: 10.1002/hep.31177.","Guaraldi G","Hepatology","2020","2020/02/14","","","10.1002/hep.31177"
"32101985","New systemic agents for hepatocellular carcinoma: an update 2020","von Felden J.","Curr Opin Gastroenterol. 2020 May;36(3):177-183. doi: 10.1097/MOG.0000000000000626.","von Felden J","Curr Opin Gastroenterol","2020","2020/02/27","","","10.1097/MOG.0000000000000626"
"32157435","An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases","Broadhurst PJ, Hart AR.","J Cancer Res Clin Oncol. 2020 May;146(5):1369-1375. doi: 10.1007/s00432-020-03177-y. Epub 2020 Mar 10.","Broadhurst PJ","J Cancer Res Clin Oncol","2020","2020/03/12","","","10.1007/s00432-020-03177-y"
"32238921","Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, Shin S, Becerra CR, Falchook G, Stoudemire J, Martin D, Kelnar K, Peltier H, Bonato V, Bader AG, Smith S, Kim S, O'Neill V, Beg MS.","Br J Cancer. 2020 May;122(11):1630-1637. doi: 10.1038/s41416-020-0802-1. Epub 2020 Apr 2.","Hong DS","Br J Cancer","2020","2020/04/03","PMC7251107","","10.1038/s41416-020-0802-1"
"32266457","A phase I study investigation of metabolism, and disposition of [(14)C]-anlotinib after an oral administration in patients with advanced refractory solid tumors","Liu Y, Liu L, Liu L, Wang T, Guo L, Wang Y, Gao Z, Shu Y.","Cancer Chemother Pharmacol. 2020 May;85(5):907-915. doi: 10.1007/s00280-020-04062-8. Epub 2020 Apr 7.","Liu Y","Cancer Chemother Pharmacol","2020","2020/04/09","PMC7188728","","10.1007/s00280-020-04062-8"
"32352320","IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation","Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S.","Future Oncol. 2020 May;16(15):975-989. doi: 10.2217/fon-2020-0162. Epub 2020 Apr 30.","Hack SP","Future Oncol","2020","2020/05/01","","","10.2217/fon-2020-0162"
"32385144","MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma","Engelhard VH, Obeng RC, Cummings KL, Petroni GR, Ambakhutwala AL, Chianese-Bullock KA, Smith KT, Lulu A, Varhegyi N, Smolkin ME, Myers P, Mahoney KE, Shabanowitz J, Buettner N, Hall EH, Haden K, Cobbold M, Hunt DF, Weiss G, Gaughan E, Slingluff CL Jr.","J Immunother Cancer. 2020 May;8(1):e000262. doi: 10.1136/jitc-2019-000262.","Engelhard VH","J Immunother Cancer","2020","2020/05/10","PMC7228659","","10.1136/jitc-2019-000262"
"32393323","Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial","Wang F, Qin S, Sun X, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Yan P, Zou J.","J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.","Wang F","J Hematol Oncol","2020","2020/05/13","PMC7216554","","10.1186/s13045-020-00886-2"
"32160294","Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ.","Blood. 2020 May 14;135(20):1739-1749. doi: 10.1182/blood.2020004823.","Jagasia M","Blood","2020","2020/03/12","PMC7229262","","10.1182/blood.2020004823"
"32402160","Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators.","N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.","Finn RS","N Engl J Med","2020","2020/05/14","","","10.1056/NEJMoa1915745"
"31996388","Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","Xie C, Duffy AG, Brar G, Fioravanti S, Mabry-Hrones D, Walker M, Bonilla CM, Wood BJ, Citrin DE, Gil Ramirez EM, Escorcia FE, Redd B, Hernandez JM, Davis JL, Gasmi B, Kleiner D, Steinberg SM, Jones JC, Greten TF.","Clin Cancer Res. 2020 May 15;26(10):2318-2326. doi: 10.1158/1078-0432.CCR-19-3624. Epub 2020 Jan 29.","Xie C","Clin Cancer Res","2020","2020/01/31","PMC8284008","NIHMS1718768","10.1158/1078-0432.CCR-19-3624"
"32086343","Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial","Lu M, Zhang P, Zhang Y, Li Z, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, Wang X, Zhou J, Peng Z, Wang W, Feng H, Wu H, Yao S, Shen L.","Clin Cancer Res. 2020 May 15;26(10):2337-2345. doi: 10.1158/1078-0432.CCR-19-4000. Epub 2020 Feb 21.","Lu M","Clin Cancer Res","2020","2020/02/23","","","10.1158/1078-0432.CCR-19-4000"
"32490343","Long-term survival outcomes following laparoscopic surgery for clinical stage 0/I rectal carcinoma","Ito M, Yamamoto S, Okuda J, Fujii S, Yamaguchi S, Otsuka K, Yoshimura K, Watanabe M; Japan Society of Laparoscopic Colorectal Surgery.","Ann Gastroenterol Surg. 2020 May 20;4(3):294-300. doi: 10.1002/ags3.12333. eCollection 2020 May.","Ito M","Ann Gastroenterol Surg","2020","2020/06/04","PMC7240150","","10.1002/ags3.12333"
"32547208","Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence","De Luca E, Marino D, Di Maio M.","Cancer Manag Res. 2020 May 20;12:3721-3729. doi: 10.2147/CMAR.S216220. eCollection 2020.","De Luca E","Cancer Manag Res","2020","2020/06/18","PMC7246316","","10.2147/CMAR.S216220"
"31385109","Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma","Sandhu S, McNeil CM, LoRusso P, Patel MR, Kabbarah O, Li C, Sanabria S, Flanagan WM, Yeh RF, Brunstein F, Nazzal D, Hicks R, Lemahieu V, Meng R, Hamid O, Infante JR.","Invest New Drugs. 2020 Jun;38(3):844-854. doi: 10.1007/s10637-019-00832-1. Epub 2019 Aug 5.","Sandhu S","Invest New Drugs","2020","2019/08/07","","","10.1007/s10637-019-00832-1"
"31404005","Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open Esophagectomy for Patients With Esophageal Cancer, Analysis of a Multicenter, Open-label, Randomized Phase III Controlled Trial: The MIRO Trial","Mariette C, Markar S, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, D'Journo XB, Brigand C, Perniceni T, Carrere N, Mabrut JY, Msika S, Peschaud F, Prudhomme M, Bonnetain F, Piessen G; FRENCH, FREGAT.","Ann Surg. 2020 Jun;271(6):1023-1029. doi: 10.1097/SLA.0000000000003559.","Mariette C","Ann Surg","2020","2019/08/13","","","10.1097/SLA.0000000000003559"
"31895753","Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)","Rozeman EA, Prevoo W, Meier MAJ, Sikorska K, Van TM, van de Wiel BA, van der Wal JE, Mallo HA, Grijpink-Ongering LG, Broeks A, Lalezari F, Reeves J, Warren S, van Thienen JV, van Tinteren H, Haanen JBAG, Kapiteijn E, Blank CU.","Melanoma Res. 2020 Jun;30(3):252-260. doi: 10.1097/CMR.0000000000000653.","Rozeman EA","Melanoma Res","2020","2020/01/03","","","10.1097/CMR.0000000000000653"
"32030887","The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose ((18) F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors","Lung MS, Hicks RJ, Pavlakis N, Link E, Jefford M, Thomson B, Wyld DK, Liauw W, Akhurst T, Kuru N, Michael M.","Asia Pac J Clin Oncol. 2020 Jun;16(3):150-157. doi: 10.1111/ajco.13307. Epub 2020 Feb 7.","Lung MS","Asia Pac J Clin Oncol","2020","2020/02/08","","","10.1111/ajco.13307"
"32107609","Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial","Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX.","J Gastroenterol. 2020 Jun;55(6):627-639. doi: 10.1007/s00535-020-01668-w. Epub 2020 Feb 27.","Kudo M","J Gastroenterol","2020","2020/02/29","PMC7242235","","10.1007/s00535-020-01668-w"
"32164877","Adjuvant (131)I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial","Li J, Xing J, Yang Y, Liu J, Wang W, Xia Y, Yan Z, Wang K, Wu D, Wu L, Wan X, Yang T, Gao C, Si A, Wang H, Wu M, Lau WY, Chen Z, Shen F.","Lancet Gastroenterol Hepatol. 2020 Jun;5(6):548-560. doi: 10.1016/S2468-1253(19)30422-4. Epub 2020 Mar 9.","Li J","Lancet Gastroenterol Hepatol","2020","2020/03/14","","","10.1016/S2468-1253(19)30422-4"
"32199197","Evolving role of regorafenib for the treatment of advanced cancers","Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J.","Cancer Treat Rev. 2020 Jun;86:101993. doi: 10.1016/j.ctrv.2020.101993. Epub 2020 Feb 20.","Grothey A","Cancer Treat Rev","2020","2020/03/22","","","10.1016/j.ctrv.2020.101993"
"32222826","Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","Vesterhus M, Karlsen TH.","J Gastroenterol. 2020 Jun;55(6):588-614. doi: 10.1007/s00535-020-01681-z. Epub 2020 Mar 28.","Vesterhus M","J Gastroenterol","2020","2020/03/31","PMC7242240","","10.1007/s00535-020-01681-z"
"32265508","Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma","Briggs A, Daniele B, Dick K, Evans TRJ, Galle PR, Hubner RA, Lopez C, Siebert U, Tremblay G.","Br J Cancer. 2020 Jun;122(12):1754-1759. doi: 10.1038/s41416-020-0817-7. Epub 2020 Apr 8.","Briggs A","Br J Cancer","2020","2020/04/09","PMC7283323","","10.1038/s41416-020-0817-7"
"32274666","Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer","Drullinsky PR, Hurvitz SA.","Breast Cancer Res Treat. 2020 Jun;181(2):233-248. doi: 10.1007/s10549-020-05618-1. Epub 2020 Apr 9.","Drullinsky PR","Breast Cancer Res Treat","2020","2020/04/11","","","10.1007/s10549-020-05618-1"
"32333527","Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study)","Smedman TM, Line PD, Hagness M, Syversveen T, Grut H, Dueland S.","BJS Open. 2020 Jun;4(3):467-477. doi: 10.1002/bjs5.50278. Epub 2020 Apr 25.","Smedman TM","BJS Open","2020","2020/04/26","PMC7260412","","10.1002/bjs5.50278"
"32335505","Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook","Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL.","Cancer Treat Rev. 2020 Jun;86:102017. doi: 10.1016/j.ctrv.2020.102017. Epub 2020 Mar 26.","Garcia J","Cancer Treat Rev","2020","2020/04/27","","","10.1016/j.ctrv.2020.102017"
"32419473","Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","Cai H, Zhang L, Li N, Zheng B, Liu M.","J Comp Eff Res. 2020 Jun;9(8):553-562. doi: 10.2217/cer-2020-0041. Epub 2020 May 18.","Cai H","J Comp Eff Res","2020","2020/05/19","","","10.2217/cer-2020-0041"
"32451495","BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ, Pedersen KS, Park JO, Ramirez RA, Abad DG, Feliu J, Muñoz A, Ponz-Sarvise M, Peled A, Lustig TM, Bohana-Kashtan O, Shaw SM, Sorani E, Chaney M, Kadosh S, Vainstein Haras A, Von Hoff DD, Hidalgo M.","Nat Med. 2020 Jun;26(6):878-885. doi: 10.1038/s41591-020-0880-x. Epub 2020 May 25.","Bockorny B","Nat Med","2020","2020/05/27","","","10.1038/s41591-020-0880-x"
"32502443","Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study","Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH; GO30140 investigators.","Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.","Lee MS","Lancet Oncol","2020","2020/06/06","","","10.1016/S1470-2045(20)30156-X"
"32581041","Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication","Wang W, Wu M, Liu M, Yan Z, Wang G, Mao D, Wang M.","J Immunother Cancer. 2020 Jun;8(1):e000793. doi: 10.1136/jitc-2020-000793. Epub 2020 Jun 23.","Wang W","J Immunother Cancer","2020","2020/06/26","PMC7312344","","10.1136/jitc-2020-000793"
"32278382","A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I","Ou L, Przybilla MJ, Ahlat O, Kim S, Overn P, Jarnes J, O'Sullivan MG, Whitley CB.","Mol Ther. 2020 Jun 3;28(6):1442-1454. doi: 10.1016/j.ymthe.2020.03.018. Epub 2020 Apr 8.","Ou L","Mol Ther","2020","2020/04/13","PMC7264433","","10.1016/j.ymthe.2020.03.018"
"32493473","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial","Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, McGuigan P, Jackson C, Boyle R, McFerran J, McDowell C, Campbell C, McFarland M, Smythe J, Thompson J, Williams B, Curley G, Laffey JG, Clarke M, O'Kane C, McAuley DF.","Trials. 2020 Jun 3;21(1):462. doi: 10.1186/s13063-020-04416-w.","Gorman E","Trials","2020","2020/06/05","PMC7267756","","10.1186/s13063-020-04416-w"
"32560632","Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatectomy for colo-rectal liver metastases","Deshayes E, Piron L, Bouvier A, Lapuyade B, Lermite E, Vervueren L, Laurent C, Pinaquy JB, Chevallier P, Dohan A, Rode A, Sengel C, Guillot C, Quenet F, Guiu B.","BMC Cancer. 2020 Jun 19;20(1):574. doi: 10.1186/s12885-020-07065-z.","Deshayes E","BMC Cancer","2020","2020/06/21","PMC7304136","","10.1186/s12885-020-07065-z"
"32430177","Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia","Zhang L, Lee C, Arnaoutova I, Anduaga J, Starost MF, Mansfield BC, Chou JY.","Biochem Biophys Res Commun. 2020 Jun 30;527(3):824-830. doi: 10.1016/j.bbrc.2020.04.124. Epub 2020 May 16.","Zhang L","Biochem Biophys Res Commun","2020","2020/05/21","PMC7309276","NIHMS1595319","10.1016/j.bbrc.2020.04.124"
"32093876","Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas - A Single Institution Phase II Study","Beaton L, Dunne EM, Yeung R, Rackley T, Weber B, Mar C, Yong-Hing CJ, Yoshida EM, DeVries K, Lee R, Duzenli C, Loewen SK, Liu M, Schellenberg D, Ma R.","Clin Oncol (R Coll Radiol). 2020 Jul;32(7):423-432. doi: 10.1016/j.clon.2020.01.028. Epub 2020 Feb 21.","Beaton L","Clin Oncol (R Coll Radiol)","2020","2020/02/26","","","10.1016/j.clon.2020.01.028"
"32147362","Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3; STELLAR-4 Investigators.","J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6.","Harrison SA","J Hepatol","2020","2020/03/10","","","10.1016/j.jhep.2020.02.027"
"32220283","Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","Kallas EG, Precioso AR, Palacios R, Thomé B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, da Graça Salomão M, da Silva A, Espinola HM, do Prado Santos J, Santos CLS, Timenetsky MDCST, Miraglia JL, Gallina NMF, Weiskopf D, Sette A, Goulart R, Salles RT, Maestri A, Sallum AME, Farhat SCL, Sakita NK, Ferreira JCOA, Silveira CGT, Costa PR, Raw I, Whitehead SS, Durbin AP, Kalil J.","Lancet Infect Dis. 2020 Jul;20(7):839-850. doi: 10.1016/S1473-3099(20)30023-2. Epub 2020 Mar 24.","Kallas EG","Lancet Infect Dis","2020","2020/03/30","","","10.1016/S1473-3099(20)30023-2"
"32378799","Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab","Fung AS, Tam VC, Meyers DE, Sim HW, Knox JJ, Zaborska V, Davies J, Ko YJ, Batuyong E, Samawi H, Cheung WY, Lee-Ying R.","Cancer Med. 2020 Jul;9(13):4640-4647. doi: 10.1002/cam4.3116. Epub 2020 May 7.","Fung AS","Cancer Med","2020","2020/05/08","PMC7333842","","10.1002/cam4.3116"
"32437694","Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma","Bailly C.","Chem Biol Interact. 2020 Jul 1;325:109124. doi: 10.1016/j.cbi.2020.109124. Epub 2020 May 11.","Bailly C","Chem Biol Interact","2020","2020/05/22","","","10.1016/j.cbi.2020.109124"
"32482534","""Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial""","Taïeb J, Benhaim L, Laurent Puig P, Le Malicot K, Emile JF, Geillon F, Tougeron D, Manfredi S, Chauvenet M, Taly V, Lepage C, André T.","Dig Liver Dis. 2020 Jul;52(7):730-733. doi: 10.1016/j.dld.2020.04.010. Epub 2020 May 29.","Taïeb J","Dig Liver Dis","2020","2020/06/03","","","10.1016/j.dld.2020.04.010"
"32491932","Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design","Kelley RK, W Oliver J, Hazra S, Benzaghou F, Yau T, Cheng AL, Rimassa L.","Future Oncol. 2020 Jul;16(21):1525-1536. doi: 10.2217/fon-2020-0283. Epub 2020 Jun 3.","Kelley RK","Future Oncol","2020","2020/06/04","","","10.2217/fon-2020-0283"
"32497895","Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study","Chen S, Zhang K, Liu W, Yu W.","Eur J Cancer. 2020 Jul;134:90-98. doi: 10.1016/j.ejca.2020.03.032. Epub 2020 Jun 1.","Chen S","Eur J Cancer","2020","2020/06/05","","","10.1016/j.ejca.2020.03.032"
"32615109","Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial","Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C.","Lancet Oncol. 2020 Jul;21(7):947-956. doi: 10.1016/S1470-2045(20)30224-2.","Mazzaferro V","Lancet Oncol","2020","2020/07/03","","","10.1016/S1470-2045(20)30224-2"
"32641137","Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer","Elshenawy MA, Badran A, Aljubran A, Alzahrani A, Rauf MS, Eldali A, Bazarbashi S.","World J Surg Oncol. 2020 Jul 8;18(1):163. doi: 10.1186/s12957-020-01930-8.","Elshenawy MA","World J Surg Oncol","2020","2020/07/10","PMC7346377","","10.1186/s12957-020-01930-8"
"32641747","Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis","O'Shaughnessy J, Cortes J, Twelves C, Goldstein LJ, Alexis K, Xie R, Barrios C, Ueno T.","Sci Rep. 2020 Jul 8;10(1):11203. doi: 10.1038/s41598-020-66980-0.","O'Shaughnessy J","Sci Rep","2020","2020/07/10","PMC7343788","","10.1038/s41598-020-66980-0"
"32646502","Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial","Saiz-Rodríguez M, Peña T, Lázaro L, González Á, Martínez A, Cordero JA, Vicente JT, Richard F, Coma MJ, de Frutos M, Labrador J, Pueyo A.","Trials. 2020 Jul 9;21(1):632. doi: 10.1186/s13063-020-04575-w.","Saiz-Rodríguez M","Trials","2020","2020/07/11","PMC7344042","","10.1186/s13063-020-04575-w"
"32674461","Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)","Riaño I, Martín L, Varela M, Serrano T, Núñez O, Mínguez B, Rodrigues PM, Perugorria MJ, Banales JM, Arenas JI.","Cancers (Basel). 2020 Jul 14;12(7):1900. doi: 10.3390/cancers12071900.","Riaño I","Cancers (Basel)","2020","2020/07/18","PMC7409102","","10.3390/cancers12071900"
"32702075","Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry","Wang C, Zhang J, Zhou S, Yu L, Han F, Ling R, Ling J.","PLoS One. 2020 Jul 23;15(7):e0236523. doi: 10.1371/journal.pone.0236523. eCollection 2020.","Wang C","PLoS One","2020","2020/07/24","PMC7377447","","10.1371/journal.pone.0236523"
"32279446","Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2","Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Drove Ubreva N, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX.","Liver Int. 2020 Aug;40(8):2008-2020. doi: 10.1111/liv.14462. Epub 2020 May 6.","Kudo M","Liver Int","2020","2020/04/13","","","10.1111/liv.14462"
"32343960","JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection","Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, Streinu-Cercel A, Bourgeois S, Buti M, Crespo J, Manuel Pascasio J, Sarrazin C, Vanwolleghem T, Shukla U, Fry J, Yogaratnam JZ.","Gastroenterology. 2020 Aug;159(2):521-533.e9. doi: 10.1053/j.gastro.2020.04.036. Epub 2020 Apr 25.","Zoulim F","Gastroenterology","2020","2020/04/29","","","10.1053/j.gastro.2020.04.036"
"32357963","MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial","Sarker D, Plummer R, Meyer T, Sodergren MH, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, Spalding DRC, Pai M, Sharma R, Pinato DJ, Spicer J, Hunter S, Kwatra V, Nicholls JP, Collin D, Nutbrown R, Glenny H, Fairbairn S, Reebye V, Voutila J, Dorman S, Andrikakou P, Lloyd P, Felstead S, Vasara J, Habib R, Wood C, Saetrom P, Huber HE, Blakey DC, Rossi JJ, Habib N.","Clin Cancer Res. 2020 Aug 1;26(15):3936-3946. doi: 10.1158/1078-0432.CCR-20-0414. Epub 2020 May 1.","Sarker D","Clin Cancer Res","2020","2020/05/03","","","10.1158/1078-0432.CCR-20-0414"
"32362018","Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): Long-term results of survival","Okuno M, Hatano E, Toda R, Nishino H, Nakamura K, Ishii T, Seo S, Taura K, Yasuchika K, Yazawa T, Zaima M, Kanazawa A, Terajima H, Kaihara S, Adachi Y, Inoue N, Furumoto K, Manaka D, Tokuka A, Furuyama H, Doi K, Hirose T, Horimatsu T, Hasegawa S, Matsumoto S, Sakai Y, Uemoto S.","J Hepatobiliary Pancreat Sci. 2020 Aug;27(8):496-509. doi: 10.1002/jhbp.747. Epub 2020 Jun 9.","Okuno M","J Hepatobiliary Pancreat Sci","2020","2020/05/04","","","10.1002/jhbp.747"
"32371538","Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials","Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, Lu Q, Gao H, Jiang H, Wang H, Yuan D, Ma H, Wang H, Li Z, Zhai B.","Clin Cancer Res. 2020 Aug 1;26(15):3979-3989. doi: 10.1158/1078-0432.CCR-19-3259. Epub 2020 May 5.","Shi D","Clin Cancer Res","2020","2020/05/07","","","10.1158/1078-0432.CCR-19-3259"
"32449239","Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis","Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T.","Cancer Sci. 2020 Aug;111(8):2747-2759. doi: 10.1111/cas.14497. Epub 2020 Jun 18.","Taniguchi M","Cancer Sci","2020","2020/05/26","PMC7419030","","10.1111/cas.14497"
"32507854","Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study","Pernot S, Pellerin O, Artru P, Montérymard C, Smith D, Raoul JL, De La Fouchardière C, Dahan L, Guimbaud R, Sefrioui D, Jouve JL, Lepage C, Tougeron D, Taieb J; for FFCD1201-DEBIRI investigators/Collaborators.","Br J Cancer. 2020 Aug;123(4):518-524. doi: 10.1038/s41416-020-0917-4. Epub 2020 Jun 8.","Pernot S","Br J Cancer","2020","2020/06/09","PMC7435188","","10.1038/s41416-020-0917-4"
"32562334","Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria","Sho T, Suda G, Ogawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Ito J, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Terasita K, Takagi T, Kamiyama T, Taketomi A, Sakamoto N.","Hepatol Res. 2020 Aug;50(8):966-977. doi: 10.1111/hepr.13511. Epub 2020 Jul 9.","Sho T","Hepatol Res","2020","2020/06/21","","","10.1111/hepr.13511"
"32577940","Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer","Ham A, Kim MH, Kim GM, Kim JH, Kim JY, Park HS, Park S, Cho YU, Park BW, Kim SI, Sohn J.","Breast Cancer Res Treat. 2020 Aug;183(1):107-116. doi: 10.1007/s10549-020-05750-y. Epub 2020 Jun 23.","Ham A","Breast Cancer Res Treat","2020","2020/06/25","","","10.1007/s10549-020-05750-y"
"32671491","[Immuno-oncology : No longer a need for interventional radiology?]","Saborowski A, Vogel A.","Radiologe. 2020 Aug;60(8):687-692. doi: 10.1007/s00117-020-00722-1.","Saborowski A","Radiologe","2020","2020/07/17","","","10.1007/s00117-020-00722-1"
"32671719","Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives","Trojan J.","Drugs. 2020 Aug;80(12):1203-1210. doi: 10.1007/s40265-020-01361-5.","Trojan J","Drugs","2020","2020/07/17","PMC7395054","","10.1007/s40265-020-01361-5"
"32710148","Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer","Kito Y, Satake H, Taniguchi H, Yamada T, Horie Y, Esaki T, Denda T, Yasui H, Izawa N, Masuishi T, Moriwaki T, Mori K, Yamazaki K.","Cancer Chemother Pharmacol. 2020 Aug;86(2):277-284. doi: 10.1007/s00280-020-04116-x. Epub 2020 Jul 24.","Kito Y","Cancer Chemother Pharmacol","2020","2020/07/26","","","10.1007/s00280-020-04116-x"
"32734398","A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401)","Samura H, Oki E, Okumura H, Yoshida T, Kai S, Kobayashi K, Kinjo T, Mori S, Tohyama T, Ohgaki K, Kawanaka H, Makiyama A, Ureshino N, Kotaka M, Shimose T, Ando K, Saeki H, Baba H, Maehara Y, Mori M.","Cancer Chemother Pharmacol. 2020 Aug;86(2):285-294. doi: 10.1007/s00280-020-04108-x. Epub 2020 Jul 30.","Samura H","Cancer Chemother Pharmacol","2020","2020/08/01","","","10.1007/s00280-020-04108-x"
"32817068","Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials","Zhu AX, Nipp RD, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Wang C, Hsu Y, Abada PB, Kudo M.","ESMO Open. 2020 Aug;5(4):e000797. doi: 10.1136/esmoopen-2020-000797.","Zhu AX","ESMO Open","2020","2020/08/21","PMC7437873","","10.1136/esmoopen-2020-000797"
"32843490","Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors","Naing A, Eder JP, Piha-Paul SA, Gimmi C, Hussey E, Zhang S, Hildebrand V, Hosagrahara V, Habermehl C, Moisan J, Papadopoulos KP.","J Immunother Cancer. 2020 Aug;8(2):e000870. doi: 10.1136/jitc-2020-000870.","Naing A","J Immunother Cancer","2020","2020/08/27","PMC7449315","","10.1136/jitc-2020-000870"
"32843493","HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","Katz SC, Moody AE, Guha P, Hardaway JC, Prince E, LaPorte J, Stancu M, Slansky JE, Jordan KR, Schulick RD, Knight R, Saied A, Armenio V, Junghans RP.","J Immunother Cancer. 2020 Aug;8(2):e001097. doi: 10.1136/jitc-2020-001097.","Katz SC","J Immunother Cancer","2020","2020/08/27","PMC7449487","","10.1136/jitc-2020-001097"
"32847838","Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial","Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK.","ESMO Open. 2020 Aug;5(4):e000714. doi: 10.1136/esmoopen-2020-000714.","Kelley RK","ESMO Open","2020","2020/08/28","PMC7451459","","10.1136/esmoopen-2020-000714"
"32745082","Using machine learning algorithms to review computed tomography scans and assess risk for cardiovascular disease: Retrospective analysis from the National Lung Screening Trial (NLST)","Stemmer A, Shadmi R, Bregman-Amitai O, Chettrit D, Blagev D, Orlovsky M, Deutsch L, Elnekave E.","PLoS One. 2020 Aug 3;15(8):e0236021. doi: 10.1371/journal.pone.0236021. eCollection 2020.","Stemmer A","PLoS One","2020","2020/08/04","PMC7398499","","10.1371/journal.pone.0236021"
"32850414","Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy Does Not Improve Treatment Outcomes for Stage II Nasopharyngeal Carcinoma: A Phase 2 Multicenter Clinical Trial","Huang X, Chen X, Zhao C, Wang J, Wang K, Wang L, Miao J, Cao C, Jin T, Zhang Y, Qu Y, Chen X, Liu Q, Zhang S, Zhang J, Luo J, Xiao J, Xu G, Gao L, Yi J.","Front Oncol. 2020 Aug 7;10:1314. doi: 10.3389/fonc.2020.01314. eCollection 2020.","Huang X","Front Oncol","2020","2020/08/28","PMC7426506","","10.3389/fonc.2020.01314"
"32795340","Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma","Shiba S, Shibuya K, Okamoto M, Okazaki S, Komatsu S, Kubota Y, Nakano T, Ohno T.","Radiat Oncol. 2020 Aug 14;15(1):195. doi: 10.1186/s13014-020-01634-z.","Shiba S","Radiat Oncol","2020","2020/08/16","PMC7427730","","10.1186/s13014-020-01634-z"
"31840815","Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer","Wolstenholme J, Fusco F, Gray AM, Moschandreas J, Virdee PS, Love S, Van Hazel G, Gibbs P, Wasan HS, Sharma RA.","Int J Cancer. 2020 Aug 15;147(4):1078-1085. doi: 10.1002/ijc.32828. Epub 2020 Jan 9.","Wolstenholme J","Int J Cancer","2020","2019/12/17","","","10.1002/ijc.32828"
"32779505","Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers","Climax J, Newsome PN, Hamza M, Weissbach M, Coughlan D, Sattar N, McGuire DK, Bhatt DL.","J Am Heart Assoc. 2020 Aug 18;9(16):e016334. doi: 10.1161/JAHA.119.016334. Epub 2020 Aug 11.","Climax J","J Am Heart Assoc","2020","2020/08/12","PMC7660824","","10.1161/JAHA.119.016334"
"32923171","Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)","Schimanski CC, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Heinemann V, Geißler M, Schulz-Abelius A, Bernhard H, Schön MR, Greil R, Galle P, Lang H, Schmidtmann I, Moehler M.","Oncoimmunology. 2020 Aug 23;9(1):1806680. doi: 10.1080/2162402X.2020.1806680.","Schimanski CC","Oncoimmunology","2020","2020/09/14","PMC7458621","","10.1080/2162402X.2020.1806680"
"32007393","Effect of remote ischemic preConditioning on liver injury in patients undergoing liver resection: the ERIC-LIVER trial","Teo JY, Ho AFW, Bulluck H, Gao F, Chong J, Koh YX, Tan EK, Abdul Latiff JB, Chua SH, Goh BKP, Chan CY, Chung AYF, Lee SY, Cheow PC, Ooi LLPJ, Davidson BR, Jevaraj PR, Hausenloy DJ.","HPB (Oxford). 2020 Sep;22(9):1250-1257. doi: 10.1016/j.hpb.2019.12.002. Epub 2020 Jan 30.","Teo JY","HPB (Oxford)","2020","2020/02/03","","","10.1016/j.hpb.2019.12.002"
"32123969","Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study","Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E; NETTER-1 study group.","Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382. doi: 10.1007/s00259-020-04709-x. Epub 2020 Mar 2.","Strosberg J","Eur J Nucl Med Mol Imaging","2020","2020/03/04","PMC7396396","","10.1007/s00259-020-04709-x"
"32169919","Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies","Matesan M, Fisher DR, Wong R, Gopal AK, Green DJ, Sandmaier BM, Bensinger W, Pagel JM, Orozco J, Press OW, Cassaday RD, Hutchinson E, Wanner M, Pal S, Thostenson C, Rajendran JG.","J Nucl Med. 2020 Sep;61(9):1300-1306. doi: 10.2967/jnumed.119.234443. Epub 2020 Mar 13.","Matesan M","J Nucl Med","2020","2020/03/15","PMC7456175","","10.2967/jnumed.119.234443"
"32278676","Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected","Sastre J, Orden V, Martínez A, Bando I, Balbín M, Bellosillo B, Palanca S, Peligros Gomez MI, Mediero B, Llovet P, Moral VM, Viéitez JM, García-Alfonso P, Calle SG, Ortiz-Morales MJ, Salud A, Quintero G, Lopez C, Díaz-Rubio E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).","Clin Colorectal Cancer. 2020 Sep;19(3):e110-e116. doi: 10.1016/j.clcc.2020.02.014. Epub 2020 Mar 6.","Sastre J","Clin Colorectal Cancer","2020","2020/04/13","","","10.1016/j.clcc.2020.02.014"
"32324927","Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort","Doi T, Fujiwara Y, Koyama T, Ikeda M, Helwig C, Watanabe M, Vugmeyster Y, Kudo M.","Oncologist. 2020 Sep;25(9):e1292-e1302. doi: 10.1634/theoncologist.2020-0249. Epub 2020 Apr 23.","Doi T","Oncologist","2020","2020/04/24","PMC7485354","","10.1634/theoncologist.2020-0249"
"32366155","The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial","Labeur TA, Hofsink Q, Takkenberg RB, van Delden OM, Mathôt RAA, Schinner R, Malfertheiner P, Amthauer H, Schütte K, Basu B, Kuhl C, Mayerle J, Ricke J, Klümpen HJ.","Acta Oncol. 2020 Sep;59(9):1028-1035. doi: 10.1080/0284186X.2020.1759826. Epub 2020 May 5.","Labeur TA","Acta Oncol","2020","2020/05/06","","","10.1080/0284186X.2020.1759826"
"32382820","Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?","Baek KA, Kim SS, Shin HC, Hwang JA, Choi SY, Lee WH, Park CH, Lee HN, Heo NH.","Abdom Radiol (NY). 2020 Sep;45(9):2705-2716. doi: 10.1007/s00261-020-02553-z.","Baek KA","Abdom Radiol (NY)","2020","2020/05/09","","","10.1007/s00261-020-02553-z"
"32387070","Intraoperative electrochemotherapy of colorectal liver metastases: A prospective phase II study","Edhemovic I, Brecelj E, Cemazar M, Boc N, Trotovsek B, Djokic M, Dezman R, Ivanecz A, Potrc S, Bosnjak M, Markelc B, Kos B, Miklavcic D, Gasljevic G, Sersa G.","Eur J Surg Oncol. 2020 Sep;46(9):1628-1633. doi: 10.1016/j.ejso.2020.04.037. Epub 2020 Apr 25.","Edhemovic I","Eur J Surg Oncol","2020","2020/05/11","","","10.1016/j.ejso.2020.04.037"
"32402681","A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases","Chun YJ, Kim SG, Lee KW, Cho SH, Kim TW, Baek JY, Park YS, Hong S, Chu CW, Beom SH, Jung M, Shin SJ, Ahn JB.","Clin Colorectal Cancer. 2020 Sep;19(3):e140-e150. doi: 10.1016/j.clcc.2020.03.004. Epub 2020 Apr 2.","Chun YJ","Clin Colorectal Cancer","2020","2020/05/14","","","10.1016/j.clcc.2020.03.004"
"32417993","Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients","Ruanglertboon W, Sorich MJ, Rowland A, Hopkins AM.","Int J Clin Oncol. 2020 Sep;25(9):1672-1677. doi: 10.1007/s10147-020-01698-7. Epub 2020 May 16.","Ruanglertboon W","Int J Clin Oncol","2020","2020/05/18","","","10.1007/s10147-020-01698-7"
"32518098","Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis","Indraccolo S, De Salvo GL, Verza M, Caccese M, Esposito G, Piga I, Del Bianco P, Pizzi M, Gardiman MP, Eoli M, Rudà R, Brandes AA, Ibrahim T, Rizzato S, Lolli I, Zagonel V, Lombardi G.","Clin Cancer Res. 2020 Sep 1;26(17):4478-4484. doi: 10.1158/1078-0432.CCR-19-4055. Epub 2020 Jun 9.","Indraccolo S","Clin Cancer Res","2020","2020/06/11","","","10.1158/1078-0432.CCR-19-4055"
"32683787","Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics","Chigutsa E, Kambhampati SRP, Karen Sykes A, Posada MM, van der Walt JS, Turner PK.","CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):523-533. doi: 10.1002/psp4.12544. Epub 2020 Aug 13.","Chigutsa E","CPT Pharmacometrics Syst Pharmacol","2020","2020/07/20","PMC7499187","","10.1002/psp4.12544"
"32712457","A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy","Hirbe AC, Eulo V, Moon CI, Luo J, Myles S, Seetharam M, Toeniskoetter J, Kershner T, Haarberg S, Agulnik M, Monga V, Milhem M, Parkes A, Robinson S, Okuno S, Attia S, Van Tine BA.","Eur J Cancer. 2020 Sep;137:1-9. doi: 10.1016/j.ejca.2020.06.016. Epub 2020 Jul 23.","Hirbe AC","Eur J Cancer","2020","2020/07/27","","","10.1016/j.ejca.2020.06.016"
"32768872","Fibrolamellar carcinoma: Challenging the challenge","Lamarca A, Frizziero M, Fulton A, McNamara MG, Filobbos R, Hubner RA, Wardell S, Valle JW.","Eur J Cancer. 2020 Sep;137:144-147. doi: 10.1016/j.ejca.2020.06.035. Epub 2020 Aug 5.","Lamarca A","Eur J Cancer","2020","2020/08/10","","","10.1016/j.ejca.2020.06.035"
"32769854","Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors","Ghobrial SN, Menda Y, Zamba GK, Mott SL, Gaimari-Varner K, Dick D, Dillon J, Howe JR, Graham M, Sunderland J, Bellizzi A, O'Dorisio TM, O'Dorisio MS.","Pancreas. 2020 Sep;49(8):1033-1036. doi: 10.1097/MPA.0000000000001625.","Ghobrial SN","Pancreas","2020","2020/08/10","PMC7447173","","10.1097/MPA.0000000000001625"
"32771858","Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data","Passaro A, Attili I, Morganti S, Del Signore E, Gianoncelli L, Spitaleri G, Stati V, Catania C, Curigliano G, de Marinis F.","Cancer Treat Rev. 2020 Sep;89:102085. doi: 10.1016/j.ctrv.2020.102085. Epub 2020 Jul 22.","Passaro A","Cancer Treat Rev","2020","2020/08/11","","","10.1016/j.ctrv.2020.102085"
"32798144","Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)","Shimoyama R, Hijioka S, Mizuno N, Ogawa G, Kataoka T, Katayama H, Machida N, Honma Y, Boku N, Hamaguchi T, Fukuda H, Terashima M, Kanemitsu Y, Furuse J; Stomach Cancer Study Group/Colorectal Cancer Study Group/Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group.","Pancreatology. 2020 Sep;20(6):1183-1188. doi: 10.1016/j.pan.2020.07.010. Epub 2020 Jul 25.","Shimoyama R","Pancreatology","2020","2020/08/17","","","10.1016/j.pan.2020.07.010"
"32827847","Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)","Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M, Goff L, Laing N, Mi G, Oliveira JM, Wasserstrom H, Lin CC.","Eur J Cancer. 2020 Sep;137:272-284. doi: 10.1016/j.ejca.2020.06.007. Epub 2020 Aug 19.","Bang YJ","Eur J Cancer","2020","2020/08/23","","","10.1016/j.ejca.2020.06.007"
"33083284","Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis","Cheon J, Chon HJ, Bang Y, Park NH, Shin JW, Kim KM, Lee HC, Lee J, Yoo C, Ryoo BY.","Liver Cancer. 2020 Sep;9(5):613-624. doi: 10.1159/000508901. Epub 2020 Jul 29.","Cheon J","Liver Cancer","2020","2020/10/21","PMC7548882","","10.1159/000508901"
"33145266","Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial","Hou Z, Zhu K, Yang X, Chen P, Zhang W, Cui Y, Zhu X, Song T, Li Q, Li H, Zhang T.","Ann Transl Med. 2020 Sep;8(17):1047. doi: 10.21037/atm-20-2990.","Hou Z","Ann Transl Med","2020","2020/11/04","PMC7576000","","10.21037/atm-20-2990"
"32899071","Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study","Hosokawa A, Yamazaki K, Matsuda C, Ueda S, Kusaba H, Okamura S, Tsuda M, Tamura T, Shinozaki K, Tsushima T, Tsuda T, Shirakawa T, Yamashita H, Morita S, Hironaka S, Muro K.","Medicine (Baltimore). 2020 Sep 4;99(36):e22060. doi: 10.1097/MD.0000000000022060.","Hosokawa A","Medicine (Baltimore)","2020","2020/09/09","PMC7478588","","10.1097/MD.0000000000022060"
"32716739","Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma","Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM.","J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.","Finn RS","J Clin Oncol","2020","2020/07/28","PMC7479760","","10.1200/JCO.20.00808"
"31621832","Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults","Healy SA, Murphy SC, Hume JCC, Shelton L, Kuntz S, Van Voorhis WC, Moodie Z, Metch B, Wang R, Silver-Brace T, Fishbaugher M, Kennedy M, Finney OC, Chaturvedi R, Marcsisin SR, Hobbs CV, Warner-Lubin M, Talley AK, Wong-Madden S, Stuart K, Wald A, Kappe SH, Kublin JG, Duffy PE.","Clin Infect Dis. 2020 Sep 12;71(6):1481-1490. doi: 10.1093/cid/ciz1010.","Healy SA","Clin Infect Dis","2020","2019/10/18","PMC7486848","","10.1093/cid/ciz1010"
"32616501","First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors","McLeod R, Kumar R, Papadatos-Pastos D, Mateo J, Brown JS, Garces AHI, Ruddle R, Decordova S, Jueliger S, Ferraldeschi R, Maiques O, Sanz-Moreno V, Jones P, Traub S, Halbert G, Mellor S, Swales KE, Raynaud FI, Garrett MD, Banerji U.","Clin Cancer Res. 2020 Sep 15;26(18):4777-4784. doi: 10.1158/1078-0432.CCR-20-0700. Epub 2020 Jul 2.","McLeod R","Clin Cancer Res","2020","2020/07/04","PMC7611345","EMS128716","10.1158/1078-0432.CCR-20-0700"
"32636319","Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma","Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK.","Clin Cancer Res. 2020 Sep 15;26(18):4795-4804. doi: 10.1158/1078-0432.CCR-19-3884. Epub 2020 Jul 7.","Kelley RK","Clin Cancer Res","2020","2020/07/09","PMC7779341","NIHMS1653838","10.1158/1078-0432.CCR-19-3884"
"33235994","Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02","Chen H, Kuhn J, Lamborn KR, Abrey LE, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WKA, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Wen PY, Gilbert MR.","Neurooncol Adv. 2020 Sep 17;2(1):vdaa124. doi: 10.1093/noajnl/vdaa124. eCollection 2020 Jan-Dec.","Chen H","Neurooncol Adv","2020","2020/11/25","PMC7668489","","10.1093/noajnl/vdaa124"
"31891240","Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment","Li Y, MacGorman K, Liu L, Chen J, Hoffmann M, Palmisano M, Zhou S.","Clin Pharmacol Drug Dev. 2020 Oct;9(7):785-796. doi: 10.1002/cpdd.760. Epub 2019 Dec 31.","Li Y","Clin Pharmacol Drug Dev","2020","2020/01/01","","","10.1002/cpdd.760"
"31965579","Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH","Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C, Lavine J, Van Natta M, Middleton M, Tonascia J, Sirlin C; NASH Clinical Research Network.","Hepatology. 2020 Oct;72(4):1219-1229. doi: 10.1002/hep.31121. Epub 2020 Oct 9.","Loomba R","Hepatology","2020","2020/01/23","PMC8055244","NIHMS1585320","10.1002/hep.31121"
"32198649","First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors","Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H, Furuse J.","Invest New Drugs. 2020 Oct;38(5):1495-1506. doi: 10.1007/s10637-020-00924-3. Epub 2020 Mar 20.","Okano N","Invest New Drugs","2020","2020/03/22","","","10.1007/s10637-020-00924-3"
"32419304","Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate","Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, Manukyan Z, Banfield C, Saunders M, Chandra D, Vincent MS, Mancuso J, Peeva E, Beebe JS.","Arthritis Rheumatol. 2020 Oct;72(10):1621-1631. doi: 10.1002/art.41316. Epub 2020 Sep 7.","Robinson MF","Arthritis Rheumatol","2020","2020/05/19","PMC7589242","","10.1002/art.41316"
"32449002","The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib","Ruanglertboon W, Sorich MJ, Logan JM, Rowland A, Hopkins AM.","J Cancer Res Clin Oncol. 2020 Oct;146(10):2693-2697. doi: 10.1007/s00432-020-03261-3. Epub 2020 May 24.","Ruanglertboon W","J Cancer Res Clin Oncol","2020","2020/05/26","","","10.1007/s00432-020-03261-3"
"32463975","Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study","Chiang NJ, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS, Shan YS, Chen LT.","Liver Int. 2020 Oct;40(10):2535-2543. doi: 10.1111/liv.14538. Epub 2020 Jun 9.","Chiang NJ","Liver Int","2020","2020/05/29","PMC7540301","","10.1111/liv.14538"
"32495229","Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases","Murono K, Nozawa H, Nagata H, Ishimaru K, Sonoda H, Emoto S, Kaneko M, Sasaki K, Otani K, Kawai K, Muro K, Ishihara S.","Int J Colorectal Dis. 2020 Oct;35(10):1945-1949. doi: 10.1007/s00384-020-03649-0. Epub 2020 Jun 3.","Murono K","Int J Colorectal Dis","2020","2020/06/05","","","10.1007/s00384-020-03649-0"
"32514802","A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial)","Mise Y, Hasegawa K, Saiura A, Oba M, Yamamoto J, Nomura Y, Takayama T, Hashiguchi Y, Shibasaki M, Sakamoto H, Yamagata S, Aoyanagi N, Kaneko H, Koyama H, Miyagawa S, Shinozaki E, Yoshida S, Nozawa H, Kokudo N.","Ann Surg Oncol. 2020 Oct;27(11):4188-4195. doi: 10.1245/s10434-020-08627-y. Epub 2020 Jun 8.","Mise Y","Ann Surg Oncol","2020","2020/06/10","","","10.1245/s10434-020-08627-y"
"32527643","Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial","Liu Y, Guo Y, Wu Z, Feng K, Tong C, Wang Y, Dai H, Shi F, Yang Q, Han W.","Cytotherapy. 2020 Oct;22(10):573-580. doi: 10.1016/j.jcyt.2020.04.088. Epub 2020 Jun 9.","Liu Y","Cytotherapy","2020","2020/06/13","","","10.1016/j.jcyt.2020.04.088"
"32594454","Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity","Lewis JH, Cottu PH, Lehr M, Dick E, Shearer T, Rencher W, Bexon AS, Campone M, Varga A, Italiano A.","Drug Saf. 2020 Oct;43(10):1045-1055. doi: 10.1007/s40264-020-00964-x.","Lewis JH","Drug Saf","2020","2020/06/29","PMC7497701","","10.1007/s40264-020-00964-x"
"32605910","Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma","Bachet JB, Blons H, Hammel P, Hariry IE, Portales F, Mineur L, Metges JP, Mulot C, Bourreau C, Cain J, Cros J, Laurent-Puig P.","Clin Cancer Res. 2020 Oct 1;26(19):5208-5216. doi: 10.1158/1078-0432.CCR-20-0950. Epub 2020 Jun 30.","Bachet JB","Clin Cancer Res","2020","2020/07/02","","","10.1158/1078-0432.CCR-20-0950"
"32646200","Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial","Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, An J, Jung J, Kim JH, Lee HC.","Clin Mol Hepatol. 2020 Oct;26(4):506-515. doi: 10.3350/cmh.2020.0038. Epub 2020 Jul 10.","Yoon SM","Clin Mol Hepatol","2020","2020/07/11","PMC7641557","","10.3350/cmh.2020.0038"
"32716114","A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma","Kudo M, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Nakashima D, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J.","Cancer Sci. 2020 Oct;111(10):3759-3769. doi: 10.1111/cas.14582. Epub 2020 Aug 26.","Kudo M","Cancer Sci","2020","2020/07/28","PMC7541009","","10.1111/cas.14582"
"32747302","Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study","Manfredi S, Turpin A, Malka D, Barbier E, Laurent-Puig P, Zaanan A, Dahan L, Lièvre A, Phelip JM, Michel P, Hautefeuille V, Legoux JL, Lepage C, Tougeron D, Aparicio T.","Dig Liver Dis. 2020 Oct;52(10):1143-1147. doi: 10.1016/j.dld.2020.06.034. Epub 2020 Jul 31.","Manfredi S","Dig Liver Dis","2020","2020/08/05","","","10.1016/j.dld.2020.06.034"
"32816079","Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy","Chiesa S, Hohaus S, Falcinelli L, D'Alò F, Martelli MF, Manfrida S, Beghella Bartoli F, Colosimo C, Valentini V, Aristei C, Balducci M.","Ann Hematol. 2020 Oct;99(10):2367-2375. doi: 10.1007/s00277-020-04220-1. Epub 2020 Aug 20.","Chiesa S","Ann Hematol","2020","2020/08/21","","","10.1007/s00277-020-04220-1"
"32841541","Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib","El Dika I, Capanu M, Chou JF, Harding JJ, Ly M, Hrabovsky AD, Do RKG, Shia J, Millang B, Ma J, O'Reilly EM, Abou-Alfa GK.","Cancer Med. 2020 Oct;9(20):7453-7459. doi: 10.1002/cam4.3389. Epub 2020 Aug 25.","El Dika I","Cancer Med","2020","2020/08/26","PMC7571806","","10.1002/cam4.3389"
"32866432","Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV.","Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.","Kumar SK","Lancet Oncol","2020","2020/09/01","PMC7591827","NIHMS1627957","10.1016/S1470-2045(20)30452-6"
"32876349","Long-term safety of vedolizumab for inflammatory bowel disease","Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, Danese S, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S.","Aliment Pharmacol Ther. 2020 Oct;52(8):1353-1365. doi: 10.1111/apt.16060. Epub 2020 Sep 2.","Loftus EV Jr","Aliment Pharmacol Ther","2020","2020/09/03","PMC7540482","","10.1111/apt.16060"
"33002436","Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S.","Lancet Oncol. 2020 Oct;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4.","Emens LA","Lancet Oncol","2020","2020/10/01","","","10.1016/S1470-2045(20)30465-4"
"33037118","Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis","Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, Gourdin T, Dirix L, Lee KW, Taylor MH, Schöffski P, Wang D, Ravaud A, Manitz J, Pennock G, Ruisi M, Gulley JL, Patel MR.","J Immunother Cancer. 2020 Oct;8(2):e001246. doi: 10.1136/jitc-2020-001246.","Apolo AB","J Immunother Cancer","2020","2020/10/10","PMC7549450","","10.1136/jitc-2020-001246"
"33051340","Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial","Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV.","J Immunother Cancer. 2020 Oct;8(2):e001001. doi: 10.1136/jitc-2020-001001.","Welsh J","J Immunother Cancer","2020","2020/10/14","PMC7555111","","10.1136/jitc-2020-001001"
"33074326","Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial","Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, André T, de Gramont A.","JAMA Netw Open. 2020 Oct 1;3(10):e2020425. doi: 10.1001/jamanetworkopen.2020.20425.","Chibaudel B","JAMA Netw Open","2020","2020/10/19","PMC7573695","","10.1001/jamanetworkopen.2020.20425"
"33095247","Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors","Bomze D, Asher N, Hasan Ali O, Flatz L, Azoulay D, Markel G, Meirson T.","JAMA Netw Open. 2020 Oct 1;3(10):e2017675. doi: 10.1001/jamanetworkopen.2020.17675.","Bomze D","JAMA Netw Open","2020","2020/10/23","PMC7584930","","10.1001/jamanetworkopen.2020.17675"
"33023131","Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?","Tovoli F, De Lorenzo S, Trevisani F.","Vaccines (Basel). 2020 Oct 2;8(4):578. doi: 10.3390/vaccines8040578.","Tovoli F","Vaccines (Basel)","2020","2020/10/07","PMC7711845","","10.3390/vaccines8040578"
"33028559","Hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study","Zenda S, Ryu A, Takashima A, Arai M, Takagi Y, Miyaji T, Mashiko T, Shimizu Y, Yamazaki N, Morizane C, Yamaguchi T, Kawaguchi T, Hanai A, Uchitomi Y, Oshiba F.","BMJ Open. 2020 Oct 6;10(10):e038276. doi: 10.1136/bmjopen-2020-038276.","Zenda S","BMJ Open","2020","2020/10/08","PMC7539604","","10.1136/bmjopen-2020-038276"
"32946741","A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver","Wang LT, Pereira LS, Flores-Garcia Y, O'Connor J, Flynn BJ, Schön A, Hurlburt NK, Dillon M, Yang ASP, Fabra-García A, Idris AH, Mayer BT, Gerber MW, Gottardo R, Mason RD, Cavett N, Ballard RB, Kisalu NK, Molina-Cruz A, Nelson J, Vistein R, Barillas-Mury C, Amino R, Baker D, King NP, Sauerwein RW, Pancera M, Cockburn IA, Zavala F, Francica JR, Seder RA.","Immunity. 2020 Oct 13;53(4):733-744.e8. doi: 10.1016/j.immuni.2020.08.014. Epub 2020 Sep 17.","Wang LT","Immunity","2020","2020/09/18","PMC7572793","NIHMS1631259","10.1016/j.immuni.2020.08.014"
"32816943","Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study","Connolly RM, Laille E, Vaishampayan U, Chung V, Kelly K, Dowlati A, Alese OB, Harvey RD, Haluska P, Siu LL, Kummar S, Piekarz R, Ivy SP, Anders NM, Downs M, O'Connor A, Scardina A, Saunders J, Rosner GL, Carducci MA, Rudek MA; ETCTN-9008 Study Team.","Clin Cancer Res. 2020 Oct 15;26(20):5329-5337. doi: 10.1158/1078-0432.CCR-20-1412. Epub 2020 Aug 14.","Connolly RM","Clin Cancer Res","2020","2020/08/21","PMC7572570","NIHMS1619715","10.1158/1078-0432.CCR-20-1412"
"33115543","Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial","Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J.","Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.","Emadi A","Trials","2020","2020/10/29","PMC7594416","","10.1186/s13063-020-04819-9"
"32400000","A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma","El Dika I, Mayer RJ, Venook AP, Capanu M, LaQuaglia MP, Kobos R, O'Neill AF, Chou JF, Ly M, Ang C, O'Reilly EM, Gordan JD, Abou-Alfa GK.","Oncologist. 2020 Nov;25(11):925-e1603. doi: 10.1634/theoncologist.2020-0367. Epub 2020 May 26.","El Dika I","Oncologist","2020","2020/05/14","PMC7648371","","10.1634/theoncologist.2020-0367"
"32535637","Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors","Fröbom R, Berglund E, Berglund D, Nilsson IL, Åhlén J, von Sivers K, Linder-Stragliotto C, Suenaert P, Karlsson-Parra A, Bränström R.","Cancer Immunol Immunother. 2020 Nov;69(11):2393-2401. doi: 10.1007/s00262-020-02625-5. Epub 2020 Jun 13.","Fröbom R","Cancer Immunol Immunother","2020","2020/06/15","PMC7568699","","10.1007/s00262-020-02625-5"
"32889778","Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival","Qin SK, Li Q, Ming Xu J, Liang J, Cheng Y, Fan Y, Jiang J, Ye H, Tao H, Li L, Zheng L, Wei Z, Li S, Meng K, Ye B, Sun Y.","Cancer Sci. 2020 Nov;111(11):4218-4231. doi: 10.1111/cas.14641. Epub 2020 Sep 24.","Qin SK","Cancer Sci","2020","2020/09/05","PMC7648021","","10.1111/cas.14641"
"32940628","Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial","Sridhar SS, Blais N, Tran B, Reaume MN, North SA, Stockler MR, Chi KN, Fleshner NE, Liu G, Robinson JW, Mukherjee SD, Rahim Y, Winquist E, Booth CM, Nguyen NT, Beardsley EK, Alimohamed NS, McDonald GT, Ding K, Parulekar WR.","JAMA Oncol. 2020 Nov 1;6(11):1751-1758. doi: 10.1001/jamaoncol.2020.3927.","Sridhar SS","JAMA Oncol","2020","2020/09/17","PMC7499236","","10.1001/jamaoncol.2020.3927"
"32966811","Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X, Zhang T, Deng Y, Xiu D, Cheng Y, Tao M, Jia R, Wang W, Li J, Fan S, Peng M, Su W.","Lancet Oncol. 2020 Nov;21(11):1500-1512. doi: 10.1016/S1470-2045(20)30496-4. Epub 2020 Sep 20.","Xu J","Lancet Oncol","2020","2020/09/23","","","10.1016/S1470-2045(20)30496-4"
"33001135","Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C.","JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12.","Yau T","JAMA Oncol","2020","2020/10/01","PMC7530824","","10.1001/jamaoncol.2020.4564"
"33343209","Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions","Weinmann A, Galle PR.","Curr Oncol. 2020 Nov;27(Suppl 3):S152-S164. doi: 10.3747/co.27.7315. Epub 2020 Nov 1.","Weinmann A","Curr Oncol","2020","2020/12/21","PMC7739523","","10.3747/co.27.7315"
"33250900","Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities","Hack SP, Zhu AX, Wang Y.","Front Immunol. 2020 Nov 5;11:598877. doi: 10.3389/fimmu.2020.598877. eCollection 2020.","Hack SP","Front Immunol","2020","2020/11/30","PMC7674951","","10.3389/fimmu.2020.598877"
"33045077","Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?","Prasanna PG, Woloschak GE, DiCarlo AL, Buchsbaum JC, Schaue D, Chakravarti A, Cucinotta FA, Formenti SC, Guha C, Hu DJ, Khan MK, Kirsch DG, Krishnan S, Leitner WW, Marples B, McBride W, Mehta MP, Rafii S, Sharon E, Sullivan JM, Weichselbaum RR, Ahmed MM, Vikram B, Coleman CN, Held KD.","Radiat Res. 2020 Nov 10;194(5):452-464. doi: 10.1667/RADE-20-00211.1.","Prasanna PG","Radiat Res","2020","2020/10/12","PMC8009137","NIHMS1670199","10.1667/RADE-20-00211.1"
"33169295","Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases","Rizzetto F, Calderoni F, De Mattia C, Defeudis A, Giannini V, Mazzetti S, Vassallo L, Ghezzi S, Sartore-Bianchi A, Marsoni S, Siena S, Regge D, Torresin A, Vanzulli A.","Eur Radiol Exp. 2020 Nov 10;4(1):62. doi: 10.1186/s41747-020-00189-8.","Rizzetto F","Eur Radiol Exp","2020","2020/11/10","PMC7652946","","10.1186/s41747-020-00189-8"
"32816889","Phase I Study of P-cadherin-targeted Radioimmunotherapy with (90)Y-FF-21101 Monoclonal Antibody in Solid Tumors","Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac H, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G.","Clin Cancer Res. 2020 Nov 15;26(22):5830-5842. doi: 10.1158/1078-0432.CCR-20-0037. Epub 2020 Aug 18.","Subbiah V","Clin Cancer Res","2020","2020/08/21","","","10.1158/1078-0432.CCR-20-0037"
"32916704","Brain ventricular enlargement in human and murine acute intermittent porphyria","Jericó D, Luis EO, Cussó L, Fernández-Seara MA, Morales X, Córdoba KM, Benito M, Sampedro A, Larriva M, Ramírez MJ, de Salamanca RE, Ortiz-de-Solorzano C, Alegre M, Prieto J, Lanciego JL, D'Avola D, González-Aseguinolaza G, Pastor MA, Desco M, Fontanellas A.","Hum Mol Genet. 2020 Nov 25;29(19):3211-3223. doi: 10.1093/hmg/ddaa204.","Jericó D","Hum Mol Genet","2020","2020/09/11","","","10.1093/hmg/ddaa204"
"33312759","Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, Han X, Wang H, Wang Y, Shen P.","Oncoimmunology. 2020 Nov 25;9(1):1846926. doi: 10.1080/2162402X.2020.1846926.","Dai H","Oncoimmunology","2020","2020/12/14","PMC7714531","","10.1080/2162402X.2020.1846926"
"32154962","Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma","Abou-Alfa GK, Mayer R, Venook AP, O'Neill AF, Beg MS, LaQuaglia M, Kingham PT, Kobos R, Basturk O, Brennan C, Yopp A, Harding JJ, Leong S, Crown J, Hoti E, Leonard G, Ly M, Bradley M, Valentino E, Markowitz D, Zukiwski A, Ren K, Gordan JD.","Oncologist. 2020 Dec;25(12):e1837-e1845. doi: 10.1634/theoncologist.2020-0093. Epub 2020 Mar 10.","Abou-Alfa GK","Oncologist","2020","2020/03/11","PMC8186410","","10.1634/theoncologist.2020-0093"
"32378261","Transcutaneous Electrical Acustimulation Improves Gastrointestinal Disturbances Induced by Transcatheter Arterial Chemoembolization in Patients With Liver Cancers","Zhu Y, Li X, Ma J, Xu W, Li M, Gong Y, Zhang B, Chen Y, Chao S, Xu Q, Lin L, Chen JDZ.","Neuromodulation. 2020 Dec;23(8):1180-1188. doi: 10.1111/ner.13158. Epub 2020 May 6.","Zhu Y","Neuromodulation","2020","2020/05/08","","","10.1111/ner.13158"
"32418078","Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial","Li S, Mei J, Wang Q, Guo Z, Lu L, Ling Y, Xu L, Chen M, Zheng L, Lin W, Zou J, Wen Y, Wei W, Guo R.","Ann Surg Oncol. 2020 Dec;27(13):5183-5190. doi: 10.1245/s10434-020-08601-8. Epub 2020 May 16.","Li S","Ann Surg Oncol","2020","2020/05/18","","","10.1245/s10434-020-08601-8"
"32548867","Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma","Harding JJ, Kelley RK, Tan B, Capanu M, Do GK, Shia J, Chou JF, Ferrer CS, Boussayoud C, Muenkel K, Yarmohammadi H, El Dika I, Khalil DN, Ruiz C, Rodriguez-Lee M, Kuhn P, Wilton J, Iyer R, Abou-Alfa GK.","Oncologist. 2020 Dec;25(12):e1825-e1836. doi: 10.1634/theoncologist.2020-0521. Epub 2020 Jul 2.","Harding JJ","Oncologist","2020","2020/06/18","PMC8186405","","10.1634/theoncologist.2020-0521"
"32552295","Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors","Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A, Abdullah SE, Niegisch G, Rosenberg JE, Bajorin DF, Grivas P, Apolo AB, Dreicer R, Hahn NM, Galsky MD, Necchi A, Srinivas S, Powles T, Choueiri TK, Pond GR.","J Urol. 2020 Dec;204(6):1173-1179. doi: 10.1097/JU.0000000000001199. Epub 2020 Jun 18.","Sonpavde G","J Urol","2020","2020/06/20","PMC7655635","NIHMS1605527","10.1097/JU.0000000000001199"
"32690442","Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy","Gilchrist VH, Jémus-Gonzalez E, Said A, Alain T.","Cytokine Growth Factor Rev. 2020 Dec;56:83-93. doi: 10.1016/j.cytogfr.2020.07.008. Epub 2020 Jul 13.","Gilchrist VH","Cytokine Growth Factor Rev","2020","2020/07/22","","","10.1016/j.cytogfr.2020.07.008"
"32710922","Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A.","J Hepatol. 2020 Dec;73(6):1460-1469. doi: 10.1016/j.jhep.2020.07.026. Epub 2020 Jul 22.","Sangro B","J Hepatol","2020","2020/07/26","PMC7751218","NIHMS1653337","10.1016/j.jhep.2020.07.026"
"32712254","A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma","Sebastian NT, Miller ED, Yang X, Diaz DA, Tan Y, Dowell J, Spain J, Rikabi A, Elliott E, Knopp M, Williams TM.","Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1276-1283. doi: 10.1016/j.ijrobp.2020.07.033. Epub 2020 Jul 23.","Sebastian NT","Int J Radiat Oncol Biol Phys","2020","2020/07/27","","","10.1016/j.ijrobp.2020.07.033"
"32776632","A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer","Kim R, Tan E, Wang E, Mahipal A, Chen DT, Cao B, Masawi F, Machado C, Yu J, Kim DW.","Oncologist. 2020 Dec;25(12):e1893-e1899. doi: 10.1634/theoncologist.2020-0759. Epub 2020 Sep 14.","Kim R","Oncologist","2020","2020/08/11","PMC8186409","","10.1634/theoncologist.2020-0759"
"32917529","Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306","Froelich MF, Petersen EL, Heinemann V, Nörenberg D, Hesse N, Gesenhues AB, Modest DP, Sommer WH, Hofmann FO, Stintzing S, Holch JW.","Clin Colorectal Cancer. 2020 Dec;19(4):291-300.e5. doi: 10.1016/j.clcc.2020.06.005. Epub 2020 Jun 22.","Froelich MF","Clin Colorectal Cancer","2020","2020/09/12","","","10.1016/j.clcc.2020.06.005"
"32971005","Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators.","Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21.","Powles T","Lancet Oncol","2020","2020/09/24","","","10.1016/S1470-2045(20)30541-6"
"33017497","Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study","Lin CC, Yang TS, Yen CJ, Cheng R, Liu J, Hsu C.","Oncologist. 2020 Dec;25(12):e1921-e1929. doi: 10.1002/onco.13550. Epub 2020 Oct 31.","Lin CC","Oncologist","2020","2020/10/05","PMC8108062","","10.1002/onco.13550"
"33057591","Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial","Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K.","JAMA Oncol. 2020 Dec 1;6(12):1931-1938. doi: 10.1001/jamaoncol.2020.4643.","Hayashi H","JAMA Oncol","2020","2020/10/15","PMC7563669","","10.1001/jamaoncol.2020.4643"
"33090186","Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis","Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T.","JAMA Oncol. 2020 Dec 1;6(12):e204930. doi: 10.1001/jamaoncol.2020.4930. Epub 2020 Dec 10.","Sonbol MB","JAMA Oncol","2020","2020/10/22","PMC7582230","","10.1001/jamaoncol.2020.4930"
"33096421","Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment","Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J.","Lung Cancer. 2020 Dec;150:90-96. doi: 10.1016/j.lungcan.2020.10.003. Epub 2020 Oct 10.","Subbiah V","Lung Cancer","2020","2020/10/23","","","10.1016/j.lungcan.2020.10.003"
"33332482","Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis","Schiffer M, Kowalski A, Zhao J, Bewersdorf JP, Lewis RS Jr, Zeidan AM.","Drugs Today (Barc). 2020 Dec;56(12):755-768. doi: 10.1358/dot.2020.56.12.3230206.","Schiffer M","Drugs Today (Barc)","2020","2020/12/17","","","10.1358/dot.2020.56.12.3230206"
"33273603","Intra-individual dynamic comparison of (18)F-PSMA-11 and (68)Ga-PSMA-11 in LNCaP xenograft bearing mice","Piron S, Verhoeven J, Descamps B, Kersemans K, De Man K, Van Laeken N, Pieters L, Vral A, Vanhove C, De Vos F.","Sci Rep. 2020 Dec 3;10(1):21068. doi: 10.1038/s41598-020-78273-7.","Piron S","Sci Rep","2020","2020/12/04","PMC7713063","","10.1038/s41598-020-78273-7"
"33287816","The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial","Jia L, Xue R, Zhu Y, Zhao J, Li J, He WP, Wang XM, Duan ZH, Ren MX, Liu HX, Xing HC, Meng QH.","BMC Med. 2020 Dec 8;18(1):383. doi: 10.1186/s12916-020-01814-4.","Jia L","BMC Med","2020","2020/12/08","PMC7722342","","10.1186/s12916-020-01814-4"
"33197225","Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline","Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG.","J Clin Oncol. 2020 Dec 20;38(36):4317-4345. doi: 10.1200/JCO.20.02672. Epub 2020 Nov 16.","Gordan JD","J Clin Oncol","2020","2020/11/16","","","10.1200/JCO.20.02672"
"33396181","Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives","Girardi DM, Pacífico JPM, Guedes de Amorim FPL, Dos Santos Fernandes G, Teixeira MC, Pereira AAL.","Pharmaceuticals (Basel). 2020 Dec 31;14(1):28. doi: 10.3390/ph14010028.","Girardi DM","Pharmaceuticals (Basel)","2020","2021/01/05","PMC7824026","","10.3390/ph14010028"
"32380571","Evolution of Systemic Therapy for Hepatocellular Carcinoma","Finn RS, Zhu AX.","Hepatology. 2021 Jan;73 Suppl 1:150-157. doi: 10.1002/hep.31306. Epub 2020 Nov 7.","Finn RS","Hepatology","2021","2020/05/08","","","10.1002/hep.31306"
"32488654","Efficacy and safety of palliative endobiliary radiofrequency ablation using a novel temperature-controlled catheter for malignant biliary stricture: a single-center prospective randomized phase II TRIAL","Kang H, Chung MJ, Cho IR, Jo JH, Lee HS, Park JY, Park SW, Song SY, Bang S.","Surg Endosc. 2021 Jan;35(1):63-73. doi: 10.1007/s00464-020-07689-z. Epub 2020 Jun 2.","Kang H","Surg Endosc","2021","2020/06/04","","","10.1007/s00464-020-07689-z"
"32583961","Evolving Role for Pharmacotherapy in NAFLD/NASH","Attia SL, Softic S, Mouzaki M.","Clin Transl Sci. 2021 Jan;14(1):11-19. doi: 10.1111/cts.12839. Epub 2020 Aug 25.","Attia SL","Clin Transl Sci","2021","2020/06/26","PMC7877845","","10.1111/cts.12839"
"32715491","Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies","Feng GS, Hanley KL, Liang Y, Lin X.","Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):104-114. doi: 10.1002/hep.31479. Epub 2020 Nov 8.","Feng GS","Hepatology","2021","2020/07/28","PMC7854886","NIHMS1627808","10.1002/hep.31479"
"32781104","A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma","Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, Nishino M, Manuszak C, Thrash EM, Severgnini M, Sanborn M, Sridharan V, Margalit DN, Tishler RB, Busse PM, Willers H, Mamon HJ, Yoo HJ, Pai SI, Wirth LJ, Haddad RI, Chau NG, Schoenfeld JD.","Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):134-144. doi: 10.1016/j.ijrobp.2020.08.018. Epub 2020 Aug 8.","Mahmood U","Int J Radiat Oncol Biol Phys","2021","2020/08/12","PMC9361179","NIHMS1826773","10.1016/j.ijrobp.2020.08.018"
"32960420","Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer","Nagao S, Yamamoto K, Oishi T, Yamaguchi S, Takehara K, Shimada M, Kigawa J.","Int J Clin Oncol. 2021 Jan;26(1):207-215. doi: 10.1007/s10147-020-01787-7. Epub 2020 Sep 22.","Nagao S","Int J Clin Oncol","2021","2020/09/22","","","10.1007/s10147-020-01787-7"
"33012782","A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer","Creelan BC, Yeh TC, Kim SW, Nogami N, Kim DW, Chow LQM, Kanda S, Taylor R, Tang W, Tang M, Angell HK, Roudier MP, Marotti M, Gibbons DL.","Br J Cancer. 2021 Jan;124(2):383-390. doi: 10.1038/s41416-020-01099-7. Epub 2020 Oct 5.","Creelan BC","Br J Cancer","2021","2020/10/05","PMC7852511","","10.1038/s41416-020-01099-7"
"33038433","COVID-19: Discovery, diagnostics and drug development","Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF.","J Hepatol. 2021 Jan;74(1):168-184. doi: 10.1016/j.jhep.2020.09.031. Epub 2020 Oct 8.","Asselah T","J Hepatol","2021","2020/10/10","PMC7543767","NIHMS1635778","10.1016/j.jhep.2020.09.031"
"33047430","Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma","Ye D, Liu J, Zhou A, Zou Q, Li H, Fu C, Hu H, Huang J, Zhu S, Jin J, Ma L, Guo J, Xiao J, Park SH, Zhang D, Qiu X, Bao Y, Zhang L, Shen W, Bi F.","Cancer Sci. 2021 Jan;112(1):305-313. doi: 10.1111/cas.14681. Epub 2020 Nov 6.","Ye D","Cancer Sci","2021","2020/10/13","PMC7780053","","10.1111/cas.14681"
"33109737","Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma","Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J.","Clin Cancer Res. 2021 Jan 1;27(1):43-51. doi: 10.1158/1078-0432.CCR-20-2488. Epub 2020 Oct 27.","Sheng X","Clin Cancer Res","2021","2020/10/28","","","10.1158/1078-0432.CCR-20-2488"
"33161366","Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians","Houron C, Danielou M, Mir O, Fromenty B, Perlemuter G, Voican CS.","Crit Rev Oncol Hematol. 2021 Jan;157:103127. doi: 10.1016/j.critrevonc.2020.103127. Epub 2020 Oct 21.","Houron C","Crit Rev Oncol Hematol","2021","2020/11/08","","","10.1016/j.critrevonc.2020.103127"
"33166497","Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group.","Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29. doi: 10.1016/S2468-1253(20)30290-9. Epub 2020 Nov 7.","Garin E","Lancet Gastroenterol Hepatol","2021","2020/11/09","","","10.1016/S2468-1253(20)30290-9"
"33263949","Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1α-C/EBPα-HNF4α axis","Xie M, Guo H, Lou G, Yao J, Liu Y, Sun Y, Yang Z, Zheng M.","J Cell Mol Med. 2021 Jan;25(2):840-854. doi: 10.1111/jcmm.16137. Epub 2020 Dec 2.","Xie M","J Cell Mol Med","2021","2020/12/02","PMC7812279","","10.1111/jcmm.16137"
"33400355","Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial","Hu H, Wang K, Huang M, Kang L, Wang W, Wang H, Qiu M, Lin R, Zhang H, Lan P, Wu X, Liu G, Wan Y, Liu M, Zhou Z, Huang Y, Li F, Zhang J, Cai Y, Ma T, Zhou J, Wang H, Ling J, Cai Y, Wu Z, Luo S, Ling L, Deng Y.","Oncologist. 2021 Jan;26(1):e90-e98. doi: 10.1634/theoncologist.2020-0563. Epub 2020 Sep 3.","Hu H","Oncologist","2021","2021/01/05","PMC7794191","","10.1634/theoncologist.2020-0563"
"33592561","First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: ""And Yet It Moves!""","Rizzo A, Brandi G.","Cancer Treat Res Commun. 2021;27:100335. doi: 10.1016/j.ctarc.2021.100335. Epub 2021 Feb 11.","Rizzo A","Cancer Treat Res Commun","2021","2021/02/16","","","10.1016/j.ctarc.2021.100335"
"34470936","[Pharmacological properties and clinical outcomes of the anti-cancer drug, cabozantinib (CABOMETYX(®))]","Osaka T, Yamaguchi N, Hara T.","Nihon Yakurigaku Zasshi. 2021;156(5):303-311. doi: 10.1254/fpj.21045.","Osaka T","Nihon Yakurigaku Zasshi","2021","2021/09/02","","","10.1254/fpj.21045"
"34515215","A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events","Schöffski P, Concin N, Suarez C, Subbiah V, Ando Y, Ruan S, Wagner JP, Mansfield K, Zhu X, Origuchi S, DiDominick S, Bialucha CU, Faris JE, Tran B.","Oncol Res Treat. 2021;44(10):547-556. doi: 10.1159/000518549. Epub 2021 Aug 19.","Schöffski P","Oncol Res Treat","2021","2021/09/13","","","10.1159/000518549"
"33466278","A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System","Ferrucci PF, Cocorocchio E, Bonomo G, Varano GM, Della Vigna P, Orsi F.","Cells. 2021 Jan 5;10(1):70. doi: 10.3390/cells10010070.","Ferrucci PF","Cells","2021","2021/01/20","PMC7824743","","10.3390/cells10010070"
"33430312","Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial","Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, Ciuleanu TE, Pusca IA, Beg MS, Purcell WT, Croitoru AE, Ilieva RN, Natošević S, Nita AL, Kalev DN, Harpaz Z, Farbstein M, Silverman MH, Bristol D, Itzhak I, Fishman P.","Cancers (Basel). 2021 Jan 7;13(2):187. doi: 10.3390/cancers13020187.","Stemmer SM","Cancers (Basel)","2021","2021/01/12","PMC7825785","","10.3390/cancers13020187"
"33151787","Standardization of (18)F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma","Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, Versari A, Chauvie S, Gallamini A, Gamberi B, Caillot D, Patriarca F, Macro M, Boccadoro M, Garderet L, Barbato S, Fanti S, Perrot A, Gay F, Sonneveld P, Karlin L, Cavo M, Bodet-Milin C, Moreau P, Kraeber-Bodéré F.","J Clin Oncol. 2021 Jan 10;39(2):116-125. doi: 10.1200/JCO.20.00386. Epub 2020 Nov 5.","Zamagni E","J Clin Oncol","2021","2020/11/05","","","10.1200/JCO.20.00386"
"33472666","Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial","Yang KL, Chi MS, Ko HL, Huang YY, Huang SC, Lin YM, Chi KH.","Radiat Oncol. 2021 Jan 20;16(1):18. doi: 10.1186/s13014-020-01742-w.","Yang KL","Radiat Oncol","2021","2021/01/21","PMC7819176","","10.1186/s13014-020-01742-w"
"33211092","Systemic targeted and immunotherapy for advanced hepatocellular carcinoma","Cersosimo RJ.","Am J Health Syst Pharm. 2021 Jan 22;78(3):187-202. doi: 10.1093/ajhp/zxaa365.","Cersosimo RJ","Am J Health Syst Pharm","2021","2020/11/19","","","10.1093/ajhp/zxaa365"
"32761328","Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study","Meijer TS, Burgmans MC, de Leede EM, de Geus-Oei LF, Boekestijn B, Handgraaf HJM, Hilling DE, Lutjeboer J, Vuijk J, Martini CH, van Erkel AR, van der Meer RW, Tijl FGJ, Speetjens FM, Kapiteijn E, Vahrmeijer AL.","Ann Surg Oncol. 2021 Feb;28(2):1130-1141. doi: 10.1245/s10434-020-08741-x. Epub 2020 Aug 5.","Meijer TS","Ann Surg Oncol","2021","2020/08/08","PMC7801354","","10.1245/s10434-020-08741-x"
"32898239","Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review","Lim H, Ramjeesingh R, Liu D, Tam VC, Knox JJ, Card PB, Meyers BM.","J Natl Cancer Inst. 2021 Feb 1;113(2):123-136. doi: 10.1093/jnci/djaa119.","Lim H","J Natl Cancer Inst","2021","2020/09/08","PMC7850551","","10.1093/jnci/djaa119"
"33031626","Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies","Minami H, Doi T, Toyoda M, Imamura Y, Kiyota N, Mitsuma A, Shimokata T, Naito Y, Matsubara N, Tajima T, Tokushige K, Ishihara K, Cameron S, Ando Y.","Cancer Sci. 2021 Feb;112(2):725-733. doi: 10.1111/cas.14678. Epub 2020 Dec 22.","Minami H","Cancer Sci","2021","2020/10/08","PMC7893979","","10.1111/cas.14678"
"33139266","Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib","Lee DW, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY, Lee Y, Kim H, Lee KH.","Clin Cancer Res. 2021 Feb 1;27(3):713-718. doi: 10.1158/1078-0432.CCR-20-3094. Epub 2020 Nov 2.","Lee DW","Clin Cancer Res","2021","2020/11/03","","","10.1158/1078-0432.CCR-20-3094"
"33140540","A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma","Wright KD, Yao X, London WB, Kao PC, Gore L, Hunger S, Geyer R, Cohen KJ, Allen JC, Katzenstein HM, Smith A, Boklan J, Nazemi K, Trippett T, Karajannis M, Herzog C, Destefano J, Direnzo J, Pietrantonio J, Greenspan L, Cassidy D, Schissel D, Perentesis J, Basu M, Mizuno T, Vinks AA, Prabhu SP, Chi SN, Kieran MW.","Pediatr Blood Cancer. 2021 Feb;68(2):e28787. doi: 10.1002/pbc.28787. Epub 2020 Nov 2.","Wright KD","Pediatr Blood Cancer","2021","2020/11/03","PMC9161236","NIHMS1794283","10.1002/pbc.28787"
"33144248","Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021)","Chen NB, Li QW, Li S, Guo SP, Wu YJ, Cheng ZJ, Li JB, Wang DQ, Liu FJ, Ai XL, Hu N, Qiu B, Liu H.","Radiother Oncol. 2021 Feb;155:105-112. doi: 10.1016/j.radonc.2020.10.035. Epub 2020 Nov 2.","Chen NB","Radiother Oncol","2021","2020/11/04","","","10.1016/j.radonc.2020.10.035"
"33153929","Comparison of 18FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective study","Monteil J, Le Brun-Ly V, Cachin F, Zasadny X, Seitz JF, Mundler O, Selvy M, Smith D, Rullier E, Lavau-Denes S, Lades G, Labrunie A, Lecaille C, Valli N, Leobon S, Terrebonne E, Deluche E, Tubiana-Mathieu N.","Dig Liver Dis. 2021 Feb;53(2):231-237. doi: 10.1016/j.dld.2020.10.012. Epub 2020 Nov 2.","Monteil J","Dig Liver Dis","2021","2020/11/06","","","10.1016/j.dld.2020.10.012"
"33243443","A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer","Chelariu-Raicu A, Nick A, Urban R, Gordinier M, Leuschner C, Bavisotto L, Molin GZD, Whisnant JK, Coleman RL.","Gynecol Oncol. 2021 Feb;160(2):418-426. doi: 10.1016/j.ygyno.2020.11.013. Epub 2020 Nov 23.","Chelariu-Raicu A","Gynecol Oncol","2021","2020/11/27","","","10.1016/j.ygyno.2020.11.013"
"33253659","Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial","Yang HK, Ji J, Han SU, Terashima M, Li G, Kim HH, Law S, Shabbir A, Song KY, Hyung WJ, Kosai NR, Kono K, Misawa K, Yabusaki H, Kinoshita T, Lau PC, Kim YW, Rao JR, Ng E, Yamada T, Yoshida K, Park DJ, Tai BC, So JBY; EXPEL study group.","Lancet Gastroenterol Hepatol. 2021 Feb;6(2):120-127. doi: 10.1016/S2468-1253(20)30315-0. Epub 2020 Nov 27.","Yang HK","Lancet Gastroenterol Hepatol","2021","2020/11/30","","","10.1016/S2468-1253(20)30315-0"
"33316634","Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience","Berlanga P, Pasqualini C, Pötschger U, Sangüesa C, Castellani MR, Cañete A, Luksch R, Elliot M, Schreier G, Kropf M, Morgenstern D, Papadakis V, Ash S, Ruud E, Brock P, Wieczorek A, Kogner P, Trahair T, Ambros P, Boterberg T, Castel V, Valteau-Couanet D, Ladenstein R.","Eur J Cancer. 2021 Feb;144:1-8. doi: 10.1016/j.ejca.2020.10.020. Epub 2020 Dec 11.","Berlanga P","Eur J Cancer","2021","2020/12/14","","","10.1016/j.ejca.2020.10.020"
"33392749","Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study","Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A.","J Gastroenterol. 2021 Feb;56(2):181-190. doi: 10.1007/s00535-020-01753-0. Epub 2021 Jan 3.","Kudo M","J Gastroenterol","2021","2021/01/04","PMC7862203","","10.1007/s00535-020-01753-0"
"33399082","Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)","Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A.","ESMO Open. 2021 Feb;6(1):100019. doi: 10.1016/j.esmoop.2020.100019. Epub 2020 Dec 31.","Pellegrino B","ESMO Open","2021","2021/01/05","PMC7808100","","10.1016/j.esmoop.2020.100019"
"33414907","A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer","Tajima H, Makino I, Gabata R, Okazaki M, Ohbatake Y, Shimbashi H, Nakanuma S, Saitoh H, Shimada M, Yamaguchi T, Okamoto K, Moriyama H, Kinoshita J, Nakamura K, Miyashita T, Ninomiya I, Fushida S, Ikeda H, Ohta T.","Mol Clin Oncol. 2021 Feb;14(2):26. doi: 10.3892/mco.2020.2188. Epub 2020 Dec 14.","Tajima H","Mol Clin Oncol","2021","2021/01/08","PMC7783717","","10.3892/mco.2020.2188"
"33420951","Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis","Blanc JF, Khemissa F, Bronowicki JP, Monterymard C, Perarnau JM, Bourgeois V, Obled S, Abdelghani MB, Mabile-Archambeaud I, Faroux R, Seitz JF, Locher C, Senellart H, Villing AL, Audemar F, Costentin C, Deplanque G, Manfredi S, Edeline J; PRODIGE 21 collaborators.","Hepatol Int. 2021 Feb;15(1):93-104. doi: 10.1007/s12072-020-10120-3. Epub 2021 Jan 9.","Blanc JF","Hepatol Int","2021","2021/01/09","","","10.1007/s12072-020-10120-3"
"33481328","Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study","Haruna Y, Yakushijin T, Kawamoto S.","Cancer Med. 2021 Feb;10(3):914-922. doi: 10.1002/cam4.3674. Epub 2021 Jan 22.","Haruna Y","Cancer Med","2021","2021/01/22","PMC7897941","","10.1002/cam4.3674"
"33541088","Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma","Uson Junior PLS, Liu AJ, Sonbol MB, Borad MJ, Bekaii-Saab TS.","Chin Clin Oncol. 2021 Feb;10(1):11. doi: 10.21037/cco-20-231.","Uson Junior PLS","Chin Clin Oncol","2021","2021/02/05","","","10.21037/cco-20-231"
"33625508","Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma","Su D, Wu B, Shi L.","JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.","Su D","JAMA Netw Open","2021","2021/02/24","PMC7905498","","10.1001/jamanetworkopen.2021.0037"
"33540837","From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis","Mohr R, Özdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, Hammerich L, Roderburg C.","Int J Mol Sci. 2021 Feb 2;22(3):1492. doi: 10.3390/ijms22031492.","Mohr R","Int J Mol Sci","2021","2021/02/05","PMC7867354","","10.3390/ijms22031492"
"33087333","Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial","Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, Liu J, Ren Z, Xiong J, Mao X, Zhang L, Yang J, Li L, Chen X, Wang Z, Gu K, Chen X, Pan Z, Ma K, Zhou X, Yu Z, Li E, Yin G, Zhang X, Wang S, Wang Q.","Clin Cancer Res. 2021 Feb 15;27(4):1003-1011. doi: 10.1158/1078-0432.CCR-20-2571. Epub 2020 Oct 21.","Xu J","Clin Cancer Res","2021","2020/10/22","","","10.1158/1078-0432.CCR-20-2571"
"33417511","Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Alonso Carrión L, Martín-Algarra S, López Castro R, Curiel T, Rodríguez-Abreu D, Redrado M, Gomà M, Rullán AJ, Calvo González A, Berrocal-Jaime A.","J Clin Oncol. 2021 Feb 20;39(6):586-598. doi: 10.1200/JCO.20.00550. Epub 2021 Jan 8.","Piulats JM","J Clin Oncol","2021","2021/01/08","","","10.1200/JCO.20.00550"
"33581798","[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.","Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.","Hofman MS","Lancet","2021","2021/02/14","","","10.1016/S0140-6736(21)00237-3"
"32533342","Primary hepatic carcinoma with inhibin positivity in a young male patient: a rare tumor previously only reported in females-case report and review of literature","Liang TZ, Whang G, Chopra S.","Virchows Arch. 2021 Mar;478(3):605-610. doi: 10.1007/s00428-020-02864-y. Epub 2020 Jun 12.","Liang TZ","Virchows Arch","2021","2020/06/14","","","10.1007/s00428-020-02864-y"
"32627871","Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis","Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T.","J Gastroenterol Hepatol. 2021 Mar;36(3):629-636. doi: 10.1111/jgh.15172. Epub 2020 Jul 16.","Yamamura S","J Gastroenterol Hepatol","2021","2020/07/07","","","10.1111/jgh.15172"
"33031846","Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial","Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park JW.","J Hepatol. 2021 Mar;74(3):603-612. doi: 10.1016/j.jhep.2020.09.026. Epub 2020 Oct 5.","Kim TH","J Hepatol","2021","2020/10/08","","","10.1016/j.jhep.2020.09.026"
"33039590","Intensity Modulated Radiation Therapy for Pleural Recurrence of Thymoma: A Prospective Phase 2 Study","Wang CL, Gao LT, Lyu CX, Wang JM, Liu J, Gu HL, Liu Y, Fu XL.","Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):775-782. doi: 10.1016/j.ijrobp.2020.09.058. Epub 2020 Oct 9.","Wang CL","Int J Radiat Oncol Biol Phys","2021","2020/10/11","","","10.1016/j.ijrobp.2020.09.058"
"33140457","A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma","Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y.","Oncologist. 2021 Mar;26(3):e367-e373. doi: 10.1002/onco.13582. Epub 2020 Nov 25.","Changou CA","Oncologist","2021","2020/11/03","PMC7930412","","10.1002/onco.13582"
"33244809","Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial","Zhou N, Zhang C, Liu D, Liu K, Wang G, Zhu H, Zhang J, Jiang M, Liu N, Zhang X.","Oncologist. 2021 Mar;26(3):e374-e381. doi: 10.1002/onco.13613. Epub 2020 Dec 28.","Zhou N","Oncologist","2021","2020/11/27","PMC7930411","","10.1002/onco.13613"
"33270098","Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT)","Ramaswamy A, Ostwal V, Sharma A, Bhargava P, Srinivas S, Goel M, Patkar S, Mandavkar S, Jadhav P, Parulekar M, Choudhari A, Gupta S.","JAMA Oncol. 2021 Mar 1;7(3):436-439. doi: 10.1001/jamaoncol.2020.6166.","Ramaswamy A","JAMA Oncol","2021","2020/12/03","PMC7716253","","10.1001/jamaoncol.2020.6166"
"33359404","Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial","Taïeb J, André T, El Hajbi F, Barbier E, Toullec C, Kim S, Bouche O, Di Fiore F, Chauvenet M, Perrier H, Evesque L, Laurent-Puig P, Emile JF, Bez J, Lepage C, Tougeron D.","Dig Liver Dis. 2021 Mar;53(3):318-323. doi: 10.1016/j.dld.2020.11.031. Epub 2020 Dec 25.","Taïeb J","Dig Liver Dis","2021","2020/12/28","","","10.1016/j.dld.2020.11.031"
"33361273","Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties","Gmeiner WH, Dominijanni A, Haber AO, Ghiraldeli LP, Caudell DL, D'Agostino R Jr, Pasche BC, Smith TL, Deng Z, Kiren S, Mani C, Palle K, Brody JR.","Mol Cancer Ther. 2021 Mar;20(3):553-563. doi: 10.1158/1535-7163.MCT-20-0516. Epub 2020 Dec 23.","Gmeiner WH","Mol Cancer Ther","2021","2020/12/28","PMC8201368","NIHMS1657415","10.1158/1535-7163.MCT-20-0516"
"33507236","An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries","Wells JC, Sharma S, Del Paggio JC, Hopman WM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM.","JAMA Oncol. 2021 Mar 1;7(3):379-385. doi: 10.1001/jamaoncol.2020.7478.","Wells JC","JAMA Oncol","2021","2021/01/28","PMC7844695","","10.1001/jamaoncol.2020.7478"
"33737344","Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma","Ma Y, Chen X, Wang A, Zhao H, Lin Q, Bao H, Zhang Y, Hong S, Tang W, Huang Y, Yang Y, Wu X, Shao Y, Fang W, Zhang L.","J Immunother Cancer. 2021 Mar;9(3):e002014. doi: 10.1136/jitc-2020-002014.","Ma Y","J Immunother Cancer","2021","2021/03/19","PMC7978327","","10.1136/jitc-2020-002014"
"33741732","Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial","Mei K, Qin S, Chen Z, Liu Y, Wang L, Zou J.","J Immunother Cancer. 2021 Mar;9(3):e002191. doi: 10.1136/jitc-2020-002191.","Mei K","J Immunother Cancer","2021","2021/03/20","PMC7986650","","10.1136/jitc-2020-002191"
"33842243","A single-center, self-controlled, phase I clinical trial of mitoxantrone hydrochloride injection for lymph tracing for sentinel lymph node identification of breast cancer","Yang B, Zheng S, Huang X, Chen J, Liu Z, Liu G, Wang S, Shao Z, Wu J.","Gland Surg. 2021 Mar;10(3):992-1001. doi: 10.21037/gs-20-694.","Yang B","Gland Surg","2021","2021/04/12","PMC8033053","","10.21037/gs-20-694"
"33653317","Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery","Fan B, Bu Z, Zhang J, Zong X, Ji X, Fu T, Jia Z, Zhang Y, Wu X.","BMC Cancer. 2021 Mar 2;21(1):216. doi: 10.1186/s12885-021-07925-2.","Fan B","BMC Cancer","2021","2021/03/03","PMC7923597","","10.1186/s12885-021-07925-2"
"33839747","Hepatocellular carcinoma progression during bridging before liver transplantation","Renner P, Da Silva T, Schnitzbauer AA, Verloh N, Schlitt HJ, Geissler EK.","BJS Open. 2021 Mar 5;5(2):zrab005. doi: 10.1093/bjsopen/zrab005.","Renner P","BJS Open","2021","2021/04/11","PMC8038254","","10.1093/bjsopen/zrab005"
"33197285","Long-term outcomes of pexidartinib in tenosynovial giant cell tumors","Gelderblom H, Wagner AJ, Tap WD, Palmerini E, Wainberg ZA, Desai J, Healey JH, van de Sande MAJ, Bernthal NM, Staals EL, Peterfy CG, Frezza AM, Hsu HH, Wang Q, Shuster DE, Stacchiotti S.","Cancer. 2021 Mar 15;127(6):884-893. doi: 10.1002/cncr.33312. Epub 2020 Nov 16.","Gelderblom H","Cancer","2021","2020/11/16","PMC7946703","NIHMS1647922","10.1002/cncr.33312"
"33757459","PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma","Pinato DJ, Cortellini A, Sukumaran A, Cole T, Pai M, Habib N, Spalding D, Sodergren MH, Martinez M, Dhillon T, Tait P, Thomas R, Ward C, Kocher H, Yip V, Slater S, Sharma R.","BMC Cancer. 2021 Mar 23;21(1):301. doi: 10.1186/s12885-021-08033-x.","Pinato DJ","BMC Cancer","2021","2021/03/24","PMC7988931","","10.1186/s12885-021-08033-x"
"33185364","A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators.","N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.","Newsome PN","N Engl J Med","2021","2020/11/13","","","10.1056/NEJMoa2028395"
"33765973","Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma","Li H, Liu Y, Jiang W, Xue J, Cheng Y, Wang J, Yang R, Zhang X.","BMC Cancer. 2021 Mar 25;21(1):318. doi: 10.1186/s12885-021-08043-9.","Li H","BMC Cancer","2021","2021/03/26","PMC7992931","","10.1186/s12885-021-08043-9"
"32273476","Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study","Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A.","Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238.","Kersten MJ","Haematologica","2021","2020/04/11","PMC8018114","","10.3324/haematol.2019.243238"
"33030848","Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer","Li Y, Vennapusa B, Chang CW, Tran D, Nakamura R, Sumiyoshi T, Hegde P, Molinero L.","Appl Immunohistochem Mol Morphol. 2021 Apr 1;29(4):258-264. doi: 10.1097/PAI.0000000000000857.","Li Y","Appl Immunohistochem Mol Morphol","2021","2020/10/08","PMC8132905","","10.1097/PAI.0000000000000857"
"33043474","Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors","Yin O, Wagner AJ, Kang J, Knebel W, Zahir H, van de Sande M, Tap WD, Gelderblom H, Healey JH, Shuster D, Stacchiotti S.","J Clin Pharmacol. 2021 Apr;61(4):480-492. doi: 10.1002/jcph.1753. Epub 2020 Oct 11.","Yin O","J Clin Pharmacol","2021","2020/10/12","PMC7969430","NIHMS1653462","10.1002/jcph.1753"
"33074442","Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial","Matsui HM, Hazama S, Nakajima M, Xu M, Matsukuma S, Tokumitsu Y, Shindo Y, Tomochika S, Yoshida S, Iida M, Suzuki N, Takeda S, Yoshino S, Ueno T, Oka M, Nagano H.","Cancer Immunol Immunother. 2021 Apr;70(4):945-957. doi: 10.1007/s00262-020-02737-y. Epub 2020 Oct 19.","Matsui HM","Cancer Immunol Immunother","2021","2020/10/19","PMC10991992","","10.1007/s00262-020-02737-y"
"33075149","Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients","Lombard A, Mistry H, Aarons L, Ogungbenro K.","Br J Clin Pharmacol. 2021 Apr;87(4):2053-2063. doi: 10.1111/bcp.14614. Epub 2020 Dec 19.","Lombard A","Br J Clin Pharmacol","2021","2020/10/19","","","10.1111/bcp.14614"
"33217113","Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study","Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, Katoh N, Eriguchi T, Oku Y, Ozawa S, Tsurugai Y, Kokubo M, Shimizu S, Ishikura S.","Hepatol Res. 2021 Apr;51(4):461-471. doi: 10.1111/hepr.13595. Epub 2021 Mar 1.","Kimura T","Hepatol Res","2021","2020/11/20","","","10.1111/hepr.13595"
"33285270","Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study","Van Limbergen EJ, Hoeben A, Lieverse RIY, Houben R, Overhof C, Postma A, Zindler J, Verhelst F, Dubois LJ, De Ruysscher D, Troost EGC, Lambin P.","Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1421-1430. doi: 10.1016/j.ijrobp.2020.11.053. Epub 2020 Dec 4.","Van Limbergen EJ","Int J Radiat Oncol Biol Phys","2021","2020/12/07","","","10.1016/j.ijrobp.2020.11.053"
"33340601","Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases","Folkert MR, Meyer JJ, Aguilera TA, Yokoo T, Sanford NN, Rule WG, Mansour J, Yopp A, Polanco P, Hannan R, Nedzi LA, Timmerman RD.","Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1387-1395. doi: 10.1016/j.ijrobp.2020.12.012. Epub 2020 Dec 16.","Folkert MR","Int J Radiat Oncol Biol Phys","2021","2020/12/19","","","10.1016/j.ijrobp.2020.12.012"
"33358124","PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer","Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D.","Dig Liver Dis. 2021 Apr;53(4):420-426. doi: 10.1016/j.dld.2020.11.036. Epub 2021 Jan 6.","Evrard C","Dig Liver Dis","2021","2020/12/28","","","10.1016/j.dld.2020.11.036"
"33399934","Correction to: Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial","Matsui H, Hazama S, Nakajima M, Xu M, Matsukuma S, Tokumitsu Y, Shindo Y, Tomochika S, Yoshida S, Iida M, Suzuki N, Takeda S, Yoshino S, Ueno T, Oka M, Nagano H.","Cancer Immunol Immunother. 2021 Apr;70(4):959. doi: 10.1007/s00262-020-02819-x.","Matsui H","Cancer Immunol Immunother","2021","2021/01/05","PMC10991183","","10.1007/s00262-020-02819-x"
"33451816","Large-Volume Hyperthermia for Safe and Cost-Effective Targeted Drug Delivery Using a Clinical Ultrasound-Guided Focused Ultrasound Device","Lyon PC, Mannaris C, Gray M, Carlisle R, Gleeson FV, Cranston D, Wu F, Coussios CC.","Ultrasound Med Biol. 2021 Apr;47(4):982-997. doi: 10.1016/j.ultrasmedbio.2020.12.008. Epub 2021 Jan 13.","Lyon PC","Ultrasound Med Biol","2021","2021/01/16","","","10.1016/j.ultrasmedbio.2020.12.008"
"33465252","Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer","Vlachostergios PJ, Niaz MJ, Skafida M, Mosallaie SA, Thomas C, Christos PJ, Osborne JR, Molina AM, Nanus DM, Bander NH, Tagawa ST.","Prostate. 2021 Apr;81(5):279-285. doi: 10.1002/pros.24104. Epub 2021 Jan 19.","Vlachostergios PJ","Prostate","2021","2021/01/19","PMC7904644","NIHMS1661599","10.1002/pros.24104"
"33525928","Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma","Ikeda M, Okusaka T, Ohno I, Mitsunaga S, Kondo S, Ueno H, Morizane C, Gemmoto K, Suna H, Ushida Y, Furuse J.","Immunotherapy. 2021 Apr;13(5):371-385. doi: 10.2217/imt-2020-0278. Epub 2021 Feb 2.","Ikeda M","Immunotherapy","2021","2021/02/02","","","10.2217/imt-2020-0278"
"33531690","Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab","Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M.","Br J Cancer. 2021 Apr;124(8):1388-1397. doi: 10.1038/s41416-021-01260-w. Epub 2021 Feb 3.","Zhu AX","Br J Cancer","2021","2021/02/03","PMC8039038","","10.1038/s41416-021-01260-w"
"33560877","Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial","Kanemitsu Y, Shitara K, Mizusawa J, Hamaguchi T, Shida D, Komori K, Ikeda S, Ojima H, Ike H, Shiomi A, Watanabe J, Takii Y, Yamaguchi T, Katsumata K, Ito M, Okuda J, Hyakudomi R, Shimada Y, Katayama H, Fukuda H; JCOG Colorectal Cancer Study Group.","J Clin Oncol. 2021 Apr 1;39(10):1098-1107. doi: 10.1200/JCO.20.02447. Epub 2021 Feb 9.","Kanemitsu Y","J Clin Oncol","2021","2021/02/09","PMC8078424","","10.1200/JCO.20.02447"
"33595631","Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in Esophageal Cancer: Results of the MIRO Randomized Clinical Trial","Nuytens F, Dabakuyo-Yonli TS, Meunier B, Gagnière J, Collet D, D'Journo XB, Brigand C, Perniceni T, Carrère N, Mabrut JY, Msika S, Peschaud F, Prudhomme M, Markar SR, Piessen G; Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Groups.","JAMA Surg. 2021 Apr 1;156(4):323-332. doi: 10.1001/jamasurg.2020.7081.","Nuytens F","JAMA Surg","2021","2021/02/17","PMC7890455","","10.1001/jamasurg.2020.7081"
"33512442","A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis","Kennedy GA, Tey SK, Buizen L, Varelias A, Gartlan KH, Curley C, Olver SD, Chang K, Butler JP, Misra A, Subramoniapillai E, Morton AJ, Durrant S, Henden AS, Moore J, Ritchie D, Gottlieb D, Cooney J, Paul SK, Hill GR.","Blood. 2021 Apr 8;137(14):1970-1979. doi: 10.1182/blood.2020009050.","Kennedy GA","Blood","2021","2021/01/29","","","10.1182/blood.2020009050"
"33836710","Frequent fragility of randomized controlled trials for HCC treatment","Zhang H, Li J, Zeng W.","BMC Cancer. 2021 Apr 9;21(1):389. doi: 10.1186/s12885-021-08133-8.","Zhang H","BMC Cancer","2021","2021/04/10","PMC8034173","","10.1186/s12885-021-08133-8"
"33874981","A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial","McEvoy NL, Clarke JL, Mc Elvaney OJ, Mc Elvaney OF, Boland F, Hyland D, Geoghegan P, Donnelly K, Friel O, Cullen A, Collins AM, Fraughen D, Martin-Loeches I, Hennessy M, Laffey JG, Mc Elvaney NG, Curley GF.","Trials. 2021 Apr 19;22(1):288. doi: 10.1186/s13063-021-05254-0.","McEvoy NL","Trials","2021","2021/04/20","PMC8054126","","10.1186/s13063-021-05254-0"
"32435962","HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: a phase I clinical trial","Yang T, Ng DM, Du N, He N, Dai X, Chen P, Wu F, Chen B, Fan X, Yan K, Zhou X, Dong M, Zheng Z, Gu L.","Surg Endosc. 2021 May;35(5):2306-2315. doi: 10.1007/s00464-020-07644-y. Epub 2020 May 20.","Yang T","Surg Endosc","2021","2020/05/22","","","10.1007/s00464-020-07644-y"
"33191450","Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study","Zong Y, Yuan J, Peng Z, Lu M, Wang X, Shen L, Zhou J.","J Cancer Res Clin Oncol. 2021 May;147(5):1529-1536. doi: 10.1007/s00432-020-03442-0. Epub 2020 Nov 15.","Zong Y","J Cancer Res Clin Oncol","2021","2020/11/16","","","10.1007/s00432-020-03442-0"
"33453146","Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma","Kobayashi N, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Hiroshima Y, Ichikawa Y.","Cancer Sci. 2021 May;112(5):1936-1942. doi: 10.1111/cas.14811. Epub 2021 Mar 12.","Kobayashi N","Cancer Sci","2021","2021/01/16","PMC8088944","","10.1111/cas.14811"
"33524900","Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial","Ikeda S, Kudo M, Izumi N, Kobayashi M, Azuma M, Meier G, Pan J, Ishii M, Kaneko S.","Value Health Reg Issues. 2021 May;24:82-89. doi: 10.1016/j.vhri.2020.05.009. Epub 2021 Jan 30.","Ikeda S","Value Health Reg Issues","2021","2021/02/01","","","10.1016/j.vhri.2020.05.009"
"33539946","Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(☆)","Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, Zhang H, Shi M, Luft A, Wolf J, Antonia S, Nakagawa K, Fairchild J, Baudelet C, Pandya D, Doshi P, Chang H, Reck M.","Ann Oncol. 2021 May;32(5):631-641. doi: 10.1016/j.annonc.2021.01.071. Epub 2021 Feb 1.","Spigel DR","Ann Oncol","2021","2021/02/04","","","10.1016/j.annonc.2021.01.071"
"33556230","Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states","Wen F, Zheng H, Zhang P, Liao W, Zhou K, Li Q.","Liver Int. 2021 May;41(5):1097-1104. doi: 10.1111/liv.14795. Epub 2021 Feb 8.","Wen F","Liver Int","2021","2021/02/08","","","10.1111/liv.14795"
"33589516","Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer","Zhou J, Li Q, Cao Y.","Cancer Res. 2021 May 1;81(9):2522-2533. doi: 10.1158/0008-5472.CAN-20-3665. Epub 2021 Feb 15.","Zhou J","Cancer Res","2021","2021/02/16","PMC8137573","NIHMS1675097","10.1158/0008-5472.CAN-20-3665"
"33646487","Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis","Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A.","Target Oncol. 2021 May;16(3):401-410. doi: 10.1007/s11523-021-00797-3. Epub 2021 Mar 1.","Bang Y","Target Oncol","2021","2021/03/01","","","10.1007/s11523-021-00797-3"
"33677106","Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway","Shah K, Panchal S, Patel B.","Pharmacol Res. 2021 May;167:105532. doi: 10.1016/j.phrs.2021.105532. Epub 2021 Mar 4.","Shah K","Pharmacol Res","2021","2021/03/07","","","10.1016/j.phrs.2021.105532"
"33724066","Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial","Meijerink MR, Ruarus AH, Vroomen LGPH, Puijk RS, Geboers B, Nieuwenhuizen S, van den Bemd BAT, Nielsen K, de Vries JJJ, van Lienden KP, Lissenberg-Witte BI, van den Tol MP, Scheffer HJ.","Radiology. 2021 May;299(2):470-480. doi: 10.1148/radiol.2021203089. Epub 2021 Mar 16.","Meijerink MR","Radiology","2021","2021/03/16","","","10.1148/radiol.2021203089"
"33771685","SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation","Kaplan DE, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee TH, Monto A, Pandya P, Schaubel D, Taddei TH.","Contemp Clin Trials. 2021 May;104:106367. doi: 10.1016/j.cct.2021.106367. Epub 2021 Mar 24.","Kaplan DE","Contemp Clin Trials","2021","2021/03/27","PMC8422958","NIHMS1734529","10.1016/j.cct.2021.106367"
"33811482","Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma","Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK.","Cancer Med. 2021 May;10(9):3059-3067. doi: 10.1002/cam4.3880. Epub 2021 Apr 2.","Harding JJ","Cancer Med","2021","2021/04/03","PMC8085979","","10.1002/cam4.3880"
"33812339","Treatment landscape of metastatic pancreatic cancer","De Dosso S, Siebenhüner AR, Winder T, Meisel A, Fritsch R, Astaras C, Szturz P, Borner M.","Cancer Treat Rev. 2021 May;96:102180. doi: 10.1016/j.ctrv.2021.102180. Epub 2021 Mar 17.","De Dosso S","Cancer Treat Rev","2021","2021/04/03","","","10.1016/j.ctrv.2021.102180"
"33928262","Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial","Pratt AG, Siebert S, Cole M, Stocken DD, Yap C, Kelly S, Shaikh M, Cranston A, Morton M, Walker J, Frame S, Ng WF, Buckley CD, McInnes IB, Filer A, Isaacs JD.","Lancet Rheumatol. 2021 Mar 9;3(5):e337-e346. doi: 10.1016/S2665-9913(21)00061-8. eCollection 2021 May.","Pratt AG","Lancet Rheumatol","2021","2021/04/30","PMC8062952","","10.1016/S2665-9913(21)00061-8"
"33939068","Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C","Yoh K, Hirashima T, Saka H, Kurata T, Ohe Y, Hida T, Mellemgaard A, Verheijen RB, Ou X, Ahmed GF, Hayama M, Sugibayashi K, Oxnard GR.","Target Oncol. 2021 May;16(3):339-355. doi: 10.1007/s11523-021-00806-5. Epub 2021 May 3.","Yoh K","Target Oncol","2021","2021/05/03","PMC8105224","","10.1007/s11523-021-00806-5"
"33976538","Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study","Li H, Qin S, Liu Y, Chen Z, Ren Z, Xiong J, Meng Z, Zhang X, Wang L, Zhang X, Zou J.","Drug Des Devel Ther. 2021 May 3;15:1873-1882. doi: 10.2147/DDDT.S304857. eCollection 2021.","Li H","Drug Des Devel Ther","2021","2021/05/12","PMC8106453","","10.2147/DDDT.S304857"
"33957901","A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker","Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ.","BMC Cancer. 2021 May 7;21(1):510. doi: 10.1186/s12885-021-08242-4.","Kelley KC","BMC Cancer","2021","2021/05/07","PMC8103752","","10.1186/s12885-021-08242-4"
"33961019","Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia","Tomowiak C, Poulain S, Herbaux C, Perrot A, Mahé B, Morel P, Aurran T, Tournilhac O, Leprêtre S, Assaad S, Villemagne B, Casasnovas O, Nollet D, Roos-Weil D, Chevret S, Leblond V.","Blood Adv. 2021 May 11;5(9):2438-2446. doi: 10.1182/bloodadvances.2020003895.","Tomowiak C","Blood Adv","2021","2021/05/07","PMC8114554","","10.1182/bloodadvances.2020003895"
"33211842","Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma","Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS.","Blood. 2021 May 13;137(19):2634-2645. doi: 10.1182/blood.2020007512.","Hamadani M","Blood","2021","2020/11/19","PMC8138546","","10.1182/blood.2020007512"
"33844533","Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Biphenyl Moiety","Sainas S, Giorgis M, Circosta P, Gaidano V, Bonanni D, Pippione AC, Bagnati R, Passoni A, Qiu Y, Cojocaru CF, Canepa B, Bona A, Rolando B, Mishina M, Ramondetti C, Buccinnà B, Piccinini M, Houshmand M, Cignetti A, Giraudo E, Al-Karadaghi S, Boschi D, Saglio G, Lolli ML.","J Med Chem. 2021 May 13;64(9):5404-5428. doi: 10.1021/acs.jmedchem.0c01549. Epub 2021 Apr 12.","Sainas S","J Med Chem","2021","2021/04/12","PMC8279415","","10.1021/acs.jmedchem.0c01549"
"34041204","Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma","Abi-Jaoudeh N, Dayyani F, Chen PJ, Fernando D, Fidelman N, Javan H, Liang PC, Hwang JI, Imagawa DK.","J Hepatocell Carcinoma. 2021 May 17;8:421-434. doi: 10.2147/JHC.S304275. eCollection 2021.","Abi-Jaoudeh N","J Hepatocell Carcinoma","2021","2021/05/27","PMC8139681","","10.2147/JHC.S304275"
"32236406","Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study","Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP.","Clin Infect Dis. 2021 May 18;72(10):1755-1763. doi: 10.1093/cid/ciaa358.","Bose P","Clin Infect Dis","2021","2020/04/03","PMC8130026","","10.1093/cid/ciaa358"
"34006331","Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets","Luo XY, Wu KM, He XX.","J Exp Clin Cancer Res. 2021 May 18;40(1):172. doi: 10.1186/s13046-021-01968-w.","Luo XY","J Exp Clin Cancer Res","2021","2021/05/19","PMC8130401","","10.1186/s13046-021-01968-w"
"34094937","A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas","Schloss J, Lacey J, Sinclair J, Steel A, Sughrue M, Sibbritt D, Teo C.","Front Oncol. 2021 May 21;11:649555. doi: 10.3389/fonc.2021.649555. eCollection 2021.","Schloss J","Front Oncol","2021","2021/06/07","PMC8176855","","10.3389/fonc.2021.649555"
"34051727","Zanubrutinib-induced liver injury: a case report and literature review","Atallah E, Wijayasiri P, Cianci N, Abdullah K, Mukherjee A, Aithal GP.","BMC Gastroenterol. 2021 May 29;21(1):244. doi: 10.1186/s12876-021-01825-2.","Atallah E","BMC Gastroenterol","2021","2021/05/30","PMC8164809","","10.1186/s12876-021-01825-2"
"32397857","The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells","Muñoz-Guardiola P, Casas J, Megías-Roda E, Solé S, Perez-Montoyo H, Yeste-Velasco M, Erazo T, Diéguez-Martínez N, Espinosa-Gil S, Muñoz-Pinedo C, Yoldi G, Abad JL, Segura MF, Moran T, Romeo M, Bosch-Barrera J, Oaknin A, Alfón J, Domènech C, Fabriàs G, Velasco G, Lizcano JM.","Autophagy. 2021 Jun;17(6):1349-1366. doi: 10.1080/15548627.2020.1761651. Epub 2020 May 25.","Muñoz-Guardiola P","Autophagy","2021","2020/05/14","PMC8204958","","10.1080/15548627.2020.1761651"
"33398094","Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD","Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM.","Bone Marrow Transplant. 2021 Jun;56(6):1316-1324. doi: 10.1038/s41409-020-01188-4. Epub 2021 Jan 4.","Mehta RS","Bone Marrow Transplant","2021","2021/01/05","","","10.1038/s41409-020-01188-4"
"33666530","Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib","Tsang J, Wong JSL, Kwok GGW, Li BCW, Leung R, Chiu J, Cheung TT, Yau T.","Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):589-598. doi: 10.1080/17474124.2021.1899808. Epub 2021 Mar 19.","Tsang J","Expert Rev Gastroenterol Hepatol","2021","2021/03/05","","","10.1080/17474124.2021.1899808"
"33744409","Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period","Chen GH, Wang GB, Huang F, Qin R, Yu XJ, Wu RL, Hou LJ, Ye ZH, Zhang XH, Zhao HC.","Transpl Immunol. 2021 Jun;66:101386. doi: 10.1016/j.trim.2021.101386. Epub 2021 Mar 18.","Chen GH","Transpl Immunol","2021","2021/03/21","","","10.1016/j.trim.2021.101386"
"33771853","A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies","Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS.","Clin Cancer Res. 2021 Jun 1;27(11):3050-3060. doi: 10.1158/1078-0432.CCR-20-4118. Epub 2021 Mar 26.","Hegde A","Clin Cancer Res","2021","2021/03/27","PMC8172466","NIHMS1690090","10.1158/1078-0432.CCR-20-4118"
"33826043","Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)","Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, Zhao J, Li Z, Wang L, Bi X, Zhao H, Liu K.","Hepatol Int. 2021 Jun;15(3):621-629. doi: 10.1007/s12072-021-10171-0. Epub 2021 Apr 7.","Sun Y","Hepatol Int","2021","2021/04/07","PMC8286948","","10.1007/s12072-021-10171-0"
"33885704","Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial","Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, Matuszak M, Park SS, Yi S, Hasan Y, Bazan J, Wong P, Yoon HA, Horton J, Gan G, Milano MT, Sigurdson ER, Moughan J, Salama JK, White J.","JAMA Oncol. 2021 Jun 1;7(6):845-852. doi: 10.1001/jamaoncol.2021.0687.","Chmura S","JAMA Oncol","2021","2021/04/22","PMC8063134","","10.1001/jamaoncol.2021.0687"
"33895682","Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study","Duffaud F, Italiano A, Bompas E, Rios M, Penel N, Mir O, Piperno-Neumann S, Chevreau C, Delcambre C, Bertucci F, Boudou-Rouquette P, Cancel M, Perrin C, Saada-Bouzid E, Monard L, Schiffler C, Chaigneau L, Hervieu A, Collard O, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group.","Eur J Cancer. 2021 Jun;150:108-118. doi: 10.1016/j.ejca.2021.03.039. Epub 2021 Apr 22.","Duffaud F","Eur J Cancer","2021","2021/04/25","","","10.1016/j.ejca.2021.03.039"
"34086477","Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study","Sharma A, Pramanik R, Kumar A, Pathy S, Kumar S, Bhoriwal S, Thulkar S, Dash NR, Pal S, Choudhary P, Pawar S, Kumar R, Gupta G.","JCO Glob Oncol. 2021 Jun;7:820-826. doi: 10.1200/GO.20.00657.","Sharma A","JCO Glob Oncol","2021","2021/06/04","PMC8457810","","10.1200/GO.20.00657"
"34151243","Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis","Bhattacharya D, Basta B, Mato JM, Craig A, Fernández-Ramos D, Lopitz-Otsoa F, Tsvirkun D, Hayardeny L, Chandar V, Schwartz RE, Villanueva A, Friedman SL.","JHEP Rep. 2021 Jan 28;3(3):100237. doi: 10.1016/j.jhepr.2021.100237. eCollection 2021 Jun.","Bhattacharya D","JHEP Rep","2021","2021/06/21","PMC8189934","","10.1016/j.jhepr.2021.100237"
"35530750","Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC)","Ghaziani TT, Dhanasekaran R.","Curr Treat Options Gastroenterol. 2021 Jun;19(2):351-368. doi: 10.1007/s11938-021-00346-x. Epub 2021 Mar 31.","Ghaziani TT","Curr Treat Options Gastroenterol","2021","2022/05/09","PMC9075739","NIHMS1801741","10.1007/s11938-021-00346-x"
"34115819","Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy","Cunningham M, Iafolla M, Kanjanapan Y, Cerocchi O, Butler M, Siu LL, Bedard PL, Ross K, Hansen B, Spreafico A, Feld JJ.","PLoS One. 2021 Jun 11;16(6):e0253070. doi: 10.1371/journal.pone.0253070. eCollection 2021.","Cunningham M","PLoS One","2021","2021/06/11","PMC8195413","","10.1371/journal.pone.0253070"
"34168480","Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial","Lin J, Li M, Chen S, Weng L, He Z.","J Inflamm Res. 2021 Jun 16;14:2557-2567. doi: 10.2147/JIR.S313056. eCollection 2021.","Lin J","J Inflamm Res","2021","2021/06/25","PMC8216733","","10.2147/JIR.S313056"
"34155211","Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors","Schneider MA, Linecker M, Fritsch R, Muehlematter UJ, Stocker D, Pestalozzi B, Samaras P, Jetter A, Kron P, Petrowsky H, Nicolau C, Lehn JM, Humar B, Graf R, Clavien PA, Limani P.","Nat Commun. 2021 Jun 21;12(1):3807. doi: 10.1038/s41467-021-24069-w.","Schneider MA","Nat Commun","2021","2021/06/22","PMC8217170","","10.1038/s41467-021-24069-w"
"32732073","Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study","Cortinovis D, Grosso F, Carlucci L, Zucali PA, Pasello G, Tiseo M, Sperandi F, Hollander L, Galli F, Torri V, Rulli E, Canova S, Maconi A, Bidoli P, Ceresoli GL, D'Incalci M; ATREUS investigators.","Clin Lung Cancer. 2021 Jul;22(4):361-370.e3. doi: 10.1016/j.cllc.2020.06.028. Epub 2020 Jul 3.","Cortinovis D","Clin Lung Cancer","2021","2020/08/01","","","10.1016/j.cllc.2020.06.028"
"33655688","Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma","Lin ZY, Yeh ML, Huang CI, Chen SC, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL.","Kaohsiung J Med Sci. 2021 Jul;37(7):616-623. doi: 10.1002/kjm2.12374. Epub 2021 Mar 3.","Lin ZY","Kaohsiung J Med Sci","2021","2021/03/03","","","10.1002/kjm2.12374"
"33824476","Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression","Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S.","Br J Cancer. 2021 Jul;125(2):190-199. doi: 10.1038/s41416-021-01334-9. Epub 2021 Apr 6.","Decaens T","Br J Cancer","2021","2021/04/07","PMC8292404","","10.1038/s41416-021-01334-9"
"33836265","Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial","Annala M, Fu S, Bacon JVW, Sipola J, Iqbal N, Ferrario C, Ong M, Wadhwa D, Hotte SJ, Lo G, Tran B, Wood LA, Gingerich JR, North SA, Pezaro CJ, Ruether JD, Sridhar SS, Kallio HML, Khalaf DJ, Wong A, Beja K, Schönlau E, Taavitsainen S, Nykter M, Vandekerkhove G, Azad AA, Wyatt AW, Chi KN.","Ann Oncol. 2021 Jul;32(7):896-905. doi: 10.1016/j.annonc.2021.03.205. Epub 2021 Apr 6.","Annala M","Ann Oncol","2021","2021/04/09","","","10.1016/j.annonc.2021.03.205"
"33867478","The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together","D'Alessio A, Cammarota A, Prete MG, Pressiani T, Rimassa L.","Curr Opin Oncol. 2021 Jul 1;33(4):386-394. doi: 10.1097/CCO.0000000000000744.","D'Alessio A","Curr Opin Oncol","2021","2021/04/19","","","10.1097/CCO.0000000000000744"
"33966002","Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?","Hendlisz A, Sclafani F.","Curr Opin Oncol. 2021 Jul 1;33(4):351-352. doi: 10.1097/CCO.0000000000000749.","Hendlisz A","Curr Opin Oncol","2021","2021/05/09","","","10.1097/CCO.0000000000000749"
"33971141","Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J.","Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559-568. doi: 10.1016/S2468-1253(21)00109-6. Epub 2021 May 8.","Qin S","Lancet Gastroenterol Hepatol","2021","2021/05/10","","","10.1016/S2468-1253(21)00109-6"
"33972742","Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression","Ryoo BY, Cheng AL, Ren Z, Kim TY, Pan H, Rau KM, Choi HJ, Park JW, Kim JH, Yen CJ, Lim HY, Zhou D, Straub J, Scheele J, Berghoff K, Qin S.","Br J Cancer. 2021 Jul;125(2):200-208. doi: 10.1038/s41416-021-01380-3. Epub 2021 May 10.","Ryoo BY","Br J Cancer","2021","2021/05/11","PMC8292411","","10.1038/s41416-021-01380-3"
"34005839","Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib","Rimini M, Yoo C, Lonardi S, Masi G, Piscaglia F, Kim HD, Rizzato MD, Salani F, Ielasi L, Forgione A, Bang Y, Soldà C, Catanese S, Sansone V, Ryu MH, Ryoo BY, Burgio V, Cucchetti A, Cascinu S, Casadei-Gardini A.","Hepatol Res. 2021 Jul;51(7):796-802. doi: 10.1111/hepr.13669. Epub 2021 May 26.","Rimini M","Hepatol Res","2021","2021/05/18","","","10.1111/hepr.13669"
"34051880","Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M.","Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.","Galle PR","Lancet Oncol","2021","2021/05/30","","","10.1016/S1470-2045(21)00151-0"
"34143971","Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group.","Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.","Ren Z","Lancet Oncol","2021","2021/06/18","","","10.1016/S1470-2045(21)00252-7"
"34786358","HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis","Fleites YA, Aguiar J, Cinza Z, Bequet M, Marrero E, Vizcaíno M, Esquivel I, Diaz M, Sin-Mayor A, Garcia M, Martinez SM, Beato A, Galarraga AG, Mendoza-Mari Y, Valdés I, García G, Lemos G, González I, Canaán-Haden C, Figueroa N, Oquendo R, Akbar SM, Mahtab MA, Uddin MH, Guillén GE, Muzio VL, Pentón E, Aguilar JC.","Euroasian J Hepatogastroenterol. 2021 Jul-Dec;11(2):59-70. doi: 10.5005/jp-journals-10018-1344.","Fleites YA","Euroasian J Hepatogastroenterol","2021","2021/11/17","PMC8566153","","10.5005/jp-journals-10018-1344"
"34480563","Preoperative high-dose glucocorticoids for early recovery after liver resection: randomized double-blinded trial","Steinthorsdottir KJ, Awada HN, Schultz NA, Larsen PN, Hillingsø JG, Jans Ø, Kehlet H, Aasvang EK.","BJS Open. 2021 Jul 6;5(5):zrab063. doi: 10.1093/bjsopen/zrab063.","Steinthorsdottir KJ","BJS Open","2021","2021/09/04","PMC8418207","","10.1093/bjsopen/zrab063"
"33947692","A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer","Jhaveri K, Drago JZ, Shah PD, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, Fornier MN, Sklarin NT, Chandarlapaty S, Modi S.","Clin Cancer Res. 2021 Jul 15;27(14):3867-3875. doi: 10.1158/1078-0432.CCR-21-0047. Epub 2021 May 4.","Jhaveri K","Clin Cancer Res","2021","2021/05/05","PMC8282678","NIHMS1702179","10.1158/1078-0432.CCR-21-0047"
"34299189","Current Options and Future Directions for NAFLD and NASH Treatment","Zhang C, Yang M.","Int J Mol Sci. 2021 Jul 15;22(14):7571. doi: 10.3390/ijms22147571.","Zhang C","Int J Mol Sci","2021","2021/07/24","PMC8306701","","10.3390/ijms22147571"
"34371533","[Progress of therapeutic vaccinations for chronic hepatitis B]","Zhang J, Wu YZ.","Zhonghua Gan Zang Bing Za Zhi. 2021 Jul 20;29(7):631-635. doi: 10.3760/cma.j.cn501113-20210710-00332.","Zhang J","Zhonghua Gan Zang Bing Za Zhi","2021","2021/08/09","","","10.3760/cma.j.cn501113-20210710-00332"
"34327297","Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases","Loupakis F, Sharma S, Derouazi M, Murgioni S, Biason P, Rizzato MD, Rasola C, Renner D, Shchegrova S, Koyen Malashevich A, Malhotra M, Sethi H, Zimmermann BG, Aleshin A, Moshkevich S, Billings PR, Sedgwick JD, Schirripa M, Munari G, Cillo U, Pilati P, Dei Tos AP, Zagonel V, Lonardi S, Fassan M.","JCO Precis Oncol. 2021 Jul 21;5:PO.21.00101. doi: 10.1200/PO.21.00101. eCollection 2021 Jul.","Loupakis F","JCO Precis Oncol","2021","2021/07/30","PMC8315303","","10.1200/PO.21.00101"
"34361985","Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting","Plaz Torres MC, Lai Q, Piscaglia F, Caturelli E, Cabibbo G, Biasini E, Pelizzaro F, Marra F, Trevisani F, Giannini EG.","J Clin Med. 2021 Jul 21;10(15):3201. doi: 10.3390/jcm10153201.","Plaz Torres MC","J Clin Med","2021","2021/08/07","PMC8347923","","10.3390/jcm10153201"
"34312190","A prospective, phase II, single-centre, cross-sectional, randomised study investigating Dehydroepiandrosterone supplementation and its Profile in Trauma: ADaPT","Bentley C, Potter C, Yakoub KM, Brock K, Homer V, Toman E, Taylor AE, Shaheen F, Gilligan LC, Athwal A, Barton D, Carrera R, Young K, Desai A, McGee K, Ermogenous C, Sur G, Greig CA, Hazeldine J, Arlt W, Lord JM, Foster MA.","BMJ Open. 2021 Jul 26;11(7):e040823. doi: 10.1136/bmjopen-2020-040823.","Bentley C","BMJ Open","2021","2021/07/27","PMC8314713","","10.1136/bmjopen-2020-040823"
"34441274","Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma","Chen BB, Shao YY, Lin ZZ, Hsu CH, Cheng AL, Hsu C, Liang PC, Shih TT.","Diagnostics (Basel). 2021 Jul 26;11(8):1340. doi: 10.3390/diagnostics11081340.","Chen BB","Diagnostics (Basel)","2021","2021/08/27","PMC8391260","","10.3390/diagnostics11081340"
"34325726","IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, Li T, Liang B, Zhang J, Cao B, Liu M, Feng Y, Ye X, Chen X, Wang L, Tian Y, Li H, Li J, Hu H, He J, Hu Y, Zhi C, Tang Z, Gong Y, Xu F, Xu L, Fan W, Zhao M, Chen D, Lian H, Yang L, Li P, Zhang Z.","J Hematol Oncol. 2021 Jul 29;14(1):118. doi: 10.1186/s13045-021-01128-9.","Pang N","J Hematol Oncol","2021","2021/07/30","PMC8323212","","10.1186/s13045-021-01128-9"
"33555033","Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment","Samant TS, Yang S, Miller M, Ji Y.","J Clin Pharmacol. 2021 Aug;61(8):1001-1009. doi: 10.1002/jcph.1825. Epub 2021 Mar 12.","Samant TS","J Clin Pharmacol","2021","2021/02/08","","","10.1002/jcph.1825"
"33624233","LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial","Dowlati A, Harvey RD, Carvajal RD, Hamid O, Klempner SJ, Kauh JSW, Peterson DA, Yu D, Chapman SC, Szpurka AM, Carlsen M, Quinlan T, Wesolowski R.","Invest New Drugs. 2021 Aug;39(4):1057-1071. doi: 10.1007/s10637-021-01084-8. Epub 2021 Feb 23.","Dowlati A","Invest New Drugs","2021","2021/02/24","","","10.1007/s10637-021-01084-8"
"33630242","Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept","González Astorga B, Salvà Ballabrera F, Aranda Aguilar E, Élez Fernández E, García-Alfonso P, González Flores E, Vera García R, Fernández Montes A, López Muñoz AM, Salud Salvia A.","Clin Transl Oncol. 2021 Aug;23(8):1520-1528. doi: 10.1007/s12094-021-02568-y. Epub 2021 Feb 25.","González Astorga B","Clin Transl Oncol","2021","2021/02/25","PMC8238745","","10.1007/s12094-021-02568-y"
"33646489","Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance)","Tran NH, Foster NR, Mahipal A, Byrne T, Hubbard J, Silva A, Mody K, Alberts S, Borad MJ.","Invest New Drugs. 2021 Aug;39(4):1072-1080. doi: 10.1007/s10637-021-01090-w. Epub 2021 Mar 1.","Tran NH","Invest New Drugs","2021","2021/03/01","PMC8282689","NIHMS1692141","10.1007/s10637-021-01090-w"
"33713359","Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients","Lu Y, Yang S, Ho YY, Ji Y.","J Clin Pharmacol. 2021 Aug;61(8):1054-1068. doi: 10.1002/jcph.1856. Epub 2021 Apr 17.","Lu Y","J Clin Pharmacol","2021","2021/03/13","","","10.1002/jcph.1856"
"33749934","Safety, Efficacy, and Pharmacokinetics of Metatinib Tromethamine Tablet in Patients with Advanced Refractory Solid Tumors: A Phase I Clinical Trial","Cheng K, Li XY, Zhou YW, Liao ZY, Qiu M, Bi F, Zheng L.","Oncologist. 2021 Aug;26(8):649-e1313. doi: 10.1002/onco.13760. Epub 2021 Apr 24.","Cheng K","Oncologist","2021","2021/03/22","PMC8342607","","10.1002/onco.13760"
"33909097","Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment","Grechko N, Skarbova V, Tomaszewska-Kiecana M, Ramlau R, Centkowski P, Drew Y, Dziadziuszko R, Zemanova M, Beltman J, Nash E, Habeck J, Liao M, Xiao J.","Cancer Chemother Pharmacol. 2021 Aug;88(2):259-270. doi: 10.1007/s00280-021-04278-2. Epub 2021 Apr 28.","Grechko N","Cancer Chemother Pharmacol","2021","2021/04/28","PMC8236452","","10.1007/s00280-021-04278-2"
"33938493","A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer","Kemeny NE, Chou JF, Capanu M, Chatila WK, Shi H, Sanchez-Vega F, Kingham TP, Connell LC, Jarnagin WR, D'Angelica MI.","Ann Surg. 2021 Aug 1;274(2):248-254. doi: 10.1097/SLA.0000000000004923.","Kemeny NE","Ann Surg","2021","2021/05/03","PMC9351589","NIHMS1822736","10.1097/SLA.0000000000004923"
"34045233","First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer","Pegram MD, Hamilton EP, Tan AR, Storniolo AM, Balic K, Rosenbaum AI, Liang M, He P, Marshall S, Scheuber A, Das M, Patel MR.","Mol Cancer Ther. 2021 Aug;20(8):1442-1453. doi: 10.1158/1535-7163.MCT-20-0014. Epub 2021 May 27.","Pegram MD","Mol Cancer Ther","2021","2021/05/28","PMC9398097","","10.1158/1535-7163.MCT-20-0014"
"34079081","Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression","Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S.","Br J Cancer. 2021 Aug;125(3):465. doi: 10.1038/s41416-021-01403-z.","Decaens T","Br J Cancer","2021","2021/06/03","PMC8329044","","10.1038/s41416-021-01403-z"
"34087115","Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial","Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V.","Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-658. doi: 10.1016/S2468-1253(21)00110-2. Epub 2021 Jun 2.","Vogel A","Lancet Gastroenterol Hepatol","2021","2021/06/04","","","10.1016/S2468-1253(21)00110-2"
"34102253","Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA.","Ann Oncol. 2021 Aug;32(8):1015-1024. doi: 10.1016/j.annonc.2021.05.353. Epub 2021 Jun 5.","Slamon DJ","Ann Oncol","2021","2021/06/08","","","10.1016/j.annonc.2021.05.353"
"34112615","Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial","Voron T, Karoui M, Lo Dico R, Malicot KL, Espin E, Cianchi F, Jürgen W, Buggenhout A, Bruzzi M, Denimal F, Cazelles A, Douard R, Lepage C, Taieb J.","Dig Liver Dis. 2021 Aug;53(8):1034-1040. doi: 10.1016/j.dld.2021.05.012. Epub 2021 Jun 8.","Voron T","Dig Liver Dis","2021","2021/06/11","","","10.1016/j.dld.2021.05.012"
"34144271","Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma","Rapposelli IG, Shimose S, Kumada T, Okamura S, Hiraoka A, Di Costanzo GG, Marra F, Tamburini E, Forgione A, Foschi FG, Silletta M, Lonardi S, Masi G, Scartozzi M, Nakano M, Shibata H, Kawata K, Pellino A, Vivaldi C, Lai E, Takata A, Tajiri K, Toyoda H, Tortora R, Campani C, Viola MG, Piscaglia F, Conti F, Fulgenzi CAM, Frassineti GL, Rizzato MD, Salani F, Astara G, Torimura T, Atsukawa M, Tada T, Burgio V, Rimini M, Cascinu S, Casadei-Gardini A.","ESMO Open. 2021 Aug;6(4):100190. doi: 10.1016/j.esmoop.2021.100190. Epub 2021 Jun 16.","Rapposelli IG","ESMO Open","2021","2021/06/18","PMC8219999","","10.1016/j.esmoop.2021.100190"
"34174189","Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou T, Shen L, Wu H, Lang J, Hu G, Luo Z, Fu Z, Qu S, Feng W, Chen X, Lin S, Zhang W, Li X, Sun Y, Lin Z, Lin Q, Lei F, Long J, Hong J, Huang X, Zeng L, Wang P, He X, Zhang B, Yang Q, Zhang X, Zou J, Fang W, Zhang L.","Lancet Oncol. 2021 Aug;22(8):1162-1174. doi: 10.1016/S1470-2045(21)00302-8. Epub 2021 Jun 23.","Yang Y","Lancet Oncol","2021","2021/06/26","","","10.1016/S1470-2045(21)00302-8"
"34189869","Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial","Salem R, Li D, Sommer N, Hernandez S, Verret W, Ding B, Lencioni R.","Cancer Med. 2021 Aug;10(16):5437-5447. doi: 10.1002/cam4.4090. Epub 2021 Jun 29.","Salem R","Cancer Med","2021","2021/06/30","PMC8366100","","10.1002/cam4.4090"
"34219000","Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer","Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators.","Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.","Miles D","Ann Oncol","2021","2021/07/05","","","10.1016/j.annonc.2021.05.801"
"34312547","Epigenetic scars of CD8(+) T cell exhaustion persist after cure of chronic infection in humans","Yates KB, Tonnerre P, Martin GE, Gerdemann U, Al Abosy R, Comstock DE, Weiss SA, Wolski D, Tully DC, Chung RT, Allen TM, Kim AY, Fidler S, Fox J, Frater J, Lauer GM, Haining WN, Sen DR.","Nat Immunol. 2021 Aug;22(8):1020-1029. doi: 10.1038/s41590-021-00979-1. Epub 2021 Jul 26.","Yates KB","Nat Immunol","2021","2021/07/27","PMC8600539","NIHMS1736924","10.1038/s41590-021-00979-1"
"34333237","Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases","Bolhuis K, van 't Erve I, Mijnals C, Delis-Van Diemen PM, Huiskens J, Komurcu A, Lopez-Yurda M, van den Broek D, Swijnenburg RJ, Meijer GA, Punt CJA, Fijneman RJA.","EBioMedicine. 2021 Aug;70:103498. doi: 10.1016/j.ebiom.2021.103498. Epub 2021 Jul 29.","Bolhuis K","EBioMedicine","2021","2021/08/01","PMC8340125","","10.1016/j.ebiom.2021.103498"
"33544279","Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC)","Rovers KP, Wassenaar ECE, Lurvink RJ, Creemers GM, Burger JWA, Los M, Huysentruyt CJR, van Lijnschoten G, Nederend J, Lahaye MJ, Deenen MJ, Wiezer MJ, Nienhuijs SW, Boerma D, de Hingh IHJT.","Ann Surg Oncol. 2021 Sep;28(9):5311-5326. doi: 10.1245/s10434-020-09558-4. Epub 2021 Feb 5.","Rovers KP","Ann Surg Oncol","2021","2021/02/05","","","10.1245/s10434-020-09558-4"
"33651116","Phase I study to assess safety, biodistribution and radiation dosimetry for (89)Zr-girentuximab in patients with renal cell carcinoma","Merkx RIJ, Lobeek D, Konijnenberg M, Jiménez-Franco LD, Kluge A, Oosterwijk E, Mulders PFA, Rijpkema M.","Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3277-3285. doi: 10.1007/s00259-021-05271-w. Epub 2021 Mar 2.","Merkx RIJ","Eur J Nucl Med Mol Imaging","2021","2021/03/02","PMC8426244","","10.1007/s00259-021-05271-w"
"33798564","A Phase 2 Study of Image-Guided Proton Therapy for Operable or Ablation-Treatable Primary Hepatocellular Carcinoma","Iwata H, Ogino H, Hattori Y, Nakajima K, Nomura K, Hashimoto S, Hayashi K, Toshito T, Sasaki S, Mizoe JE, Shibamoto Y.","Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):117-126. doi: 10.1016/j.ijrobp.2021.03.049. Epub 2021 Mar 31.","Iwata H","Int J Radiat Oncol Biol Phys","2021","2021/04/02","","","10.1016/j.ijrobp.2021.03.049"
"33881209","A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)","Cash T, Fox E, Liu X, Minard CG, Reid JM, Scheck AC, Weigel BJ, Wetmore C.","Pediatr Blood Cancer. 2021 Sep;68(9):e29065. doi: 10.1002/pbc.29065. Epub 2021 Apr 21.","Cash T","Pediatr Blood Cancer","2021","2021/04/21","PMC9090141","NIHMS1703050","10.1002/pbc.29065"
"33928928","A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer","Kotecki N, Vuagnat P, O'Neil BH, Jalal S, Rottey S, Prenen H, Benhadji KA, Xia M, Szpurka AM, Saha A, Wallin J, Suriyapperuma S, Galvao VR, Geeganage S, Doman TN, Gandhi L, Xu X, Bendell J.","J Immunother. 2021 Sep 1;44(7):264-275. doi: 10.1097/CJI.0000000000000368.","Kotecki N","J Immunother","2021","2021/04/30","","","10.1097/CJI.0000000000000368"
"34051329","CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B.","J Hepatol. 2021 Sep;75(3):600-609. doi: 10.1016/j.jhep.2021.04.047. Epub 2021 May 26.","Kudo M","J Hepatol","2021","2021/05/29","","","10.1016/j.jhep.2021.04.047"
"34085761","Tissue pharmacokinetics of DHP107, a novel lipid-based oral formulation of paclitaxel, in mice and patients by positron emission tomography","Moon BS, Park HS, Sunwoo J, Lee IH, Kim A, Moon SJ, Lee H, Son MH, Kim SB, Park SM, Woo SK, Jang JH, Kim BS, Kim JH, Kim SE, Lee H.","Clin Transl Sci. 2021 Sep;14(5):1747-1755. doi: 10.1111/cts.13003. Epub 2021 Jun 4.","Moon BS","Clin Transl Sci","2021","2021/06/04","PMC8504807","","10.1111/cts.13003"
"34108184","Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study","Finn RS, Kudo M, Cheng AL, Wyrwicz L, Ngan RKC, Blanc JF, Baron AD, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus CE, Ikezawa H, Funahashi Y, Evans TRJ.","Clin Cancer Res. 2021 Sep 1;27(17):4848-4858. doi: 10.1158/1078-0432.CCR-20-4219. Epub 2021 Jun 9.","Finn RS","Clin Cancer Res","2021","2021/06/10","PMC9401497","","10.1158/1078-0432.CCR-20-4219"
"34126063","Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)","Haber PK, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, Buckstein M, Kim E, Villanueva A, Schwartz M, Llovet JM.","Gastroenterology. 2021 Sep;161(3):879-898. doi: 10.1053/j.gastro.2021.06.008. Epub 2021 Jun 12.","Haber PK","Gastroenterology","2021","2021/06/14","","","10.1053/j.gastro.2021.06.008"
"34217908","Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer","Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Padam S, Tang A, Martinez N, Schmolze D, Presant C, Ebrahimi B, Yeon C, Sedrak M, Patel N, Portnow J, Lee P, Mortimer J.","Eur J Cancer. 2021 Sep;154:11-20. doi: 10.1016/j.ejca.2021.05.035. Epub 2021 Jul 1.","Yuan Y","Eur J Cancer","2021","2021/07/04","PMC8691850","NIHMS1721455","10.1016/j.ejca.2021.05.035"
"34245216","Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria","Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Shigesawa T, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N.","Hepatol Res. 2021 Sep;51(9):979-989. doi: 10.1111/hepr.13693. Epub 2021 Jul 20.","Sho T","Hepatol Res","2021","2021/07/10","","","10.1111/hepr.13693"
"34385069","Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials","Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berché R, Pedrola A, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Viaplana C, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Carles J, Felip E, Tabernero J, Dienstmann R, Garralda E.","Eur J Cancer. 2021 Sep;155:168-178. doi: 10.1016/j.ejca.2021.05.040. Epub 2021 Aug 9.","Matos I","Eur J Cancer","2021","2021/08/13","","","10.1016/j.ejca.2021.05.040"
"34397130","The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials","Hayes AR, Chan DLH, Chan BA, Pavlakis N.","J Neuroendocrinol. 2021 Sep;33(9):e13015. doi: 10.1111/jne.13015. Epub 2021 Aug 16.","Hayes AR","J Neuroendocrinol","2021","2021/08/16","","","10.1111/jne.13015"
"34452710","Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types","King-Kallimanis BL, Lederer NM, Kim J, Nair A, Horodniceanu E, Bhatnagar V, Kluetz PG.","Value Health. 2021 Sep;24(9):1302-1307. doi: 10.1016/j.jval.2021.04.1279. Epub 2021 Jun 24.","King-Kallimanis BL","Value Health","2021","2021/08/28","","","10.1016/j.jval.2021.04.1279"
"34491510","Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience","Rimini M, Yoo C, Lonardi S, Masi G, Granito A, Bang Y, Rizzato MD, Vivaldi C, Ielasi L, Kim HD, Bergamo F, Salani F, Leoni S, Ryoo BY, Ryoo MH, Burgio V, Cascinu S, Casadei-Gardini A.","Target Oncol. 2021 Sep;16(5):653-661. doi: 10.1007/s11523-021-00834-1. Epub 2021 Sep 7.","Rimini M","Target Oncol","2021","2021/09/07","","","10.1007/s11523-021-00834-1"
"34570206","Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma","Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z.","JAMA Netw Open. 2021 Sep 1;4(9):e2126992. doi: 10.1001/jamanetworkopen.2021.26992.","Zhang YJ","JAMA Netw Open","2021","2021/09/27","PMC8477266","","10.1001/jamanetworkopen.2021.26992"
"34513746","Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances","Charneau J, Suzuki T, Shimomura M, Fujinami N, Nakatsura T.","J Hepatocell Carcinoma. 2021 Sep 2;8:1035-1054. doi: 10.2147/JHC.S291558. eCollection 2021.","Charneau J","J Hepatocell Carcinoma","2021","2021/09/13","PMC8424432","","10.2147/JHC.S291558"
"34328338","Development of a (99m)Tc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer","Zhao L, Liu C, Xing Y, He J, O'Doherty J, Huang W, Zhao J.","Mol Pharm. 2021 Sep 6;18(9):3616-3622. doi: 10.1021/acs.molpharmaceut.1c00569. Epub 2021 Jul 30.","Zhao L","Mol Pharm","2021","2021/07/30","","","10.1021/acs.molpharmaceut.1c00569"
"34504196","Perioperative rifaximin is not associated with enhanced functional and volumetric recovery after major liver resection","Bednarsch J, Czigany Z, Loosen SH, Heij L, Ruckgaber L, Maes H, Krause JP, Reen M, Toteva B, Vosdellen T, Bruners P, Lang SA, Ulmer TF, Roderburg C, Luedde T, Neumann UP.","Sci Rep. 2021 Sep 9;11(1):17936. doi: 10.1038/s41598-021-97442-w.","Bednarsch J","Sci Rep","2021","2021/09/10","PMC8429542","","10.1038/s41598-021-97442-w"
"34527608","A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma","Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A.","J Hepatocell Carcinoma. 2021 Sep 9;8:1129-1145. doi: 10.2147/JHC.S318865. eCollection 2021.","Kaseb AO","J Hepatocell Carcinoma","2021","2021/09/16","PMC8437411","","10.2147/JHC.S318865"
"34526044","Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial","Ni J, Zhou Y, Wu L, Ai X, Dong X, Chu Q, Han C, Wang X, Zhu Z.","Radiat Oncol. 2021 Sep 15;16(1):177. doi: 10.1186/s13014-021-01905-3.","Ni J","Radiat Oncol","2021","2021/09/16","PMC8444553","","10.1186/s13014-021-01905-3"
"34185551","Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial","Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F.","J Clin Oncol. 2021 Sep 20;39(27):3002-3011. doi: 10.1200/JCO.21.00163. Epub 2021 Jun 29.","Qin S","J Clin Oncol","2021","2021/06/29","PMC8445562","","10.1200/JCO.21.00163"
"34292792","Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study","Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK.","J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22.","Kelley RK","J Clin Oncol","2021","2021/07/22","PMC8445563","","10.1200/JCO.20.03555"
"34622226","Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis","Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, Luo HY, Li JB, Wang FH, Qiu MZ, Lv ZD, Wang DS, Li YH, Zhang DS, Xu RH.","Cell Rep Med. 2021 Aug 27;2(9):100383. doi: 10.1016/j.xcrm.2021.100383. eCollection 2021 Sep 21.","Wang F","Cell Rep Med","2021","2021/10/08","PMC8484502","","10.1016/j.xcrm.2021.100383"
"34563169","CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure","Coquan E, Brachet PE, Licaj I, Leconte A, Castera M, Lequesne J, Meriaux E, Bonnet I, Lelaidier A, Clarisse B, Joly F.","BMC Cancer. 2021 Sep 25;21(1):1054. doi: 10.1186/s12885-021-08758-9.","Coquan E","BMC Cancer","2021","2021/09/26","PMC8465776","","10.1186/s12885-021-08758-9"
"36654400","Complete biosynthesis of the potential medicine icaritin by engineered Saccharomyces cerevisiae and Escherichia coli","Wang P, Li C, Li X, Huang W, Wang Y, Wang J, Zhang Y, Yang X, Yan X, Wang Y, Zhou Z.","Sci Bull (Beijing). 2021 Sep 30;66(18):1906-1916. doi: 10.1016/j.scib.2021.03.002. Epub 2021 Mar 7.","Wang P","Sci Bull (Beijing)","2021","2023/01/19","","","10.1016/j.scib.2021.03.002"
"33745266","Sonazoid-enhanced ultrasonography: comparison with CT/MRI Liver Imaging Reporting and Data System in patients with suspected hepatocellular carcinoma","Hwang JA, Jeong WK, Min JH, Kim YY, Heo NH, Lim HK.","Ultrasonography. 2021 Oct;40(4):486-498. doi: 10.14366/usg.20120. Epub 2021 Jan 15.","Hwang JA","Ultrasonography","2021","2021/03/22","PMC8446493","","10.14366/usg.20120"
"33811367","Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N.","Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19.","Gawrieh S","Hepatology","2021","2021/04/03","","","10.1002/hep.31843"
"33856599","A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma","Chan SL, Cheng PNM, Liu AM, Chan LL, Li L, Chu CM, Chong CCN, Lau YM, Yeo W, Ng KKC, Yu SCH, Mok TSK, Chan AWH.","Invest New Drugs. 2021 Oct;39(5):1375-1382. doi: 10.1007/s10637-021-01111-8. Epub 2021 Apr 15.","Chan SL","Invest New Drugs","2021","2021/04/15","PMC8426309","","10.1007/s10637-021-01111-8"
"33860346","Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy","Królicki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kuliński R, Rola R, Merlo A, Morgenstern A.","Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3595-3605. doi: 10.1007/s00259-021-05350-y. Epub 2021 Apr 15.","Królicki L","Eur J Nucl Med Mol Imaging","2021","2021/04/16","PMC8440247","","10.1007/s00259-021-05350-y"
"34030885","Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases","Kokudo T, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Ishihara S, Makuuchi M, Kokudo N, Hasegawa K.","Surgery. 2021 Oct;170(4):1151-1154. doi: 10.1016/j.surg.2021.04.012. Epub 2021 May 22.","Kokudo T","Surgery","2021","2021/05/25","","","10.1016/j.surg.2021.04.012"
"34136936","Prospective assessment of diagnostic efficacy and safety of Sonazoid(TM) and SonoVue(®) ultrasound contrast agents in patients with focal liver lesions","Lv K, Zhai H, Jiang Y, Liang P, Xu HX, Du L, Chou YH, Xie X, Luo Y, Lee YJ, Lee JY, Hu B, Luo B, Wang Y, Luan Y, Kalli C, Chen K, Wang W, Liang JD.","Abdom Radiol (NY). 2021 Oct;46(10):4647-4659. doi: 10.1007/s00261-021-03010-1. Epub 2021 Jun 16.","Lv K","Abdom Radiol (NY)","2021","2021/06/17","PMC8435522","","10.1007/s00261-021-03010-1"
"34213592","The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer","Liao MZ, Prenen H, Dutta S, Upreti VV.","Cancer Chemother Pharmacol. 2021 Oct;88(4):665-672. doi: 10.1007/s00280-021-04319-w. Epub 2021 Jul 2.","Liao MZ","Cancer Chemother Pharmacol","2021","2021/07/02","PMC8367910","","10.1007/s00280-021-04319-w"
"34251745","Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study","Woei-A-Jin FJSH, Weijl NI, Burgmans MC, Fariña Sarasqueta A, van Wezel JT, Wasser MNJM, Coenraad MJ, Burggraaf J, Osanto S.","Oncologist. 2021 Oct;26(10):854-864. doi: 10.1002/onco.13901. Epub 2021 Aug 4.","Woei-A-Jin FJSH","Oncologist","2021","2021/07/12","PMC8488766","","10.1002/onco.13901"
"34270868","Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework","Chan P, Marchand M, Yoshida K, Vadhavkar S, Wang N, Lin A, Wu B, Ballinger M, Sternheim N, Jin JY, Bruno R.","CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1171-1182. doi: 10.1002/psp4.12686. Epub 2021 Aug 4.","Chan P","CPT Pharmacometrics Syst Pharmacol","2021","2021/07/16","PMC8520743","","10.1002/psp4.12686"
"34621052","Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S; ARREST investigator study group; Sanyal AJ.","Nat Med. 2021 Oct;27(10):1825-1835. doi: 10.1038/s41591-021-01495-3. Epub 2021 Oct 7.","Ratziu V","Nat Med","2021","2021/10/08","","","10.1038/s41591-021-01495-3"
"34638446","Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials","Chen BB, Lin ZZ, Shao YY, Hsu C, Hsu CH, Cheng AL, Liang PC, Shih TT.","Cancers (Basel). 2021 Oct 1;13(19):4962. doi: 10.3390/cancers13194962.","Chen BB","Cancers (Basel)","2021","2021/10/13","PMC8508238","","10.3390/cancers13194962"
"34642494","Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, Tami Y, You S, Yates P, Tao Y, Cremer J, Campbell F, Elston R, Theodore D, Paff M, Bennett CF, Kwoh TJ.","Nat Med. 2021 Oct;27(10):1725-1734. doi: 10.1038/s41591-021-01513-4. Epub 2021 Oct 12.","Yuen MF","Nat Med","2021","2021/10/13","PMC8516644","","10.1038/s41591-021-01513-4"
"34722310","Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models","Deng S, Solinas A, Calvisi DF.","Front Oncol. 2021 Oct 13;11:756672. doi: 10.3389/fonc.2021.756672. eCollection 2021.","Deng S","Front Oncol","2021","2021/11/01","PMC8548824","","10.3389/fonc.2021.756672"
"34168049","Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors","Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ.","Clin Cancer Res. 2021 Oct 15;27(20):5510-5518. doi: 10.1158/1078-0432.CCR-21-0810. Epub 2021 Jun 24.","Foster CC","Clin Cancer Res","2021","2021/06/25","","","10.1158/1078-0432.CCR-21-0810"
"34237154","Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study","Ding X, Sun W, Li W, Shen Y, Guo X, Teng Y, Liu X, Zheng L, Li W, Chen J.","Cancer. 2021 Oct 15;127(20):3782-3793. doi: 10.1002/cncr.33677. Epub 2021 Jul 8.","Ding X","Cancer","2021","2021/07/08","","","10.1002/cncr.33677"
"34759817","Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials","Zhang W, Gu J, Bian C, Huang G.","Front Pharmacol. 2021 Oct 25;12:686876. doi: 10.3389/fphar.2021.686876. eCollection 2021.","Zhang W","Front Pharmacol","2021","2021/11/11","PMC8574003","","10.3389/fphar.2021.686876"
"34771637","Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy","Kudo M.","Cancers (Basel). 2021 Oct 30;13(21):5475. doi: 10.3390/cancers13215475.","Kudo M","Cancers (Basel)","2021","2021/11/13","PMC8582435","","10.3390/cancers13215475"
"34097307","Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC","Chen B, Wu JX, Cheng SH, Wang LM, Rong WQ, Wu F, Wang SL, Jin J, Liu YP, Song YW, Ren H, Fang H, Tang Y, Li N, Li YX, Wang WH.","Hepatology. 2021 Nov;74(5):2595-2604. doi: 10.1002/hep.31993. Epub 2021 Sep 16.","Chen B","Hepatology","2021","2021/06/07","PMC8672362","","10.1002/hep.31993"
"34109764","Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects","Mohamed MF, Coppola S, Feng T, Camp HS, Kim E, Othman AA.","Clin Pharmacol Drug Dev. 2021 Nov;10(11):1335-1344. doi: 10.1002/cpdd.957. Epub 2021 Jun 9.","Mohamed MF","Clin Pharmacol Drug Dev","2021","2021/06/10","PMC8596765","","10.1002/cpdd.957"
"34133768","Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure","Koelfat KVK, Picot D, Chang X, Desille-Dugast M, van Eijk HM, van Kuijk SMJ, Lenicek M, Layec S, Carsin M, Dussaulx L, Seynhaeve E, Trivin F, Lacaze L, Thibault R, Schaap FG, Olde Damink SWM.","Hepatology. 2021 Nov;74(5):2670-2683. doi: 10.1002/hep.32017. Epub 2021 Aug 26.","Koelfat KVK","Hepatology","2021","2021/06/16","PMC8596508","","10.1002/hep.32017"
"34173317","Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology","Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Touchefeu Y, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX.","Liver Int. 2021 Nov;41(11):2759-2767. doi: 10.1111/liv.14994. Epub 2021 Aug 8.","Galle PR","Liver Int","2021","2021/06/26","","","10.1111/liv.14994"
"34190375","Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial","Grande E, Rodriguez-Antona C, López C, Alonso-Gordoa T, Benavent M, Capdevila J, Teulé A, Custodio A, Sevilla I, Hernando J, Gajate P, Molina-Cerrillo J, Díez JJ, Santos M, Lanillos J, García-Carbonero R.","Oncologist. 2021 Nov;26(11):941-949. doi: 10.1002/onco.13885. Epub 2021 Jul 14.","Grande E","Oncologist","2021","2021/06/30","PMC8571752","","10.1002/onco.13885"
"34255901","Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial","Gao Y, Guo J, Bao X, Xiong F, Ma Y, Tan B, Yu L, Zhao Y, Lu J.","Oncologist. 2021 Nov;26(11):e1919-e1930. doi: 10.1002/onco.13899. Epub 2021 Jul 26.","Gao Y","Oncologist","2021","2021/07/13","PMC8571770","","10.1002/onco.13899"
"34265433","Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study","Ai X, Wang Q, Cheng Y, Liu X, Cao L, Chen J, Dong X, Zhou J, Fan Y, Huang C, Cui J, Wang Y, Chen G, Ding C, Gao B, Li X, Wang Z, Zhang H, Ding L, Wang Y, Yuan X, Cheng H, Wang T, Lu S.","J Thorac Oncol. 2021 Nov;16(11):1959-1963. doi: 10.1016/j.jtho.2021.06.023. Epub 2021 Jul 12.","Ai X","J Thorac Oncol","2021","2021/07/15","","","10.1016/j.jtho.2021.06.023"
"34324028","Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment","Akce M, El-Khoueiry A, Piha-Paul SA, Bacque E, Pan P, Zhang ZY, Ewesuedo R, Gupta D, Tang Y, Milton A, Zajic S, Judson PL, O'Bryant CL.","Cancer Chemother Pharmacol. 2021 Nov;88(5):825-836. doi: 10.1007/s00280-021-04329-8. Epub 2021 Jul 29.","Akce M","Cancer Chemother Pharmacol","2021","2021/07/29","PMC8484145","","10.1007/s00280-021-04329-8"
"34355801","A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer","Xu J, Bai Y, Sun H, Bai C, Jia R, Li Y, Zhang W, Liu L, Huang C, Guan M, Zhou J, Su W.","Cancer. 2021 Nov 1;127(21):3975-3984. doi: 10.1002/cncr.33803. Epub 2021 Aug 6.","Xu J","Cancer","2021","2021/08/06","","","10.1002/cncr.33803"
"34407972","Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer","Hashimoto A, Sarker D, Reebye V, Jarvis S, Sodergren MH, Kossenkov A, Sanseviero E, Raulf N, Vasara J, Andrikakou P, Meyer T, Huang KW, Plummer R, Chee CE, Spalding D, Pai M, Khan S, Pinato DJ, Sharma R, Basu B, Palmer D, Ma YT, Evans J, Habib R, Martirosyan A, Elasri N, Reynaud A, Rossi JJ, Cobbold M, Habib NA, Gabrilovich DI.","Clin Cancer Res. 2021 Nov 1;27(21):5961-5978. doi: 10.1158/1078-0432.CCR-21-0986. Epub 2021 Aug 18.","Hashimoto A","Clin Cancer Res","2021","2021/08/19","PMC8756351","NIHMS1765432","10.1158/1078-0432.CCR-21-0986"
"34537483","Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma","Liu T, Li Q, Lin Z, Wang P, Chen Y, Fu Y, Ding Z.","Int Immunopharmacol. 2021 Nov;100:108128. doi: 10.1016/j.intimp.2021.108128. Epub 2021 Sep 17.","Liu T","Int Immunopharmacol","2021","2021/09/19","","","10.1016/j.intimp.2021.108128"
"34563992","Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial","Aramaki O, Takayama T, Moriguchi M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M; ACE 500 study group.","Eur J Cancer. 2021 Nov;157:373-382. doi: 10.1016/j.ejca.2021.08.027. Epub 2021 Sep 23.","Aramaki O","Eur J Cancer","2021","2021/09/26","","","10.1016/j.ejca.2021.08.027"
"34804015","Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?","Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, Mo J, Wang L, Wang K.","Front Immunol. 2021 Nov 2;12:731527. doi: 10.3389/fimmu.2021.731527. eCollection 2021.","Zhao S","Front Immunol","2021","2021/11/22","PMC8600564","","10.3389/fimmu.2021.731527"
"34887636","Comprehensive radiomics nomogram for predicting survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma","Tang YY, Zhao YN, Zhang T, Chen ZY, Ma XL.","World J Gastroenterol. 2021 Nov 7;27(41):7173-7189. doi: 10.3748/wjg.v27.i41.7173.","Tang YY","World J Gastroenterol","2021","2021/12/10","PMC8613648","","10.3748/wjg.v27.i41.7173"
"34763711","IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis","Vergis N, Patel V, Bogdanowicz K, Czyzewska-Khan J, Fiorentino F, Day E, Cross M, Foster N, Lord E, Goldin R, Forrest E, Thursz M.","Trials. 2021 Nov 11;22(1):792. doi: 10.1186/s13063-021-05719-2.","Vergis N","Trials","2021","2021/11/12","PMC8581959","","10.1186/s13063-021-05719-2"
"33745079","Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis","Casadei-Gardini A, Rimassa L, Rimini M, Yoo C, Ryoo BY, Lonardi S, Masi G, Kim HD, Vivaldi C, Ryu MH, Rizzato MD, Salani F, Bang Y, Pellino A, Catanese S, Burgio V, Cascinu S, Cucchetti A.","J Cancer Res Clin Oncol. 2021 Dec;147(12):3665-3671. doi: 10.1007/s00432-021-03602-w. Epub 2021 Mar 20.","Casadei-Gardini A","J Cancer Res Clin Oncol","2021","2021/03/21","","","10.1007/s00432-021-03602-w"
"33839979","Correction to: Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial","Li S, Mei J, Wang Q, Guo Z, Lu L, Ling Y, Xu L, Chen M, Zheng L, Lin W, Zou J, Wen Y, Wei W, Guo R.","Ann Surg Oncol. 2021 Dec;28(Suppl 3):874. doi: 10.1245/s10434-021-09813-2.","Li S","Ann Surg Oncol","2021","2021/04/11","","","10.1245/s10434-021-09813-2"
"34309846","Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial","Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, Liu Y, Meng Z, Zhang X, Wang L, Zhang X, Zou J.","Int J Cancer. 2021 Dec 1;149(11):1944-1954. doi: 10.1002/ijc.33751. Epub 2021 Sep 8.","Chen X","Int J Cancer","2021","2021/07/26","","","10.1002/ijc.33751"
"34420823","Efficacy of perioperative chemotherapy in resected colorectal liver metastasis: A systematic review and meta-analysis","Bosma NA, Keehn AR, Lee-Ying R, Karim S, MacLean AR, Brenner DR.","Eur J Surg Oncol. 2021 Dec;47(12):3113-3122. doi: 10.1016/j.ejso.2021.07.024. Epub 2021 Jul 31.","Bosma NA","Eur J Surg Oncol","2021","2021/08/23","","","10.1016/j.ejso.2021.07.024"
"34429245","Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study","Lai E, Puzzoni M, Ziranu P, Cremolini C, Lonardi S, Banzi M, Mariani S, Liscia N, Cinieri S, Dettori M, Mencoboni M, Nappo F, Piacentini G, Labianca R, Zucchelli G, Boccaccino A, Conca V, Pusceddu V, Zaniboni A, Scartozzi M; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente, Italian Group for the Study of Gastrointestinal Tumors).","Clin Colorectal Cancer. 2021 Dec;20(4):e253-e262. doi: 10.1016/j.clcc.2021.07.008. Epub 2021 Jul 31.","Lai E","Clin Colorectal Cancer","2021","2021/08/25","","","10.1016/j.clcc.2021.07.008"
"34454995","Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma","Ricke J, Schinner R, Seidensticker M, Gasbarrini A, van Delden OM, Amthauer H, Peynircioglu B, Bargellini I, Iezzi R, De Toni EN, Malfertheiner P, Pech M, Sangro B.","J Hepatol. 2021 Dec;75(6):1387-1396. doi: 10.1016/j.jhep.2021.07.037. Epub 2021 Aug 27.","Ricke J","J Hepatol","2021","2021/08/29","","","10.1016/j.jhep.2021.07.037"
"34520230","Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial","Kanemitsu Y, Shimizu Y, Mizusawa J, Inaba Y, Hamaguchi T, Shida D, Ohue M, Komori K, Shiomi A, Shiozawa M, Watanabe J, Suto T, Kinugasa Y, Takii Y, Bando H, Kobatake T, Inomata M, Shimada Y, Katayama H, Fukuda H; JCOG Colorectal Cancer Study Group.","J Clin Oncol. 2021 Dec 1;39(34):3789-3799. doi: 10.1200/JCO.21.01032. Epub 2021 Sep 14.","Kanemitsu Y","J Clin Oncol","2021","2021/09/14","","","10.1200/JCO.21.01032"
"34591334","Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study","Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, Torimura T, Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A.","Hepatol Res. 2021 Dec;51(12):1229-1241. doi: 10.1111/hepr.13718. Epub 2021 Oct 21.","Rimini M","Hepatol Res","2021","2021/09/30","","","10.1111/hepr.13718"
"34661089","Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study","Ma H, Lim TH, Leerapun A, Weltman M, Jia J, Lim YS, Tangkijvanich P, Sukeepaisarnjaroen W, Ji Y, Le Bert N, Li D, Zhang Y, Hamatake R, Tan N, Li C, Strasser SI, Ding H, Yoon JH, Stace NH, Ahmed T, Anderson DE, Yan L, Bertoletti A, Zhu Q, Yuen MF.","JHEP Rep. 2021 Sep 8;3(6):100361. doi: 10.1016/j.jhepr.2021.100361. eCollection 2021 Dec.","Ma H","JHEP Rep","2021","2021/10/18","PMC8502773","","10.1016/j.jhepr.2021.100361"
"34695377","Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial","Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP.","Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1025-1035. doi: 10.1016/S2468-1253(21)00305-8. Epub 2021 Oct 23.","Tai D","Lancet Gastroenterol Hepatol","2021","2021/10/25","","","10.1016/S2468-1253(21)00305-8"
"34826225","Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata","Eisman S, Sinclair R.","Expert Opin Investig Drugs. 2021 Dec;30(12):1169-1174. doi: 10.1080/13543784.2021.2012149. Epub 2021 Dec 20.","Eisman S","Expert Opin Investig Drugs","2021","2021/11/26","","","10.1080/13543784.2021.2012149"
"34848480","Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01)","Matsuhashi N, Takahashi T, Tanaka C, Yawata K, Yamada M, Iwata Y, Kiyama S, Mizutani C, Tajima JY, Ishihara T, Yoshida K.","Anticancer Res. 2021 Dec;41(12):6247-6257. doi: 10.21873/anticanres.15445.","Matsuhashi N","Anticancer Res","2021","2021/12/01","","","10.21873/anticanres.15445"
"34850325","Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","Meng F, Zhao J, Tan AT, Hu W, Wang SY, Jin J, Wu J, Li Y, Shi L, Fu JL, Yu S, Shen Y, Liu L, Luan J, Shi M, Xie Y, Zhou CB, Wong RW, Lu-En W, Koh S, Bertoletti A, Wang T, Zhang JY, Wang FS.","Hepatol Int. 2021 Dec;15(6):1402-1412. doi: 10.1007/s12072-021-10250-2. Epub 2021 Nov 30.","Meng F","Hepatol Int","2021","2021/12/01","PMC8651587","","10.1007/s12072-021-10250-2"
"34541864","Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial","Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, Herrmann K, Brown E, Zuckerman D, Wilson G, Kim TY, Weaver A, Ross P, Harris WP, Graham J, Mills J, Yubero Esteban A, Johnson MS, Sofocleous CT, Padia SA, Lewandowski RJ, Garin E, Sinclair P, Salem R; EPOCH Investigators.","J Clin Oncol. 2021 Dec 10;39(35):3897-3907. doi: 10.1200/JCO.21.01839. Epub 2021 Sep 20.","Mulcahy MF","J Clin Oncol","2021","2021/09/20","PMC8660005","","10.1200/JCO.21.01839"
"34415578","Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study","Harding JJ, Yang TS, Chen YY, Feng YH, Yen CJ, Ho CL, Huang WT, El Dika I, Akce M, Tan B, Cohen SA, Meyer T, Sarker D, Lee DW, Ryoo BY, Lim HY, Johnston A, Bomalaski JS, O'Reilly EM, Qin S, Abou-Alfa GK.","Cancer. 2021 Dec 15;127(24):4585-4593. doi: 10.1002/cncr.33870. Epub 2021 Aug 20.","Harding JJ","Cancer","2021","2021/08/20","","","10.1002/cncr.33870"
"34593531","TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)","Kawazoe A, Itahashi K, Yamamoto N, Kotani D, Kuboki Y, Taniguchi H, Harano K, Naito Y, Suzuki M, Fukutani M, Higuchi T, Ikeno T, Wakabayashi M, Sato A, Koyama S, Nishikawa H, Shitara K.","Clin Cancer Res. 2021 Dec 15;27(24):6709-6715. doi: 10.1158/1078-0432.CCR-21-1929. Epub 2021 Sep 30.","Kawazoe A","Clin Cancer Res","2021","2021/10/01","","","10.1158/1078-0432.CCR-21-1929"
"34907910","Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers","Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan AM, Goff LW, Goyal L, Lacy J, Li D, Patel AK, He AR, Abou-Alfa GK, Spencer K, Kim EJ, Davis SL, McRee AJ, Kunk PR, Goyal S, Liu Y, Dennison L, Xavier S, Mohan AA, Zhu Q, Wang-Gillam A, Poklepovic A, Chen HX, Sharon E, Lesinski GB, Azad NS.","J Clin Invest. 2021 Dec 15;131(24):e152670. doi: 10.1172/JCI152670.","Yarchoan M","J Clin Invest","2021","2021/12/15","PMC8670844","","10.1172/JCI152670"
"35070043","Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy","Sho T, Morikawa K, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Sakamoto N.","World J Gastrointest Oncol. 2021 Dec 15;13(12):2076-2087. doi: 10.4251/wjgo.v13.i12.2076.","Sho T","World J Gastrointest Oncol","2021","2022/01/24","PMC8713309","","10.4251/wjgo.v13.i12.2076"
"34614506","Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active","Garcia JS, Kim HT, Murdock HM, Cutler CS, Brock J, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, Loschi F, Ryan J, Fell G, Karp HQ, Lucas F, Kim AS, Potter D, Mashaka T, Stone RM, DeAngelo DJ, Letai A, Lindsley RC, Soiffer RJ, Antin JH.","Blood Adv. 2021 Dec 28;5(24):5536-5545. doi: 10.1182/bloodadvances.2021005566.","Garcia JS","Blood Adv","2021","2021/10/06","PMC8714724","","10.1182/bloodadvances.2021005566"
"33993366","Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma","Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J.","Cancer Immunol Immunother. 2022 Jan;71(1):25-38. doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16.","Sun L","Cancer Immunol Immunother","2022","2021/05/16","PMC10992323","","10.1007/s00262-021-02957-w"
"34110489","Survival predictors of (177)Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)","Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT.","J Cancer Res Clin Oncol. 2022 Jan;148(1):225-236. doi: 10.1007/s00432-021-03672-w. Epub 2021 Jun 10.","Swiha MM","J Cancer Res Clin Oncol","2022","2021/06/10","PMC8752529","","10.1007/s00432-021-03672-w"
"34236269","The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion","Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Nakatani M, Kariya S, Yamaguchi T, Yoshida K, Yoshii K, Sekimoto M.","Cancer Invest. 2022 Jan;40(1):81-89. doi: 10.1080/07357907.2021.1952594. Epub 2021 Aug 26.","Kaibori M","Cancer Invest","2022","2021/07/08","","","10.1080/07357907.2021.1952594"
"34362624","Effects of preoperative oral carbohydrate administration combined with postoperative early oral intake in elderly patients undergoing hepatectomy with acute-phase inflammation and subjective symptom burden: A prospective randomized controlled study","Feng J, Xu R, Li K, Li F, Gao M, Han Q, Feng H, Ye H.","Asian J Surg. 2022 Jan;45(1):386-395. doi: 10.1016/j.asjsur.2021.06.042. Epub 2021 Aug 3.","Feng J","Asian J Surg","2022","2021/08/07","","","10.1016/j.asjsur.2021.06.042"
"34431518","Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)","Liu L, Erickson NT, Ricard I, von Weikersthal LF, Lerch MM, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Scheithauer W, Link H, Höffkes HG, Moehler M, Gesenhues AB, Theurich S, Michl M, Modest DP, Algül H, Stintzing S, Heinemann V, Holch JW.","Int J Cancer. 2022 Jan 1;150(1):112-123. doi: 10.1002/ijc.33775. Epub 2021 Sep 6.","Liu L","Int J Cancer","2022","2021/08/25","","","10.1002/ijc.33775"
"34480530","Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases","Nierop PM, Höppener DJ, Buisman FE, van der Stok EP, Galjart B, Balachandran VP, Jarnagin WR, Kingham TP, Shia J, Mauer M, Nordlinger B, Julié C, Groot Koerkamp B, Doukas M, Vermeulen PB, Grünhagen DJ, D'Angelica MI, Verhoef C.","J Pathol Clin Res. 2022 Jan;8(1):48-64. doi: 10.1002/cjp2.235. Epub 2021 Sep 4.","Nierop PM","J Pathol Clin Res","2022","2021/09/04","PMC8682940","","10.1002/cjp2.235"
"34607037","Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT)","Xiao A, Luke JJ, Partouche J, Karrison T, Chmura SJ, Al-Hallaq HA.","Pract Radiat Oncol. 2022 Jan-Feb;12(1):68-77. doi: 10.1016/j.prro.2021.09.005. Epub 2021 Oct 1.","Xiao A","Pract Radiat Oncol","2022","2021/10/04","","","10.1016/j.prro.2021.09.005"
"34786871","Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels","Hsu PY, Cheng TS, Chuang SC, Chang WT, Liang PC, Hsu CT, Wei YJ, Jang TY, Yeh ML, Huang CI, Lin YH, Wang CW, Hsieh MY, Hou NJ, Hsieh MH, Tsai YS, Ko YM, Lin CC, Chen KY, Dai CY, Lin ZY, Chen SC, Huang JF, Chuang WL, Huang CF, Yu ML.","Cancer Med. 2022 Jan;11(1):104-116. doi: 10.1002/cam4.4430. Epub 2021 Nov 16.","Hsu PY","Cancer Med","2022","2021/11/17","PMC8704159","","10.1002/cam4.4430"
"34914889","Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B.","Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.","Yau T","Lancet Oncol","2022","2021/12/16","","","10.1016/S1470-2045(21)00604-5"
"35024653","Risk associations of long-term HbA1c variability and obesity on cancer events and cancer-specific death in 15,286 patients with diabetes - A prospective cohort study","Mao D, Lau ESH, Wu H, Yang A, Shi M, Fan B, Tam CHT, Chow E, Kong APS, Ma RCW, Luk A, Chan JCN.","Lancet Reg Health West Pac. 2021 Nov 12;18:100315. doi: 10.1016/j.lanwpc.2021.100315. eCollection 2022 Jan.","Mao D","Lancet Reg Health West Pac","2021","2022/01/13","PMC8669375","","10.1016/j.lanwpc.2021.100315"
"35101942","Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy","Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, Yin W, Fang W.","J Immunother Cancer. 2022 Jan;10(1):e003133. doi: 10.1136/jitc-2021-003133.","Shi J","J Immunother Cancer","2022","2022/02/01","PMC8804705","","10.1136/jitc-2021-003133"
"35418272","Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials","Zeng L, Su J, Qiu W, Jin X, Qiu Y, Yu W.","Cancer Control. 2022 Jan-Dec;29:10732748221092924. doi: 10.1177/10732748221092924.","Zeng L","Cancer Control","2022","2022/04/14","PMC9014721","","10.1177/10732748221092924"
"36155490","Targeting Tumor Microenvironment in Liver Cancers: Rationale, Current Progress, and Future Perspective","Duda DG.","Keio J Med. 2022;71(3):71. doi: 10.2302/kjm.71-004-ABST.","Duda DG","Keio J Med","2022","2022/09/26","","","10.2302/kjm.71-004-ABST"
"34648352","Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial","Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M.","J Clin Oncol. 2022 Jan 10;40(2):150-160. doi: 10.1200/JCO.21.00608. Epub 2021 Oct 14.","Li QJ","J Clin Oncol","2022","2021/10/14","","","10.1200/JCO.21.00608"
"35013377","Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial","Radosevic A, Quesada R, Serlavos C, Sánchez J, Zugazaga A, Sierra A, Coll S, Busto M, Aguilar G, Flores D, Arce J, Maiques JM, Garcia-Retortillo M, Carrion JA, Visa L, Villamonte M, Pueyo E, Berjano E, Trujillo M, Sánchez-Velázquez P, Grande L, Burdio F.","Sci Rep. 2022 Jan 10;12(1):316. doi: 10.1038/s41598-021-03802-x.","Radosevic A","Sci Rep","2022","2022/01/11","PMC8748896","","10.1038/s41598-021-03802-x"
"34649272","Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma","Chow VA, Cassaday RD, Gooley TA, Smith SD, Sandmaier BM, Green DJ, Orozco JJ, Tuazon SA, Matesan M, Fisher DR, Maloney DG, Press OW, Gopal AK.","Blood Adv. 2022 Jan 11;6(1):37-45. doi: 10.1182/bloodadvances.2021005056.","Chow VA","Blood Adv","2022","2021/10/14","PMC8753215","","10.1182/bloodadvances.2021005056"
"35141162","Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination","Wang Y, Wang CQ, Sun P, Liu PP, Yang H, Wang HY, Rao HL, Li S, Jiang WQ, Huang JJ, Li ZM.","Front Oncol. 2022 Jan 24;12:796738. doi: 10.3389/fonc.2022.796738. eCollection 2022.","Wang Y","Front Oncol","2022","2022/02/10","PMC8818987","","10.3389/fonc.2022.796738"
"35200551","Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only-A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort","Seidensticker M, Steffen IG, Bargellini I, Berg T, Benito A, Gebauer B, Iezzi R, Loewe C, Karçaaltincaba M, Pech M, Sengel C, van Delden O, Vandecaveye V, Zech CJ, Ricke J.","Curr Oncol. 2022 Jan 27;29(2):565-577. doi: 10.3390/curroncol29020051.","Seidensticker M","Curr Oncol","2022","2022/02/24","PMC8870455","","10.3390/curroncol29020051"
"34920062","Microbial arginine deiminase: A multifaceted green catalyst in biomedical sciences","Kawatra A, Dhankhar R, Gulati P.","Int J Biol Macromol. 2022 Jan 31;196:151-162. doi: 10.1016/j.ijbiomac.2021.12.015. Epub 2021 Dec 15.","Kawatra A","Int J Biol Macromol","2022","2021/12/17","","","10.1016/j.ijbiomac.2021.12.015"
"32964588","A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma","Liu YC, Su CW, Ko PS, Lee RC, Liu CJ, Huang YH, Gau JP, Liu JH.","Asia Pac J Clin Oncol. 2022 Feb;18(1):19-27. doi: 10.1111/ajco.13443. Epub 2020 Sep 22.","Liu YC","Asia Pac J Clin Oncol","2022","2020/09/23","","","10.1111/ajco.13443"
"33855585","Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial","Öcal O, Schütte K, Kupčinskas J, Morkunas E, Jurkeviciute G, de Toni EN, Ben Khaled N, Berg T, Malfertheiner P, Klümpen HJ, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Palmer D, Seidensticker R, Wildgruber M, Sangro B, Pech M, Ricke J, Seidensticker M.","J Cancer Res Clin Oncol. 2022 Feb;148(2):475-485. doi: 10.1007/s00432-021-03627-1. Epub 2021 Apr 14.","Öcal O","J Cancer Res Clin Oncol","2022","2021/04/15","PMC8800931","","10.1007/s00432-021-03627-1"
"34402068","Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function","Sane R, Malhi V, Sutaria DS, Cho E, Twomey P, Craggs C, Wang J, Harris A, Musib L.","J Clin Pharmacol. 2022 Feb;62(2):171-181. doi: 10.1002/jcph.1941. Epub 2021 Dec 23.","Sane R","J Clin Pharmacol","2022","2021/08/17","PMC9303630","","10.1002/jcph.1941"
"34463809","Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting","Johnsson K, Brynolfsson J, Sahlstedt H, Nickols NG, Rettig M, Probst S, Morris MJ, Bjartell A, Eiber M, Anand A.","Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1041-1051. doi: 10.1007/s00259-021-05497-8. Epub 2021 Aug 31.","Johnsson K","Eur J Nucl Med Mol Imaging","2022","2021/08/31","PMC8803714","","10.1007/s00259-021-05497-8"
"34534511","Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group.","Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14.","Ader F","Lancet Infect Dis","2022","2021/09/17","PMC8439621","","10.1016/S1473-3099(21)00485-0"
"34626838","IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain","Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, Mok TSK, Finley G, Aerts JG, Orlandi F, Moro-Sibilot D, Jotte RM, Stroyakovskiy D, Villaruz LC, Rodríguez-Abreu D, Wan-Teck Lim D, Merritt D, Coleman S, Lee A, Shankar G, Yu W, Bara I, Nishio M.","J Thorac Oncol. 2022 Feb;17(2):309-323. doi: 10.1016/j.jtho.2021.09.014. Epub 2021 Oct 7.","Nogami N","J Thorac Oncol","2022","2021/10/09","","","10.1016/j.jtho.2021.09.014"
"34715322","A Transarterial Chemoembolization of Balloon-Occluded Alternate Infusions of Cisplatin and Gelatin Particles for Hepatocellular Carcinoma: A Phase I/II Multicenter Prospective Study of Safety and Efficacy","Hoshiai S, Irie T, Mori K, Hasegawa N, Fukuda K, Ishige K, Mori K, Arai H, Takahashi N, Nakajima T.","J Vasc Interv Radiol. 2022 Feb;33(2):169-176.e1. doi: 10.1016/j.jvir.2021.10.015. Epub 2021 Oct 27.","Hoshiai S","J Vasc Interv Radiol","2022","2021/10/29","","","10.1016/j.jvir.2021.10.015"
"34748961","Turning down the heat: The case for mild hyperthermia and thermosensitive liposomes","Regenold M, Bannigan P, Evans JC, Waspe A, Temple MJ, Allen C.","Nanomedicine. 2022 Feb;40:102484. doi: 10.1016/j.nano.2021.102484. Epub 2021 Nov 5.","Regenold M","Nanomedicine","2022","2021/11/08","","","10.1016/j.nano.2021.102484"
"34811502","Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study","Manca P, Corallo S, Lonardi S, Fucà G, Busico A, Leone AG, Corti F, Antoniotti C, Procaccio L, Smiroldo V, Ratti M, Murialdo R, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Prisciandaro M, Ambrosini M, Raimondi A, Morano F, Pietrantonio F.","Br J Cancer. 2022 Feb;126(3):449-455. doi: 10.1038/s41416-021-01591-8. Epub 2021 Nov 22.","Manca P","Br J Cancer","2022","2021/11/23","PMC8810873","","10.1038/s41416-021-01591-8"
"34939373","Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial","Cheng Y, Wang Q, Li K, Shi J, Wu L, Han B, Chen G, He J, Wang J, Qin H, Li X.","Cancer Med. 2022 Feb;11(4):1081-1087. doi: 10.1002/cam4.4507. Epub 2021 Dec 23.","Cheng Y","Cancer Med","2022","2021/12/23","PMC8855912","","10.1002/cam4.4507"
"34953443","Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study","Baciarello G, Özgüroğlu M, Mundle S, Leitz G, Richarz U, Hu P, Feyerabend S, Matsubara N, Chi KN, Fizazi K.","Eur J Cancer. 2022 Feb;162:56-64. doi: 10.1016/j.ejca.2021.11.026. Epub 2021 Dec 23.","Baciarello G","Eur J Cancer","2022","2021/12/25","","","10.1016/j.ejca.2021.11.026"
"35179586","Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial","Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T.","JAMA Netw Open. 2022 Feb 1;5(2):e2149040. doi: 10.1001/jamanetworkopen.2021.49040.","Mettu NB","JAMA Netw Open","2022","2022/02/18","PMC8857687","","10.1001/jamanetworkopen.2021.49040"
"35212754","Representation of Investigators by Gender Among Authors of Phase 3 Oncology Trials Worldwide","Muquith M, Pham T, Espinoza M, Hsiehchen D.","JAMA Netw Open. 2022 Feb 1;5(2):e220031. doi: 10.1001/jamanetworkopen.2022.0031.","Muquith M","JAMA Netw Open","2022","2022/02/25","PMC8881765","","10.1001/jamanetworkopen.2022.0031"
"35255600","State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis","Cho Y, Lee YH.","Endocrinol Metab (Seoul). 2022 Feb;37(1):38-52. doi: 10.3803/EnM.2022.102. Epub 2022 Feb 28.","Cho Y","Endocrinol Metab (Seoul)","2022","2022/03/08","PMC8901956","","10.3803/EnM.2022.102"
"35130943","Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction","Voon PJ, Chen EX, Chen HX, Lockhart AC, Sahebjam S, Kelly K, Vaishampayan UN, Subbiah V, Razak AR, Renouf DJ, Hotte SJ, Singh A, Bedard PL, Hansen AR, Ivy SP, Wang L, Stayner LA, Siu LL, Spreafico A.","J Exp Clin Cancer Res. 2022 Feb 7;41(1):51. doi: 10.1186/s13046-021-02236-7.","Voon PJ","J Exp Clin Cancer Res","2022","2022/02/08","PMC8819907","","10.1186/s13046-021-02236-7"
"34905388","Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)","Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M.","J Clin Oncol. 2022 Feb 10;40(5):468-480. doi: 10.1200/JCO.21.01963. Epub 2021 Dec 14.","Lyu N","J Clin Oncol","2022","2021/12/14","","","10.1200/JCO.21.01963"
"35265635","A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen","Yin J, Wen M, Cheng J, Hu L, Yang L, Chang X, Zhou Z, Li H, Liu Y, Li J.","Front Med (Lausanne). 2022 Feb 21;9:712466. doi: 10.3389/fmed.2022.712466. eCollection 2022.","Yin J","Front Med (Lausanne)","2022","2022/03/10","PMC8899006","","10.3389/fmed.2022.712466"
"35015819","Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma","Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS.","Blood Adv. 2022 Feb 22;6(4):1143-1151. doi: 10.1182/bloodadvances.2021006240.","Nastoupil LJ","Blood Adv","2022","2022/01/11","PMC8864656","","10.1182/bloodadvances.2021006240"
"33788029","High-intensity focused ultrasound alone or combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with unsuitable indications for hepatectomy and radiofrequency ablation: a phase II clinical trial","Gu L, Shen Z, Ji L, Ng DM, Du N, He N, Fan X, Yan K, Zheng Z, Chen B, Ma L, Qiu G, Chen P, Zheng J, Yang T.","Surg Endosc. 2022 Mar;36(3):1857-1867. doi: 10.1007/s00464-021-08465-3. Epub 2021 Mar 31.","Gu L","Surg Endosc","2022","2021/03/31","","","10.1007/s00464-021-08465-3"
"34215673","A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for (68)Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors","Virgolini I, Bahri S, Kjaer A, Grønbæk H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey-Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J.","J Nucl Med. 2022 Mar;63(3):376-383. doi: 10.2967/jnumed.121.261936. Epub 2021 Jul 2.","Virgolini I","J Nucl Med","2022","2021/07/03","PMC8978200","","10.2967/jnumed.121.261936"
"34282496","Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma","Ohira M, Hotta R, Tanaka Y, Matsuura T, Tekin A, Selvaggi G, Vianna R, Ricordi C, Ruiz P, Nishida S, Tzakis AG, Ohdan H.","Cancer Immunol Immunother. 2022 Mar;71(3):589-599. doi: 10.1007/s00262-021-03005-3. Epub 2021 Jul 19.","Ohira M","Cancer Immunol Immunother","2022","2021/07/20","PMC10991360","","10.1007/s00262-021-03005-3"
"34564871","Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors","Zhou X, Ouerdani A, Diderichsen PM, Gupta N.","J Clin Pharmacol. 2022 Mar;62(3):422-433. doi: 10.1002/jcph.1974. Epub 2021 Oct 26.","Zhou X","J Clin Pharmacol","2022","2021/09/26","PMC9297904","","10.1002/jcph.1974"
"34621044","Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade","Kelley RK, Miksad R, Cicin I, Chen Y, Klümpen HJ, Kim S, Lin ZZ, Youkstetter J, Hazra S, Sen S, Cheng AL, El-Khoueiry AB, Meyer T, Abou-Alfa GK.","Br J Cancer. 2022 Mar;126(4):569-575. doi: 10.1038/s41416-021-01532-5. Epub 2021 Oct 7.","Kelley RK","Br J Cancer","2022","2021/10/08","PMC8854685","","10.1038/s41416-021-01532-5"
"34740311","GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions","Brun S, Bestion E, Raymond E, Bassissi F, Jilkova ZM, Mezouar S, Rachid M, Novello M, Tracz J, Hamaï A, Lalmanach G, Vanderlynden L, Legouffe R, Stauber J, Schubert T, Plach MG, Courcambeck J, Drouot C, Jacquemot G, Serdjebi C, Roth G, Baudoin JP, Ansaldi C, Decaens T, Halfon P.","Autophagy. 2022 Mar;18(3):678-694. doi: 10.1080/15548627.2021.1988357. Epub 2021 Nov 5.","Brun S","Autophagy","2022","2021/11/06","PMC9037544","","10.1080/15548627.2021.1988357"
"34740705","EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N.","J Hepatol. 2022 Mar;76(3):506-517. doi: 10.1016/j.jhep.2021.10.018. Epub 2021 Nov 3.","Ratziu V","J Hepatol","2022","2021/11/06","","","10.1016/j.jhep.2021.10.018"
"34762296","Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study","Katzenstein HM, Malogolowkin MH, Krailo MD, Piao J, Towbin AJ, McCarville MB, Tiao GM, Dunn SP, Langham MR, McGahren ED, Finegold MJ, Ranganathan S, Weldon CB, Thompson PA, Trobaugh-Lotrario AD, O'Neill AF, Furman WL, Chung N, Randazzo J, Rodriguez-Galindo C, Meyers RL.","Cancer. 2022 Mar 1;128(5):1057-1065. doi: 10.1002/cncr.34014. Epub 2021 Nov 11.","Katzenstein HM","Cancer","2022","2021/11/11","PMC9066555","NIHMS1752046","10.1002/cncr.34014"
"34792284","Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma","Cheon J, Yoo C, Hong JY, Kim HS, Lee DW, Lee MA, Kim JW, Kim I, Oh SB, Hwang JE, Chon HJ, Lim HY.","Liver Int. 2022 Mar;42(3):674-681. doi: 10.1111/liv.15102. Epub 2021 Nov 29.","Cheon J","Liver Int","2022","2021/11/18","","","10.1111/liv.15102"
"34922649","Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial","Fisher BA, Veenith T, Slade D, Gaskell C, Rowland M, Whitehouse T, Scriven J, Parekh D, Balasubramaniam MS, Cooke G, Morley N, Gabriel Z, Wise MP, Porter J, McShane H, Ho LP, Newsome PN, Rowe A, Sharpe R, Thickett DR, Bion J, Gates S, Richards D, Kearns P; CATALYST investigators.","Lancet Respir Med. 2022 Mar;10(3):255-266. doi: 10.1016/S2213-2600(21)00460-4. Epub 2021 Dec 16.","Fisher BA","Lancet Respir Med","2022","2021/12/19","PMC8676420","","10.1016/S2213-2600(21)00460-4"
"34971492","Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab","Terranova N, French J, Dai H, Wiens M, Khandelwal A, Ruiz-Garcia A, Manitz J, von Heydebreck A, Ruisi M, Chin K, Girard P, Venkatakrishnan K.","CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):333-347. doi: 10.1002/psp4.12754. Epub 2022 Jan 19.","Terranova N","CPT Pharmacometrics Syst Pharmacol","2022","2021/12/31","PMC8923733","","10.1002/psp4.12754"
"35027324","Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49","Pernot S, Pellerin O, Mineur L, Monterymard C, Smith D, Lapuyade B, Gallois C, Khemissa Akouz F, De Baere T, Tougeron D, Thirot-Bidault A, Audemar F, Simon M, Lecaille C, Louafi S, Lepage C, Ducreux M, Taieb J.","Dig Liver Dis. 2022 Mar;54(3):324-330. doi: 10.1016/j.dld.2021.12.012. Epub 2022 Jan 11.","Pernot S","Dig Liver Dis","2022","2022/01/14","","","10.1016/j.dld.2021.12.012"
"35065057","Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P.","Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20.","Kaseb AO","Lancet Gastroenterol Hepatol","2022","2022/01/22","PMC8840977","NIHMS1775116","10.1016/S2468-1253(21)00427-1"
"35065058","Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M.","Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229. doi: 10.1016/S2468-1253(21)00385-X. Epub 2022 Jan 20.","Marron TU","Lancet Gastroenterol Hepatol","2022","2022/01/22","PMC9901534","NIHMS1861486","10.1016/S2468-1253(21)00385-X"
"35195881","The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib","Piscitelli J, Chen J, LaBadie RR, Salageanu J, Chung CH, Tan W.","Clin Drug Investig. 2022 Mar;42(3):221-235. doi: 10.1007/s40261-022-01125-x. Epub 2022 Feb 23.","Piscitelli J","Clin Drug Investig","2022","2022/02/23","PMC8930943","","10.1007/s40261-022-01125-x"
"35288469","Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF.","J Immunother Cancer. 2022 Mar;10(3):e004233. doi: 10.1136/jitc-2021-004233.","Lheureux S","J Immunother Cancer","2022","2022/03/15","PMC8921950","","10.1136/jitc-2021-004233"
"35528745","Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials","Brown TJ, Gupta A, Sedhom R, Beg MS, Karasic TB, Yarchoan M.","Gastrointest Tumors. 2021 Dec 22;9(1):19-26. doi: 10.1159/000521625. eCollection 2022 Mar.","Brown TJ","Gastrointest Tumors","2021","2022/05/09","PMC9021659","","10.1159/000521625"
"35274717","A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma","Monge C, Pehrsson EC, Xie C, Duffy AG, Mabry D, Wood BJ, Kleiner DE, Steinberg SM, Figg WD, Redd B, Budhu A, Wang S, Tandon M, Ma L, Wei Wang X, Greten TF.","Oncologist. 2022 Mar 11;27(3):e273-e285. doi: 10.1093/oncolo/oyab073.","Monge C","Oncologist","2022","2022/03/11","PMC8914487","","10.1093/oncolo/oyab073"
"35274724","Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)","Ostwal V, Ramaswamy A, Gota V, Bhargava PG, Srinivas S, Shriyan B, Jadhav S, Goel M, Patkar S, Mandavkar S, Naughane D, Daddi A, Nashikkar C, Shetty N, Ankathi SK, Banavali SD.","Oncologist. 2022 Mar 11;27(3):165-e222. doi: 10.1093/oncolo/oyab008.","Ostwal V","Oncologist","2022","2022/03/11","PMC8914502","","10.1093/oncolo/oyab008"
"35316879","[Stereotactic body radiation therapy for patients with lung and liver oligometastases from colorectal cancer: a phase Ⅱ trial]","Lei JQ, Liu WY, Tang Y, Tang Y, Li N, Ren H, Yihebali C, Sun YK, Zhang W, Bi XY, Zhao JJ, Fang H, Lu NN, Zhou AP, Wang SL, Song YW, Liu YP, Chen B, Qi SN, Cai JQ, Li YX, Jin J.","Zhonghua Zhong Liu Za Zhi. 2022 Mar 23;44(3):282-290. doi: 10.3760/cma.j.cn112152-20200413-00339.","Lei JQ","Zhonghua Zhong Liu Za Zhi","2022","2022/03/22","","","10.3760/cma.j.cn112152-20200413-00339"
"35346270","MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial","Hoegen P, Zhang KS, Tonndorf-Martini E, Weykamp F, Regnery S, Naumann P, Lang K, Ristau J, Körber SA, Dreher C, Buchele C, Rippke C, Renkamp CK, Paul KM, König L, Büsch C, Krisam J, Sedlaczek O, Schlemmer HP, Niyazi M, Corradini S, Debus J, Klüter S, Hörner-Rieber J.","Radiat Oncol. 2022 Mar 27;17(1):59. doi: 10.1186/s13014-022-02033-2.","Hoegen P","Radiat Oncol","2022","2022/03/29","PMC8958771","","10.1186/s13014-022-02033-2"
"35040959","Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection","Gane EJ, Schwabe C, Berliba E, Tangkijvanich P, Jucov A, Ghicavii N, Verbinnen T, Lenz O, Talloen W, Kakuda TN, Westland C, Patel M, Yogaratnam JZ, Dragone L, Van Remoortere P.","J Antimicrob Chemother. 2022 Mar 31;77(4):1102-1110. doi: 10.1093/jac/dkab491.","Gane EJ","J Antimicrob Chemother","2022","2022/01/18","PMC8969529","","10.1093/jac/dkab491"
"34385343","Phase I Trial of (99m)Tc-(HE)(3)-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer","Bragina O, Chernov V, Schulga A, Konovalova E, Garbukov E, Vorobyeva A, Orlova A, Tashireva L, Sörensen J, Zelchan R, Medvedeva A, Deyev S, Tolmachev V.","J Nucl Med. 2022 Apr;63(4):528-535. doi: 10.2967/jnumed.121.262542. Epub 2021 Aug 12.","Bragina O","J Nucl Med","2022","2021/08/13","PMC8973295","","10.2967/jnumed.121.262542"
"34605045","BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial","Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielsen M, Goodman Z, Charles ED.","Hepatology. 2022 Apr;75(4):912-923. doi: 10.1002/hep.32181. Epub 2021 Dec 13.","Lawitz EJ","Hepatology","2022","2021/10/04","PMC9299674","","10.1002/hep.32181"
"34735674","A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients","Yau T, Cheng PNM, Chiu J, Kwok GGW, Leung R, Liu AM, Cheung TT, Ng CT.","Invest New Drugs. 2022 Apr;40(2):314-321. doi: 10.1007/s10637-021-01178-3. Epub 2021 Nov 4.","Yau T","Invest New Drugs","2022","2021/11/04","","","10.1007/s10637-021-01178-3"
"34817191","Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study","Rong D, He B, Tang W, Xie S, Kuang S, Grazioli L, Hussain SM, Yang Y, Wang J.","AJR Am J Roentgenol. 2022 Apr;218(4):687-698. doi: 10.2214/AJR.21.26818. Epub 2021 Nov 24.","Rong D","AJR Am J Roentgenol","2022","2021/11/24","","","10.2214/AJR.21.26818"
"34853874","A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol","Fidelman N.","Cardiovasc Intervent Radiol. 2022 Apr;45(4):413-414. doi: 10.1007/s00270-021-03010-0. Epub 2021 Dec 1.","Fidelman N","Cardiovasc Intervent Radiol","2022","2021/12/02","","","10.1007/s00270-021-03010-0"
"34902530","Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS.","J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.","Cheng AL","J Hepatol","2022","2021/12/13","","","10.1016/j.jhep.2021.11.030"
"35015210","The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation","Westhoff CL, Guo H, Wang Z, Hibshoosh H, Polaneczky M, Pike MC, Ha R.","Breast Cancer Res Treat. 2022 Apr;192(2):321-329. doi: 10.1007/s10549-021-06503-1. Epub 2022 Jan 11.","Westhoff CL","Breast Cancer Res Treat","2022","2022/01/11","PMC10088437","NIHMS1888274","10.1007/s10549-021-06503-1"
"35072565","Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials","Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Personeni N, Rimassa L.","Expert Opin Investig Drugs. 2022 Apr;31(4):401-413. doi: 10.1080/13543784.2022.2032641. Epub 2022 Feb 10.","Cammarota A","Expert Opin Investig Drugs","2022","2022/01/24","","","10.1080/13543784.2022.2032641"
"35081747","Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol","Ben Khaled N, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rössler D, Teupser D, Ehmer U, Bitzer M, Waldschmidt D, Fuchs M, Reuken PA, Lange CM, Wege H, Kandulski A, Dechêne A, Venerito M, Berres ML, Luedde T, Kubisch I, Reiter FP, De Toni EN.","Future Oncol. 2022 Apr;18(12):1423-1435. doi: 10.2217/fon-2021-1261. Epub 2022 Jan 27.","Ben Khaled N","Future Oncol","2022","2022/01/27","","","10.2217/fon-2021-1261"
"35119481","Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment","Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M.","Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412. doi: 10.1007/s00270-021-03031-9. Epub 2022 Feb 4.","Llovet JM","Cardiovasc Intervent Radiol","2022","2022/02/04","PMC8940827","","10.1007/s00270-021-03031-9"
"35212487","XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX)","Zhu XD, Huang MZ, Wang YS, Feng WJ, Chen ZY, He YF, Zhang XW, Liu X, Wang CC, Zhang W, Ying JE, Wu J, Yang L, Qin YR, Luo JF, Zhao XY, Li WH, Zhang Z, Qiu LX, Geng QR, Zou JL, Zhang JY, Zheng H, Song XF, Wu SS, Zhang CY, Gong Z, Liu QQ, Wang XF, Xu Q, Wang Q, Ji JM, Zhao J, Guo WJ.","Cancer Commun (Lond). 2022 Apr;42(4):314-326. doi: 10.1002/cac2.12278. Epub 2022 Feb 25.","Zhu XD","Cancer Commun (Lond)","2022","2022/02/25","PMC9017757","","10.1002/cac2.12278"
"35226112","A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma","Abuhelwa AY, Badaoui S, Yuen HY, McKinnon RA, Ruanglertboon W, Shankaran K, Tuteja A, Sorich MJ, Hopkins AM.","Cancer Chemother Pharmacol. 2022 Apr;89(4):479-485. doi: 10.1007/s00280-022-04411-9. Epub 2022 Feb 28.","Abuhelwa AY","Cancer Chemother Pharmacol","2022","2022/02/28","PMC8956540","","10.1007/s00280-022-04411-9"
"35292724","A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer","Brown LC, Halabi S, Somarelli JA, Humeniuk M, Wu Y, Oyekunle T, Howard L, Huang J, Anand M, Davies C, Patel P, Staats J, Weinhold KJ, Harrison MR, Zhang T, George DJ, Armstrong AJ.","Prostate Cancer Prostatic Dis. 2022 Apr;25(4):762-769. doi: 10.1038/s41391-022-00524-7. Epub 2022 Mar 15.","Brown LC","Prostate Cancer Prostatic Dis","2022","2022/03/16","PMC8923335","","10.1038/s41391-022-00524-7"
"35379737","Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X.","J Immunother Cancer. 2022 Apr;10(4):e004656. doi: 10.1136/jitc-2022-004656.","Xia Y","J Immunother Cancer","2022","2022/04/05","PMC8981365","","10.1136/jitc-2022-004656"
"35433482","Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report","Feng Y, Li C, Ji Y, Liu Y, Gan L, Yu Y, Liu T.","Front Oncol. 2022 Apr 1;12:801924. doi: 10.3389/fonc.2022.801924. eCollection 2022.","Feng Y","Front Oncol","2022","2022/04/18","PMC9012136","","10.3389/fonc.2022.801924"
"35428211","Phase I study of [(131)I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol","Thivat E, Rouanet J, Auzeloux P, Sas N, Jouberton E, Levesque S, Billoux T, Mansard S, Molnar I, Chanchou M, Fois G, Maigne L, Chezal JM, Miot-Noirault E, D'Incan M, Durando X, Cachin F.","BMC Cancer. 2022 Apr 15;22(1):417. doi: 10.1186/s12885-022-09495-3.","Thivat E","BMC Cancer","2022","2022/04/16","PMC9013026","","10.1186/s12885-022-09495-3"
"35436807","[The prediction value of enhanced magnetic resonance imaging nomogram model for dual phenotype hepatocellular carcinoma]","Wu Q, Yu YX, Fan YF, Hu S, Yao FR, Wang XM, Hu CH.","Zhonghua Yi Xue Za Zhi. 2022 Apr 19;102(15):1086-1092. doi: 10.3760/cma.j.cn112137-20211030-02406.","Wu Q","Zhonghua Yi Xue Za Zhi","2022","2022/04/18","","","10.3760/cma.j.cn112137-20211030-02406"
"33833145","A Prospective Multicenter Phase II Study on the Feasibility and Efficacy of S-1 and Oxaliplatin Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer","Sakamoto Y, Morohashi H, Miura T, Tsutsumi S, Takahashi S, Hirama K, Wakiya T, Hakamada K.","Dis Colon Rectum. 2022 May 1;65(5):663-671. doi: 10.1097/DCR.0000000000001927.","Sakamoto Y","Dis Colon Rectum","2022","2021/04/09","","","10.1097/DCR.0000000000001927"
"34107296","Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial","van Dams R, Wu TC, Kishan AU, Raldow AC, Chu FI, Hernandez J, Cao M, Lamb JM, Mikaeilian A, Low DA, Steinberg ML, Lee P.","Radiother Oncol. 2022 May;170:14-20. doi: 10.1016/j.radonc.2021.06.005. Epub 2021 Jun 6.","van Dams R","Radiother Oncol","2022","2021/06/09","","","10.1016/j.radonc.2021.06.005"
"34413142","(18)F-4FMFES and (18)F-FDG PET/CT in Estrogen Receptor-Positive Endometrial Carcinomas: Preliminary Report","Paquette M, Espinosa-Bentancourt E, Lavallée É, Phoenix S, Lapointe-Milot K, Bessette P, Guérin B, Turcotte ÉE.","J Nucl Med. 2022 May;63(5):702-707. doi: 10.2967/jnumed.121.262617. Epub 2021 Aug 19.","Paquette M","J Nucl Med","2022","2021/08/20","","","10.2967/jnumed.121.262617"
"34413145","CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of (89)Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody","Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS, Wu AM, Ulaner GA, Wolchok JD, Postow MA, Pandit-Taskar N.","J Nucl Med. 2022 May;63(5):720-726. doi: 10.2967/jnumed.121.262485. Epub 2021 Aug 19.","Farwell MD","J Nucl Med","2022","2021/08/20","PMC9051598","","10.2967/jnumed.121.262485"
"34992255","Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial","Ychou M, Rivoire M, Thezenas S, Guimbaud R, Ghiringhelli F, Mercier-Blas A, Mineur L, Francois E, Khemissa F, Chauvenet M, Kianmanesh R, Fonck M, Houyau P, Aparicio T, Galais MP, Audemar F, Assenat E, Lopez-Crapez E, Jouffroy C, Adenis A, Adam R, Bouché O.","Br J Cancer. 2022 May;126(9):1264-1270. doi: 10.1038/s41416-021-01644-y. Epub 2022 Jan 6.","Ychou M","Br J Cancer","2022","2022/01/07","PMC9042909","","10.1038/s41416-021-01644-y"
"35103539","Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial","Zheng K, Zhu X, Fu S, Cao G, Li WQ, Xu L, Chen H, Wu D, Yang R, Wang K, Liu W, Wang H, Bao Q, Liu M, Hao C, Shen L, Xing B, Wang X.","Radiology. 2022 May;303(2):455-464. doi: 10.1148/radiol.211545. Epub 2022 Feb 1.","Zheng K","Radiology","2022","2022/02/01","","","10.1148/radiol.211545"
"35146939","Neoadjuvant concurrent chemoradiotherapy using infusional gemcitabine in locally advanced rectal cancer: A phase II trial","Bazarbashi S, Elshenawy MA, Badran A, Aljubran A, Alzahrani A, Almanea H, Alsuhaibani A, Alashwah A, Neimatallah M, Abduljabbar A, Ashari L, Alhomoud S, Ghebeh H, Elhassan T, Alsanea N, Mohiuddin M.","Cancer Med. 2022 May;11(10):2056-2066. doi: 10.1002/cam4.4590. Epub 2022 Feb 10.","Bazarbashi S","Cancer Med","2022","2022/02/11","PMC9119355","","10.1002/cam4.4590"
"35149641","Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy","El-Sayed MH, Ebeid FSE, Zekri AR, Massetto B, Kersey K, Zhang F, Gaggar A, Elsayed W, El-Haddad A.","J Pediatr Gastroenterol Nutr. 2022 May 1;74(5):626-630. doi: 10.1097/MPG.0000000000003406. Epub 2022 Feb 10.","El-Sayed MH","J Pediatr Gastroenterol Nutr","2022","2022/02/12","","","10.1097/MPG.0000000000003406"
"35254550","A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer","Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, Horinouchi H, Kinoshita T, Yoshikawa T, Muro K, Nishikawa H, Suna H, Kodera Y.","Gastric Cancer. 2022 May;25(3):619-628. doi: 10.1007/s10120-022-01286-w. Epub 2022 Mar 7.","Hasegawa H","Gastric Cancer","2022","2022/03/07","PMC9013329","","10.1007/s10120-022-01286-w"
"35277362","Systematic review of oral pharmacotherapeutic options for the management of uterine fibroids","Rovelli RJ, Cieri-Hutcherson NE, Hutcherson TC.","J Am Pharm Assoc (2003). 2022 May-Jun;62(3):674-682.e5. doi: 10.1016/j.japh.2022.02.004. Epub 2022 Feb 11.","Rovelli RJ","J Am Pharm Assoc (2003)","2022","2022/03/12","","","10.1016/j.japh.2022.02.004"
"35286730","Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer","Zhang T, Kephart J, Bronson E, Anand M, Daly C, Spasojevic I, Bakthavatsalam S, Franz K, Berg H, Karachaliou GS, James OG, Howard L, Halabi S, Harrison MR, Armstrong AJ, George DJ.","Prostate. 2022 May;82(7):858-866. doi: 10.1002/pros.24329. Epub 2022 Mar 14.","Zhang T","Prostate","2022","2022/03/14","","","10.1002/pros.24329"
"35364421","Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Yau T, Gurary EB, Siegel AB, Wang A, Cheng AL, Zhu AX; KEYNOTE-224 Investigators.","Eur J Cancer. 2022 May;167:1-12. doi: 10.1016/j.ejca.2022.02.009. Epub 2022 Mar 29.","Kudo M","Eur J Cancer","2022","2022/04/01","","","10.1016/j.ejca.2022.02.009"
"35427833","Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial","Haag GM, Springfeld C, Grün B, Apostolidis L, Zschäbitz S, Dietrich M, Berger AK, Weber TF, Zoernig I, Schaaf M, Waberer L, Müller DW, Al-Batran SE, Halama N, Jaeger D.","Eur J Cancer. 2022 May;167:112-122. doi: 10.1016/j.ejca.2022.03.017. Epub 2022 Apr 12.","Haag GM","Eur J Cancer","2022","2022/04/15","","","10.1016/j.ejca.2022.03.017"
"35525913","A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma","Kobayashi S, Fukushima T, Ueno M, Moriya S, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Suzuki M, Uojima H, Hidaka H, Kusano C, Suzuki M, Morimoto M.","BMC Cancer. 2022 May 7;22(1):517. doi: 10.1186/s12885-022-09625-x.","Kobayashi S","BMC Cancer","2022","2022/05/07","PMC9080183","","10.1186/s12885-022-09625-x"
"35693370","Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review","Ahmed NR, Kulkarni VV, Pokhrel S, Akram H, Abdelgadir A, Chatterjee A, Khan S.","Cureus. 2022 May 8;14(5):e24829. doi: 10.7759/cureus.24829. eCollection 2022 May.","Ahmed NR","Cureus","2022","2022/06/13","PMC9173657","","10.7759/cureus.24829"
"35646705","3,5,3'-Triiodothyronine-Loaded Liposomes Inhibit Hepatocarcinogenesis Via Inflammation-Associated Macrophages","Sun G, Hou X, Zhang L, Zhang H, Shao C, Li F, Zong C, Li R, Shi J, Yang X, Zhang L.","Front Oncol. 2022 May 10;12:877982. doi: 10.3389/fonc.2022.877982. eCollection 2022.","Sun G","Front Oncol","2022","2022/06/01","PMC9135096","","10.3389/fonc.2022.877982"
"35247915","Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab","Rosenblat TL, McDevitt MR, Carrasquillo JA, Pandit-Taskar N, Frattini MG, Maslak PG, Park JH, Douer D, Cicic D, Larson SM, Scheinberg DA, Jurcic JG.","Clin Cancer Res. 2022 May 13;28(10):2030-2037. doi: 10.1158/1078-0432.CCR-21-3712.","Rosenblat TL","Clin Cancer Res","2022","2022/03/05","PMC9106874","NIHMS1787819","10.1158/1078-0432.CCR-21-3712"
"35596181","Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study","Zhou L, Wu X, Chi Z, Si L, Sheng X, Kong Y, Mao L, Lian B, Tang B, Yan X, Wang X, Bai X, Li S, Wei X, Li J, Yang Q, Guo J, Cui C.","BMC Cancer. 2022 May 20;22(1):565. doi: 10.1186/s12885-022-09663-5.","Zhou L","BMC Cancer","2022","2022/05/20","PMC9123656","","10.1186/s12885-022-09663-5"
"34170477","Association between liver enzymes and metabolic syndrome: results of the enrollment phase of Tabari cohort","Aliabadi PK, Sohrab M, Hessami A, Afshari M, Kashi Z, Kheradmand M, Hedayatizadeh-Omran A, Alizadeh-Navaei R, Moosazadeh M.","Ir J Med Sci. 2022 Jun;191(3):1201-1208. doi: 10.1007/s11845-021-02694-0. Epub 2021 Jun 25.","Aliabadi PK","Ir J Med Sci","2022","2021/06/25","","","10.1007/s11845-021-02694-0"
"34480522","Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805","Karam JA, Puligandla M, Flaherty KT, Uzzo RG, Matin SF, Pins MR, Wood CG, Kane C, Jewett MAS, Kim SE, Dutcher JP, DiPaola RS, Haas NB.","BJU Int. 2022 Jun;129(6):718-722. doi: 10.1111/bju.15587. Epub 2021 Sep 23.","Karam JA","BJU Int","2022","2021/09/04","PMC9423939","NIHMS1830140","10.1111/bju.15587"
"35044101","Risk Associations of Glycemic Burden and Obesity With Liver Cancer-A 10-Year Analysis of 15,280 Patients With Type 2 Diabetes","Mao D, Lau ESH, Wu H, Yang A, Fan B, Shi M, Tam CHT, Chow E, Kong APS, Ma RCW, Luk A, Chan JCN.","Hepatol Commun. 2022 Jun;6(6):1350-1360. doi: 10.1002/hep4.1891. Epub 2022 Jan 19.","Mao D","Hepatol Commun","2022","2022/01/19","PMC9134801","","10.1002/hep4.1891"
"35211831","A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study","Matsumura M, Hasegawa K, Oba M, Yamaguchi K, Uetake H, Yoshino T, Morita S, Takahashi K, Unno M, Shimada Y, Muro K, Matsuhashi N, Mori M, Baba H, Shimada M, Mise Y, Kawaguchi Y, Kagimura T, Ishigure K, Saiura A, Sugihara K, Kokudo N.","Langenbecks Arch Surg. 2022 Jun;407(4):1345-1356. doi: 10.1007/s00423-022-02434-7. Epub 2022 Feb 25.","Matsumura M","Langenbecks Arch Surg","2022","2022/02/25","","","10.1007/s00423-022-02434-7"
"35247922","Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials","Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC, Gonzalez-Gugel E, Zhu AX.","Clin Cancer Res. 2022 Jun 1;28(11):2297-2305. doi: 10.1158/1078-0432.CCR-21-4000.","Llovet JM","Clin Cancer Res","2022","2022/03/05","PMC9662930","","10.1158/1078-0432.CCR-21-4000"
"35258371","(90)Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial","Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, Verhelst X, Aerts M, Vanlander A, Berrevoet F, Troisi RI, Van Vlierberghe H, Defreyne L.","Radiology. 2022 Jun;303(3):699-710. doi: 10.1148/radiol.211806. Epub 2022 Mar 8.","Dhondt E","Radiology","2022","2022/03/08","","","10.1148/radiol.211806"
"35287469","Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation","Azhie A, Grant RC, Herman M, Wang L, Knox JJ, Bhat M.","Future Oncol. 2022 Jun;18(18):2173-2191. doi: 10.2217/fon-2021-1635. Epub 2022 Mar 15.","Azhie A","Future Oncol","2022","2022/03/15","","","10.2217/fon-2021-1635"
"35312753","Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy","Lee S, Shroff RT, Makawita S, Xiao L, Danner De Armas A, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, Wolff RA, Javle M.","Clin Cancer Res. 2022 Jun 1;28(11):2229-2236. doi: 10.1158/1078-0432.CCR-21-3548.","Lee S","Clin Cancer Res","2022","2022/03/21","","","10.1158/1078-0432.CCR-21-3548"
"35363627","Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial","Saviano A, Habersetzer F, Lupberger J, Simo-Noumbissie P, Schuster C, Doffoël M, Schmidt-Mutter C, Baumert TF.","Clin Transl Gastroenterol. 2022 Jun 1;13(6):e00492. doi: 10.14309/ctg.0000000000000492.","Saviano A","Clin Transl Gastroenterol","2022","2022/04/01","PMC9236598","","10.14309/ctg.0000000000000492"
"35576956","Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group.","Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13.","Wang J","Lancet Oncol","2022","2022/05/16","","","10.1016/S1470-2045(22)00224-8"
"35655320","A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillén-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Delord JP.","J Exp Clin Cancer Res. 2022 Jun 2;41(1):189. doi: 10.1186/s13046-022-02383-5.","Chan SL","J Exp Clin Cancer Res","2022","2022/06/02","PMC9161616","","10.1186/s13046-022-02383-5"
"35720374","A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma","Bae WK, Lee BC, Kim HJ, Lee JJ, Chung IJ, Cho SB, Koh YS.","Front Immunol. 2022 Jun 2;13:879452. doi: 10.3389/fimmu.2022.879452. eCollection 2022.","Bae WK","Front Immunol","2022","2022/06/20","PMC9202498","","10.3389/fimmu.2022.879452"
"35278074","Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies","Al-Showbaki L, Almugbel FA, Alqaisi HA, Amir E, Chen EX.","Oncologist. 2022 Jun 8;27(6):487-492. doi: 10.1093/oncolo/oyac031.","Al-Showbaki L","Oncologist","2022","2022/03/12","PMC9177107","","10.1093/oncolo/oyac031"
"35348754","Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma","Yuan S, Fu Q, Zhao L, Fu X, Li T, Han L, Qin P, Ren Y, Huo M, Li Z, Lu C, Yuan L, Gao Q, Wang Z.","Oncologist. 2022 Jun 8;27(6):e463-e470. doi: 10.1093/oncolo/oyab068.","Yuan S","Oncologist","2022","2022/03/29","PMC9177116","","10.1093/oncolo/oyab068"
"35744805","Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data","Fishman P.","Molecules. 2022 Jun 8;27(12):3680. doi: 10.3390/molecules27123680.","Fishman P","Molecules","2022","2022/06/24","PMC9229414","","10.3390/molecules27123680"
"35081255","Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ.","Blood. 2022 Jun 9;139(23):3366-3375. doi: 10.1182/blood.2021011583.","Perl AE","Blood","2022","2022/01/26","PMC9197557","","10.1182/blood.2021011583"
"35421228","Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial","Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer DH, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL, Ogasawara S, Daniele B, Chan SL, Knox JJ, Qin S, Siegel AB, Chisamore M, Hatogai K, Wang A, Finn RS, Zhu AX.","Clin Cancer Res. 2022 Jun 13;28(12):2547-2554. doi: 10.1158/1078-0432.CCR-21-3807.","Verset G","Clin Cancer Res","2022","2022/04/14","PMC9784157","","10.1158/1078-0432.CCR-21-3807"
"35421231","Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma","Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L.","Clin Cancer Res. 2022 Jun 13;28(12):2555-2566. doi: 10.1158/1078-0432.CCR-21-4424.","Löffler MW","Clin Cancer Res","2022","2022/04/14","","","10.1158/1078-0432.CCR-21-4424"
"35836768","Development and Validation of a Nomogram for 90-day Outcome in Patients with Hepatitis B Virus-related Acute-on-chronic Liver Failure","Yang J, Xue R, Wu J, Jia L, Li J, Yu H, Zhu Y, Dong J, Meng Q.","J Clin Transl Hepatol. 2022 Jun 28;10(3):458-466. doi: 10.14218/JCTH.2021.00202. Epub 2021 Oct 18.","Yang J","J Clin Transl Hepatol","2022","2022/07/15","PMC9240246","","10.14218/JCTH.2021.00202"
"33753615","Predictors of toxicity after neoadjuvant chemoradiotherapy for locally advanced gall bladder cancer","Loyal A, Chopra S, Goel M, Mehta S, Patil P, Patkar S, Shrivastava S, Engineer R.","Indian J Cancer. 2022 Jul-Sep;59(3):368-374. doi: 10.4103/ijc.IJC_822_19.","Loyal A","Indian J Cancer","2022","2021/03/23","","","10.4103/ijc.IJC_822_19"
"34297268","Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma","Bockorny B, Bullock AJ, Abrams TA, Faintuch S, Alsop DC, Goldberg SN, Ahmed M, Miksad RA.","Dig Dis Sci. 2022 Jul;67(7):3455-3463. doi: 10.1007/s10620-021-07156-2. Epub 2021 Jul 23.","Bockorny B","Dig Dis Sci","2022","2021/07/23","","","10.1007/s10620-021-07156-2"
"34407602","Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study","Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, Chua N, González-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Bolen C, Knapp A, Sellam G, Nielsen T, Sahin D, Vitolo U, Trněný M.","Haematologica. 2022 Jul 1;107(7):1633-1642. doi: 10.3324/haematol.2021.278663.","Kostakoglu L","Haematologica","2022","2021/08/19","PMC9244811","","10.3324/haematol.2021.278663"
"34696564","Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials","Yin Q, Dai L, Sun R, Ke P, Liu L, Jiang B.","Cancer Res Treat. 2022 Jul;54(3):803-816. doi: 10.4143/crt.2021.764. Epub 2021 Oct 25.","Yin Q","Cancer Res Treat","2022","2021/10/26","PMC9296924","","10.4143/crt.2021.764"
"35029306","Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy","de Wit R, Powles T, Castellano D, Necchi A, Lee JL, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN, Drakaki A, Yu EY, Zimmermann AH, Long A, Walgren RA, Gao L, Bell-McGuinn KM, Petrylak DP.","Br J Clin Pharmacol. 2022 Jul;88(7):3182-3192. doi: 10.1111/bcp.15233. Epub 2022 Feb 7.","de Wit R","Br J Clin Pharmacol","2022","2022/01/14","PMC9302693","","10.1111/bcp.15233"
"35426841","Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men","Minczeles NS, de Herder WW, Konijnenberg MW, Feelders RA, Brabander T, Hofland J.","Clin Nucl Med. 2022 Jul 1;47(7):599-605. doi: 10.1097/RLU.0000000000004203. Epub 2022 Apr 15.","Minczeles NS","Clin Nucl Med","2022","2022/04/15","","","10.1097/RLU.0000000000004203"
"35466524","A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma","Chan PY, Phillips MM, Ellis S, Johnston A, Feng X, Arora A, Hay G, Cohen VML, Sagoo MS, Bomalaski JS, Sheaff MT, Szlosarek PW.","Pigment Cell Melanoma Res. 2022 Jul;35(4):461-470. doi: 10.1111/pcmr.13042. Epub 2022 May 16.","Chan PY","Pigment Cell Melanoma Res","2022","2022/04/25","PMC9322321","","10.1111/pcmr.13042"
"35472008","Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial","van Vuren A, Kerkhoffs JL, Schols S, Rijneveld A, Nur E, Peereboom D, Gandon Y, Welsing P, van Wijk R, Schutgens R, van Solinge W, Marx J, Leiner T, Biemond B, van Beers E.","Am J Hematol. 2022 Jul;97(7):924-932. doi: 10.1002/ajh.26581. Epub 2022 May 10.","van Vuren A","Am J Hematol","2022","2022/04/26","PMC9325377","","10.1002/ajh.26581"
"35472243","Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study","Hubbard JM, Tőke ER, Moretto R, Graham RP, Youssoufian H, Lőrincz O, Molnár L, Csiszovszki Z, Mitchell JL, Wessling J, Tóth J, Cremolini C.","Clin Cancer Res. 2022 Jul 1;28(13):2818-2829. doi: 10.1158/1078-0432.CCR-22-0112.","Hubbard JM","Clin Cancer Res","2022","2022/04/26","PMC9365360","","10.1158/1078-0432.CCR-22-0112"
"35534642","Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801","Hosokawa S, Ichihara E, Harada D, Kuyama S, Inoue K, Gemba K, Ichikawa H, Kato Y, Oda N, Oze I, Tamura T, Kozuki T, Umeno T, Kubo T, Hotta K, Bessho A, Maeda Y, Kiura K.","Int J Clin Oncol. 2022 Jul;27(7):1139-1144. doi: 10.1007/s10147-022-02164-2. Epub 2022 May 10.","Hosokawa S","Int J Clin Oncol","2022","2022/05/09","","","10.1007/s10147-022-02164-2"
"35567919","First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours","Schöffski P, Awada A, de la Bigne AM, Felloussi Z, Burbridge M, Cantero F, Colombo R, Maruzzelli S, Ammattatelli K, de Jonge M, Aftimos P, Dumez H, Sleijfer S.","Eur J Cancer. 2022 Jul;169:135-145. doi: 10.1016/j.ejca.2022.04.001. Epub 2022 May 11.","Schöffski P","Eur J Cancer","2022","2022/05/14","","","10.1016/j.ejca.2022.04.001"
"35794623","Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers","Baldini C, Danlos FX, Varga A, Texier M, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A.","J Exp Clin Cancer Res. 2022 Jul 7;41(1):217. doi: 10.1186/s13046-022-02423-0.","Baldini C","J Exp Clin Cancer Res","2022","2022/07/06","PMC9260998","","10.1186/s13046-022-02423-0"
"35840914","Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma","Wang H, Zhu X, Zhao Y, Dong D, Li L, Cai Y, Li Y, Wang W.","BMC Cancer. 2022 Jul 15;22(1):771. doi: 10.1186/s12885-022-09819-3.","Wang H","BMC Cancer","2022","2022/07/15","PMC9287866","","10.1186/s12885-022-09819-3"
"35902898","A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients","Nodehi RS, Kalantari B, Raafat J, Ansarinejad N, Moazed V, Mortazavizadeh SMR, Hosseinzadeh M, Ghaderi B, Jenabian A, Qadyani M, Haghighat S, Allahyari A, Mirzania M, Seghatoleslami M, Payandeh M, Alikhasi A, Kafi H, Shahi F.","BMC Pharmacol Toxicol. 2022 Jul 28;23(1):57. doi: 10.1186/s40360-022-00599-x.","Nodehi RS","BMC Pharmacol Toxicol","2022","2022/07/28","PMC9336069","","10.1186/s40360-022-00599-x"
"34780081","Changes in therapeutic options for hepatocellular carcinoma in Asia","Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N.","Liver Int. 2022 Aug;42(9):2055-2066. doi: 10.1111/liv.15101. Epub 2021 Nov 29.","Ogasawara S","Liver Int","2022","2021/11/15","","","10.1111/liv.15101"
"35216869","A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial","Watanabe G, Mise Y, Oba M, Saiura A, Inoue Y, Takahashi Y, Kishi Y, Suyama K, Takayama T, Noie T, Nishioka Y, Akamatsu N, Arita J, Kokudo N, Hasegawa K.","HPB (Oxford). 2022 Aug;24(8):1245-1251. doi: 10.1016/j.hpb.2022.02.001. Epub 2022 Feb 9.","Watanabe G","HPB (Oxford)","2022","2022/02/26","","","10.1016/j.hpb.2022.02.001"
"35504436","Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma","Liu CH, Peng CM, Hwang JI, Liang PC, Chen PJ, Abi-Jaoudeh N, Giiang LH, Tyan YS.","J Vasc Interv Radiol. 2022 Aug;33(8):926-933.e1. doi: 10.1016/j.jvir.2022.04.031. Epub 2022 Apr 30.","Liu CH","J Vasc Interv Radiol","2022","2022/05/03","","","10.1016/j.jvir.2022.04.031"
"35635652","Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)","Ishiyama S, Yamada T, Nakamura M, Enomoto M, Sugimoto K, Yokomizo H, Kosugi C, Ohta R, Ishimaru K, Sonoda H, Ishibashi K, Kuramochi H, Yoshida Y, Ichikawa D, Hirata K, Yoshida H, Hashiguchi Y, Ishida H, Koda K, Katsumata K, Sakamoto K.","Int J Clin Oncol. 2022 Aug;27(8):1300-1308. doi: 10.1007/s10147-022-02179-9. Epub 2022 May 30.","Ishiyama S","Int J Clin Oncol","2022","2022/05/31","","","10.1007/s10147-022-02179-9"
"35728123","Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment","Wilbaux M, Demanse D, Gu Y, Jullion A, Myers A, Katsanou V, Meille C.","CPT Pharmacometrics Syst Pharmacol. 2022 Aug;11(8):1122-1134. doi: 10.1002/psp4.12831. Epub 2022 Jun 21.","Wilbaux M","CPT Pharmacometrics Syst Pharmacol","2022","2022/06/21","PMC9381917","","10.1002/psp4.12831"
"35739268","Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y.","Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23.","Zhu AX","Nat Med","2022","2022/06/23","","","10.1038/s41591-022-01868-2"
"35798016","Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T.","Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.","Kelley RK","Lancet Oncol","2022","2022/07/07","","","10.1016/S1470-2045(22)00326-6"
"35816951","A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S, Saunders MP, Gilbert DC, Jensen LH, Samalin E, Spindler KL, Tamberi S, Demols A, Guren MG, Arnold D, Fakih M, Kayyal T, Cornfeld M, Tian C, Catlett M, Smith M, Spano JP.","ESMO Open. 2022 Aug;7(4):100529. doi: 10.1016/j.esmoop.2022.100529. Epub 2022 Jul 8.","Rao S","ESMO Open","2022","2022/07/11","PMC9463376","","10.1016/j.esmoop.2022.100529"
"35843174","Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases","Ceelen W, Sandra L, de Sande LV, Graversen M, Mortensen MB, Vermeulen A, Gasthuys E, Reynders D, Cosyns S, Hoorens A, Willaert W.","EBioMedicine. 2022 Aug;82:104151. doi: 10.1016/j.ebiom.2022.104151. Epub 2022 Jul 15.","Ceelen W","EBioMedicine","2022","2022/07/17","PMC9297106","","10.1016/j.ebiom.2022.104151"
"35914916","Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study - protocol for a randomised, multicentre, phase 3 trial","Pacelli F, Gerardi C, Rulli E, Abatini C, Rotolo S, Garattini S, Melotti G, Torri V, Galli F, Rulli E, Di Giorgio A; CHECK Investigators.","BMJ Open. 2022 Aug 1;12(8):e051324. doi: 10.1136/bmjopen-2021-051324.","Pacelli F","BMJ Open","2022","2022/08/01","PMC9345052","","10.1136/bmjopen-2021-051324"
"36007963","Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)","Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ.","J Immunother Cancer. 2022 Aug;10(8):e005332. doi: 10.1136/jitc-2022-005332.","Johnson B","J Immunother Cancer","2022","2022/08/25","PMC9422817","","10.1136/jitc-2022-005332"
"38319892","Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B.","NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.","Abou-Alfa GK","NEJM Evid","2022","2024/02/06","","","10.1056/EVIDoa2100070"
"38319896","Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, He P, Kurland JF, Cohen G, Valle JW.","NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.","Oh DY","NEJM Evid","2022","2024/02/06","","","10.1056/EVIDoa2200015"
"36017002","Protocol of Kupffer phase whole liver scan for metastases: A single-center prospective study","Wu Q, Liu Y, Sun D, Wang Y, Wei X, Li J, Liu B, Wang S, Zhou Y, Hu H, Zhang R, Jiao Q, Li Y, Ying T.","Front Med (Lausanne). 2022 Aug 9;9:911807. doi: 10.3389/fmed.2022.911807. eCollection 2022.","Wu Q","Front Med (Lausanne)","2022","2022/08/26","PMC9396128","","10.3389/fmed.2022.911807"
"34907081","Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies","Kudo M, Montal R, Finn RS, Castet F, Ueshima K, Nishida N, Haber PK, Hu Y, Chiba Y, Schwartz M, Meyer T, Lencioni R, Llovet JM.","Clin Cancer Res. 2022 Aug 15;28(16):3443-3451. doi: 10.1158/1078-0432.CCR-21-3135.","Kudo M","Clin Cancer Res","2022","2021/12/15","","","10.1158/1078-0432.CCR-21-3135"
"35435967","Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma","Zhu AX, Dayyani F, Yen CJ, Ren Z, Bai Y, Meng Z, Pan H, Dillon P, Mhatre SK, Gaillard VE, Hernandez S, Kelley RK, Sangro B.","Clin Cancer Res. 2022 Aug 15;28(16):3537-3545. doi: 10.1158/1078-0432.CCR-21-3275.","Zhu AX","Clin Cancer Res","2022","2022/04/18","PMC9662926","","10.1158/1078-0432.CCR-21-3275"
"35679062","Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials","Yukami H, Kawazoe A, Lin YT, Koyama S, Fukuoka S, Hara H, Takahashi N, Kojima T, Asayama M, Yoshii T, Bando H, Kotani D, Nakamura Y, Kuboki Y, Mishima S, Wakabayashi M, Kuwata T, Goto M, Higuchi K, Yoshino T, Doi T, Nishikawa H, Shitara K.","Clin Cancer Res. 2022 Aug 15;28(16):3480-3488. doi: 10.1158/1078-0432.CCR-22-0630.","Yukami H","Clin Cancer Res","2022","2022/06/09","PMC9662898","","10.1158/1078-0432.CCR-22-0630"
"36207947","[Analysis of the diagnosis and treatment of 24 cases of hepatic perivascular epithelioid cell tumor]","Liu B, Zhou WY, Xiao YT, Cheng YH, Ge YH, Nie SD, Lyu P.","Zhonghua Gan Zang Bing Za Zhi. 2022 Aug 20;30(8):889-894. doi: 10.3760/cma.j.cn501113-20201013-00551.","Liu B","Zhonghua Gan Zang Bing Za Zhi","2022","2022/10/08","","","10.3760/cma.j.cn501113-20201013-00551"
"35999521","Benefit of a flash dose of corticosteroids in digestive surgical oncology: a multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH)","Magnin J, Fournel I, Doussot A, Régimbeau JM, Zerbib P, Piessen G, Beyer-Berjot L, Deguelte S, Lakkis Z, Schwarz L, Orry D, Ayav A, Muscari F, Mauvais F, Passot G, Trelles N, Venara A, Benoist S, Messager M, Fuks D, Borraccino B, Trésallet C, Valverde A, Souche FR, Herrero A, Gaujoux S, Lefevre J, Bourredjem A, Cransac A, Ortega-Deballon P.","BMC Cancer. 2022 Aug 23;22(1):913. doi: 10.1186/s12885-022-09998-z.","Magnin J","BMC Cancer","2022","2022/08/23","PMC9400297","","10.1186/s12885-022-09998-z"
"36091003","Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study","Li D, Xu L, Ji J, Bao D, Hu J, Qian Y, Zhou Y, Chen Z, Li D, Li X, Zhang X, Wang H, Yi C, Shi M, Pang Y, Liu S, Xu X.","Front Immunol. 2022 Aug 26;13:944062. doi: 10.3389/fimmu.2022.944062. eCollection 2022.","Li D","Front Immunol","2022","2022/09/12","PMC9459134","","10.3389/fimmu.2022.944062"
"36097772","Influence of different region of interest sizes on CT-based radiomics model for microvascular invasion prediction in hepatocellular carcinoma","Zhao H, Feng Z, Li H, Yao S, Zheng W, Rong P.","Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Aug 28;47(8):1049-1057. doi: 10.11817/j.issn.1672-7347.2022.220027.","Zhao H","Zhong Nan Da Xue Xue Bao Yi Xue Ban","2022","2022/09/13","PMC10950113","","10.11817/j.issn.1672-7347.2022.220027"
"34541612","Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial","Öcal O, Rössler D, Gasbarrini A, Berg T, Klümpen HJ, Bargellini I, Peynircioglu B, van Delden O, Schulz C, Schütte K, Iezzi R, Pech M, Malfertheiner P, Sangro B, Ricke J, Seidensticker M.","J Cancer Res Clin Oncol. 2022 Sep;148(9):2487-2496. doi: 10.1007/s00432-021-03803-3. Epub 2021 Sep 20.","Öcal O","J Cancer Res Clin Oncol","2022","2021/09/20","PMC9349099","","10.1007/s00432-021-03803-3"
"34999237","Metastatic uveal melanoma: The final frontier","Rantala ES, Hernberg MM, Piperno-Neumann S, Grossniklaus HE, Kivelä TT.","Prog Retin Eye Res. 2022 Sep;90:101041. doi: 10.1016/j.preteyeres.2022.101041. Epub 2022 Jan 6.","Rantala ES","Prog Retin Eye Res","2022","2022/01/09","","","10.1016/j.preteyeres.2022.101041"
"35058319","Prospective Phase II Trial of Prognostication by (68)Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy","Carlsen EA, Loft M, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A.","J Nucl Med. 2022 Sep;63(9):1371-1377. doi: 10.2967/jnumed.121.263177. Epub 2022 Jan 20.","Carlsen EA","J Nucl Med","2022","2022/01/21","PMC9454472","","10.2967/jnumed.121.263177"
"35526675","Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies","Beaton L, Tregidgo HFJ, Znati SA, Forsyth S, Counsell N, Clarkson MJ, Bandula S, Chouhan M, Lowe HL, Thin MZ, Hague J, Sharma D, Pollok JM, Davidson BR, Raja J, Munneke G, Stuckey DJ, Bascal ZA, Wilde PE, Cooper S, Ryan S, Czuczman P, Boucher E, Hartley JA, Atkinson D, Lewis AL, Jansen M, Meyer T, Sharma RA.","J Vasc Interv Radiol. 2022 Sep;33(9):1034-1044.e29. doi: 10.1016/j.jvir.2022.04.033. Epub 2022 May 5.","Beaton L","J Vasc Interv Radiol","2022","2022/05/08","","","10.1016/j.jvir.2022.04.033"
"35657463","Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin","Martin RCG 2nd, Simo KA, Hansen P, Rocha F, Philips P, McMasters KM, Tatum CM, Kelly LR, Driscoll M, Sharma VR, Crocenzi TS, Scoggins CR.","Ann Surg Oncol. 2022 Sep;29(9):5462-5473. doi: 10.1245/s10434-022-11932-3. Epub 2022 Jun 3.","Martin RCG 2nd","Ann Surg Oncol","2022","2022/06/03","","","10.1245/s10434-022-11932-3"
"35764236","Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide","Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair M, Garassino MC, de Castro Junior G, Bischoff H, Lam S, Cardona A, Morris S, Liu SV.","J Thorac Oncol. 2022 Sep;17(9):1122-1129. doi: 10.1016/j.jtho.2022.05.016. Epub 2022 Jun 25.","Reck M","J Thorac Oncol","2022","2022/06/28","","","10.1016/j.jtho.2022.05.016"
"35843739","Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors","Starks DC, Rojas-Espaillat L, Meissner T, Williams CB.","Gynecol Oncol. 2022 Sep;166(3):403-409. doi: 10.1016/j.ygyno.2022.07.005. Epub 2022 Jul 15.","Starks DC","Gynecol Oncol","2022","2022/07/17","","","10.1016/j.ygyno.2022.07.005"
"35907408","Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","DeZern AE, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA.","Lancet Haematol. 2022 Sep;9(9):e660-e669. doi: 10.1016/S2352-3026(22)00206-X. Epub 2022 Jul 27.","DeZern AE","Lancet Haematol","2022","2022/07/30","PMC9444987","NIHMS1828110","10.1016/S2352-3026(22)00206-X"
"35970102","FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314)","Modest DP, Karthaus M, Kasper S, Moosmann N, Keitel V, Kiani A, Uhlig J, Jacobasch L, Fischer V Weikersthal L, Fuchs M, Kaiser F, Lerchenmüller C, Sent D, Junghanß C, Held S, Lorenzen S, Kaczirek K, Jung A, Stintzing S, Heinemann V.","Eur J Cancer. 2022 Sep;173:297-306. doi: 10.1016/j.ejca.2022.07.012. Epub 2022 Aug 12.","Modest DP","Eur J Cancer","2022","2022/08/15","","","10.1016/j.ejca.2022.07.012"
"36158588","Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial","Chan SL, Chotipanich C, Choo SP, Kwang SW, Mo F, Worakitsitisatorn A, Tai D, Sundar R, Ng DCE, Loke KSH, Li L, Ng KKC, Peng YW, Yu SC.","Liver Cancer. 2022 Jun 15;11(5):451-459. doi: 10.1159/000525489. eCollection 2022 Sep.","Chan SL","Liver Cancer","2022","2022/09/26","PMC9485918","","10.1159/000525489"
"36175037","Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)","Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M.","J Immunother Cancer. 2022 Sep;10(9):e005413. doi: 10.1136/jitc-2022-005413.","Atkins MB","J Immunother Cancer","2022","2022/09/29","PMC9528604","","10.1136/jitc-2022-005413"
"36115673","Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma","Zhang B, Yue J, Shi X, Cui K, Li L, Zhang C, Sun P, Zhong J, Li Z, Zhao L.","BMJ Open. 2022 Sep 17;12(9):e060955. doi: 10.1136/bmjopen-2022-060955.","Zhang B","BMJ Open","2022","2022/09/17","PMC9486305","","10.1136/bmjopen-2022-060955"
"36212504","A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases","Feng AW, Guo JH, Gao S, Kou FX, Liu SX, Liu P, Chen H, Wang XD, Xu HF, Cao G, Zhu X.","Front Oncol. 2022 Sep 21;12:913017. doi: 10.3389/fonc.2022.913017. eCollection 2022.","Feng AW","Front Oncol","2022","2022/10/10","PMC9532863","","10.3389/fonc.2022.913017"
"35165764","Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers","Zheng Y, Mislang ARA, Coward J, Cosman R, Cooper A, Underhill C, Zhu J, Xiong J, Jiang O, Wang H, Xie Y, Zhou Y, Jin X, Li B, Wang ZM, Kwek KY, Xia D, Xia Y, Xu N.","Cancer Immunol Immunother. 2022 Oct;71(10):2371-2379. doi: 10.1007/s00262-022-03160-1. Epub 2022 Feb 15.","Zheng Y","Cancer Immunol Immunother","2022","2022/02/15","PMC10991425","","10.1007/s00262-022-03160-1"
"35643250","Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial","Buckstein M, Kim E, Özbek U, Tabrizian P, Gunasekaran G, Facciuto M, Rosenzweig K, Llovet JM, Schwartz M.","Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):221-230. doi: 10.1016/j.ijrobp.2022.05.021. Epub 2022 May 26.","Buckstein M","Int J Radiat Oncol Biol Phys","2022","2022/06/01","","","10.1016/j.ijrobp.2022.05.021"
"35710899","RESIRT: A Phase 1 Study of Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres in Patients With Primary Renal Cell Carcinoma","de Souza PL, Aslan P, Clark W, Nour R, de Silva S.","Clin Genitourin Cancer. 2022 Oct;20(5):442-451. doi: 10.1016/j.clgc.2022.05.006. Epub 2022 May 18.","de Souza PL","Clin Genitourin Cancer","2022","2022/06/17","","","10.1016/j.clgc.2022.05.006"
"35714812","Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy","Yuen MF, Heo J, Kumada H, Suzuki F, Suzuki Y, Xie Q, Jia J, Karino Y, Hou J, Chayama K, Imamura M, Lao-Tan JY, Lim SG, Tanaka Y, Xie W, Yoon JH, Duan Z, Kurosaki M, Park SJ, Labio ME, Kumar R, Kweon YO, Yim HJ, Tao Y, Cremer J, Elston R, Davies M, Baptiste-Brown S, Han K, Campbell FM, Paff M, Theodore D.","J Hepatol. 2022 Oct;77(4):967-977. doi: 10.1016/j.jhep.2022.05.031. Epub 2022 Jun 15.","Yuen MF","J Hepatol","2022","2022/06/17","","","10.1016/j.jhep.2022.05.031"
"35785525","Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials","An J, Han S, Kim HI, Shim JH.","Hepatol Commun. 2022 Oct;6(10):2886-2900. doi: 10.1002/hep4.2025. Epub 2022 Jul 4.","An J","Hepatol Commun","2022","2022/07/05","PMC9512463","","10.1002/hep4.2025"
"35970035","Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial","Ohba A, Ueno H, Shiba S, Okano N, Kobayashi T, Nagashima F, Sasahira N, Sasaki M, Imaoka H, Sakamoto Y, Kondo S, Morizane C, Ozaka M, Ikeda M, Furuse J, Okusaka T.","Eur J Cancer. 2022 Oct;174:40-47. doi: 10.1016/j.ejca.2022.06.010. Epub 2022 Aug 12.","Ohba A","Eur J Cancer","2022","2022/08/15","","","10.1016/j.ejca.2022.06.010"
"35970037","Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials","Fulgenzi CAM, D'Alessio A, Airoldi C, Scotti L, Demirtas CO, Gennari A, Cortellini A, Pinato DJ.","Eur J Cancer. 2022 Oct;174:57-67. doi: 10.1016/j.ejca.2022.06.058. Epub 2022 Aug 12.","Fulgenzi CAM","Eur J Cancer","2022","2022/08/15","","","10.1016/j.ejca.2022.06.058"
"35981413","Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial","Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, Li Q, Xu L, Zhang Y, Wei W, Chen M, Kan A, Shi M.","Eur J Cancer. 2022 Oct;174:68-77. doi: 10.1016/j.ejca.2022.07.005. Epub 2022 Aug 15.","Lai Z","Eur J Cancer","2022","2022/08/18","","","10.1016/j.ejca.2022.07.005"
"35987165","Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study","Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E, Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Ziti-Ljajic S, Massard C.","ESMO Open. 2022 Oct;7(5):100562. doi: 10.1016/j.esmoop.2022.100562. Epub 2022 Aug 18.","Simonelli M","ESMO Open","2022","2022/08/20","PMC9588873","","10.1016/j.esmoop.2022.100562"
"35994789","A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer","Yang X, Ren H, Li Z, Zhang L, Shao Y, Li H, Yang X, Sun Y, Zhang X, Wang Z, Fu J.","ESMO Open. 2022 Oct;7(5):100565. doi: 10.1016/j.esmoop.2022.100565. Epub 2022 Aug 19.","Yang X","ESMO Open","2022","2022/08/22","PMC9588898","","10.1016/j.esmoop.2022.100565"
"35998838","Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy","Wang L, Qiu L, Ke Q, Ji H, Wu J.","Radiother Oncol. 2022 Oct;175:101-111. doi: 10.1016/j.radonc.2022.08.019. Epub 2022 Aug 22.","Wang L","Radiother Oncol","2022","2022/08/23","","","10.1016/j.radonc.2022.08.019"
"36001228","Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial","Li JX, Su TS, Gong WF, Zhong JH, Yan LY, Zhang J, Li LQ, He ML, Zhang RJ, Du YQ, Wang XT, Liang SX, Xiang BD.","Hepatol Int. 2022 Oct;16(5):1179-1187. doi: 10.1007/s12072-022-10396-7. Epub 2022 Aug 24.","Li JX","Hepatol Int","2022","2022/08/24","PMC9525355","","10.1007/s12072-022-10396-7"
"35849151","Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study","Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, Chen MH.","Clin Cancer Res. 2022 Oct 3;28(19):4248-4257. doi: 10.1158/1078-0432.CCR-22-1152.","Chiang NJ","Clin Cancer Res","2022","2022/07/18","PMC9527499","","10.1158/1078-0432.CCR-22-1152"
"36254201","Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma","Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y.","J Hepatocell Carcinoma. 2022 Oct 11;9:1065-1079. doi: 10.2147/JHC.S369951. eCollection 2022.","Kaseb AO","J Hepatocell Carcinoma","2022","2022/10/18","PMC9569161","","10.2147/JHC.S369951"
"36241629","Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas","Paik PK, Luo J, Ai N, Kim R, Ahn L, Biswas A, Coker C, Ma W, Wong P, Buonocore DJ, Lai WV, Chaft JE, Acharyya S, Massagué J, Kris MG.","Nat Commun. 2022 Oct 15;13(1):6095. doi: 10.1038/s41467-022-33719-6.","Paik PK","Nat Commun","2022","2022/10/14","PMC9568581","","10.1038/s41467-022-33719-6"
"36290898","Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial","Franceschini D, Comito T, Di Gallo A, Vernier V, Marzo MA, Di Cristina L, Marini B, Lo Faro L, Stefanini S, Spoto R, Dominici L, Franzese C, Scorsetti M.","Curr Oncol. 2022 Oct 17;29(10):7858-7867. doi: 10.3390/curroncol29100621.","Franceschini D","Curr Oncol","2022","2022/10/27","PMC9600565","","10.3390/curroncol29100621"
"36241241","[Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study]","Zhang L, Gong JF, Pan HM, Bai YX, Liu TS, Cheng Y, Chen YC, Huang JY, Xu TT, Ge FJ, Hsu WL, Shi J, Hu XC, Shen L.","Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Oct 18;54(5):971-980. doi: 10.19723/j.issn.1671-167X.2022.05.026.","Zhang L","Beijing Da Xue Xue Bao Yi Xue Ban","2022","2022/10/14","PMC9568390","","10.19723/j.issn.1671-167X.2022.05.026"
"36270753","Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study","Nishina T, Fujita T, Yoshizuka N, Sugibayashi K, Murayama K, Kuboki Y.","BMJ Open. 2022 Oct 21;12(10):e055718. doi: 10.1136/bmjopen-2021-055718.","Nishina T","BMJ Open","2022","2022/10/21","PMC9594513","","10.1136/bmjopen-2021-055718"
"36271374","Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis","Yang TK, Yu YF, Tsai CL, Li HJ, Yang PS, Huang KW, Cheng JC.","BMC Cancer. 2022 Oct 21;22(1):1085. doi: 10.1186/s12885-022-10174-6.","Yang TK","BMC Cancer","2022","2022/10/22","PMC9587661","","10.1186/s12885-022-10174-6"
"36273186","High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial","Lertbutsayanukul C, Kitpanit S, Kannarunimit D, Chakkabat C, Oonsiri S, Thephamongkhol K, Puataweepong P, Katanyoo K, Sukhaboon J, Tovanabut C, Chongsathientham S, Treeratsapanich P, Soonthornrak J, Prayongrat A.","Trials. 2022 Oct 22;23(1):897. doi: 10.1186/s13063-022-06822-8.","Lertbutsayanukul C","Trials","2022","2022/10/23","PMC9587557","","10.1186/s13063-022-06822-8"
"36307826","Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study","La Verde N, Damia G, Garrone O, Santini D, Fabi A, Ciccarese M, Generali DG, Nunzi M, Poletto E, Ferraris E, Cretella E, Scandurra G, Meattini I, Bertolini AS, Cavanna L, Collovà E, Romagnoli E, Rulli E, Legramandi L, Guffanti F, Bramati A, Moretti A, Cassano A, Vici P, Torri V, Farina G; PAINTER investigators.","Breast Cancer Res. 2022 Oct 28;24(1):71. doi: 10.1186/s13058-022-01560-w.","La Verde N","Breast Cancer Res","2022","2022/10/29","PMC9615373","","10.1186/s13058-022-01560-w"
"36389724","Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy","Qiao W, Wang Q, Hu C, Zhang Y, Li J, Sun Y, Yuan C, Wang W, Liu B, Zhang Y.","Front Immunol. 2022 Oct 28;13:1019772. doi: 10.3389/fimmu.2022.1019772. eCollection 2022.","Qiao W","Front Immunol","2022","2022/11/17","PMC9650042","","10.3389/fimmu.2022.1019772"
"35253915","Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation","Barnault R, Verzeroli C, Fournier C, Michelet M, Redavid AR, Chicherova I, Plissonnier ML, Adrait A, Khomich O, Chapus F, Richaud M, Hervieu M, Reiterer V, Centonze FG, Lucifora J, Bartosch B, Rivoire M, Farhan H, Couté Y, Mirakaj V, Decaens T, Mehlen P, Gibert B, Zoulim F, Parent R.","Hepatology. 2022 Nov;76(5):1345-1359. doi: 10.1002/hep.32446. Epub 2022 Apr 1.","Barnault R","Hepatology","2022","2022/03/07","","","10.1002/hep.32446"
"35352698","Immunogenicity and safety of a bivalent, adjuvant system 04-adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15-25: a randomized, double-blind, phase III, noninferiority clinical trial","Afshani SM, Mirhassani R, Hosseini H, Hosseini R, Tehranian A, Malekzadeh R, Ostovar A, Abdolghaffari AH, Ghobadi MA, Hedayatjoo B, Hazegh Fetratjoo D, Rezagholi Z, Anari A, Moini A.","Eur J Cancer Prev. 2022 Nov 1;31(6):558-567. doi: 10.1097/CEJ.0000000000000753. Epub 2022 Mar 29.","Afshani SM","Eur J Cancer Prev","2022","2022/03/30","","","10.1097/CEJ.0000000000000753"
"35752223","Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies","Lampertico P, Roulot D, Wedemeyer H.","J Hepatol. 2022 Nov;77(5):1422-1430. doi: 10.1016/j.jhep.2022.06.010. Epub 2022 Jun 22.","Lampertico P","J Hepatol","2022","2022/06/25","","","10.1016/j.jhep.2022.06.010"
"35776182","TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial","Zhu HD, Li X, Ji JS, Huang M, Shao GL, Lu J, Zhao XY, Li HL, Yang ZQ, Tu JF, Zhou JM, Zeng CH, Teng GJ.","Eur Radiol. 2022 Nov;32(11):7335-7343. doi: 10.1007/s00330-022-08848-7. Epub 2022 Jul 1.","Zhu HD","Eur Radiol","2022","2022/07/01","","","10.1007/s00330-022-08848-7"
"35829749","Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery","Roosen J, Westlund Gotby LEL, Arntz MJ, Fütterer JJ, Janssen MJR, Konijnenberg MW, van Wijk MWM, Overduin CG, Nijsen JFW.","Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4705-4715. doi: 10.1007/s00259-022-05902-w. Epub 2022 Jul 13.","Roosen J","Eur J Nucl Med Mol Imaging","2022","2022/07/13","PMC9606012","","10.1007/s00259-022-05902-w"
"36113779","A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases","Kim K, Yu JI, Park HC, Yoo GS, Lim DH, Noh JM, Jeong WK.","Radiother Oncol. 2022 Nov;176:9-16. doi: 10.1016/j.radonc.2022.09.003. Epub 2022 Sep 14.","Kim K","Radiother Oncol","2022","2022/09/16","","","10.1016/j.radonc.2022.09.003"
"36173619","Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial","Olson R, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Baker S, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresene S, Tyldesley S.","JAMA Oncol. 2022 Nov 1;8(11):1644-1650. doi: 10.1001/jamaoncol.2022.4394.","Olson R","JAMA Oncol","2022","2022/09/29","PMC9523552","","10.1001/jamaoncol.2022.4394"
"36196767","Sonazoid™ versus SonoVue(®) for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study","Kang HJ, Lee JM, Yoon JH, Yoo J, Choi Y, Joo I, Han JK.","Korean J Radiol. 2022 Nov;23(11):1067-1077. doi: 10.3348/kjr.2022.0388. Epub 2022 Sep 30.","Kang HJ","Korean J Radiol","2022","2022/10/05","PMC9614293","","10.3348/kjr.2022.0388"
"36261050","PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.","Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16.","Buteau JP","Lancet Oncol","2022","2022/10/19","","","10.1016/S1470-2045(22)00605-2"
"36406648","A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C","Chen CY, Chuang WL, Qin A, Zhang WH, Zhu LY, Zhang GQ, Chen JJ, Lo CC, Zhou X, Mao X, Shang J, Kuo HT, Xie W, Chen CH, Lo GH, Jun DW, Dang S, Tsai CY, Wang TF, Lai HH, Tseng KC, Huang YW, Chen PJ.","JGH Open. 2022 Oct 10;6(11):782-791. doi: 10.1002/jgh3.12825. eCollection 2022 Nov.","Chen CY","JGH Open","2022","2022/11/21","PMC9667409","","10.1002/jgh3.12825"
"36442892","Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study","Kimura M, Ogawa E, Harada K, Imamura J, Saio M, Ikura Y, Yatsuhashi H, Murata K, Miura K, Ieiri I, Tanaka A, Kimura K.","BMJ Open Gastroenterol. 2022 Nov;9(1):e001001. doi: 10.1136/bmjgast-2022-001001.","Kimura M","BMJ Open Gastroenterol","2022","2022/11/28","PMC9710334","","10.1136/bmjgast-2022-001001"
"36450386","Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study","de la Torre-Aláez M, Matilla A, Varela M, Iñarrairaegui M, Reig M, Lledó JL, Arenas JI, Lorente S, Testillano M, Márquez L, Da Fonseca L, Argemí J, Gómez-Martin C, Rodriguez-Fraile M, Bilbao JI, Sangro B.","J Immunother Cancer. 2022 Nov;10(11):e005457. doi: 10.1136/jitc-2022-005457.","de la Torre-Aláez M","J Immunother Cancer","2022","2022/11/30","PMC9716796","","10.1136/jitc-2022-005457"
"36727020","A Rare Event of Liver Dysfunction on Sotorasib and Management Strategy","Kinahan H.","J Adv Pract Oncol. 2022 Nov;13(8):812-815. doi: 10.6004/jadpro.2022.13.8.7. Epub 2022 Nov 1.","Kinahan H","J Adv Pract Oncol","2022","2023/02/02","PMC9881741","","10.6004/jadpro.2022.13.8.7"
"36367894","Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma","Mena E, Shih J, Chung JY, Jones J, Rabiee A, Monge C, Turkbey B, Lindenberg L, Salerno KE, Kassin M, Wood B, Hernandez J, Maass-Moreno R, Saboury B, Jakhete N, Molitoris JK, Unger KR, Choyke PL, Escorcia FE.","PLoS One. 2022 Nov 11;17(11):e0277407. doi: 10.1371/journal.pone.0277407. eCollection 2022.","Mena E","PLoS One","2022","2022/11/11","PMC9651549","","10.1371/journal.pone.0277407"
"36405383","Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy","Li SQ, Yang Y, Ye LS.","World J Gastroenterol. 2022 Nov 14;28(42):6034-6044. doi: 10.3748/wjg.v28.i42.6034.","Li SQ","World J Gastroenterol","2022","2022/11/21","PMC9669824","","10.3748/wjg.v28.i42.6034"
"36421345","Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360)","Comito T, Loi M, Franzese C, Clerici E, Franceschini D, Badalamenti M, Teriaca MA, Rimassa L, Pedicini V, Poretti D, Solbiati LA, Torzilli G, Ceriani R, Lleo A, Aghemo A, Santoro A, Scorsetti M.","Curr Oncol. 2022 Nov 16;29(11):8802-8813. doi: 10.3390/curroncol29110692.","Comito T","Curr Oncol","2022","2022/11/24","PMC9689962","","10.3390/curroncol29110692"
"36410831","Adoptive immunotherapy with natural killer cells from peripheral blood CD34(+) stem cells to prevent hepatocellular carcinoma recurrence after curative hepatectomy: a study protocol for an open-label, single-arm phase I study","Ohira M, Kobayashi T, Tanaka Y, Imaoka Y, Sato K, Imaoka K, Nakano R, Doskali M, Piao J, Nakamura M, Yoshida T, Ichinohe T, Kawano R, Yoshimura K, Ueda K, Tamura N, Hirata T, Imamura M, Aikata H, Tanimine N, Kuroda S, Tahara H, Ide K, Ohdan H.","BMJ Open. 2022 Nov 21;12(11):e064526. doi: 10.1136/bmjopen-2022-064526.","Ohira M","BMJ Open","2022","2022/11/21","PMC9680173","","10.1136/bmjopen-2022-064526"
"35471602","Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials","Fujiwara Y, Horita N, Harrington M, Namkoong H, Miyashita H, Galsky MD.","Cancer Immunol Immunother. 2022 Dec;71(12):2837-2848. doi: 10.1007/s00262-022-03203-7. Epub 2022 Apr 26.","Fujiwara Y","Cancer Immunol Immunother","2022","2022/04/26","PMC10992785","","10.1007/s00262-022-03203-7"
"35589409","Safety and Efficacy of (166)Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study","Reinders MTM, van Erpecum KJ, Smits MLJ, Braat AJAT, Bruijne J, Bruijnen R, Sprengers D, Man RA, Vegt E, IJzermans JNM, Moelker A, Lam MGEH.","J Nucl Med. 2022 Dec;63(12):1891-1898. doi: 10.2967/jnumed.122.263823. Epub 2022 May 19.","Reinders MTM","J Nucl Med","2022","2022/05/19","PMC9730925","","10.2967/jnumed.122.263823"
"35985545","Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B","Ji D, Chen Y, Bi J, Shang Q, Liu H, Wang JB, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Wang X, Chen D, Li Z, Dong Z, Yang Y.","J Hepatol. 2022 Dec;77(6):1515-1524. doi: 10.1016/j.jhep.2022.07.018. Epub 2022 Aug 18.","Ji D","J Hepatol","2022","2022/08/19","","","10.1016/j.jhep.2022.07.018"
"36058995","Study Protocol COVER-ALL: Clinical Impact of a Volumetric Image Method for Confirming Tumour Coverage with Ablation on Patients with Malignant Liver Lesions","Lin YM, Paolucci I, Anderson BM, O'Connor CS, Rigaud B, Briones-Dimayuga M, Jones KA, Brock KK, Fellman BM, Odisio BC.","Cardiovasc Intervent Radiol. 2022 Dec;45(12):1860-1867. doi: 10.1007/s00270-022-03255-3. Epub 2022 Sep 4.","Lin YM","Cardiovasc Intervent Radiol","2022","2022/09/04","PMC9712233","NIHMS1835162","10.1007/s00270-022-03255-3"
"36183738","Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial","Schilsky ML, Czlonkowska A, Zuin M, Cassiman D, Twardowschy C, Poujois A, Gondim FAA, Denk G, Cury RG, Ott P, Moore J, Ala A, D'Inca R, Couchonnal-Bedoya E, D'Hollander K, Dubois N, Kamlin COF, Weiss KH; CHELATE trial investigators.","Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1092-1102. doi: 10.1016/S2468-1253(22)00270-9. Epub 2022 Sep 30.","Schilsky ML","Lancet Gastroenterol Hepatol","2022","2022/10/02","","","10.1016/S2468-1253(22)00270-9"
"36197682","Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma: A Nonrandomized Controlled Trial","Wu F, Chen B, Dong D, Rong W, Wang H, Wang L, Wang S, Jin J, Song Y, Liu Y, Fang H, Tang Y, Li N, Zhu X, Li Y, Wang W, Wu J.","JAMA Surg. 2022 Dec 1;157(12):1089-1096. doi: 10.1001/jamasurg.2022.4702.","Wu F","JAMA Surg","2022","2022/10/05","PMC9535533","","10.1001/jamasurg.2022.4702"
"36356410","A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)","Schmidt M, Lübbe K, Decker T, Thill M, Bauer L, Müller V, Link T, Furlanetto J, Reinisch M, Mundhenke C, Hoffmann O, Zahn MO, Müller L, Denkert C, van Mackelenbergh M, Fasching PA, Burchardi N, Nekljudova V, Loibl S.","ESMO Open. 2022 Dec;7(6):100601. doi: 10.1016/j.esmoop.2022.100601. Epub 2022 Nov 7.","Schmidt M","ESMO Open","2022","2022/11/10","PMC9832733","","10.1016/j.esmoop.2022.100601"
"36589722","Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial","Li D, Toh HC, Merle P, Tsuchiya K, Hernandez S, Verret W, Nicholas A, Kudo M.","Liver Cancer. 2022 Jul 13;11(6):558-571. doi: 10.1159/000525671. eCollection 2022 Dec.","Li D","Liver Cancer","2022","2023/01/02","PMC9801180","","10.1159/000525671"
"36912078","A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)","Mahmood S, Li D, Lee A, Rowe J, Beg M, Kasturi V, Iyer R, Abrams T, Dayyani F.","Future Oncol. 2022 Dec;18(40):4465-4471. doi: 10.2217/fon-2022-0844. Epub 2023 Mar 13.","Mahmood S","Future Oncol","2022","2023/03/13","","","10.2217/fon-2022-0844"
"36533188","Emerging pharmacological treatment options for MAFLD","Rojas Á, Lara-Romero C, Muñoz-Hernández R, Gato S, Ampuero J, Romero-Gómez M.","Ther Adv Endocrinol Metab. 2022 Dec 10;13:20420188221142452. doi: 10.1177/20420188221142452. eCollection 2022.","Rojas Á","Ther Adv Endocrinol Metab","2022","2022/12/19","PMC9747889","","10.1177/20420188221142452"
"36503610","A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)","Elias C, Zeidan YH, Bouferraa Y, Mukherji D, Temraz S, Charafeddine M, Al Darazi M, Shamseddine A.","BMC Cancer. 2022 Dec 12;22(1):1296. doi: 10.1186/s12885-022-10373-1.","Elias C","BMC Cancer","2022","2022/12/12","PMC9743639","","10.1186/s12885-022-10373-1"
"36514060","Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with (90)Y resin microspheres for chemo-refractory colorectal liver metastases","Fidelman N, Atreya CE, Griffith M, Milloy MA, Carnevale J, Cinar P, Venook AP, Van Loon K.","BMC Cancer. 2022 Dec 13;22(1):1307. doi: 10.1186/s12885-022-10401-0.","Fidelman N","BMC Cancer","2022","2022/12/13","PMC9749246","","10.1186/s12885-022-10401-0"
"36581917","Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial","Zhu X, Sun L, Song N, He W, Xie B, Hu J, Zhang J, Yang J, Dai J, Bian D, Xia H, Sun F, Xiong A, Luo J, Zhang L, Yu H, Liu M, Liu H, Wang H, Zhang H, Chen C, Wu C, Duan L, Zhu Y, Zhang P, Jiang G.","BMC Med. 2022 Dec 30;20(1):493. doi: 10.1186/s12916-022-02696-4.","Zhu X","BMC Med","2022","2022/12/29","PMC9801594","","10.1186/s12916-022-02696-4"
"35129069","Feasibility and safety of targeting mitochondria for cancer therapy - preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor","Hayat U, Elliott GT, Olszanski AJ, Altieri DC.","Cancer Biol Ther. 2022 Dec 31;23(1):117-126. doi: 10.1080/15384047.2022.2029132.","Hayat U","Cancer Biol Ther","2022","2022/02/07","PMC8820820","","10.1080/15384047.2022.2029132"
"35579989","Special issue ""The advance of solid tumor research in China"": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China","Su C, Zhou J, Qiang H, Zhao J, Chang Q, Ji X, Li J, Xie M, Chu T.","Int J Cancer. 2023 Jan 1;152(1):15-23. doi: 10.1002/ijc.34123. Epub 2022 Jun 17.","Su C","Int J Cancer","2023","2022/05/17","","","10.1002/ijc.34123"
"35681110","A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer","Jo H, Kim ST, Lee J, Park SH, Park JO, Park YS, Lim HY, Yu JI, Park HC, Choi DH, Park Y, Cho YB, Huh JW, Yun SH, Kim HC, Lee WY, Kang WK.","Cancer Res Treat. 2023 Jan;55(1):189-195. doi: 10.4143/crt.2021.1527. Epub 2022 Jun 8.","Jo H","Cancer Res Treat","2023","2022/06/10","PMC9873315","","10.4143/crt.2021.1527"
"35858154","Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer","Rugo HS, Umanzor GA, Barrios FJ, Vasallo RH, Chivalan MA, Bejarano S, Ramírez JR, Fein L, Kowalyszyn RD, Kramer ED, Wang H, Kwan MR, Cutler DL; Oraxol Study Consortium Investigators.","J Clin Oncol. 2023 Jan 1;41(1):65-74. doi: 10.1200/JCO.21.02953. Epub 2022 Jul 20.","Rugo HS","J Clin Oncol","2023","2022/07/20","PMC9788977","","10.1200/JCO.21.02953"
"35921605","Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)","Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, Liang Y, Fan H, Qiao L, Li F, Zhuang W, Peng B, Wang J, Li J, Kuang M.","J Clin Oncol. 2023 Jan 1;41(1):117-127. doi: 10.1200/JCO.22.00392. Epub 2022 Aug 3.","Peng Z","J Clin Oncol","2023","2022/08/03","","","10.1200/JCO.22.00392"
"36108891","Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma","Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, Fung J, Pillai A, Liao CY, Sharma M, Liauw SL.","Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):202-213. doi: 10.1016/j.ijrobp.2022.09.052. Epub 2022 Sep 13.","Juloori A","Int J Radiat Oncol Biol Phys","2023","2022/09/15","","","10.1016/j.ijrobp.2022.09.052"
"36309908","Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial","Xie XF, Zhang QY, Huang JY, Chen LP, Lan XF, Bai X, Song L, Xiong SL, Guo SJ, Du CW.","Breast Cancer Res Treat. 2023 Jan;197(1):93-101. doi: 10.1007/s10549-022-06770-6. Epub 2022 Oct 30.","Xie XF","Breast Cancer Res Treat","2023","2022/10/30","PMC9823079","","10.1007/s10549-022-06770-6"
"36341767","Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study","Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, López CL, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutcus CE, Lencioni R.","J Hepatol. 2023 Jan;78(1):133-141. doi: 10.1016/j.jhep.2022.09.006. Epub 2022 Sep 20.","Kudo M","J Hepatol","2023","2022/11/07","","","10.1016/j.jhep.2022.09.006"
"36370742","Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial","Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE.","Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10.","Watts JM","Lancet Haematol","2023","2022/11/12","","","10.1016/S2352-3026(22)00292-7"
"36513143","State of the art and perspectives in pediatric hepatocellular carcinoma","Digiacomo G, Serra RP, Turrini E, Tiri A, Cavazzoni A, Alfieri R, Bertolini P.","Biochem Pharmacol. 2023 Jan;207:115373. doi: 10.1016/j.bcp.2022.115373. Epub 2022 Dec 10.","Digiacomo G","Biochem Pharmacol","2023","2022/12/13","","","10.1016/j.bcp.2022.115373"
"36565566","Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment","Rigault E, Lacas B, Glehen O, Smith D, Dupont-Bierre E, Guimbaud R, Malka D, Boige V, Fuerea A, Pignon JP, Ducreux M.","Cancer Treat Res Commun. 2023;34:100674. doi: 10.1016/j.ctarc.2022.100674. Epub 2022 Dec 16.","Rigault E","Cancer Treat Res Commun","2023","2022/12/24","","","10.1016/j.ctarc.2022.100674"
"36627145","New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors","Bamias A, Merseburger A, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Calabrò F, Kramer M, de Velasco G, Zakopoulou R, Tzannis K, Sternberg CN.","J Immunother Cancer. 2023 Jan;11(1):e005977. doi: 10.1136/jitc-2022-005977.","Bamias A","J Immunother Cancer","2023","2023/01/10","PMC9835946","","10.1136/jitc-2022-005977"
"36727222","A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol","He J, Liu Y, Liu C, Hu H, Sun L, Xu D, Li J, Wang J, Chen X, Lin R, Jiang Y, Zhang Y, Zhang W, Cheng Y, Wu X, Fang M, Li E, Xu Y, Chen Y, Li J, Cui Y, Pan Z, Zhang S, Yuan Y, Ding K.","Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231152350. doi: 10.1177/15330338231152350.","He J","Technol Cancer Res Treat","2023","2023/02/02","PMC9900663","","10.1177/15330338231152350"
"36745819","Looking for the phoenix: the current research on radiation countermeasures","Chmil V, Filipová A, Tichý A.","Int J Radiat Biol. 2023;99(8):1148-1166. doi: 10.1080/09553002.2023.2173822. Epub 2023 Feb 6.","Chmil V","Int J Radiat Biol","2023","2023/02/06","","","10.1080/09553002.2023.2173822"
"37040510","Comprehensive Metabolic Profiling and Genome-wide Analysis Reveal Therapeutic Modalities for Hepatocellular Carcinoma","Qi F, Li J, Qi Z, Zhang J, Zhou B, Yang B, Qin W, Cui W, Xia J.","Research (Wash D C). 2023;6:0036. doi: 10.34133/research.0036. Epub 2023 Jan 13.","Qi F","Research (Wash D C)","2023","2023/04/11","PMC10076022","","10.34133/research.0036"
"36255393","Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer","Vaishampayan UN, Thakur A, Chen W, Deol A, Patel M, Dobson K, Dickow B, Schalk D, Schienschang A, Whitaker S, Polend A, Fontana JA, Heath EI, Lum LG.","Clin Cancer Res. 2023 Jan 4;29(1):122-133. doi: 10.1158/1078-0432.CCR-22-1601.","Vaishampayan UN","Clin Cancer Res","2023","2022/10/18","PMC9812860","NIHMS1844898","10.1158/1078-0432.CCR-22-1601"
"36681832","Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis","Yao Y, Sun X, Huang H, Wang Z, Fang X, Chen M, Chen Z, Weng H, Guo C, Hong H, Huang H, Lin T.","Radiat Oncol. 2023 Jan 21;18(1):15. doi: 10.1186/s13014-022-02168-2.","Yao Y","Radiat Oncol","2023","2023/01/21","PMC9862810","","10.1186/s13014-022-02168-2"
"36707808","Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy","Taieb J, Price T, Vidot L, Chevallier B, Wyrwicz L, Bachet JB.","BMC Cancer. 2023 Jan 27;23(1):94. doi: 10.1186/s12885-022-10489-4.","Taieb J","BMC Cancer","2023","2023/01/28","PMC9881327","","10.1186/s12885-022-10489-4"
"36762057","Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)","Xu CR, Chen Q, Zhou C, Wu L, Li W, Zhang H, Li Y, Xu F, Xiong J, Wang Q, Zhang H, Jiang Y, Yin H, Wu Q, Dai Q, Hu J, Chen J, Zhang J, Wu G, Yin J, Zhao J, Liu B, Shan J, Sheng L, Chen Q, Han Z, Shi H, Liu Y, Chen J, Wu YL.","Transl Lung Cancer Res. 2023 Jan 31;12(1):127-140. doi: 10.21037/tlcr-22-852. Epub 2023 Jan 16.","Xu CR","Transl Lung Cancer Res","2023","2023/02/10","PMC9903092","","10.21037/tlcr-22-852"
"35981899","Prospective Phase II Trial of [(68)Ga]Ga-NODAGA-E[c(RGDyK)](2) PET/CT Imaging of Integrin α(v)β(3) for Prognostication in Patients with Neuroendocrine Neoplasms","Carlsen EA, Loft M, Loft A, Czyzewska D, Andreassen M, Langer SW, Knigge U, Kjaer A.","J Nucl Med. 2023 Feb;64(2):252-259. doi: 10.2967/jnumed.122.264383. Epub 2022 Aug 18.","Carlsen EA","J Nucl Med","2023","2022/08/18","PMC9902862","","10.2967/jnumed.122.264383"
"36127767","Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study","Shi GM, Huang XY, Wen TF, Song TQ, Kuang M, Mou HB, Bao LQ, Zhao HT, Zhao H, Feng XL, Zhang BX, Peng T, Zhang YB, Li XC, Yu HS, Cao Y, Liu LX, Zhang T, Wang WL, Ran JH, Liu YB, Gong W, Chen MX, Cao L, Luo Y, Wang Y, Zhou H, Yang GH, Fan J, Zhou J.","Cancer Med. 2023 Feb;12(4):4137-4146. doi: 10.1002/cam4.5273. Epub 2022 Sep 20.","Shi GM","Cancer Med","2023","2022/09/20","PMC9972033","","10.1002/cam4.5273"
"36258065","Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures","Ding Z, Wu H, Zeng Y, Kuang M, Yang W, Meng Z, Chen Y, Hao C, Zou S, Sun H, Liu C, Lin K, Shi G, Wang X, Fu X, Chen R, Chen Y, Liang R, Kano T, Pan H, Yang S, Fan J, Zhou J.","Hepatol Int. 2023 Feb;17(1):180-189. doi: 10.1007/s12072-022-10421-9. Epub 2022 Oct 18.","Ding Z","Hepatol Int","2023","2022/10/18","PMC9895009","","10.1007/s12072-022-10421-9"
"36494608","Gadoxetate disodium-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: late portal venous phase may improve identification of enhancing capsule","Kim H, Kim SS, Shin HC, Choi SY, Lee JE, Lee WH, Park CH, Lee HN, Kim SY, Park H, Heo NH.","Abdom Radiol (NY). 2023 Feb;48(2):621-629. doi: 10.1007/s00261-022-03756-2. Epub 2022 Dec 9.","Kim H","Abdom Radiol (NY)","2023","2022/12/09","","","10.1007/s00261-022-03756-2"
"36529152","Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC.","Lancet Gastroenterol Hepatol. 2023 Feb;8(2):169-178. doi: 10.1016/S2468-1253(22)00339-9. Epub 2022 Dec 15.","Chiang CL","Lancet Gastroenterol Hepatol","2023","2022/12/18","","","10.1016/S2468-1253(22)00339-9"
"36538259","A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors","Moreno V, Perets R, Peretz-Yablonski T, Fourneau N, Girgis S, Guo Y, Hellemans P, Verona R, Pendás N, Xia Q, Geva R, Calvo E.","Invest New Drugs. 2023 Feb;41(1):93-104. doi: 10.1007/s10637-022-01319-2. Epub 2022 Dec 20.","Moreno V","Invest New Drugs","2023","2022/12/20","","","10.1007/s10637-022-01319-2"
"36584563","Ultra-low-dose hepatic multiphase CT using deep learning-based image reconstruction algorithm focused on arterial phase in chronic liver disease: A non-inferiority study","Lee HJ, Kim JS, Lee JK, Lee HA, Pak S.","Eur J Radiol. 2023 Feb;159:110659. doi: 10.1016/j.ejrad.2022.110659. Epub 2022 Dec 20.","Lee HJ","Eur J Radiol","2023","2022/12/30","","","10.1016/j.ejrad.2022.110659"
"36754451","Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","Monge C, Xie C, Myojin Y, Coffman K, Hrones DM, Wang S, Hernandez JM, Wood BJ, Levy EB, Juburi I, Hewitt SM, Kleiner DE, Steinberg SM, Figg WD, Redd B, Homan P, Cam M, Ruf B, Duffy AG, Greten TF.","J Immunother Cancer. 2023 Feb;11(2):e005640. doi: 10.1136/jitc-2022-005640.","Monge C","J Immunother Cancer","2023","2023/02/08","PMC9923269","","10.1136/jitc-2022-005640"
"36819673","Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: A randomized, double-blind, placebo-parallel controlled phase II clinical trial","Yang M, Pei B, Hu Q, Li X, Fang X, Huang X, Yang Z, Chen J, He D, Sun G, Lv P, Wang L, Zhang Z, Lai L, Huang C.","Front Nutr. 2023 Feb 2;10:1094081. doi: 10.3389/fnut.2023.1094081. eCollection 2023.","Yang M","Front Nutr","2023","2023/02/23","PMC9932900","","10.3389/fnut.2023.1094081"
"36844221","Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment","Al Mahtab M, Akbar SMF, Aguilar JC, Yoshida O, Khan S, Gerardo GN, Hiasa Y.","Front Med (Lausanne). 2023 Feb 8;10:1032531. doi: 10.3389/fmed.2023.1032531. eCollection 2023.","Al Mahtab M","Front Med (Lausanne)","2023","2023/02/27","PMC9945514","","10.3389/fmed.2023.1032531"
"36477555","Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma","Song X, Kelley RK, Khan AA, Standifer N, Zhou D, Lim K, Krishna R, Liu L, Wang K, McCoon P, Negro A, He P, Gibbs M, Kurland JF, Abou-Alfa GK.","Clin Cancer Res. 2023 Feb 16;29(4):754-763. doi: 10.1158/1078-0432.CCR-22-1983.","Song X","Clin Cancer Res","2023","2022/12/08","PMC9932581","","10.1158/1078-0432.CCR-22-1983"
"36702123","Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results","Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Saeed A, Ripp J, Collins Z, Mulvaney K, Shugrue M, Firth-Braun J, Godwin AK, Madan R, Phadnis M, Sun W.","Cell Rep Med. 2023 Feb 21;4(2):100916. doi: 10.1016/j.xcrm.2023.100916. Epub 2023 Jan 25.","Saeed A","Cell Rep Med","2023","2023/01/26","PMC9975105","","10.1016/j.xcrm.2023.100916"
"36841796","Prospective evaluation of Gadoxetate-enhanced magnetic resonance imaging and computed tomography for hepatocellular carcinoma detection and transplant eligibility assessment with explant histopathology correlation","Jhaveri KS, Babaei Jandaghi A, Bhayana R, Elbanna KY, Espin-Garcia O, Fischer SE, Ghanekar A, Sapisochin G.","Cancer Imaging. 2023 Feb 25;23(1):22. doi: 10.1186/s40644-023-00532-3.","Jhaveri KS","Cancer Imaging","2023","2023/02/25","PMC9960413","","10.1186/s40644-023-00532-3"
"36915466","Clinical significance and changes to the immune microenvironment of colorectal cancer patients with liver metastasis","Wang T, Tang L, Ouyang B, Chen X, Qi J.","J Gastrointest Oncol. 2023 Feb 28;14(1):206-212. doi: 10.21037/jgo-22-1169. Epub 2023 Feb 1.","Wang T","J Gastrointest Oncol","2023","2023/03/14","PMC10007917","","10.21037/jgo-22-1169"
"35790787","Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer","Roy S, Sun Y, Wallis CJD, Morgan SC, Grimes S, Malone J, Kishan AU, Mukherjee D, Spratt DE, Saad F, Malone S.","Prostate Cancer Prostatic Dis. 2023 Mar;26(1):119-125. doi: 10.1038/s41391-022-00560-3. Epub 2022 Jul 5.","Roy S","Prostate Cancer Prostatic Dis","2023","2022/07/05","","","10.1038/s41391-022-00560-3"
"36152015","Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study","Borad MJ, Bai LY, Richards D, Mody K, Hubbard J, Rha SY, Soong J, McCormick D, Tse E, O'Brien D, Bayat A, Ahn D, Davis SL, Park JO, Oh DY.","Hepatology. 2023 Mar 1;77(3):760-773. doi: 10.1002/hep.32804. Epub 2023 Feb 17.","Borad MJ","Hepatology","2023","2022/09/24","","","10.1002/hep.32804"
"36251165","Effect of a High-Fat Meal on Single-Dose Rencofilstat (CRV431) Oral Bioavailability in Healthy Human Subjects","Remenchik E, Mayo PR, Hobbs TM, Greytok JA, Foster EP, Zhao C, Ure D, Trepanier DJ, Foster RT.","Clin Pharmacol Drug Dev. 2023 Mar;12(3):287-293. doi: 10.1002/cpdd.1179. Epub 2022 Oct 17.","Remenchik E","Clin Pharmacol Drug Dev","2023","2022/10/17","","","10.1002/cpdd.1179"
"36310409","Carbon ion radiotherapy with pencil beam scanning for hepatocellular carcinoma: Long-term outcomes from a phase I trial","Hong Z, Zhang W, Cai X, Yu Z, Sun J, Wang W, Lin L, Zhao J, Cheng J, Zhang G, Zhang Q, Jiang G, Wang Z.","Cancer Sci. 2023 Mar;114(3):976-983. doi: 10.1111/cas.15633. Epub 2022 Nov 15.","Hong Z","Cancer Sci","2023","2022/10/31","PMC9986066","","10.1111/cas.15633"
"36455168","Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial","Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, Meng Z, Bai Y, Chen X, Liu X, Xiao J, Ho GF, Mao Y, Wang X, Ying J, Li J, Zhong W, Zhou Y, Siegel AB, Hao C.","J Clin Oncol. 2023 Mar 1;41(7):1434-1443. doi: 10.1200/JCO.22.00620. Epub 2022 Dec 1.","Qin S","J Clin Oncol","2023","2022/12/01","PMC9995104","","10.1200/JCO.22.00620"
"36534786","Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection","Jacobson JM, Zahrieh D, Strand CA, Cruz-Correa M, Pungpapong S, Roberts LR, Mandrekar SJ, Rodriguez LM, Boyer J, Marrero I, Kraynyak KA, Morrow MP, Sylvester AJ, Pawlicki JM, Gillespie E, Barranco E, Richmond E, Umar A, Weiner DB, Limburg PJ; Cancer Prevention Network.","Cancer Prev Res (Phila). 2023 Mar 1;16(3):163-173. doi: 10.1158/1940-6207.CAPR-22-0217.","Jacobson JM","Cancer Prev Res (Phila)","2023","2022/12/19","PMC9992130","NIHMS1857920","10.1158/1940-6207.CAPR-22-0217"
"36535566","Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RK, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL.","Ann Oncol. 2023 Mar;34(3):251-261. doi: 10.1016/j.annonc.2022.12.007. Epub 2022 Dec 16.","Chan ATC","Ann Oncol","2023","2022/12/19","","","10.1016/j.annonc.2022.12.007"
"36571256","Immunotherapy in hepatocellular carcinoma: How does underlying liver disease influence therapeutic strategy and outcomes?","Roth GS, Villeret F, Decaens T, Merle P, Nahon P.","Liver Int. 2023 Mar;43(3):546-557. doi: 10.1111/liv.15504. Epub 2023 Jan 6.","Roth GS","Liver Int","2023","2022/12/26","","","10.1111/liv.15504"
"36609911","Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)","Futamura M, Ishihara K, Nagao Y, Ogiso A, Niwa Y, Nakada T, Kawaguchi Y, Ikawa A, Kumazawa I, Mori R, Kitazawa M, Hosono Y, Kuno M, Kawajiri M, Nakakami A, Takeuchi M, Morikawa A, Tokumaru Y, Katagiri Y, Asano Y, Mushika Y, Shimokawa T, Matsuhasih N.","Breast Cancer. 2023 Mar;30(2):293-301. doi: 10.1007/s12282-022-01425-2. Epub 2023 Jan 7.","Futamura M","Breast Cancer","2023","2023/01/07","PMC9950177","","10.1007/s12282-022-01425-2"
"36624292","Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial","Tong TML, Burgmans MC, Speetjens FM, van Erkel AR, van der Meer RW, van Rijswijk CSP, Jonker-Bos MA, Roozen CFM, Sporrel-Blokland M, Lutjeboer J, van Persijn van Meerten EL, Martini CH, Zoethout RWM, Tijl FGJ, Blank CU, Kapiteijn E.","Cardiovasc Intervent Radiol. 2023 Mar;46(3):350-359. doi: 10.1007/s00270-022-03338-1. Epub 2023 Jan 9.","Tong TML","Cardiovasc Intervent Radiol","2023","2023/01/09","","","10.1007/s00270-022-03338-1"
"36625066","A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression","Al-Kali A, Tibes R, Atherton P, Palmer J, Alkhateeb HB, Patnaik M, Begna K, Gangat N, Hashmi S, He R, Litzow M.","Am J Hematol. 2023 Mar;98(3):472-480. doi: 10.1002/ajh.26831. Epub 2023 Jan 22.","Al-Kali A","Am J Hematol","2023","2023/01/10","","","10.1002/ajh.26831"
"36634853","Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: A propensity score-matched analysis based on phase II study","Long L, Chen B, Wang H, Zhao Y, Wu F, Wang L, Rong W, Wu J, Li Y, Wang W.","Radiother Oncol. 2023 Mar;180:109462. doi: 10.1016/j.radonc.2022.109462. Epub 2023 Jan 9.","Long L","Radiother Oncol","2023","2023/01/12","","","10.1016/j.radonc.2022.109462"
"36753834","Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial","Wang X, Wu X, Yang Y, Xu W, Tian H, Lian B, Chi Z, Si L, Sheng X, Kong Y, Zhou L, Mao L, Li S, Tang B, Yan X, Bai X, Guo J, Cui C.","Eur J Cancer. 2023 Mar;182:57-65. doi: 10.1016/j.ejca.2022.12.027. Epub 2023 Jan 12.","Wang X","Eur J Cancer","2023","2023/02/08","","","10.1016/j.ejca.2022.12.027"
"36757445","Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial","Guo C, Zhang J, Huang X, Chen Y, Sheng J, Huang X, Sun J, Xiao W, Sun K, Gao S, Que R, Shen Y, Zhang M, Wu J, Bai X, Liang T.","Hepatol Commun. 2023 Feb 9;7(3):e0054. doi: 10.1097/HC9.0000000000000054. eCollection 2023 Mar 1.","Guo C","Hepatol Commun","2023","2023/02/09","PMC9916103","","10.1097/HC9.0000000000000054"
"36787089","First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors","Harding JJ, Jungels C, Machiels JP, Smith DC, Walker C, Ji T, Jiang P, Li X, Asatiani E, Van Cutsem E, Abou-Alfa GK.","Target Oncol. 2023 Mar;18(2):181-193. doi: 10.1007/s11523-023-00948-8. Epub 2023 Feb 14.","Harding JJ","Target Oncol","2023","2023/02/14","PMC10042765","","10.1007/s11523-023-00948-8"
"37097715","PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma","Fessas P, Scheiner B, D'Alessio A, M Fulgenzi CA, Korolewicz J, Ward C, Tait P, Thomas R, Cortellini A, Sharma R, Pinato DJ.","Future Oncol. 2023 Mar;19(7):499-507. doi: 10.2217/fon-2022-0916. Epub 2023 Apr 25.","Fessas P","Future Oncol","2023","2023/04/25","","","10.2217/fon-2022-0916"
"36856616","Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients","Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernandéz-Peñas P, Gin D, Sidhu S, Paddon VL, Banney LA, Lim A, Upjohn E, Schaider H, Ganhewa AD, Nguyen J, McKenzie CA, Prakash S, McLean C, Lochhead A, Ibbetson J, Dettrick A, Landgren A, Allnutt KJ, Allison C, Davenport RB, Mumford BP, Wong B, Stagg B, Tedman A, Gribbin H, Edwards HA, De Rosa N, Stewart T, Doolan BJ, Kok Y, Simpson K, Low ZM, Kovitwanichkanont T, Scolyer RA, Dhillon HM, Vardy JL, Chadban SJ, Bowen DG, Chen AC, Damian DL.","N Engl J Med. 2023 Mar 2;388(9):804-812. doi: 10.1056/NEJMoa2203086.","Allen NC","N Engl J Med","2023","2023/03/01","","","10.1056/NEJMoa2203086"
"36928584","Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, Chen Y, Yang GH, Lu JC, Meng XL, Wang XY, Sun L, Ge NL, Huang XW, Qiu SJ, Yang XR, Gao Q, He YF, Xu Y, Sun J, Ren ZG, Fan J, Zhou J.","Signal Transduct Target Ther. 2023 Mar 17;8(1):106. doi: 10.1038/s41392-023-01317-7.","Shi GM","Signal Transduct Target Ther","2023","2023/03/17","PMC10020443","","10.1038/s41392-023-01317-7"
"36931679","Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis","Yu S, Zhang S, Xu H, Yang G, Xu F, Yang L, Chen D, An G, Wang Y.","BMJ Open. 2023 Mar 17;13(3):e059457. doi: 10.1136/bmjopen-2021-059457.","Yu S","BMJ Open","2023","2023/03/17","PMC10030562","","10.1136/bmjopen-2021-059457"
"36512738","Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial","Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F.","J Clin Oncol. 2023 Mar 20;41(9):1747-1757. doi: 10.1200/JCO.22.00972. Epub 2022 Dec 13.","Yau T","J Clin Oncol","2023","2022/12/13","PMC10022845","","10.1200/JCO.22.00972"
"36990492","SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol","Espinasse A, Solovyeva O, Dimairo M, Weir C, Jaki T, Mander A, Kightley A, Evans J, Lee S, Bedding A, Hopewell S, Rantell K, Liu R, Chan AW, De Bono J, Yap C.","BMJ Open. 2023 Mar 29;13(3):e068173. doi: 10.1136/bmjopen-2022-068173.","Espinasse A","BMJ Open","2023","2023/03/29","PMC10069529","","10.1136/bmjopen-2022-068173"
"39086673","Gene therapy and genome editing for type I glycogen storage diseases","Chou JY, Mansfield BC.","Front Mol Med. 2023 Mar 31;3:1167091. doi: 10.3389/fmmed.2023.1167091. eCollection 2023.","Chou JY","Front Mol Med","2023","2024/08/01","PMC11285695","","10.3389/fmmed.2023.1167091"
"35482076","Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial","Shen Y, Lu J, Hu F, Qian J, Zhang X, Zhong R, Zhong H, Chu T, Han B.","J Cancer Res Clin Oncol. 2023 Apr;149(4):1417-1424. doi: 10.1007/s00432-022-03964-9. Epub 2022 Apr 28.","Shen Y","J Cancer Res Clin Oncol","2023","2022/04/28","","","10.1007/s00432-022-03964-9"
"36115817","Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial","Aparicio T, Bouché O, Etienne PL, Barbier E, Mineur L, Desgrippes R, Guérin-Meyer V, Hocine F, Martin J, Le Brun-Ly V, Cretin J, Desramé J, Rinaldi Y, Cany L, Falandry C, Lefevre LB, Marous M, Terrebonne E, Mosser L, Turpin J, Turpin A, Bauguion L, Reichling C, Van den Eynde M, Carola E, Hiret S.","Dig Liver Dis. 2023 Apr;55(4):541-548. doi: 10.1016/j.dld.2022.08.036. Epub 2022 Sep 14.","Aparicio T","Dig Liver Dis","2023","2022/09/17","","","10.1016/j.dld.2022.08.036"
"36190656","Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models","Wu Q, Yu YX, Zhang T, Zhu WJ, Fan YF, Wang XM, Hu CH.","J Magn Reson Imaging. 2023 Apr;57(4):1185-1196. doi: 10.1002/jmri.28391. Epub 2022 Aug 17.","Wu Q","J Magn Reson Imaging","2023","2022/10/03","","","10.1002/jmri.28391"
"36525610","Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study","Li SH, Mei J, Cheng Y, Li Q, Wang QX, Fang CK, Lei QC, Huang HK, Cao MR, Luo R, Deng JD, Jiang YC, Zhao RC, Lu LH, Zou JW, Deng M, Lin WP, Guan RG, Wen YH, Li JB, Zheng L, Guo ZX, Ling YH, Chen HW, Zhong C, Wei W, Guo RP.","J Clin Oncol. 2023 Apr 1;41(10):1898-1908. doi: 10.1200/JCO.22.01142. Epub 2022 Dec 16.","Li SH","J Clin Oncol","2023","2022/12/16","PMC10082249","","10.1200/JCO.22.01142"
"36801448","Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism","Ferguson D, Eichler SJ, Yiew NKH, Colca JR, Cho K, Patti GJ, Shew TM, Lutkewitte AJ, Mukherjee S, McCommis KS, Niemi NM, Finck BN.","Mol Metab. 2023 Apr;70:101694. doi: 10.1016/j.molmet.2023.101694. Epub 2023 Feb 18.","Ferguson D","Mol Metab","2023","2023/02/21","PMC9989691","","10.1016/j.molmet.2023.101694"
"36801606","The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial","Bolhuis K, Bond MJG, Van Amerongen MJ, Komurcu A, Chapelle T, Dejong CHC, Engelbrecht MRW, Gerhards MF, Grünhagen DJ, van Gulik TM, Hermans JJ, De Jong KP, Kazemier G, Klaase JM, Kok NFM, Leclercq WKG, Liem MSL, van Lienden KP, Molenaar IQ, Neumann UP, Patijn GA, Rijken AM, Ruers TM, Verhoef C, de Wilt JHW, May AM, Punt CJA, Swijnenburg RJ; Dutch Colorectal Cancer Group Liver Expert Panel.","Eur J Cancer. 2023 Apr;183:49-59. doi: 10.1016/j.ejca.2023.01.013. Epub 2023 Jan 31.","Bolhuis K","Eur J Cancer","2023","2023/02/21","","","10.1016/j.ejca.2023.01.013"
"36804053","Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial","Merle P, Blanc JF, Edeline J, Le Malicot K, Allaire M, Assenat E, Guarssifi M, Bouattour M, Péron JM, Laurent-Puig P, Levrero M, Costentin C, Guiu B, Sokol H, Tougeron D, Aparicio T, Nault JC, Phelip JM.","Dig Liver Dis. 2023 Apr;55(4):464-470. doi: 10.1016/j.dld.2023.01.161. Epub 2023 Feb 16.","Merle P","Dig Liver Dis","2023","2023/02/21","","","10.1016/j.dld.2023.01.161"
"36863095","Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases","Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A.","ESMO Open. 2023 Apr;8(2):100884. doi: 10.1016/j.esmoop.2023.100884. Epub 2023 Feb 28.","Hecht JR","ESMO Open","2023","2023/03/02","PMC10163149","","10.1016/j.esmoop.2023.100884"
"36897180","Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial","Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD.","Obstet Gynecol. 2023 Apr 1;141(4):737-747. doi: 10.1097/AOG.0000000000005114. Epub 2023 Mar 9.","Neal-Perry G","Obstet Gynecol","2023","2023/03/10","PMC10026946","","10.1097/AOG.0000000000005114"
"36907947","A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer","Tsimafeyeu I, Statsenko G, Vladimirova L, Besova N, Artamonova E, Raskin G, Rykov I, Mochalova A, Utyashev I, Gorbacheva S, Kazey V, Gavrilova E, Dragun N, Moiseyenko V, Tjulandin S.","Invest New Drugs. 2023 Apr;41(2):324-332. doi: 10.1007/s10637-023-01340-z. Epub 2023 Mar 13.","Tsimafeyeu I","Invest New Drugs","2023","2023/03/13","","","10.1007/s10637-023-01340-z"
"37139154","TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial","Qi W, Peng W, Qi X, Qiu Z, Wen T, Li C.","Front Oncol. 2023 Apr 17;13:1138570. doi: 10.3389/fonc.2023.1138570. eCollection 2023.","Qi W","Front Oncol","2023","2023/05/04","PMC10149831","","10.3389/fonc.2023.1138570"
"36917859","Cu(2-x)Se nanoparticles suppress cell proliferation and migration in hepatocellular carcinoma by impairing mitochondrial respiration","Liu Y, Liu W, Li G, Lai W, Hu C, Zhang Q, Zhou M, Lu L, Huang J.","Biomed Mater. 2023 Apr 19;18(3). doi: 10.1088/1748-605X/acc43e.","Liu Y","Biomed Mater","2023","2023/03/14","","","10.1088/1748-605X/acc43e"
"37087404","[Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure]","Wang C, Li Y, Guan Y, Yang SJ, Yin JC, Zhang CF, Guo QS, Shi WN.","Zhonghua Yi Xue Za Zhi. 2023 Apr 25;103(16):1210-1216. doi: 10.3760/cma.j.cn112137-20221101-02275.","Wang C","Zhonghua Yi Xue Za Zhi","2023","2023/04/22","","","10.3760/cma.j.cn112137-20221101-02275"
"37173972","A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy","Lazzaro A, Hartshorn KL.","Cancers (Basel). 2023 Apr 27;15(9):2506. doi: 10.3390/cancers15092506.","Lazzaro A","Cancers (Basel)","2023","2023/05/13","PMC10177076","","10.3390/cancers15092506"
"36715850","Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program","Kakehasi AM, Radominski SC, Baravalle MD, Palazuelos FCI, Garcia-Garcia C, Arruda MS, Curi M, Liu J, Qiao M, Velez-Sanchez P, Vargas JI.","Clin Rheumatol. 2023 May;42(5):1249-1258. doi: 10.1007/s10067-023-06513-y. Epub 2023 Jan 30.","Kakehasi AM","Clin Rheumatol","2023","2023/01/30","PMC9886207","","10.1007/s10067-023-06513-y"
"36877215","Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study","Jiang H, Li H, Song G, Di L, Shao B, Yan Y, Liu X, Chen Y, Zhang R, Ran R, Liu Y, Gui X, Wang N, Wang H.","Breast Cancer Res Treat. 2023 May;199(1):67-79. doi: 10.1007/s10549-023-06894-3. Epub 2023 Mar 6.","Jiang H","Breast Cancer Res Treat","2023","2023/03/06","PMC9986665","","10.1007/s10549-023-06894-3"
"36892833","Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial","Fakih M, Sandhu J, Lim D, Li X, Li S, Wang C.","JAMA Oncol. 2023 May 1;9(5):627-634. doi: 10.1001/jamaoncol.2022.7845.","Fakih M","JAMA Oncol","2023","2023/03/09","PMC9999273","","10.1001/jamaoncol.2022.7845"
"36934202","Low dose of contrast agent and low radiation liver computed tomography with deep-learning-based contrast boosting model in participants at high-risk for hepatocellular carcinoma: prospective, randomized, double-blind study","Kang HJ, Lee JM, Ahn C, Bae JS, Han S, Kim SW, Yoon JH, Han JK.","Eur Radiol. 2023 May;33(5):3660-3670. doi: 10.1007/s00330-023-09520-4. Epub 2023 Mar 18.","Kang HJ","Eur Radiol","2023","2023/03/19","","","10.1007/s00330-023-09520-4"
"37060431","A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies","Chee CE, Ooi M, Lee SC, Sundar R, Heong V, Yong WP, Ng CH, Wong A, Lim JSJ, Tan DSP, Soo R, Tan JTC, Yang S, Thura M, Al-Aidaroos AQ, Chng WJ, Zeng Q, Goh BC.","Target Oncol. 2023 May;18(3):391-402. doi: 10.1007/s11523-023-00962-w. Epub 2023 Apr 15.","Chee CE","Target Oncol","2023","2023/04/15","PMC10192144","","10.1007/s11523-023-00962-w"
"37142371","Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; STAMPEDE investigators.","Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1.","Attard G","Lancet Oncol","2023","2023/05/04","","","10.1016/S1470-2045(23)00148-1"
"37215362","Clinical Benefits of Neoadjuvant Radiotherapy on the Postoperative Recurrence of Centrally Located Hepatocellular Carcinoma: A Real-World Evidence Based on Phase II Clinical Trial","Tao C, Wu F, Wang H, Wang L, Liu Y, Wu A, Zheng L, Wang Y, Chen B, Rong W, Wu J.","J Hepatocell Carcinoma. 2023 May 16;10:753-764. doi: 10.2147/JHC.S403287. eCollection 2023.","Tao C","J Hepatocell Carcinoma","2023","2023/05/22","PMC10199680","","10.2147/JHC.S403287"
"37226111","Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials","Huang D, Ke L, Cui H, Li S.","BMC Cancer. 2023 May 24;23(1):474. doi: 10.1186/s12885-023-10960-w.","Huang D","BMC Cancer","2023","2023/05/24","PMC10207853","","10.1186/s12885-023-10960-w"
"37375747","Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients","El-Tanani M, Ahmed KA, Shakya AK, Ammari WG, Al-Shudifat AE.","Pharmaceuticals (Basel). 2023 May 29;16(6):799. doi: 10.3390/ph16060799.","El-Tanani M","Pharmaceuticals (Basel)","2023","2023/06/28","PMC10300804","","10.3390/ph16060799"
"36511379","A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score","Fornarini G, Rebuzzi SE, Buti S, Rescigno P, Merseburger A, Sternberg CN, de Giorgi U, Basso U, Maruzzo M, Giannatempo P, Ponzano M, Giunta EF, Catalano F, Murianni V, Damassi A, Cremante M, Gandini A, Puglisi S, Llaja Obispo MA, Signori A, Banna GL.","Minerva Urol Nephrol. 2023 Jun;75(3):308-318. doi: 10.23736/S2724-6051.22.05135-7. Epub 2022 Dec 13.","Fornarini G","Minerva Urol Nephrol","2023","2022/12/13","","","10.23736/S2724-6051.22.05135-7"
"36576547","Low-contrast-dose liver CT using low monoenergetic images with deep learning-based denoising for assessing hepatocellular carcinoma: a randomized controlled noninferiority trial","Bae JS, Lee JM, Kim SW, Park S, Han S, Yoon JH, Joo I, Hong H.","Eur Radiol. 2023 Jun;33(6):4344-4354. doi: 10.1007/s00330-022-09298-x. Epub 2022 Dec 28.","Bae JS","Eur Radiol","2023","2022/12/28","","","10.1007/s00330-022-09298-x"
"36822922","Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial)","Sposito C, Pietrantonio F, Maspero M, Di Benedetto F, Vivarelli M, Tisone G, De Carlis L, Romagnoli R, Gruttadauria S, Colledan M, Agnes S, Ettorre G, Baccarani U, Torzilli G, Di Sandro S, Pinelli D, Caccamo L, Sartore Bianchi A, Spreafico C, Torri V, Mazzaferro V.","Clin Colorectal Cancer. 2023 Jun;22(2):250-255. doi: 10.1016/j.clcc.2023.01.003. Epub 2023 Feb 3.","Sposito C","Clin Colorectal Cancer","2023","2023/02/23","","","10.1016/j.clcc.2023.01.003"
"36877527","Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial","Qiu KY, Wang JY, Huang LB, Li CG, Xu LH, Liu RY, Chen HQ, Ruan YS, Zhen ZJ, Li CK, Fang JP.","Am J Hematol. 2023 Jun;98(6):869-880. doi: 10.1002/ajh.26910. Epub 2023 Mar 17.","Qiu KY","Am J Hematol","2023","2023/03/06","","","10.1002/ajh.26910"
"36921766","Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease","He K, Hong DS, Tang C, Sezen D, Cox L, Maleki A, Bertolet G, Nguyen QN, Comeaux NI, Schuda L, Chen D, Welsh JW.","Radiother Oncol. 2023 Jun;183:109618. doi: 10.1016/j.radonc.2023.109618. Epub 2023 Mar 13.","He K","Radiother Oncol","2023","2023/03/15","","","10.1016/j.radonc.2023.109618"
"36940407","Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)","Olofsson Bagge R, Nelson A, Shafazand A, All-Eriksson C, Cahlin C, Elander N, Helgadottir H, Kiilgaard JF, Kinhult S, Ljuslinder I, Mattsson J, Rizell M, Sternby Eilard M, Ullenhag GJ, Nilsson JA, Ny L, Lindnér P.","J Clin Oncol. 2023 Jun 1;41(16):3042-3050. doi: 10.1200/JCO.22.01705. Epub 2023 Mar 20.","Olofsson Bagge R","J Clin Oncol","2023","2023/03/20","PMC10414734","","10.1200/JCO.22.01705"
"37090117","Modeling cross-talk of RNA modification enzymes reveals tumor microenvironment-associated clinical significance and immunotherapy prediction in hepatobiliary malignancy","Qi F, Li J, Qi Z, Zhou B, Yang B, Zhang J, Qin W.","MedComm (2020). 2023 Apr 18;4(3):e256. doi: 10.1002/mco2.256. eCollection 2023 Jun.","Qi F","MedComm (2020)","2023","2023/04/24","PMC10113697","","10.1002/mco2.256"
"37188895","A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma","Okusaka T, Morimoto M, Eguchi Y, Nakamura S, Iino S, Kageyama R.","Drugs R D. 2023 Jun;23(2):99-107. doi: 10.1007/s40268-023-00416-8. Epub 2023 May 15.","Okusaka T","Drugs R D","2023","2023/05/15","PMC10293504","","10.1007/s40268-023-00416-8"
"37261531","Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study","Dicpinigaitis PV, Morice AH, Smith JA, Sher MR, Vaezi M, Guilleminault L, Niimi A, Gude K, Krahn U, Saarinen R, Pires PV, Wosnitza M, McGarvey L; PAGANINI Investigators.","Lung. 2023 Jun;201(3):255-266. doi: 10.1007/s00408-023-00621-x. Epub 2023 Jun 1.","Dicpinigaitis PV","Lung","2023","2023/06/01","PMC10234230","","10.1007/s00408-023-00621-x"
"37269841","Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J.","Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4.","Fizazi K","Lancet Oncol","2023","2023/06/03","PMC10641914","NIHMS1940683","10.1016/S1470-2045(23)00158-4"
"37075781","Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators.","Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.","Kelley RK","Lancet","2023","2023/04/19","","","10.1016/S0140-6736(23)00727-4"
"37426321","Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial","Chen YX, Yang P, Du SS, Zhuang Y, Huang C, Hu Y, Zhu WC, Yu YY, Liu TS, Zeng ZC.","World J Gastroenterol. 2023 Jun 28;29(24):3871-3882. doi: 10.3748/wjg.v29.i24.3871.","Chen YX","World J Gastroenterol","2023","2023/07/10","PMC10324536","","10.3748/wjg.v29.i24.3871"
"36697207","Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection","Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanaka Y, Janczewska E, Nahass RG, Bourgeois S, Buti M, Lampertico P, Lenz O, Verbinnen T, Vandenbossche J, Talloen W, Kalmeijer R, Beumont M, Biermer M, Shukla U.","Gut. 2023 Jul;72(7):1385-1398. doi: 10.1136/gutjnl-2022-328041. Epub 2023 Jan 25.","Janssen HLA","Gut","2023","2023/01/25","PMC10313999","","10.1136/gutjnl-2022-328041"
"36929310","Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial","Nakajima M, Hazama S, Tokumitsu Y, Shindo Y, Matsui H, Matsukuma S, Nakagami Y, Tamada K, Udaka K, Sakamoto M, Saito A, Kouki Y, Uematsu T, Xu M, Iida M, Tsunedomi R, Suzuki N, Takeda S, Ioka T, Doi S, Nagano H.","Hepatol Res. 2023 Jul;53(7):649-660. doi: 10.1111/hepr.13900. Epub 2023 Mar 30.","Nakajima M","Hepatol Res","2023","2023/03/17","","","10.1111/hepr.13900"
"37059159","Clinical Trial Landscape in NASH","Harrison SA, Loomba R, Dubourg J, Ratziu V, Noureddin M.","Clin Gastroenterol Hepatol. 2023 Jul;21(8):2001-2014. doi: 10.1016/j.cgh.2023.03.041. Epub 2023 Apr 12.","Harrison SA","Clin Gastroenterol Hepatol","2023","2023/04/14","","","10.1016/j.cgh.2023.03.041"
"37249821","Interpersonal Values of Patients Participating in Phase II-III Clinical Trials: Implications for Clinical Trial Representativeness","Gouveia R, Cruz VT, Antão J, Almeida L.","Pharmaceut Med. 2023 Jul;37(4):319-329. doi: 10.1007/s40290-023-00479-7. Epub 2023 May 30.","Gouveia R","Pharmaceut Med","2023","2023/05/30","","","10.1007/s40290-023-00479-7"
"37290468","Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial","Liu LT, Liu H, Huang Y, Yang JH, Xie SY, Li YY, Guo SS, Qi B, Li XY, Chen DP, Jin F, Sun XS, Yang ZC, Liu SL, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Qiu F, Yang Q, Liang YJ, Jia GD, Wen DX, Yan JJ, Zhao C, Chen QY, Sun R, Tang LQ, Mai HQ.","Lancet Oncol. 2023 Jul;24(7):798-810. doi: 10.1016/S1470-2045(23)00232-2. Epub 2023 Jun 5.","Liu LT","Lancet Oncol","2023","2023/06/08","","","10.1016/S1470-2045(23)00232-2"
"37329889","First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group","Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, Rijken AM, Verhoef C, de Wilt JHW, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MRW, van Lienden KP, Molenaar IQ, de Valk B, Haberkorn BCM, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, Komurcu A, Lopez-Yurda M, Swijnenburg RJ, Punt CJA; Dutch Colorectal Cancer Study Group.","Lancet Oncol. 2023 Jul;24(7):757-771. doi: 10.1016/S1470-2045(23)00219-X. Epub 2023 Jun 14.","Bond MJG","Lancet Oncol","2023","2023/06/17","","","10.1016/S1470-2045(23)00219-X"
"37402581","Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial","Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J.","J Immunother Cancer. 2023 Jul;11(7):e006871. doi: 10.1136/jitc-2023-006871.","Altan M","J Immunother Cancer","2023","2023/07/04","PMC10335483","","10.1136/jitc-2023-006871"
"37425214","Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022)","Sidali S, Sritharan N, Campani C, Gregory J, Durand F, Ganne-Carrié N, Ronot M, Lévy V, Nault JC.","JHEP Rep. 2023 Apr 7;5(7):100755. doi: 10.1016/j.jhepr.2023.100755. eCollection 2023 Jul.","Sidali S","JHEP Rep","2023","2023/07/10","PMC10326696","","10.1016/j.jhepr.2023.100755"
"37496225","[Ramucirumab Treatment for Unresectable Advanced Hepatocellular Carcinoma-A Review of Clinical Trial Data and Real-World Evidence in Japan]","Jin L, Tanizawa Y, Kuzuya T.","Gan To Kagaku Ryoho. 2023 Jul;50(7):799-807.","Jin L","Gan To Kagaku Ryoho","2023","2023/07/27","","",""
"37400832","Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes","Servetto A, Di Maio M, Salomone F, Napolitano F, Paratore C, Di Costanzo F, Viscardi G, Santaniello A, Formisano L, Bianco R.","BMC Med. 2023 Jul 3;21(1):234. doi: 10.1186/s12916-023-02953-0.","Servetto A","BMC Med","2023","2023/07/03","PMC10318754","","10.1186/s12916-023-02953-0"
"37516867","Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)","Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C.","BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0.","Vienot A","BMC Cancer","2023","2023/07/29","PMC10387199","","10.1186/s12885-023-11065-0"
"36651961","Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma","Lutzky J, Sullivan RJ, Cohen JV, Ren Y, Li A, Haq R.","J Cancer Res Clin Oncol. 2023 Aug;149(9):6059-6066. doi: 10.1007/s00432-022-04510-3. Epub 2023 Jan 18.","Lutzky J","J Cancer Res Clin Oncol","2023","2023/01/18","PMC10356892","","10.1007/s00432-022-04510-3"
"36656974","Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial","Sato M, Akamatsu M, Shima T, Ikegami T, Yanase M, Mikami S, Imamura J, Nakatsuka T, Tateishi R, Yamauchi N, Ushiku T, Okanoue T, Fujishiro M, Hida E, Koike K.","Am J Gastroenterol. 2023 Aug 1;118(8):1365-1372. doi: 10.14309/ajg.0000000000002143. Epub 2022 Dec 14.","Sato M","Am J Gastroenterol","2023","2023/01/19","PMC10392885","","10.14309/ajg.0000000000002143"
"37000264","Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)","Chekerov R, Arndt T, Pietzner K, Canzler U, Wimberger P, Strauß HG, Mahner S, Woelber L, de Gregorio N, Stocker G, von Abel E, Neunhoeffer T, Belau AK, Mustea A, Yalinkaya I, Braicu EI, Richter R, Sehouli J; NOGGO ovarian cancer study group.","J Cancer Res Clin Oncol. 2023 Aug;149(10):7637-7649. doi: 10.1007/s00432-023-04647-9. Epub 2023 Mar 31.","Chekerov R","J Cancer Res Clin Oncol","2023","2023/03/31","PMC10374680","","10.1007/s00432-023-04647-9"
"37165980","Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)","Sangro B, Yau T, El-Khoueiry AB, Kudo M, Shen Y, Tschaika M, Roy A, Feng Y, Gao L, Aras U.","Clin Transl Sci. 2023 Aug;16(8):1445-1457. doi: 10.1111/cts.13544. Epub 2023 May 30.","Sangro B","Clin Transl Sci","2023","2023/05/11","PMC10432868","","10.1111/cts.13544"
"37223896","A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma","Zhou C, Li Y, Li J, Song B, Li H, Liang B, Gu S, Li H, Chen C, Li S, Peng C, Liu F, Xiao J, Long X, Li P, Xiong Z, Yi X, Liao W, Shi L.","Clin Cancer Res. 2023 Aug 1;29(15):2816-2825. doi: 10.1158/1078-0432.CCR-23-0410.","Zhou C","Clin Cancer Res","2023","2023/05/24","","","10.1158/1078-0432.CCR-23-0410"
"37268553","Intra-operative High-Intensity Focused Ultrasound in Patients With Colorectal Liver Metastases: A Prospective Ablate-and-Resect Study","Dupré A, Rivoire M, Metzger S, Cropet C, Vincenot J, Peyrat P, Chen Y, Pérol D, Melodelima D.","Ultrasound Med Biol. 2023 Aug;49(8):1845-1851. doi: 10.1016/j.ultrasmedbio.2023.04.010. Epub 2023 May 31.","Dupré A","Ultrasound Med Biol","2023","2023/06/02","","","10.1016/j.ultrasmedbio.2023.04.010"
"37430016","Unresectable Intermediate-Size (3-5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial","van der Lei S, Dijkstra M, Nieuwenhuizen S, Schulz HH, Vos DJW, Versteeg KS, Buffart TE, Swijnenburg RJ, de Vries JJJ, Bruynzeel AME, van den Tol MP, Scheffer HJ, Puijk RS, Haasbeek CJA, Meijerink MR; and COLLISION Trial Group.","Cardiovasc Intervent Radiol. 2023 Aug;46(8):1076-1085. doi: 10.1007/s00270-023-03498-8. Epub 2023 Jul 10.","van der Lei S","Cardiovasc Intervent Radiol","2023","2023/07/10","PMC10382334","","10.1007/s00270-023-03498-8"
"37471053","Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma","Yamada T, Fujiwara N, Kubota N, Matsushita Y, Nakatsuka T, Kurosaki S, Minami T, Tateishi R, Ichida A, Arita J, Hasegawa K, Koike K, Fujishiro M, Nakagawa H.","Hepatol Commun. 2023 Jul 17;7(8):e0209. doi: 10.1097/HC9.0000000000000209. eCollection 2023 Aug 1.","Yamada T","Hepatol Commun","2023","2023/07/20","PMC10351952","","10.1097/HC9.0000000000000209"
"37577112","Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial","Shapiro AE, Sarkis E, Acloque J, Free A, Gonzalez-Rojas Y, Hussain R, Juarez E, Moya J, Parikh N, Inman D, Cebrik D, Nader A, Noormohamed N, Wang Q, Skingsley A, Austin D, Peppercorn A, Agostini ML, Parra S, Chow S, Mogalian E, Pang PS, Hong DK, Sager JE, Yeh WW, Alexander EL, Gaffney LA, Kohli A.","Open Forum Infect Dis. 2023 Jul 14;10(8):ofad354. doi: 10.1093/ofid/ofad354. eCollection 2023 Aug.","Shapiro AE","Open Forum Infect Dis","2023","2023/08/14","PMC10414803","","10.1093/ofid/ofad354"
"37789782","Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: a real-world assessment","Chen D, Chen X, Xu L, Wang Y, Zhu L, Kang M.","Neoplasma. 2023 Aug;70(4):580-587. doi: 10.4149/neo_2023_230413N206.","Chen D","Neoplasma","2023","2023/10/04","","","10.4149/neo_2023_230413N206"
"37265425","Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma","Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, Berz D, Andrianov V, Crago W, Holcomb M, Hussain A, Veldstra C, Kalabus J, O'Neill B, Senne L, Rowell E, Heidt AB, Willis KM, Eckelman BP.","Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. doi: 10.1158/1078-0432.CCR-23-0974.","Subbiah V","Clin Cancer Res","2023","2023/06/02","PMC10425732","","10.1158/1078-0432.CCR-23-0974"
"37664025","Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms","Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK.","Front Oncol. 2023 Aug 16;13:1223282. doi: 10.3389/fonc.2023.1223282. eCollection 2023.","Grünwald V","Front Oncol","2023","2023/09/04","PMC10471185","","10.3389/fonc.2023.1223282"
"37637501","Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial","Guo J, Bao X, Liu F, Guo J, Wu Y, Xiong F, Lu J.","J Hepatocell Carcinoma. 2023 Aug 21;10:1379-1388. doi: 10.2147/JHC.S416933. eCollection 2023.","Guo J","J Hepatocell Carcinoma","2023","2023/08/28","PMC10455792","","10.2147/JHC.S416933"
"36781824","Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects","Fishman P, Stemmer SM, Bareket-Samish A, Silverman MH, Kerns WD.","Purinergic Signal. 2023 Sep;19(3):513-522. doi: 10.1007/s11302-023-09925-2. Epub 2023 Feb 13.","Fishman P","Purinergic Signal","2023","2023/02/13","PMC10539266","","10.1007/s11302-023-09925-2"
"37037359","Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial)","Méndez Romero A, van der Holt B, Willemssen FEJA, de Man RA, Heijmen BJM, Habraken S, Westerveld H, van Delden OM, Klümpen HJ, Tjwa ETTL, Braam PM, Jenniskens SFM, Vanwolleghem T, Weytjens R, d'Archambeau O, de Vos-Geelen J, Buijsen J, van der Leij C, den Toom W, Sprengers D, IJzermans JNM, Moelker A.","Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):45-52. doi: 10.1016/j.ijrobp.2023.03.064. Epub 2023 Apr 8.","Méndez Romero A","Int J Radiat Oncol Biol Phys","2023","2023/04/10","","","10.1016/j.ijrobp.2023.03.064"
"37212707","Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework","Shemesh CS, Chan P, Marchand M, Gonçalves A, Vadhavkar S, Wu B, Li C, Jin JY, Hack SP, Bruno R.","Clin Pharmacol Ther. 2023 Sep;114(3):644-651. doi: 10.1002/cpt.2953. Epub 2023 Jun 2.","Shemesh CS","Clin Pharmacol Ther","2023","2023/05/22","","","10.1002/cpt.2953"
"37338553","Comparison of non-radiomics imaging features and radiomics models based on contrast-enhanced ultrasound and Gd-EOB-DTPA-enhanced MRI for predicting microvascular invasion in hepatocellular carcinoma within 5 cm","Zheng R, Zhang X, Liu B, Zhang Y, Shen H, Xie X, Li S, Huang G.","Eur Radiol. 2023 Sep;33(9):6462-6472. doi: 10.1007/s00330-023-09789-5. Epub 2023 Jun 20.","Zheng R","Eur Radiol","2023","2023/06/20","","","10.1007/s00330-023-09789-5"
"37364001","Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment","Roschewski M, Patel MR, Reagan PM, Saba NS, Collins GP, Arkenau HT, de Vos S, Nuttall B, Acar M, Burke K, White RD, Udriste M, Sharma S, Dougherty B, Stetson D, Jenkins D, Mortlock A, Forcina A, Munugalavadla V, Flinn I.","Clin Cancer Res. 2023 Sep 1;29(17):3301-3312. doi: 10.1158/1078-0432.CCR-22-2483.","Roschewski M","Clin Cancer Res","2023","2023/06/26","PMC10472096","","10.1158/1078-0432.CCR-22-2483"
"37471075","Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial","Katipally RR, Martinez CA, Pugh SA, Bridgewater JA, Primrose JN, Domingo E, Maughan TS, Talamonti MS, Posner MC, Weichselbaum RR, Pitroda SP; with the S:CORT Consortium.","JAMA Oncol. 2023 Sep 1;9(9):1245-1254. doi: 10.1001/jamaoncol.2023.2535.","Katipally RR","JAMA Oncol","2023","2023/07/20","PMC10360005","","10.1001/jamaoncol.2023.2535"
"37474271","Phase I Study of [(68)Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)","Gondry O, Xavier C, Raes L, Heemskerk J, Devoogdt N, Everaert H, Breckpot K, Lecocq Q, Decoster L, Fontaine C, Schallier D, Aspeslagh S, Vaneycken I, Raes G, Van Ginderachter JA, Lahoutte T, Caveliers V, Keyaerts M.","J Nucl Med. 2023 Sep;64(9):1378-1384. doi: 10.2967/jnumed.122.264853. Epub 2023 Jul 20.","Gondry O","J Nucl Med","2023","2023/07/20","PMC10478821","","10.2967/jnumed.122.264853"
"37494583","Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study","Kang M, Xue F, Xu S, Shi J, Mo Y.","Radiol Oncol. 2023 Jul 26;57(3):405-410. doi: 10.2478/raon-2023-0036. eCollection 2023 Sep 1.","Kang M","Radiol Oncol","2023","2023/07/26","PMC10476909","","10.2478/raon-2023-0036"
"37506588","Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers","Borcoman E, Lalanne A, Delord JP, Cassier PA, Rolland F, Salas S, Limacher JM, Capitain O, Lantz O, Ekwegbara C, Jeannot E, Cyrta J, Tran-Perennou C, Castel-Ajgal Z, Marret G, Piaggio E, Brandely M, Tavernaro A, Makhloufi H, Bendjama K, Le Tourneau C.","Eur J Cancer. 2023 Sep;191:112981. doi: 10.1016/j.ejca.2023.112981. Epub 2023 Jul 11.","Borcoman E","Eur J Cancer","2023","2023/07/28","","","10.1016/j.ejca.2023.112981"
"37585218","Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review","Duarte Lau F, Giugliano RP.","JAMA Cardiol. 2023 Sep 1;8(9):879-887. doi: 10.1001/jamacardio.2023.2402.","Duarte Lau F","JAMA Cardiol","2023","2023/08/16","","","10.1001/jamacardio.2023.2402"
"37680942","RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","Fu Q, Zheng Y, Fang W, Zhao Q, Zhao P, Liu L, Zhai Y, Tong Z, Zhang H, Lin M, Zhu X, Wang H, Wang Y, Liu Z, Yuan D, Bao X, Gao W, Dai X, Li Z, Liang T.","EClinicalMedicine. 2023 Aug 30;63:102175. doi: 10.1016/j.eclinm.2023.102175. eCollection 2023 Sep.","Fu Q","EClinicalMedicine","2023","2023/09/08","PMC10480529","","10.1016/j.eclinm.2023.102175"
"37709297","Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)","Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Kawabata H, Yasojima H, Tomioka N, Yoshimura K, Takano T.","J Immunother Cancer. 2023 Sep;11(9):e007126. doi: 10.1136/jitc-2023-007126.","Masuda J","J Immunother Cancer","2023","2023/09/14","PMC10503337","","10.1136/jitc-2023-007126"
"37730273","Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S.","J Immunother Cancer. 2023 Sep;11(9):e007366. doi: 10.1136/jitc-2023-007366.","Zhang W","J Immunother Cancer","2023","2023/09/20","PMC10514649","","10.1136/jitc-2023-007366"
"37771776","Phase I clinical evaluation of (99m)Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer","Bragina O, Chernov V, Larkina M, Rybina A, Zelchan R, Garbukov E, Oroujeni M, Loftenius A, Orlova A, Sörensen J, Frejd FY, Tolmachev V.","Theranostics. 2023 Sep 4;13(14):4858-4871. doi: 10.7150/thno.86770. eCollection 2023.","Bragina O","Theranostics","2023","2023/09/29","PMC10526658","","10.7150/thno.86770"
"37650206","[The application value of Gd-EOB-DTPA enhanced MRI based radiomics in the differential diagnosis of iso-or hyperintensity HCC and focal nodular hyperplasia in hepatobiliary phase]","Mao HY, Yu YX, Zhang JY, Zhang T, Fan YF, Hu S, Wang XM, Hu CH.","Zhonghua Yi Xue Za Zhi. 2023 Sep 5;103(33):2599-2606. doi: 10.3760/cma.j.cn112137-20230117-00095.","Mao HY","Zhonghua Yi Xue Za Zhi","2023","2023/08/31","","","10.3760/cma.j.cn112137-20230117-00095"
"37704828","The potential immuno-stimulating effect of curcumin, piperine, and taurine combination in hepatocellular carcinoma; a pilot study","Kotb RR, Afifi AM, El-Houseini ME, Ezz-Elarab M, Basalious EB, Omran MM, Abdellateif MS.","Discov Oncol. 2023 Sep 13;14(1):169. doi: 10.1007/s12672-023-00785-1.","Kotb RR","Discov Oncol","2023","2023/09/13","PMC10499730","","10.1007/s12672-023-00785-1"
"37712875","A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors","Hanna GJ, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodon J, Ahn MJ, Kim HR, Schneeweiss A, Ribera JM, DeAngelo D, Perez Garcia JM, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl FD, Garralda E.","Cancer Res Commun. 2023 Sep 14;3(9):1853-1861. doi: 10.1158/2767-9764.CRC-23-0333.","Hanna GJ","Cancer Res Commun","2023","2023/09/15","PMC10501326","","10.1158/2767-9764.CRC-23-0333"
"37459133","A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma","Lee YB, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim HC, Paeng JC, Yoon JH, Kim YJ.","Clin Cancer Res. 2023 Sep 15;29(18):3650-3658. doi: 10.1158/1078-0432.CCR-23-0581.","Lee YB","Clin Cancer Res","2023","2023/07/17","","","10.1158/1078-0432.CCR-23-0581"
"37715133","Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)","Xie L, Liang X, Xu J, Sun X, Liu K, Sun K, Li Y, Tang X, Li X, Zhan X, Niu X, Guo W.","BMC Cancer. 2023 Sep 15;23(1):868. doi: 10.1186/s12885-023-11390-4.","Xie L","BMC Cancer","2023","2023/09/15","PMC10503089","","10.1186/s12885-023-11390-4"
"37594310","OTTM: an automated classification tool for translational drug discovery from omics data","Yang X, Zhang B, Wang S, Lu Y, Chen K, Luo C, Sun A, Zhang H.","Brief Bioinform. 2023 Sep 20;24(5):bbad301. doi: 10.1093/bib/bbad301.","Yang X","Brief Bioinform","2023","2023/08/18","PMC10516341","","10.1093/bib/bbad301"
"37741832","Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer","Taraborrelli L, Şenbabaoğlu Y, Wang L, Lim J, Blake K, Kljavin N, Gierke S, Scherl A, Ziai J, McNamara E, Owyong M, Rao S, Calviello AK, Oreper D, Jhunjhunwala S, Argiles G, Bendell J, Kim TW, Ciardiello F, Wongchenko MJ, de Sauvage FJ, de Sousa E Melo F, Yan Y, West NR, Murthy A.","Nat Commun. 2023 Sep 23;14(1):5945. doi: 10.1038/s41467-023-41618-7.","Taraborrelli L","Nat Commun","2023","2023/09/23","PMC10517947","","10.1038/s41467-023-41618-7"
"37518005","Preoperative Chemotherapy Followed by Hepatectomy for Potentially Resectable UICC7 Stage IIIA, IIIB Hepatocellular Carcinoma; A Phase II Clinical Trial","Goto Y, Niizeki T, Fukutomi S, Shirono T, Shimose S, Iwamoto H, Kojima S, Kanno H, Uchino Y, Sasaki S, Shirahama N, Muroya D, Nomura Y, Akashi M, Nakayama G, Hirakawa Y, Sato T, Yoshitomi M, Sakai H, Hisaka T, Kakuma T, Koga H, Torimura T, Akagi Y, Okuda K.","Kurume Med J. 2023 Sep 25;68(3.4):239-245. doi: 10.2739/kurumemedj.MS6834010. Epub 2023 Jul 28.","Goto Y","Kurume Med J","2023","2023/07/30","","","10.2739/kurumemedj.MS6834010"
"37752423","Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial","Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S.","BMC Cancer. 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2.","Corti F","BMC Cancer","2023","2023/09/26","PMC10523723","","10.1186/s12885-023-11287-2"
"37770273","Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol","Huang JT, Zhong JH, Zhang J, Gong WF, Ma L, Li LQ, Xiang BD.","BMJ Open. 2023 Sep 28;13(9):e067730. doi: 10.1136/bmjopen-2022-067730.","Huang JT","BMJ Open","2023","2023/09/28","PMC10546157","","10.1136/bmjopen-2022-067730"
"37499670","Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group.","Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24.","Qin S","Lancet","2023","2023/07/27","","","10.1016/S0140-6736(23)00961-3"
"37257661","Single-Masked Randomized Phase 2 Study Assessing 2 Forms of Hypofractionated Proton Therapy in Patients With Large Choroidal Melanomas","Thariat J, Mathis T, Pace-Loscos T, Peyrichon ML, Maschi C, Rosier L, Nguyen M, Bonnin N, Aloi D, Gastaud L, Gaucher D, Caujolle JP, Château Y, Herault J.","Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):357-369. doi: 10.1016/j.ijrobp.2023.04.028. Epub 2023 May 29.","Thariat J","Int J Radiat Oncol Biol Phys","2023","2023/05/31","","","10.1016/j.ijrobp.2023.04.028"
"37265026","Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report","Wu L, Cheng Y, Huang D, Sun Y, Zhou C, Zhou J, Guo Y, Shao J, Zhang W, Lu S.","Anticancer Drugs. 2023 Oct 1;34(9):1058-1064. doi: 10.1097/CAD.0000000000001527. Epub 2023 Jun 2.","Wu L","Anticancer Drugs","2023","2023/06/02","PMC10501349","","10.1097/CAD.0000000000001527"
"37382662","Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside","Li L, Lin X, Wang L, Ma X, Zeng Z, Liu F, Jia B, Zhu H, Wu A, Yang Z.","Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3735-3749. doi: 10.1007/s00259-023-06313-1. Epub 2023 Jun 29.","Li L","Eur J Nucl Med Mol Imaging","2023","2023/06/29","","","10.1007/s00259-023-06313-1"
"37493665","Application of an artificial intelligence-based tool in [(18)F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma","Sachpekidis C, Enqvist O, Ulén J, Kopp-Schneider A, Pan L, Jauch A, Hajiyianni M, John L, Weinhold N, Sauer S, Goldschmidt H, Edenbrandt L, Dimitrakopoulou-Strauss A.","Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3697-3708. doi: 10.1007/s00259-023-06339-5. Epub 2023 Jul 26.","Sachpekidis C","Eur J Nucl Med Mol Imaging","2023","2023/07/26","PMC10547616","","10.1007/s00259-023-06339-5"
"37605479","Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer","Mitsunaga S, Ikeda M, Imaoka H, Sasaki M, Watanabe K, Sato A, Aoki K, Ochiai A, Makikawa M, Nishidate M, Yamaguchi K, Terao K, Sawada N, Fujitomo T, Fujii E, Kato A, Tsunoda H.","Cancer Sci. 2023 Oct;114(10):4006-4019. doi: 10.1111/cas.15929. Epub 2023 Aug 21.","Mitsunaga S","Cancer Sci","2023","2023/08/22","PMC10551603","","10.1111/cas.15929"
"37772548","Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy","Yamamura K, Beppu T, Miyata T, Mima K, Okabe H, Nitta H, Imai K, Hayashi H, Oda E, Karashima R, Ozaki N, Isiko T.","Anticancer Res. 2023 Oct;43(10):4285-4293. doi: 10.21873/anticanres.16623.","Yamamura K","Anticancer Res","2023","2023/09/29","","","10.21873/anticanres.16623"
"37793772","Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial","Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P.","Lancet Haematol. 2023 Oct;10(10):e813-e824. doi: 10.1016/S2352-3026(23)00218-1.","Dimopoulos MA","Lancet Haematol","2023","2023/10/04","","","10.1016/S2352-3026(23)00218-1"
"37797632","Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial","Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, Liu D, Lou H, Bai L, Liu T, Li Y, Li Y, Fan Q, Feng M, Zhong H, Huang Y, Lou G, Wang J, Lin X, Chen Y, An R, Li C, Zhou Q, Huang X, Guo Z, Wang S, Li G, Fei J, Zhu L, Zhu H, Li X, Li F, Liao S, Min Q, Tang L, Shan F, Gong J, Gao Y, Zhou J, Lu Z, Li X, Li J, Ren H, Liu X, Yang H, Li W, Song W, Wang ZM, Li B, Xia M, Wu X, Ji J.","Lancet Oncol. 2023 Oct;24(10):1134-1146. doi: 10.1016/S1470-2045(23)00411-4.","Gao X","Lancet Oncol","2023","2023/10/05","","","10.1016/S1470-2045(23)00411-4"
"37901764","Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials","Tan DJH, Tang ASP, Lim WH, Ng CH, Nah B, Fu C, Xiao J, Koh B, Tay PWL, Tan EX, Teng M, Syn N, Muthiah MD, Tamaki N, Lee SW, Kim BK, Yau T, Vogel A, Loomba R, Huang DQ.","Liver Cancer. 2023 Mar 28;12(5):445-456. doi: 10.1159/000529824. eCollection 2023 Oct.","Tan DJH","Liver Cancer","2023","2023/10/30","PMC10601853","","10.1159/000529824"
"37471457","A Phase II Study of Optimized Individualized Adaptive Radiotherapy for Hepatocellular Carcinoma","Herr DJ, Wang C, Mendiratta-Lala M, Matuszak M, Mayo CS, Cao Y, Parikh ND, Ten Haken R, Owen D, Evans JR, Stanescu T, Yan M, Dawson LA, Schipper M, Lawrence TS, Cuneo KC.","Clin Cancer Res. 2023 Oct 2;29(19):3852-3858. doi: 10.1158/1078-0432.CCR-23-1044.","Herr DJ","Clin Cancer Res","2023","2023/07/20","PMC10592290","NIHMS1920858","10.1158/1078-0432.CCR-23-1044"
"37708904","NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O'Reilly EM.","Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11.","Wainberg ZA","Lancet","2023","2023/09/14","","","10.1016/S0140-6736(23)01366-1"
"37860278","Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody","Bähr-Mahmud H, Ellinghaus U, Stadler CR, Fischer L, Lindemann C, Chaturvedi A, Diekmann J, Wöll S, Biermann I, Hebich B, Scharf C, Siefke M, Roth AS, Rao M, Brettschneider K, Ewen EM, Şahin U, Türeci Ö.","Oncoimmunology. 2023 Oct 16;12(1):2255041. doi: 10.1080/2162402X.2023.2255041. eCollection 2023.","Bähr-Mahmud H","Oncoimmunology","2023","2023/10/20","PMC10583639","","10.1080/2162402X.2023.2255041"
"37869360","Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study","Kuter DJ, Bussel JB, Ghanima W, Cooper N, Gernsheimer T, Lambert MP, Liebman HA, Tarantino MD, Lee M, Guo H, Daak A.","Ther Adv Hematol. 2023 Oct 18;14:20406207231205431. doi: 10.1177/20406207231205431. eCollection 2023.","Kuter DJ","Ther Adv Hematol","2023","2023/10/23","PMC10585997","","10.1177/20406207231205431"
"37858212","Renal protection CT protocol using low-dose and low-concentration iodine contrast medium in at-risk patients of HCC and with chronic kidney disease: a randomized controlled non-inferiority trial","Yoon JH, Park JY, Lee SM, Lee ES, Kim JH, Lee JM.","Cancer Imaging. 2023 Oct 19;23(1):100. doi: 10.1186/s40644-023-00616-0.","Yoon JH","Cancer Imaging","2023","2023/10/20","PMC10588122","","10.1186/s40644-023-00616-0"
"37858184","Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study","Hsu C, Chang YF, Yen CJ, Xu YW, Dong M, Tong YZ.","BMC Med. 2023 Oct 20;21(1):395. doi: 10.1186/s12916-023-03098-w.","Hsu C","BMC Med","2023","2023/10/20","PMC10588186","","10.1186/s12916-023-03098-w"
"37961215","Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysis","Wang L, Oill AT, Blanchard M, Wu M, Hibbard J, Sepulveda S, Peter L, Kilpatrick J, Munoz M, Stiller T, Shulkin N, Wagner J, Dolatabadi A, Nisis M, Shepphird J, Sanchez G, Lingaraju C, Manchanda M, Natri H, Kouakanou L, Sun G, Oliver-Cervantes C, Georges J, Aftabizadeh M, Forman S, Priceman S, Ressler J, Arvanitis L, Cotter J, D'Apuzzo M, Tamrazi B, Badie B, Davidson T, Banovich N, Brown C.","Res Sq [Preprint]. 2023 Oct 23:rs.3.rs-3454977. doi: 10.21203/rs.3.rs-3454977/v1.","Wang L","Res Sq","2023","2023/11/14","PMC10635314","","10.21203/rs.3.rs-3454977/v1"
"37942328","The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial","Qiao Q, Han C, Ye S, Li J, Shao G, Bai Y, Xu A, Sun M, Wang W, Wu J, Huang M, Song L, Huang L, Liu T, Liu W, Wang ZM, Li B, Xia M, Bai L.","Front Immunol. 2023 Oct 24;14:1238667. doi: 10.3389/fimmu.2023.1238667. eCollection 2023.","Qiao Q","Front Immunol","2023","2023/11/09","PMC10627805","","10.3389/fimmu.2023.1238667"
"37884523","Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","Zhang TQ, Geng ZJ, Zuo MX, Li JB, Huang JH, Huang ZL, Wu PH, Gu YK.","Signal Transduct Target Ther. 2023 Oct 27;8(1):413. doi: 10.1038/s41392-023-01663-6.","Zhang TQ","Signal Transduct Target Ther","2023","2023/10/26","PMC10603153","","10.1038/s41392-023-01663-6"
"37437885","Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial","Al-Hendy A, Zhou YF, Faustmann T, Groettrup-Wolfers E, Laapas K, Parke S, Seitz C.","F S Sci. 2023 Nov;4(4):317-326. doi: 10.1016/j.xfss.2023.06.003. Epub 2023 Jul 10.","Al-Hendy A","F S Sci","2023","2023/07/12","","","10.1016/j.xfss.2023.06.003"
"37524230","First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection","Gane EJ, Kim W, Lim TH, Tangkijvanich P, Yoon JH, Sievert W, Sukeepaisarnjaroen W, Thompson AJ, Pavlovic V, Surujbally B, Wat C, Brown BD, Achneck HE, Yuen MF.","J Hepatol. 2023 Nov;79(5):1139-1149. doi: 10.1016/j.jhep.2023.07.026. Epub 2023 Jul 29.","Gane EJ","J Hepatol","2023","2023/07/31","","","10.1016/j.jhep.2023.07.026"
"37632518","Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors","Choi W, Lee Y, Choi BK, Park BM, Kim YH, Yun T, Lee WJ, Yoo H, Baek JY, Woo SM, Lim MC, Kwon BS.","Cytotherapy. 2023 Nov;25(11):1236-1241. doi: 10.1016/j.jcyt.2023.07.006. Epub 2023 Aug 25.","Choi W","Cytotherapy","2023","2023/08/26","","","10.1016/j.jcyt.2023.07.006"
"37783154","Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ","Zhang M, Barroso E, Ruart M, Peña L, Peyman M, Aguilar-Recarte D, Montori-Grau M, Rada P, Cugat C, Montironi C, Zarei M, Jurado-Aguilar J, Camins A, Balsinde J, Valverde ÁM, Wahli W, Palomer X, Vázquez-Carrera M.","Biomed Pharmacother. 2023 Nov;167:115623. doi: 10.1016/j.biopha.2023.115623. Epub 2023 Sep 30.","Zhang M","Biomed Pharmacother","2023","2023/10/02","","","10.1016/j.biopha.2023.115623"
"37787790","Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis","Chao J, Wang S, Wang H, Zhang N, Wang Y, Yang X, Zhu C, Ning C, Zhang X, Xue J, Zhang L, Piao M, Wang M, Yang X, Lu L, Zhao H.","Cancer Immunol Immunother. 2023 Nov;72(11):3717-3726. doi: 10.1007/s00262-023-03523-2. Epub 2023 Oct 3.","Chao J","Cancer Immunol Immunother","2023","2023/10/03","PMC10991235","","10.1007/s00262-023-03523-2"
"37812518","A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer","Laccetti AL, Bodei L, O'Donoghue JA, Weber WA, Morris MJ.","Clin Nucl Med. 2023 Nov 1;48(11):937-944. doi: 10.1097/RLU.0000000000004818.","Laccetti AL","Clin Nucl Med","2023","2023/10/09","","","10.1097/RLU.0000000000004818"
"37832198","Microvascular invasion-negative hepatocellular carcinoma: Prognostic value of qualitative and quantitative Gd-EOB-DTPA MRI analysis","Wang L, Liang M, Feng B, Li D, Cong R, Chen Z, Wang S, Ma X, Zhao X.","Eur J Radiol. 2023 Nov;168:111146. doi: 10.1016/j.ejrad.2023.111146. Epub 2023 Oct 6.","Wang L","Eur J Radiol","2023","2023/10/13","","","10.1016/j.ejrad.2023.111146"
"37975371","Clinical efficacy and safety of adjuvant immunotherapy (Tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study","Shi JW, Zhou Y, Wu S.","Eur Rev Med Pharmacol Sci. 2023 Nov;27(21):10472-10480. doi: 10.26355/eurrev_202311_34324.","Shi JW","Eur Rev Med Pharmacol Sci","2023","2023/11/17","","","10.26355/eurrev_202311_34324"
"38039047","Comparing the clinical efficacy and safety of second-line targeted therapy and immunotherapy in patients with mid- to advanced stages of hepatocellular carcinoma - A systematic review and meta-analysis of randomized clinical trials","Li JF, Fu YX, Zhang HC, Ma H, Yuan GJ, Tan Y.","Eur Rev Med Pharmacol Sci. 2023 Nov;27(22):11156-11168. doi: 10.26355/eurrev_202311_34485.","Li JF","Eur Rev Med Pharmacol Sci","2023","2023/12/01","","","10.26355/eurrev_202311_34485"
"38320074","Tremelimumab (Imjudo) in Combination With Durvalumab (Imfinzi): CADTH Reimbursement Recommendation: Indication: For the first-line treatment of adult patients with unresectable hepatocellular carcinoma who require systemic therapy","","Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov. Report No.: PC0308.","","Tremelimumab (Imjudo) in Combination With Durvalumab (Imfinzi): CADTH Reimbursement Recommendation: Indication: For the first-line treatment of adult patients with unresectable hepatocellular carcinoma who require systemic therapy","2023","2023/11/01","","",""
"37963740","[Effect of recombinant human thrombin for hemostasis in liver resection: a randomized controlled phase Ⅲ clinical trial]","Yan S, Tu CY, Du CY, Luo J, Liu JF, Liu TQ, Liu Q, Liu J, Li XH, Wang LC, Fang ZP, Yi WM, Chen YJ, Li QL, Ni Y, Wu JC, Qin CJ, Gu YL, Lu Z, Lun ZJ, Du LX, Chen G, Zheng QC, Sun KJ, Han WQ, Yu J.","Zhonghua Yi Xue Za Zhi. 2023 Nov 14;103(42):3416-3423. doi: 10.3760/cma.j.cn112137-20230911-00438.","Yan S","Zhonghua Yi Xue Za Zhi","2023","2023/11/14","","","10.3760/cma.j.cn112137-20230911-00438"
"37871608","Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators.","Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20.","Qin S","Lancet","2023","2023/10/23","","","10.1016/S0140-6736(23)01796-8"
"38030258","Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol","Hull MA, Ow PL, Ruddock S, Brend T, Smith AF, Marshall H, Song M, Chan AT, Garrett WS, Yilmaz O, Drew DA, Collinson F, Cockbain AJ, Jones R, Loadman PM, Hall PS, Moriarty C, Cairns DA, Toogood GJ.","BMJ Open. 2023 Nov 29;13(11):e077427. doi: 10.1136/bmjopen-2023-077427.","Hull MA","BMJ Open","2023","2023/11/29","PMC10689403","","10.1136/bmjopen-2023-077427"
"37604269","Combined inhibition of surface CD51 and γ-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma","Cai J, Wang J, Jiang C, Ye L, He X, Huang J, Sun X, Ren Z, Lai X, Qiu Y, Wang H, Lv G, Zheng J, Lu T, Chen H, Liu Y, Chen H, Guan Y, Wang Y, Wang T, Yao J, Sui X, Kang Y, Zhang Y, Li H, Wang J, Li W, Chen G, Yang Y, Xiang AP.","J Hepatol. 2023 Dec;79(6):1418-1434. doi: 10.1016/j.jhep.2023.08.007. Epub 2023 Aug 19.","Cai J","J Hepatol","2023","2023/08/21","","","10.1016/j.jhep.2023.08.007"
"37671641","Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)","Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B.","Future Oncol. 2023 Dec;19(38):2505-2516. doi: 10.2217/fon-2023-0486. Epub 2023 Sep 6.","Abou-Alfa GK","Future Oncol","2023","2023/09/06","","","10.2217/fon-2023-0486"
"37747668","Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study","Zheng C, Gu XT, Huang XL, Wei YC, Chen L, Luo NB, Lin HS, Jin-Yuan L.","Radiol Med. 2023 Dec;128(12):1460-1471. doi: 10.1007/s11547-023-01726-2. Epub 2023 Sep 25.","Zheng C","Radiol Med","2023","2023/09/25","PMC10700214","","10.1007/s11547-023-01726-2"
"37796513","Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial","Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, Satoh T, Marino D, Assenat E, Li S, Chen Y, Boisserie F, Abdrashitov R, Finn RS, Vogel A, Zhu AX.","JAMA Oncol. 2023 Dec 1;9(12):1651-1659. doi: 10.1001/jamaoncol.2023.4003.","Qin S","JAMA Oncol","2023","2023/10/05","PMC10557031","","10.1001/jamaoncol.2023.4003"
"37853185","GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy","Lu LL, Xiao SX, Lin ZY, Bai JJ, Li W, Song ZQ, Zhou YH, Lu B, Wu WZ.","Cell Biol Toxicol. 2023 Dec;39(6):3101-3119. doi: 10.1007/s10565-023-09821-w. Epub 2023 Oct 19.","Lu LL","Cell Biol Toxicol","2023","2023/10/18","","","10.1007/s10565-023-09821-w"
"37863080","Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial","Kowdley KV, Modi NB, Peltekian K, Vierling JM, Ferris C, Valone FH, Gupta S.","Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1118-1128. doi: 10.1016/S2468-1253(23)00250-9. Epub 2023 Oct 17.","Kowdley KV","Lancet Gastroenterol Hepatol","2023","2023/10/20","","","10.1016/S2468-1253(23)00250-9"
"37917289","Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development","Wojciechowski J, S Purohit V, Huh Y, Banfield C, Nicholas T.","Clin Pharmacokinet. 2023 Dec;62(12):1765-1779. doi: 10.1007/s40262-023-01318-3. Epub 2023 Nov 2.","Wojciechowski J","Clin Pharmacokinet","2023","2023/11/02","PMC10684409","","10.1007/s40262-023-01318-3"
"37922632","Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial","Malka D, Verret B, Faron M, Guimbaud R, Caramella C, Edeline J, Galais MP, Bengrine-Lefevre L, Smith D, Dupont-Bierre E, De Baere T, Goéré D, Dartigues P, Lacroix L, Boige V, Gelli M, Pignon JP, Ducreux M.","Eur J Cancer. 2023 Dec;195:113400. doi: 10.1016/j.ejca.2023.113400. Epub 2023 Oct 28.","Malka D","Eur J Cancer","2023","2023/11/03","","","10.1016/j.ejca.2023.113400"
"37968194","Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial","Huang WK, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN.","Eur J Cancer. 2023 Dec;195:113286. doi: 10.1016/j.ejca.2023.113286. Epub 2023 Nov 13.","Huang WK","Eur J Cancer","2023","2023/11/15","","","10.1016/j.ejca.2023.113286"
"38039993","Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators.","Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2.","Llovet JM","Lancet Oncol","2023","2023/12/01","","","10.1016/S1470-2045(23)00469-2"
"38247334","Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial","Liu D, Mu H, Liu C, Zhang W, Cui Y, Wu Q, Zhu X, Fang F, Zhang W, Xing W, Li Q, Song T, Lu W, Li H.","Neoplasma. 2023 Dec;70(6):811-818. doi: 10.4149/neo_2023_230806N413.","Liu D","Neoplasma","2023","2024/01/22","","","10.4149/neo_2023_230806N413"
"38415359","Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023","Boustani J, Huguet F, Vendrely V.","Cancer Radiother. 2023 Dec;27(8):768-777. doi: 10.1016/j.canrad.2023.08.001. Epub 2023 Oct 26.","Boustani J","Cancer Radiother","2023","2024/02/28","","","10.1016/j.canrad.2023.08.001"
"38042834","The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial","Peng W, Yi M, Qi X, Qi W, Li C, Wen T.","Trials. 2023 Dec 2;24(1):781. doi: 10.1186/s13063-023-07822-y.","Peng W","Trials","2023","2023/12/02","PMC10693690","","10.1186/s13063-023-07822-y"
"37329569","Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study","Zhang CS, Zeng ZM, Zhuo MY, Luo JR, Zhuang XH, Xu JN, Zeng J, Ma J, Lin HF.","Oncologist. 2023 Dec 11;28(12):e1239-e1247. doi: 10.1093/oncolo/oyad169.","Zhang CS","Oncologist","2023","2023/06/17","PMC10712726","","10.1093/oncolo/oyad169"
"37819944","Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)","He M, Huang Y, Du Z, Lai Z, Ouyang H, Shen J, Wen D, Li Q, Zhang Y, Wei W, Chen M, Xu L, Kan A, Shi M.","Clin Cancer Res. 2023 Dec 15;29(24):5104-5115. doi: 10.1158/1078-0432.CCR-23-0060.","He M","Clin Cancer Res","2023","2023/10/11","","","10.1158/1078-0432.CCR-23-0060"
"38114893","Bicarbonate ringer's solution could improve the intraoperative acid-base equilibrium and reduce hepatocellular enzyme levels after deceased donor liver transplantation: a randomized controlled study","Li Q, Liu Y, Wang Y, Shan X, Liu C, Li Z, Cao J, Dou J, Xu G, Wang Q, Qie X.","BMC Anesthesiol. 2023 Dec 19;23(1):418. doi: 10.1186/s12871-023-02383-8.","Li Q","BMC Anesthesiol","2023","2023/12/20","PMC10729548","","10.1186/s12871-023-02383-8"
"38115002","Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?","Potter GE, Callier V, Shrestha B, Joshi S, Dwivedi A, Silva JC, Laurens MB, Follmann DA, Deye GA.","Malar J. 2023 Dec 19;22(1):383. doi: 10.1186/s12936-023-04802-0.","Potter GE","Malar J","2023","2023/12/20","PMC10729369","","10.1186/s12936-023-04802-0"
"38196590","Alliance for Clinical Trials in Oncology (Alliance) trial A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur)","Hitchcock KE, Miller ED, Shi Q, Dixon JG, Gholami S, White SB, Wu C, Goulet CC, George M, Jee KW, Wright CL, Yaeger R, Shergill A, Hong TS, George TJ, O'Reilly EM, Meyerhardt JA, Romesser PB.","Res Sq [Preprint]. 2023 Dec 23:rs.3.rs-3773522. doi: 10.21203/rs.3.rs-3773522/v1.","Hitchcock KE","Res Sq","2023","2024/01/10","PMC10775493","","10.21203/rs.3.rs-3773522/v1"
"38203603","Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results","Qin A, Wu CR, Ho MC, Tsai CY, Chen PJ.","Int J Mol Sci. 2023 Dec 28;25(1):433. doi: 10.3390/ijms25010433.","Qin A","Int J Mol Sci","2023","2024/01/11","PMC10778875","","10.3390/ijms25010433"
"37734683","PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B","Chun HS, Papatheodoridis GV, Lee M, Lee HA, Kim YH, Kim SH, Oh YS, Park SJ, Kim J, Lee HA, Kim HY, Kim TH, Yoon EL, Jun DW, Ahn SH, Sypsa V, Yurdaydin C, Lampertico P, Calleja JL, Janssen H, Dalekos GN, Goulis J, Berg T, Buti M, Kim SU, Kim YJ.","J Hepatol. 2024 Jan;80(1):20-30. doi: 10.1016/j.jhep.2023.09.011. Epub 2023 Sep 19.","Chun HS","J Hepatol","2024","2023/09/21","","","10.1016/j.jhep.2023.09.011"
"37736793","A phase I study of the ceramide nanoliposome in patients with advanced solid tumors","Ciner A, Gourdin T, Davidson J, Parette M, Walker SJ, Fox TE, Jiang Y.","Cancer Chemother Pharmacol. 2024 Jan;93(1):23-29. doi: 10.1007/s00280-023-04588-7. Epub 2023 Sep 22.","Ciner A","Cancer Chemother Pharmacol","2024","2023/09/22","PMC10796569","","10.1007/s00280-023-04588-7"
"37807937","Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study","Hamdy M, El-Beshlawy A, Veríssimo MPA, Kanter J, Inusa B, Williams S, Lee D, Temin NT, Fradette C, Tricta F, Ebeid FSE, Kwiatkowski JL, Elalfy MS.","Pediatr Blood Cancer. 2024 Jan;71(1):e30711. doi: 10.1002/pbc.30711. Epub 2023 Oct 9.","Hamdy M","Pediatr Blood Cancer","2024","2023/10/09","","","10.1002/pbc.30711"
"37903909","Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial","Jo JH, Kim YT, Choi HS, Kim HG, Lee HS, Choi YW, Kim DU, Lee KH, Kim EJ, Han JH, Lee SO, Park CH, Choi EK, Kim JW, Cho JY, Lee WJ, Moon HR, Park MS, Kim S, Song SY.","Br J Cancer. 2024 Jan;130(1):43-52. doi: 10.1038/s41416-023-02474-w. Epub 2023 Oct 30.","Jo JH","Br J Cancer","2024","2023/10/31","PMC10781743","","10.1038/s41416-023-02474-w"
"37995598","Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial","Melisi D, Zecchetto C, Merz V, Malleo G, Landoni L, Quinzii A, Casalino S, Fazzini F, Gaule M, Pesoni C, Casetti L, Esposito A, Marchegiani G, Piazzola C, D'Onofrio M, de Robertis R, Gabbrielli A, Bernardoni L, Crino SF, Pietrobono S, Luchini C, Aliberti C, Martignoni G, Milleri S, Butturini G, Scarpa A, Salvia R, Bassi C.","Eur J Cancer. 2024 Jan;196:113430. doi: 10.1016/j.ejca.2023.113430. Epub 2023 Nov 11.","Melisi D","Eur J Cancer","2024","2023/11/23","","","10.1016/j.ejca.2023.113430"
"38061214","A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)","Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T.","Eur J Cancer. 2024 Jan;197:113469. doi: 10.1016/j.ejca.2023.113469. Epub 2023 Dec 2.","Watanabe S","Eur J Cancer","2024","2023/12/07","","","10.1016/j.ejca.2023.113469"
"38109282","Discarded livers tested by normothermic machine perfusion in the VITTAL trial: Secondary end points and 5-year outcomes","Mergental H, Laing RW, Kirkham AJ, Clarke G, Boteon YL, Barton D, Neil DAH, Isaac JR, Roberts KJ, Abradelo M, Schlegel A, Dasari BVM, Ferguson JW, Cilliers H, Morris C, Friend PJ, Yap C, Afford SC, Perera MTPR, Mirza DF.","Liver Transpl. 2024 Jan 1;30(1):30-45. doi: 10.1097/LVT.0000000000000270. Epub 2023 Dec 15.","Mergental H","Liver Transpl","2024","2023/12/18","","","10.1097/LVT.0000000000000270"
"38157806","Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program","Passiglia F, Lucia Reale M, Lo Russo G, Pasello G, Minuti G, Bulotta A, Galetta D, Pelizzari G, Sini C, Bria E, Roca E, Pilotto S, Genova C, Metro G, Citarella F, Chiari R, Cortinovis D, Delmonte A, Russo A, Tiseo M, Cerea G, Carta A, Scotti V, Vavalà T, Brambilla M, Buffoni L, Buosi R, Catania C, Gori S, Grisanti S, Agustoni F, Garbo E, Malapelle U, Novello S.","Lung Cancer. 2024 Jan;187:107444. doi: 10.1016/j.lungcan.2023.107444. Epub 2023 Dec 15.","Passiglia F","Lung Cancer","2024","2023/12/29","","","10.1016/j.lungcan.2023.107444"
"38194882","Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial","Chen C, Li Z, Xiong X, Yao A, Wang S, Liu X, Liu X, Wang J.","ESMO Open. 2024 Jan;9(1):102206. doi: 10.1016/j.esmoop.2023.102206. Epub 2024 Jan 9.","Chen C","ESMO Open","2024","2024/01/09","PMC10820330","","10.1016/j.esmoop.2023.102206"
"37535056","A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy","Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero MÁ, Couselo EM, Rodríguez-Abreu D, Boni V, Schuchter LM, Gonzalez-Cao M, Arance A, Wei W, Ganti AK, Hauke RJ, Berrocal A, Iannotti NO, Hsu FJ, Kluger HM.","Clin Cancer Res. 2024 Jan 5;30(1):74-81. doi: 10.1158/1078-0432.CCR-23-0475.","Weiss SA","Clin Cancer Res","2024","2023/08/03","PMC10767304","","10.1158/1078-0432.CCR-23-0475"
"38184304","VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial","Coffman-D'Annibale K, Myojin Y, Monge C, Xie C, Hrones DM, Wood BJ, Levy EB, Kleiner D, Figg WD, Steinberg SM, Redd B, Greten TF.","J Immunother Cancer. 2024 Jan 6;12(1):e008079. doi: 10.1136/jitc-2023-008079.","Coffman-D'Annibale K","J Immunother Cancer","2024","2024/01/06","PMC10773432","","10.1136/jitc-2023-008079"
"38218177","The long and winding road: Adjuvant therapy for early-stage hepatocellular carcinoma","D'Alessio A, Rimassa L.","Med. 2024 Jan 12;5(1):7-9. doi: 10.1016/j.medj.2023.11.004.","D'Alessio A","Med","2024","2024/01/13","","","10.1016/j.medj.2023.11.004"
"38231624","Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19","Cao B, Wang Y, Lu H, Huang C, Yang Y, Shang L, Chen Z, Jiang R, Liu Y, Lin L, Peng P, Wang F, Gong F, Hu H, Cheng C, Yao X, Ye X, Zhou H, Shen Y, Liu C, Wang C, Yi Z, Hu B, Xu J, Gu X, Shen J, Xu Y, Zhang L, Fan J, Tang R, Wang C.","N Engl J Med. 2024 Jan 18;390(3):230-241. doi: 10.1056/NEJMoa2301425.","Cao B","N Engl J Med","2024","2024/01/17","PMC11156186","","10.1056/NEJMoa2301425"
"38272561","Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders","Huffman BM, Singh H, Ali LR, Horick N, Wang SJ, Hoffman MT, Metayer KA, Murray S, Bird A, Abrams TA, Biller LH, Chan JA, Meyerhardt JA, McCleary NJ, Goessling W, Patel AK, Wisch JS, Yurgelun MB, Mouw K, Reardon B, Van Allen EM, Zerillo JA, Clark JW, Parikh A, Mayer RJ, Schlechter B, Ng K, Kumar S, Del Vecchio Fitz C, Kuperwasser C, Hanna GJ, Coveler AL, Rubinson DA, Welsh EL, Pfaff K, Rodig S, Dougan SK, Cleary JM.","J Immunother Cancer. 2024 Jan 25;12(1):e008436. doi: 10.1136/jitc-2023-008436.","Huffman BM","J Immunother Cancer","2024","2024/01/25","PMC10824013","","10.1136/jitc-2023-008436"
"38287317","iCare - a self-directed, interactive online program to improve health and wellbeing for people living with upper gastrointestinal or hepato-pancreato-biliary cancers, and their informal carers: the study protocol for a Phase II randomised controlled trial","Livingston PM, Winter N, Ugalde A, Orellana L, Mikocka-Walus A, Jefford M, Zalcberg J, Orford N, Hutchinson AM, Barbour A, Kiss N, Smithers BM, Watson DI, McCaffrey N, White V; iCare Advisory Group.","BMC Cancer. 2024 Jan 29;24(1):144. doi: 10.1186/s12885-024-11861-2.","Livingston PM","BMC Cancer","2024","2024/01/29","PMC10826031","","10.1186/s12885-024-11861-2"
"36113085","Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease","Tran TB, Downing L, Elmes JB, Arnall JR, Moore DC.","J Pharm Pract. 2024 Feb;37(1):184-189. doi: 10.1177/08971900221125827. Epub 2022 Sep 15.","Tran TB","J Pharm Pract","2024","2022/09/16","","","10.1177/08971900221125827"
"37717786","Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC)","Weinberg BA, Wang H, Noel MS, He AR, Marshall JL, Weiner LM, Fishbein TM, Hodgins NE, Winslow ER, Jackson PG, Guerra JF, Aguila F, Unger KR.","Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):362-367. doi: 10.1016/j.ijrobp.2023.09.015. Epub 2023 Sep 16.","Weinberg BA","Int J Radiat Oncol Biol Phys","2024","2023/09/17","","","10.1016/j.ijrobp.2023.09.015"
"37943351","Recurrent Colorectal Liver Metastases: Upfront Local Treatment versus Neoadjuvant Systemic Therapy Followed by Local Treatment (COLLISION RELAPSE): Study Protocol of a Phase III Prospective Randomized Controlled Trial","Dijkstra M, Kuiper BI, Schulz HH, van der Lei S, Puijk RS, Vos DJW, Timmer FEF, Scheffer HJ, Buffart TE, van den Tol MP, Lissenberg-Witte BI, Swijnenburg RJ, Versteeg KS, Meijerink MR; COLLISION Trial Group.","Cardiovasc Intervent Radiol. 2024 Feb;47(2):253-262. doi: 10.1007/s00270-023-03602-y. Epub 2023 Nov 9.","Dijkstra M","Cardiovasc Intervent Radiol","2024","2023/11/09","PMC10844349","","10.1007/s00270-023-03602-y"
"38006531","Phase I Safety and Feasibility Pilot of Hepatic Artery Infusion Chemotherapy in a Rural Catchment Area Using The Codman Vascular Catheter with The Medtronic SynchroMed II Pump for Intrahepatic Cancers","McDonald HG, Zaki OA, Wright MJ, Jayswal R, Weiss H, Nair RT, Ganesh H, Ellis S, Kolesar JM, Moss J, Barry-Hundeyin M, Pandalai PK, Kim J, Patel RA, Cavnar MJ.","Ann Surg Oncol. 2024 Feb;31(2):1252-1263. doi: 10.1245/s10434-023-14519-8. Epub 2023 Nov 25.","McDonald HG","Ann Surg Oncol","2024","2023/11/25","","","10.1245/s10434-023-14519-8"
"38038862","Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma","Huynh JC, Cho M, Monjazeb A, Al-Obeidi E, Singh A, Tam K, Lara F, Martinez A, Garcia L, Kim EJ.","Invest New Drugs. 2024 Feb;42(1):35-43. doi: 10.1007/s10637-023-01416-w. Epub 2023 Dec 1.","Huynh JC","Invest New Drugs","2024","2023/12/01","PMC10891185","","10.1007/s10637-023-01416-w"
"38157649","Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202","Kobayashi S, Nakachi K, Ikeda M, Konishi M, Ogawa G, Sugiura T, Yanagimoto H, Morinaga S, Wada H, Shimada K, Takahashi Y, Nakagohri T, Kamata K, Shimizu Y, Ajiki T, Hirano S, Gotohda N, Ueno M, Okusaka T, Furuse J.","Eur J Surg Oncol. 2024 Feb;50(2):107324. doi: 10.1016/j.ejso.2023.107324. Epub 2023 Dec 20.","Kobayashi S","Eur J Surg Oncol","2024","2023/12/29","","","10.1016/j.ejso.2023.107324"
"38212068","Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial","Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, Assenat E, Tacher V, Palard X, Déandreis D, Mariano-Goulart D, Amaddeo G, Boudjema K, Hollebecque A, Meerun MA, Regnault H, Vibert E, Campillo-Gimenez B, Edeline J.","J Nucl Med. 2024 Feb 1;65(2):264-269. doi: 10.2967/jnumed.123.266211.","Garin E","J Nucl Med","2024","2024/01/11","PMC10858378","","10.2967/jnumed.123.266211"
"38270822","Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort","Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA.","Invest New Drugs. 2024 Feb;42(1):127-135. doi: 10.1007/s10637-024-01420-8. Epub 2024 Jan 25.","Emiloju OE","Invest New Drugs","2024","2024/01/25","","","10.1007/s10637-024-01420-8"
"38274492","Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection","Janssen HL, Lim YS, Kim HJ, Sowah L, Tseng CH, Coffin CS, Elkhashab M, Ahn SH, Nguyen AH, Chen D, Wallin JJ, Fletcher SP, McDonald C, Yang JC, Gaggar A, Brainard DM, Fung S, Kim YJ, Kao JH, Chuang WL, Brooks AE, Dunbar PR.","JHEP Rep. 2023 Nov 30;6(2):100975. doi: 10.1016/j.jhepr.2023.100975. eCollection 2024 Feb.","Janssen HL","JHEP Rep","2023","2024/01/26","PMC10808922","","10.1016/j.jhepr.2023.100975"
"38288897","Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [(177)Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer","Ha S, O JH, Park C, Boo SH, Yoo IR, Moon HW, Chi DY, Lee JY.","Korean J Radiol. 2024 Feb;25(2):179-188. doi: 10.3348/kjr.2023.0656.","Ha S","Korean J Radiol","2024","2024/01/30","PMC10831299","","10.3348/kjr.2023.0656"
"38361920","Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial","Qiu X, Lu C, Sha H, Zhu Y, Kong W, Tong F, Wang Q, Meng F, Liu B, Du J.","Front Immunol. 2024 Feb 1;15:1210859. doi: 10.3389/fimmu.2024.1210859. eCollection 2024.","Qiu X","Front Immunol","2024","2024/02/16","PMC10867188","","10.3389/fimmu.2024.1210859"
"38457252","Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: A real-world multicenter study","Li D, Jin Y, Lin M, Zeng C, Guo Q, Liu Y, Zhang J.","Cancer Med. 2024 Feb;13(4):e6762. doi: 10.1002/cam4.6762.","Li D","Cancer Med","2024","2024/03/08","PMC10923034","","10.1002/cam4.6762"
"38350888","Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur)","Hitchcock KE, Miller ED, Shi Q, Dixon JG, Gholami S, White SB, Wu C, Goulet CC, George M, Jee KW, Wright CL, Yaeger R, Shergill A, Hong TS, George TJ, O'Reilly EM, Meyerhardt JA, Romesser PB.","BMC Cancer. 2024 Feb 13;24(1):201. doi: 10.1186/s12885-024-11899-2.","Hitchcock KE","BMC Cancer","2024","2024/02/13","PMC10863118","","10.1186/s12885-024-11899-2"
"38351013","Review of brachytherapy clinical trials: a cross-sectional analysis of ClinicalTrials.gov","Chen D, Parsa R, Chauhan K, Lukovic J, Han K, Taggar A, Raman S.","Radiat Oncol. 2024 Feb 13;19(1):22. doi: 10.1186/s13014-024-02415-8.","Chen D","Radiat Oncol","2024","2024/02/13","PMC10863227","","10.1186/s13014-024-02415-8"
"38358542","Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study","Zhu M, Liu Z, Chen S, Luo Z, Tu J, Qiao L, Wu J, Fan W, Peng Z.","Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776. Online ahead of print.","Zhu M","Hepatology","2024","2024/02/15","","","10.1097/HEP.0000000000000776"
"38388167","First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial","Ren S, Wang X, Han BH, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C.","J Immunother Cancer. 2024 Feb 21;12(2):e007227. doi: 10.1136/jitc-2023-007227.","Ren S","J Immunother Cancer","2024","2024/02/22","PMC10882294","","10.1136/jitc-2023-007227"
"38543063","Pharmakokinetics of Mistletoe Lectins after Intravenous Application of a Mistletoe Product in Healthy Subjects","Lederer AK, Rieger S, Schink M, Huber R.","Pharmaceuticals (Basel). 2024 Feb 22;17(3):278. doi: 10.3390/ph17030278.","Lederer AK","Pharmaceuticals (Basel)","2024","2024/03/28","PMC10975571","","10.3390/ph17030278"
"37966630","Prognostic Effect of Performance Status on Outcomes of Patients with Colorectal Cancer Receiving First-Line Chemotherapy: A Meta-analysis","Colloca GA, Venturino A.","J Gastrointest Cancer. 2024 Mar;55(1):418-426. doi: 10.1007/s12029-023-00983-8. Epub 2023 Nov 15.","Colloca GA","J Gastrointest Cancer","2024","2023/11/15","","","10.1007/s12029-023-00983-8"
"38087705","Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial","Cruz-Lim EM, Mou B, Baker S, Arbour G, Stefanyk K, Jiang W, Liu M, Bergman A, Schellenberg D, Alexander A, Berrang T, Bang A, Chng N, Matthews Q, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson R.","Clin Oncol (R Coll Radiol). 2024 Mar;36(3):148-156. doi: 10.1016/j.clon.2023.11.041. Epub 2023 Dec 3.","Cruz-Lim EM","Clin Oncol (R Coll Radiol)","2024","2023/12/13","","","10.1016/j.clon.2023.11.041"
"38147153","Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial","Choi JW, Kim HC, Han J, Jang MJ, Chung JW.","Cardiovasc Intervent Radiol. 2024 Mar;47(3):372-378. doi: 10.1007/s00270-023-03621-9. Epub 2023 Dec 26.","Choi JW","Cardiovasc Intervent Radiol","2024","2023/12/26","","","10.1007/s00270-023-03621-9"
"38215573","A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305","Argiris A, Flamand Y, Savvides P, Johnson JM, Vathiotis I, Levine M, Li S, Forastiere AA, Burtness B.","Eur J Cancer. 2024 Mar;199:113509. doi: 10.1016/j.ejca.2023.113509. Epub 2023 Dec 29.","Argiris A","Eur J Cancer","2024","2024/01/12","","","10.1016/j.ejca.2023.113509"
"38224916","MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters","van Overeem Felter M, Møller PK, Josipovic M, Bekke SN, Bernchou U, Serup-Hansen E, Madsen K, Parikh PJ, Kim J, Geertsen P, Behrens CP, Vogelius IR, Pøhl M, Schytte T, Persson GF.","Radiother Oncol. 2024 Mar;192:110090. doi: 10.1016/j.radonc.2024.110090. Epub 2024 Jan 13.","van Overeem Felter M","Radiother Oncol","2024","2024/01/15","","","10.1016/j.radonc.2024.110090"
"38237621","Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Biörserud C, Björnsson B, Bringeland EA, Elander N, Garresori H, Grønbech JE, Haux J, Hemmingsson O, Liljefors MG, Myklebust TÅ, Nymo LS, Peltola K, Pfeiffer P, Sallinen V, Sandström P, Sparrelid E, Stenvold H, Søreide K, Tingstedt B, Verbeke C, Öhlund D, Klint L, Dueland S, Lassen K; Nordic Pancreatic Cancer Trial-1 study group.","Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15.","Labori KJ","Lancet Gastroenterol Hepatol","2024","2024/01/18","","","10.1016/S2468-1253(23)00405-3"
"38241818","Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation","Cohen R, Raeisi M, Chibaudel B, Yoshino T, Shi Q, Zalcberg JR, Adams R, Cremolini C, Grothey A, Mayer RJ, Van Cutsem E, Tabernero J, Bando H, Misumi T, Overman MJ, André T, de Gramont A.","Eur J Cancer. 2024 Mar;199:113537. doi: 10.1016/j.ejca.2024.113537. Epub 2024 Jan 15.","Cohen R","Eur J Cancer","2024","2024/01/19","","","10.1016/j.ejca.2024.113537"
"38242982","Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial","Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Qin YY, Shi J, Guo WX, Lu CD, Zheng YX, Zhou FG, Yan ML, Zhou HK, Liang C, Zhang F, Wei WJ, Lau WY, Li JJ, Liu YF, Cheng SQ.","Nat Med. 2024 Mar;30(3):708-715. doi: 10.1038/s41591-023-02786-7. Epub 2024 Jan 19.","Wang K","Nat Med","2024","2024/01/19","","","10.1038/s41591-023-02786-7"
"38300386","Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System","Lang W, Deng L, Huang B, Zhong D, Zhang G, Lu M, Ouyang M.","Clin Drug Investig. 2024 Mar;44(3):149-162. doi: 10.1007/s40261-024-01343-5. Epub 2024 Feb 1.","Lang W","Clin Drug Investig","2024","2024/02/01","","","10.1007/s40261-024-01343-5"
"38361511","Britannin inhibits cell proliferation, migration and glycolysis by downregulating KLF5 in lung cancer","Wang Y, Yu B, Qu M, Liu F, Wu X.","Exp Ther Med. 2024 Jan 22;27(3):109. doi: 10.3892/etm.2024.12397. eCollection 2024 Mar.","Wang Y","Exp Ther Med","2024","2024/02/16","PMC10867720","","10.3892/etm.2024.12397"
"38374347","Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial","Kim HD, Jung S, Lim HY, Ryoo BY, Ryu MH, Chuah S, Chon HJ, Kang B, Hong JY, Lee HC, Moon DB, Kim KH, Kim TW, Tai D, Chew V, Lee JS, Finn RS, Koh JY, Yoo C.","Nat Med. 2024 Mar;30(3):699-707. doi: 10.1038/s41591-024-02824-y. Epub 2024 Feb 19.","Kim HD","Nat Med","2024","2024/02/20","PMC10957471","","10.1038/s41591-024-02824-y"
"38413420","Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial)","Zhu HD, Li X, Sun JH, Zhu X, Liu ZY, Li HL, Lu J, Yan ZP, Shao GL, He XF, Chao M, Lu LG, Zhong BY, Li R, Zhang Q, Teng GJ.","Cardiovasc Intervent Radiol. 2024 Mar;47(3):325-336. doi: 10.1007/s00270-024-03666-4. Epub 2024 Feb 27.","Zhu HD","Cardiovasc Intervent Radiol","2024","2024/02/27","PMC10920424","","10.1007/s00270-024-03666-4"
"38491813","Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials","Benjamin DJ, Haslam A, Prasad V.","Cancer Med. 2024 Mar;13(5):e7049. doi: 10.1002/cam4.7049.","Benjamin DJ","Cancer Med","2024","2024/03/16","PMC10943275","","10.1002/cam4.7049"
"38494922","First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome","Narayan R, Piérola AA, Donnellan WB, Yordi AM, Abdul-Hay M, Platzbecker U, Subklewe M, Kadia TM, Alonso-Domínguez JM, McCloskey J, Bradford K, Curtis M, Daskalakis N, Guttke C, Safer K, Hiebert B, Murphy J, Li X, Duchin K, Esteban D.","Clin Transl Sci. 2024 Mar;17(3):e13742. doi: 10.1111/cts.13742.","Narayan R","Clin Transl Sci","2024","2024/03/18","PMC10945216","","10.1111/cts.13742"
"38363156","CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma","Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, Yaqubie A, Lopez J, Huang B, Tang YW, Wen Y, Schwartz LH, El-Khoueiry AB, Knox JJ, Rajdev L, Bertagnolli MM, Meyerhardt JA, O'Reilly EM, Venook AP.","Cancer Res Commun. 2024 Mar 7;4(3):682-690. doi: 10.1158/2767-9764.CRC-22-0516.","Abou-Alfa GK","Cancer Res Commun","2024","2024/02/16","PMC10919207","","10.1158/2767-9764.CRC-22-0516"
"38454445","S100A9(+)CD14(+) monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function","Tu X, Chen L, Zheng Y, Mu C, Zhang Z, Wang F, Ren Y, Duan Y, Zhang H, Tong Z, Liu L, Sun X, Zhao P, Wang L, Feng X, Fang W, Liu X.","J Exp Clin Cancer Res. 2024 Mar 8;43(1):72. doi: 10.1186/s13046-024-02985-1.","Tu X","J Exp Clin Cancer Res","2024","2024/03/08","PMC10921725","","10.1186/s13046-024-02985-1"
"38467639","The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial","Hsiehchen D, Beg MS, Kainthla R, Lohrey J, Kazmi SM, Khosama L, Maxwell MC, Kline H, Katz C, Hassan A, Kubota N, Siglinsky E, Pillai AK, Youssoufian H, Mockbee C, Culm K, Uhlik M, Benjamin L, Brekken RA, Ahn C, Singal AG, Zhu H, Hoshida Y, Yopp AC.","Nat Commun. 2024 Mar 11;15(1):2178. doi: 10.1038/s41467-024-46542-y.","Hsiehchen D","Nat Commun","2024","2024/03/12","PMC10928173","","10.1038/s41467-024-46542-y"
"37979133","The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients","Ghesquières H, Krzisch D, Nicolas-Virelizier E, Kanoun S, Gac AC, Guidez S, Touati M, Laribi K, Morschhauser F, Bonnet C, Waultier-Rascalou A, Orsini-Piocelle F, André M, Fournier M, Morand F, Berriolo-Riedinger A, Burroni B, Damotte D, Traverse-Glehen A, Quittet P, Casasnovas O.","Blood. 2024 Mar 14;143(11):983-995. doi: 10.1182/blood.2023021564.","Ghesquières H","Blood","2024","2023/11/18","","","10.1182/blood.2023021564"
"38502074","Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial","Simon TG, Wilechansky RM, Stoyanova S, Grossman A, Dichtel LE, Lauer GM, Miller KK, Hoshida Y, Corey KE, Loomba R, Chung RT, Chan AT.","JAMA. 2024 Mar 19;331(11):920-929. doi: 10.1001/jama.2024.1215.","Simon TG","JAMA","2024","2024/03/19","PMC10951738","","10.1001/jama.2024.1215"
"38519913","An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer","Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E.","Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8.","Levy A","Mol Cancer","2024","2024/03/23","PMC10960440","","10.1186/s12943-024-01970-8"
"37981040","Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients","Vaishampayan UN, Heilbrun L, Vaishampayan N, Harper FWK, Shi D, Smith D, Green K, Guru K, Li Q, Kuettel M, Chatta G, Maier J, Dickow B, Moore TF, George S.","Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1472-1480. doi: 10.1016/j.ijrobp.2023.11.024. Epub 2023 Nov 18.","Vaishampayan UN","Int J Radiat Oncol Biol Phys","2024","2023/11/19","","","10.1016/j.ijrobp.2023.11.024"
"38151184","Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040","El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B.","Ann Oncol. 2024 Apr;35(4):381-391. doi: 10.1016/j.annonc.2023.12.008. Epub 2023 Dec 25.","El-Khoueiry AB","Ann Oncol","2024","2023/12/27","","","10.1016/j.annonc.2023.12.008"
"38199382","Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials","Lynch C, Korpics MC, Katipally RR, Wu T, Bestvina CM, Pitroda S, Chmura SJ, Juloori A.","Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1519-1530. doi: 10.1016/j.ijrobp.2024.01.002. Epub 2024 Jan 9.","Lynch C","Int J Radiat Oncol Biol Phys","2024","2024/01/10","","","10.1016/j.ijrobp.2024.01.002"
"38287179","A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","Burris HA, Berlin J, Arkenau T, Cote GM, Lolkema MP, Ferrer-Playan J, Kalapur A, Bolleddula J, Locatelli G, Goddemeier T, Gounaris I, de Bono J.","Br J Cancer. 2024 Apr;130(7):1131-1140. doi: 10.1038/s41416-023-02436-2. Epub 2024 Jan 29.","Burris HA","Br J Cancer","2024","2024/01/29","PMC10991509","","10.1038/s41416-023-02436-2"
"38291865","Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study","Cai M, Huang W, Liang W, Guo Y, Liang L, Lin L, Xie L, Zhou J, Chen Y, Cao B, Wu J, Zhu K.","Liver Int. 2024 Apr;44(4):920-930. doi: 10.1111/liv.15831. Epub 2024 Jan 30.","Cai M","Liver Int","2024","2024/01/31","","","10.1111/liv.15831"
"38347177","PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study","Gou M, Zhang Y, Wang Z, Qian N, Dai G.","Invest New Drugs. 2024 Apr;42(2):171-178. doi: 10.1007/s10637-024-01425-3. Epub 2024 Feb 12.","Gou M","Invest New Drugs","2024","2024/02/12","PMC10944415","","10.1007/s10637-024-01425-3"
"38364832","Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study","Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L.","Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13.","Yau T","Lancet Gastroenterol Hepatol","2024","2024/02/16","","","10.1016/S2468-1253(23)00454-5"
"38422585","A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma","Enzler T, Nguyen A, Misleh J, Cline VJ, Johns M, Shumway N, Paulson S, Siegel R, Larson T, Messersmith W, Richards D, Chaves J, Pierce E, Zalupski M, Sahai V, Orr D, Ruste SA, Haun A, Kawabe T.","Eur J Cancer. 2024 Apr;201:113950. doi: 10.1016/j.ejca.2024.113950. Epub 2024 Feb 22.","Enzler T","Eur J Cancer","2024","2024/02/29","","","10.1016/j.ejca.2024.113950"
"38423782","Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study","Eigler C, McDougall L, Bauman A, Bernhardt P, Hentschel M, Blackham KA, Nicolas G, Fani M, Wild D, Cordier D.","J Nucl Med. 2024 Apr 1;65(4):573-579. doi: 10.2967/jnumed.123.266817.","Eigler C","J Nucl Med","2024","2024/02/29","","","10.2967/jnumed.123.266817"
"38424197","Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M, Finn RS.","Nat Rev Clin Oncol. 2024 Apr;21(4):294-311. doi: 10.1038/s41571-024-00868-0. Epub 2024 Feb 29.","Llovet JM","Nat Rev Clin Oncol","2024","2024/02/29","","","10.1038/s41571-024-00868-0"
"38424308","Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration","Piscitelli J, Reddy MB, Wollenberg L, Del Frari L, Gong J, Wood L, Zhang Y, Matschke K, Williams JH.","Clin Pharmacokinet. 2024 Apr;63(4):483-496. doi: 10.1007/s40262-024-01352-9. Epub 2024 Feb 29.","Piscitelli J","Clin Pharmacokinet","2024","2024/02/29","PMC11052825","","10.1007/s40262-024-01352-9"
"38469902","A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present","Fettiplace A, Matis-Mitchell S, Molodetskyi O, Söderbergh M, Oscarsson J, Lin M, Ravikiran S, Billger M, Ambery P.","Expert Opin Drug Saf. 2024 Apr;23(4):477-486. doi: 10.1080/14740338.2024.2328816. Epub 2024 Mar 24.","Fettiplace A","Expert Opin Drug Saf","2024","2024/03/12","","","10.1080/14740338.2024.2328816"
"38547893","LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study","Musher BL, Rowinsky EK, Smaglo BG, Abidi W, Othman M, Patel K, Jawaid S, Jing J, Brisco A, Leen AM, Wu M, Sandin LC, Wenthe J, Eriksson E, Ullenhag GJ, Grilley B, Leja-Jarblad J, Hilsenbeck SG, Brenner MK, Loskog ASI.","Lancet Oncol. 2024 Apr;25(4):488-500. doi: 10.1016/S1470-2045(24)00079-2.","Musher BL","Lancet Oncol","2024","2024/03/28","","","10.1016/S1470-2045(24)00079-2"
"38547895","Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study","Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, Vernerey D, Taïeb J, Borg C.","Lancet Oncol. 2024 Apr;25(4):518-528. doi: 10.1016/S1470-2045(24)00081-0.","Kim S","Lancet Oncol","2024","2024/03/28","","","10.1016/S1470-2045(24)00081-0"
"38584166","Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial","Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G, Northcott J, Lyle J, Rochestie S, Peters J, Connor JT, Jaffee EM, Csiki I, Weiner DB, Perales-Puchalt A, Sardesai NY.","Nat Med. 2024 Apr;30(4):1044-1053. doi: 10.1038/s41591-024-02894-y. Epub 2024 Apr 7.","Yarchoan M","Nat Med","2024","2024/04/07","PMC11031401","","10.1038/s41591-024-02894-y"
"38617599","A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma","Santoro A, Assenat E, Yau T, Delord JP, Maur M, Knox J, Cattan S, Lee KH, Del Conte G, Springfeld C, Leo E, Xyrafas A, Fairchild L, Mardjuadi F, Chan SL.","JHEP Rep. 2024 Jan 28;6(4):101021. doi: 10.1016/j.jhepr.2024.101021. eCollection 2024 Apr.","Santoro A","JHEP Rep","2024","2024/04/15","PMC11009449","","10.1016/j.jhepr.2024.101021"
"38608150","Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study","Krul MF, Kok NFM, Osmani H, Buisman FE, Groot Koerkamp B, Grunhagen DJ, Verhoef C, Mostert B, Snaebjornsson P, Westerink B, Klompenhouwer EG, Donswijk ML, Ruers TJM, Douma JAJ, van Blijderveen N, Kingham TP, D'Angelica MI, Kemeny NE, Bolhuis K, Buffart TE, Kuhlmann KFD.","Br J Surg. 2024 Apr 3;111(4):znae089. doi: 10.1093/bjs/znae089.","Krul MF","Br J Surg","2024","2024/04/12","","","10.1093/bjs/znae089"
"38573183","Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R in liver cancer","Li Y, Xu Z, Li Y, Jiang T, Meng F, Fu J, Huang L, Wang F, Wang X, Wang F.","Future Oncol. 2024 Apr 4:1-14. doi: 10.2217/fon-2023-0872. Online ahead of print.","Li Y","Future Oncol","2024","2024/04/04","","","10.2217/fon-2023-0872"
"38589856","A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study","Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V.","BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6.","Niger M","BMC Cancer","2024","2024/04/08","PMC11003088","","10.1186/s12885-024-12225-6"
"38672201","Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma","Etzion O, Bareket-Samish A, Yardeni D, Fishman P.","Biomedicines. 2024 Apr 11;12(4):848. doi: 10.3390/biomedicines12040848.","Etzion O","Biomedicines","2024","2024/04/27","PMC11047856","","10.3390/biomedicines12040848"
"38627377","Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial","Li Z, Liu J, Zhang B, Yue J, Shi X, Cui K, Liu Z, Chang Z, Sun Z, Li M, Yang Y, Ma Z, Li L, Zhang C, Sun P, Zhong J, Zhao L.","Nat Commun. 2024 Apr 16;15(1):3260. doi: 10.1038/s41467-024-47420-3.","Li Z","Nat Commun","2024","2024/04/16","PMC11021407","","10.1038/s41467-024-47420-3"
"38627914","Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis","Wojciechowski J, Mukherjee A, Banfield C, Nicholas T.","Clin Pharmacol Ther. 2024 Apr 16. doi: 10.1002/cpt.3251. Online ahead of print.","Wojciechowski J","Clin Pharmacol Ther","2024","2024/04/17","","","10.1002/cpt.3251"
"38551394","First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors","Yarchoan M, Powderly JD, Bastos BR, Karasic TB, Crysler OV, Munster PN, McKean MA, Emens LA, Saenger YM, Ged Y, Stagg R, Smith S, Whiting CC, Moon A, Prasit P, Jenkins Y, Standifer N, Dubensky TW, Whiting SH, Ulahannan SV.","Cancer Res Commun. 2024 Apr 18;4(4):1100-1110. doi: 10.1158/2767-9764.CRC-24-0082.","Yarchoan M","Cancer Res Commun","2024","2024/03/29","PMC11025498","","10.1158/2767-9764.CRC-24-0082"
"38637772","Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma","Zhu M, Jin M, Zhao X, Shen S, Chen Y, Xiao H, Wei G, He Q, Li B, Peng Z.","BMC Med. 2024 Apr 19;22(1):165. doi: 10.1186/s12916-024-03381-4.","Zhu M","BMC Med","2024","2024/04/18","PMC11027363","","10.1186/s12916-024-03381-4"
"37988648","Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials","Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, Yao X, Shi B, Liu J, Hu C, Liu Z, Guo H, Yu G, Ji Z, Ying J, Ling Y, Yu S, Hu Y, Guo J, Fang J, Zhou A, Guo J.","J Clin Oncol. 2024 Apr 20;42(12):1391-1402. doi: 10.1200/JCO.22.02912. Epub 2023 Nov 21.","Sheng X","J Clin Oncol","2024","2023/11/21","PMC11095880","","10.1200/JCO.22.02912"
"38261969","Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3","Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, Agarwal N, Gupta S, Fléchon A, Ramamurthy C, Davis NB, Recio-Boiles A, Sternberg CN, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa ST, Loriot Y.","J Clin Oncol. 2024 Apr 20;42(12):1415-1425. doi: 10.1200/JCO.22.02835. Epub 2024 Jan 23.","Grivas P","J Clin Oncol","2024","2024/01/23","PMC11095901","","10.1200/JCO.22.02835"
"38650037","Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial","Xu L, Chen J, Liu C, Song X, Zhang Y, Zhao H, Yan S, Jia W, Wu Z, Guo Y, Yang J, Gong W, Ma Y, Yang X, Gao Z, Zhang N, Zheng X, Li M, Su D, Chen M.","BMC Med. 2024 Apr 23;22(1):172. doi: 10.1186/s12916-024-03356-5.","Xu L","BMC Med","2024","2024/04/22","PMC11036623","","10.1186/s12916-024-03356-5"
"38730548","Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume","Chang E, Wong FCL, Chasen BA, Erwin WD, Das P, Holliday EB, Koong AC, Ludmir EB, Minsky BD, Noticewala SS, Smith GL, Taniguchi CM, Rodriguez MJ, Beddar S, Martin-Paulpeter RM, Niedzielski JS, Sawakuchi GO, Schueler E, Perles LA, Xiao L, Szklaruk J, Park PC, Dasari AN, Kaseb AO, Kee BK, Lee SS, Overman MJ, Willis JA, Wolff RA, Tzeng CD, Vauthey JN, Koay EJ.","JNCI Cancer Spectr. 2024 Apr 30;8(3):pkae037. doi: 10.1093/jncics/pkae037.","Chang E","JNCI Cancer Spectr","2024","2024/05/11","PMC11164414","","10.1093/jncics/pkae037"
"37586908","Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA)","Di Nardo P, Basile D, Siciliano A, Pelizzari G, Corvaja C, Buriolla S, Ongaro E, Maria Grazia D, Garattini SK, Foltran L, Guardascione M, Casagrande M, Buonadonna A, Prantera T, Aprile G, Puglisi F.","Dig Liver Dis. 2024 May;56(5):786-794. doi: 10.1016/j.dld.2023.07.013. Epub 2023 Aug 14.","Di Nardo P","Dig Liver Dis","2024","2023/08/16","","","10.1016/j.dld.2023.07.013"
"38382875","Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators.","Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19.","Sangro B","Ann Oncol","2024","2024/02/21","","","10.1016/j.annonc.2024.02.005"
"38537314","A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability","Moreau M, Alouani E, Flecchia C, Falcoz A, Gallois C, Auclin E, André T, Cohen R, Hollebecque A, Turpin A, Pernot S, Masson T, Di Fiore F, Dutherge M, Mazard T, Hautefeuille V, Van Laethem JL, De la Fouchardière C, Perkins G, Ben-Abdelghani M, Sclafani F, Aparicio T, Kim S, Vernerey D, Taieb J, Guimbaud R, Tougeron D.","Eur J Cancer. 2024 May;202:114033. doi: 10.1016/j.ejca.2024.114033. Epub 2024 Mar 21.","Moreau M","Eur J Cancer","2024","2024/03/27","","","10.1016/j.ejca.2024.114033"
"38546944","A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor","Evans L, Walker R, MacDiarmid J, Brahmbhatt H, Anazodo A, McCowage G, Gifford AJ, Kavallaris M, Trahair T, Ziegler DS.","Target Oncol. 2024 May;19(3):333-342. doi: 10.1007/s11523-024-01051-2. Epub 2024 Mar 28.","Evans L","Target Oncol","2024","2024/03/28","PMC11111512","","10.1007/s11523-024-01051-2"
"38604979","Global phase 3 results show that bevacizumab with immunotherapy has activity in liver cancer","Nierengarten MB.","Cancer. 2024 May 1;130(9):1547-1548. doi: 10.1002/cncr.35295.","Nierengarten MB","Cancer","2024","2024/04/11","","","10.1002/cncr.35295"
"38689424","Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial","Zeng TM, Jiang TY, Yang G, Cheng Z, Lou C, Wei W, Tao CJ, Hu S, Wang H, Cui XW, Tan YX, Dong LW, Wang HY, Yuan ZG.","Clin Transl Med. 2024 May;14(5):e1675. doi: 10.1002/ctm2.1675.","Zeng TM","Clin Transl Med","2024","2024/05/01","PMC11061377","","10.1002/ctm2.1675"
"38711003","Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study","Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V.","BMC Cancer. 2024 May 6;24(1):563. doi: 10.1186/s12885-024-12328-0.","Niger M","BMC Cancer","2024","2024/05/06","PMC11071222","","10.1186/s12885-024-12328-0"
"38734383","Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial","Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Manuilov D, Mercier RC, Da BL, Chee GM, Li M, Flaherty JF, Lau AH, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Lampertico P.","J Hepatol. 2024 May 9:S0168-8278(24)00333-7. doi: 10.1016/j.jhep.2024.05.001. Online ahead of print.","Wedemeyer H","J Hepatol","2024","2024/05/11","","","10.1016/j.jhep.2024.05.001"
"38777717","The Barthel Index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study","Yang T, Liu DQ, Qiu W, Fan ZQ, Sun LY, Wang NY, Wang H, Yang YF, Li J, Zhou YH, Chen TH, Wang XM, Gu WM, Liang YJ, Gu LH, Xu JH, Wang MD, Sun XD, Lv GY.","Am J Surg. 2024 May 9:S0002-9610(24)00269-1. doi: 10.1016/j.amjsurg.2024.05.002. Online ahead of print.","Yang T","Am J Surg","2024","2024/05/22","","","10.1016/j.amjsurg.2024.05.002"
"38727837","Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study","Ren S, Xiong A, Yu J, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C.","Cancer Immunol Immunother. 2024 May 10;73(7):124. doi: 10.1007/s00262-024-03715-4.","Ren S","Cancer Immunol Immunother","2024","2024/05/10","PMC11087418","","10.1007/s00262-024-03715-4"
"38734543","Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial","Ah-Thiane L, Campion L, Allouache N, Meyer E, Pommier P, Mesgouez-Nebout N, Serre AA, Créhange G, Guimas V, Rio E, Sargos P, Ladoire S, Mahier Ait Oukhatar C, Supiot S.","Eur Urol Oncol. 2024 May 10:S2588-9311(24)00108-1. doi: 10.1016/j.euo.2024.04.014. Online ahead of print.","Ah-Thiane L","Eur Urol Oncol","2024","2024/05/11","","","10.1016/j.euo.2024.04.014"
"38521087","Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021","GBD 2021 Fertility and Forecasting Collaborators.","Lancet. 2024 May 18;403(10440):2057-2099. doi: 10.1016/S0140-6736(24)00550-6. Epub 2024 Mar 20.","GBD 2021 Fertility and Forecasting Collaborators","Lancet","2024","2024/03/23","PMC11122687","","10.1016/S0140-6736(24)00550-6"
"38764430","Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial","Azim HA, Saleh MA, Essam Eldin P, Abdelhafeez AAM, Hassan M, Kassem L.","J Chemother. 2024 May 20:1-9. doi: 10.1080/1120009X.2024.2342741. Online ahead of print.","Azim HA","J Chemother","2024","2024/05/20","","","10.1080/1120009X.2024.2342741"
"38769368","Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial","Lin YD, Wu GS, Rao MY, Liu YH, Han YW, Zhang J, Zhang JW.","Sci Rep. 2024 May 20;14(1):11486. doi: 10.1038/s41598-024-62523-z.","Lin YD","Sci Rep","2024","2024/05/20","PMC11106273","","10.1038/s41598-024-62523-z"
"38683104","A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma","Buchbinder EI, Cohen JV, Tarantino G, Lian CG, Liu D, Haq R, Hodi FS, Lawrence DP, Giobbie-Hurder A, Knoerzer D, Sullivan RJ.","Cancer Res Commun. 2024 May 21;4(5):1321-1327. doi: 10.1158/2767-9764.CRC-24-0036.","Buchbinder EI","Cancer Res Commun","2024","2024/04/29","PMC11107576","","10.1158/2767-9764.CRC-24-0036"
"38330179","Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency","van Beers EJ, Al-Samkari H, Grace RF, Barcellini W, Glenthøj A, DiBacco M, Wind-Rotolo M, Xu R, Beynon V, Patel P, Porter JB, Kuo KHM.","Blood Adv. 2024 May 28;8(10):2433-2441. doi: 10.1182/bloodadvances.2023011743.","van Beers EJ","Blood Adv","2024","2024/02/08","PMC11112604","","10.1182/bloodadvances.2023011743"
"38814482","Outcomes of definitive carbon-ion radiotherapy for cT1bN0M0 esophageal squamous cell carcinoma","Isozaki T, Ishikawa H, Yamada S, Nabeya Y, Minashi K, Murakami K, Matsubara H.","Esophagus. 2024 May 30. doi: 10.1007/s10388-024-01067-7. Online ahead of print.","Isozaki T","Esophagus","2024","2024/05/30","","","10.1007/s10388-024-01067-7"
"35988688","Interventional radiology meets immuno-oncology for hepatocellular carcinoma","Salem R, Greten TF.","J Hepatol. 2024 Jun;80(6):967-976. doi: 10.1016/j.jhep.2022.08.003. Epub 2022 Aug 19.","Salem R","J Hepatol","2024","2022/08/21","","","10.1016/j.jhep.2022.08.003"
"37399245","Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology","Iavarone M, Nault JC, Cabibbo G, Torres F, Reig M.","Hepatology. 2024 Jun 1;79(6):1452-1462. doi: 10.1097/HEP.0000000000000527. Epub 2023 Jul 3.","Iavarone M","Hepatology","2024","2023/07/03","PMC11095876","","10.1097/HEP.0000000000000527"
"38374403","Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001)","Ozawa M, Watanabe J, Ishibe A, Goto K, Fujii Y, Nakagawa K, Suwa Y, Suwa H, Masui H, Sugita M, Mochizuki Y, Yamagishi S, Hasegawa S, Homma Y, Momiyama M, Kumamoto T, Matsuyama R, Takeda K, Taguri M, Endo I.","Cancer Chemother Pharmacol. 2024 Jun;93(6):565-573. doi: 10.1007/s00280-024-04648-6. Epub 2024 Feb 19.","Ozawa M","Cancer Chemother Pharmacol","2024","2024/02/20","","","10.1007/s00280-024-04648-6"
"38404184","Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study","Bishnoi S, Kotasek D, Aghmesheh M, Yau T, Cosman R, Prawira A, Moore M, Chan SL, Mant A, Eek R, Zielinski R, Su R, Pan Z, Ma Y, Li F, Li P, Tse AN.","Cancer. 2024 Jun 1;130(11):1991-2002. doi: 10.1002/cncr.35226. Epub 2024 Feb 26.","Bishnoi S","Cancer","2024","2024/02/26","","","10.1002/cncr.35226"
"38522597","Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer","Franceschini D, Franzese C, Comito T, Ilieva MB, Spoto R, Marzo AM, Dominici L, Massaro M, Bellu L, Badalamenti M, Mancosu P, Scorsetti M.","Radiother Oncol. 2024 Jun;195:110240. doi: 10.1016/j.radonc.2024.110240. Epub 2024 Mar 22.","Franceschini D","Radiother Oncol","2024","2024/03/24","","","10.1016/j.radonc.2024.110240"
"38568599","Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial","Peng Z, Fan W, Liu Z, Xiao H, Wu J, Tang R, Tu J, Qiao L, Huang F, Xie W, Zhuang W, Guo W, Li S, Hua Y, Shen S, He Q, Li D, Li J, Kuang M.","JAMA Surg. 2024 Jun 1;159(6):616-624. doi: 10.1001/jamasurg.2024.0506.","Peng Z","JAMA Surg","2024","2024/04/03","PMC10993157","","10.1001/jamasurg.2024.0506"
"38750621","SafeHeal Colovac Colorectal Anastomosis Protection Device evaluation (SAFE-2) pivotal study: an international randomized controlled study to evaluate the safety and effectiveness of the Colovac Colorectal Anastomosis Protection Device","Hain E, Lefèvre JH, Ricardo A, Lee S, Zaghiyan K, McLemore E, Sherwinter D, Rhee R, Wilson M, Martz J, Maykel J, Marks J, Marcet J, Rouanet P, Maggiori L, Komen N, De Hous N, Lakkis Z, Tuech JJ, Attiyeh F, Cotte E, Sylla P.","Colorectal Dis. 2024 Jun;26(6):1271-1284. doi: 10.1111/codi.17012. Epub 2024 May 15.","Hain E","Colorectal Dis","2024","2024/05/15","","","10.1111/codi.17012"
"38844309","Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","Melero I, Yau T, Kang YK, Kim TY, Santoro A, Sangro B, Kudo M, Hou MM, Matilla A, Tovoli F, Knox J, He AR, El-Rayes B, Acosta-Rivera M, Lim HY, Soleymani S, Yao J, Neely J, Tschaika M, Hsu C, El-Khoueiry AB.","Ann Oncol. 2024 Jun;35(6):537-548. doi: 10.1016/j.annonc.2024.03.005. Epub 2024 May 22.","Melero I","Ann Oncol","2024","2024/06/06","","","10.1016/j.annonc.2024.03.005"
"38865672","Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study","Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL.","JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.","Srkalovic G","JCO Precis Oncol","2024","2024/06/12","","","10.1200/PO.24.00026"
"38898592","Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study","Baranda JC, Robbrecht D, Sullivan R, Doger B, Santoro A, Barve M, Grob JJ, Bechter O, Vieito M, de Miguel MJ, Schadendorf D, Johnson M, Pouzin C, Cantalloube C, Wang R, Lee J, Chen X, Demers B, Amrate A, Abbadessa G, Hodi FS.","Clin Transl Sci. 2024 Jun;17(6):e13854. doi: 10.1111/cts.13854.","Baranda JC","Clin Transl Sci","2024","2024/06/20","PMC11186846","","10.1111/cts.13854"
"39088680","Epcoritamab (Epkinly): CADTH Reimbursement Recommendation: Indication: Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma Grade 3B after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy","","Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun. Report No.: PC0334.","","Epcoritamab (Epkinly): CADTH Reimbursement Recommendation: Indication: Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma Grade 3B after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy","2024","2024/06/01","","",""
"38512117","A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1","Agarwal N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, Colomba E, Gravis G, Mourey L, Oudard S, Fléchon A, González M, Rey PM, Schweizer MT, Gallardo E, Johnston E, Balar A, Haddad N, Appiah AK, Nacerddine K, Piulats JM.","Clin Cancer Res. 2024 Jun 3;30(11):2377-2383. doi: 10.1158/1078-0432.CCR-23-3436.","Agarwal N","Clin Cancer Res","2024","2024/03/21","PMC11145166","","10.1158/1078-0432.CCR-23-3436"
"38578610","Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study","Pinato DJ, D'Alessio A, Fulgenzi CAM, Schlaak AE, Celsa C, Killmer S, Blanco JM, Ward C, Stikas CV, Openshaw MR, Acuti N, Nteliopoulos G, Balcells C, Keun HC, Goldin RD, Ross PJ, Cortellini A, Thomas R, Young AM, Danckert N, Tait P, Marchesi JR, Bengsch B, Sharma R.","Clin Cancer Res. 2024 Jun 3;30(11):2433-2443. doi: 10.1158/1078-0432.CCR-24-0177.","Pinato DJ","Clin Cancer Res","2024","2024/04/05","PMC11145164","","10.1158/1078-0432.CCR-24-0177"
"38857045","Stereotactic Body Radiotherapy and Liver Transplant for Liver Cancer: A Nonrandomized Controlled Trial","Lee VH, Vardhanabhuti V, Wong TC, Lam KO, Choi HC, Chiu KW, Ho PP, Leung DK, Szeto MH, Choi KF, Chan SC, Leung TW, Khong PL, Lo CM.","JAMA Netw Open. 2024 Jun 3;7(6):e2415998. doi: 10.1001/jamanetworkopen.2024.15998.","Lee VH","JAMA Netw Open","2024","2024/06/10","PMC11165380","","10.1001/jamanetworkopen.2024.15998"
"38858156","Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial","Zhang J, Yang Y, Wu Z, Zhang S, Lin Z, Liu H, Hu J, Zhang T, Tang J, Xue J.","BMJ Open. 2024 Jun 10;14(6):e077903. doi: 10.1136/bmjopen-2023-077903.","Zhang J","BMJ Open","2024","2024/06/10","PMC11168160","","10.1136/bmjopen-2023-077903"
"38861301","IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma","Badhrinarayanan S, Cotter C, Zhu H, Lin YC, Kudo M, Li D.","Future Oncol. 2024 Jun 10:1-9. doi: 10.1080/14796694.2024.2355863. Online ahead of print.","Badhrinarayanan S","Future Oncol","2024","2024/06/11","","","10.1080/14796694.2024.2355863"
"38952554","Large-scale, prospective observational study of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors in a real-world clinical setting","Komatsu Y, Muro K, Chosa M, Hirano K, Sunaya T, Ayukawa K, Hattori K, Nishida T.","Front Oncol. 2024 Jun 17;14:1412144. doi: 10.3389/fonc.2024.1412144. eCollection 2024.","Komatsu Y","Front Oncol","2024","2024/07/02","PMC11215966","","10.3389/fonc.2024.1412144"
"38900435","Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial","Fan W, Zhu B, Chen S, Wu Y, Zhao X, Qiao L, Huang Z, Tang R, Chen J, Lau WY, Chen M, Li J, Kuang M, Peng Z.","JAMA Oncol. 2024 Jun 20:e241831. doi: 10.1001/jamaoncol.2024.1831. Online ahead of print.","Fan W","JAMA Oncol","2024","2024/06/20","PMC11190833","","10.1001/jamaoncol.2024.1831"
"38843860","Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, Bernthal NM, López Pousa A, Razak AA, Italiano A, Ahmed M, Le Cesne A, Tinoco G, Boye K, Martín-Broto J, Palmerini E, Tafuto S, Pratap S, Powers BC, Reichardt P, Casado Herráez A, Rutkowski P, Tait C, Zarins F, Harrow B, Sharma MG, Ruiz-Soto R, Sherman ML, Blay JY, Tap WD; MOTION investigators.","Lancet. 2024 Jun 22;403(10445):2709-2719. doi: 10.1016/S0140-6736(24)00885-7. Epub 2024 Jun 3.","Gelderblom H","Lancet","2024","2024/06/06","","","10.1016/S0140-6736(24)00885-7"
"38279693","Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO-HBP-005): Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group","Kobayashi S, Tomokuni A, Takeda Y, Wada H, Katsura Y, Hashimoto K, Tomimaru Y, Asaoka T, Yamada T, Tsujie M, Noda T, Morita S, Nagano H, Mori M, Doki Y, Eguchi H; Clinical Study Group of Osaka University, Hepato‐Biliary‐Pancreatic Group.","Hepatol Res. 2024 Jul;54(7):667-677. doi: 10.1111/hepr.14013. Epub 2024 Jan 27.","Kobayashi S","Hepatol Res","2024","2024/01/27","","","10.1111/hepr.14013"
"38467379","Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study","Choi SH, Lee BM, Kim J, Kim DY, Seong J.","J Hepatol. 2024 Jul;81(1):84-92. doi: 10.1016/j.jhep.2024.03.003. Epub 2024 Mar 11.","Choi SH","J Hepatol","2024","2024/03/11","","","10.1016/j.jhep.2024.03.003"
"38630781","Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors","Steeghs N, Gomez-Roca C, Rohrberg KS, Mau-Sørensen M, Robbrecht D, Tabernero J, Ahmed S, Rodríguez-Ruiz ME, Ardeshir C, Schmid D, Sleiman N, Watson C, Piper-Lepoutre H, Dejardin D, Evers S, Boetsch C, Charo J, Teichgräber V, Melero I.","Clin Cancer Res. 2024 Jul 1;30(13):2693-2701. doi: 10.1158/1078-0432.CCR-23-3567.","Steeghs N","Clin Cancer Res","2024","2024/04/17","PMC11215403","","10.1158/1078-0432.CCR-23-3567"
"38716823","Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial","Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group.","Aliment Pharmacol Ther. 2024 Jul;60(2):233-245. doi: 10.1111/apt.18037. Epub 2024 May 8.","Tada T","Aliment Pharmacol Ther","2024","2024/05/08","","","10.1111/apt.18037"
"38755096","IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","Dent R, André F, Gonçalves A, Martin M, Schmid P, Schütz F, Kümmel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortés J.","Ann Oncol. 2024 Jul;35(7):630-642. doi: 10.1016/j.annonc.2024.04.001. Epub 2024 May 15.","Dent R","Ann Oncol","2024","2024/05/16","","","10.1016/j.annonc.2024.04.001"
"38861871","Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials","Li H, Wu Y, Zou H, Koner S, Plichta JK, Tolaney SM, Zhang J, He YW, Wei Q, Tang L, Zhang H, Zhang B, Guo Y, Chen X, Li K, Lian L, Ma F, Luo S.","EBioMedicine. 2024 Jul;105:105186. doi: 10.1016/j.ebiom.2024.105186. Epub 2024 Jun 10.","Li H","EBioMedicine","2024","2024/06/11","PMC11215206","","10.1016/j.ebiom.2024.105186"
"38886336","Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial","Martinelli E, Ciardiello D, Martini G, Napolitano S, Del Tufo S, D'Ambrosio L, De Chiara M, Famiglietti V, Nacca V, Cardone C, Avallone A, Cremolini C, Pietrantonio F, Maiello E, Granata V, Troiani T, Cappabianca S, Ciardiello F, Nardone V, Reginelli A.","Clin Drug Investig. 2024 Jul;44(7):541-548. doi: 10.1007/s40261-024-01372-0. Epub 2024 Jun 17.","Martinelli E","Clin Drug Investig","2024","2024/06/17","","","10.1007/s40261-024-01372-0"
"38959698","A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)","Olofsson Bagge R, Nelson A, Shafazand A, Cahlin C, Carneiro A, Helgadottir H, Levin M, Rizell M, Ullenhag G, Wirén S, Lindnér P, Nilsson JA, Ny L.","ESMO Open. 2024 Jul;9(7):103623. doi: 10.1016/j.esmoop.2024.103623. Epub 2024 Jul 2.","Olofsson Bagge R","ESMO Open","2024","2024/07/03","PMC11269777","","10.1016/j.esmoop.2024.103623"
"39078299","Dotatate PET/CT and (225)Ac-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer","Ulaner GA, VanderMolen LA, Li G, Ferreira D.","Radiology. 2024 Jul;312(1):e233408. doi: 10.1148/radiol.233408.","Ulaner GA","Radiology","2024","2024/07/30","","","10.1148/radiol.233408"
"38971950","PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers","Kristeleit R, Leary A, Oaknin A, Redondo A, George A, Chui S, Seiller A, Liste-Hermoso M, Willis J, Shemesh CS, Xiao J, Lin KK, Molinero L, Guan Y, Ray-Coquard I, Mileshkin L.","Br J Cancer. 2024 Jul 6. doi: 10.1038/s41416-024-02776-7. Online ahead of print.","Kristeleit R","Br J Cancer","2024","2024/07/06","","","10.1038/s41416-024-02776-7"
"38973009","A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC)","Wigg A, Tibballs J, Woodman R, Stuart K, Le H, Roberts SK, Olynyk JK, Strasser SI, Wallace M, Martin J, Haworth A, Hardcastle N, Loo KF, Tang C, Lee YY, Chu J, De Abreu Lourenco R, Koukourou A, De Boo D, McLean K, Buck J, Sawhney R, Nicoll A, Dev A, Wood M, Braund A, Weltman M, Khor R, Levy M, Wang T, Potter M, Haridy J, Raj A, Duncan O, Zekry A, Collier N, O'Beirne J, Holliday C, Trada Y, Tronidjaja J, George J, Pryor D.","BMC Cancer. 2024 Jul 8;24(1):813. doi: 10.1186/s12885-024-12504-2.","Wigg A","BMC Cancer","2024","2024/07/07","PMC11229272","","10.1186/s12885-024-12504-2"
"38687583","Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial","Chen Y, Du C, Shen S, Zhang W, Shan Y, Lyu A, Wu J, Shang C, Luo X, Wei J, Xiao H, Qiu J, Hua Y, Wang S, Wang T, Dai S, Zhang S, Xie B, Wu Y, Hao C.","Clin Cancer Res. 2024 Jul 15;30(14):2937-2944. doi: 10.1158/1078-0432.CCR-24-0006.","Chen Y","Clin Cancer Res","2024","2024/04/30","","","10.1158/1078-0432.CCR-24-0006"
"39030637","Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial","Hao Y, Xie F, Zhou Y, Li C, Zhang X, Shen J, Yao M, Sun X, Zhou J, Wen T, Peng W.","Trials. 2024 Jul 19;25(1):490. doi: 10.1186/s13063-024-08340-1.","Hao Y","Trials","2024","2024/07/19","PMC11264851","","10.1186/s13063-024-08340-1"
"39041200","STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer","Saeed A, Tabernero J, Parikh A, den Eynde MV, Karthaus M, Gerlinger M, Wang Z, Wang G, Smith R, Hecht JR.","Future Oncol. 2024 Jul 23:1-11. doi: 10.1080/14796694.2024.2352276. Online ahead of print.","Saeed A","Future Oncol","2024","2024/07/23","","","10.1080/14796694.2024.2352276"
"39044160","Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial","Karthaus M, Heinemann V, Riera-Knorrenschild J, Kretzschmar A, Welslau M, Kaiser U, Pelz H, Ettrich TJ, Held S, Kehmann L, Hess J, Reisländer T, Weiss L; TALLISUR study group.","BMC Cancer. 2024 Jul 23;24(1):887. doi: 10.1186/s12885-024-12599-7.","Karthaus M","BMC Cancer","2024","2024/07/23","PMC11267741","","10.1186/s12885-024-12599-7"
"39089633","Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Dao TV, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL.","J Hepatol. 2024 Jul 30:S0168-8278(24)02424-3. doi: 10.1016/j.jhep.2024.07.017. Online ahead of print.","Lau G","J Hepatol","2024","2024/08/01","","","10.1016/j.jhep.2024.07.017"
"38380807","Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence","Qin XY, Shirakami Y, Honda M, Yeh SH, Numata K, Lai YY, Li CL, Wei F, Xu Y, Imai K, Takai K, Chuma M, Komatsu N, Furutani Y, Gailhouste L, Aikata H, Chayama K, Enomoto M, Tateishi R, Kawaguchi K, Yamashita T, Kaneko S, Nagaoka K, Tanaka M, Sasaki Y, Tanaka Y, Baba H, Miura K, Ochi S, Masaki T, Kojima S, Matsuura T, Shimizu M, Chen PJ, Moriwaki H, Suzuki H.","Int J Cancer. 2024 Aug 1;155(3):582-594. doi: 10.1002/ijc.34893. Epub 2024 Feb 21.","Qin XY","Int J Cancer","2024","2024/02/21","","","10.1002/ijc.34893"
"38570034","Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment","Chan SL, Ryoo BY, Mo F, Chan LL, Cheon J, Li L, Wong KH, Yim N, Kim H, Yoo C.","J Hepatol. 2024 Aug;81(2):258-264. doi: 10.1016/j.jhep.2024.03.033. Epub 2024 Apr 1.","Chan SL","J Hepatol","2024","2024/04/03","","","10.1016/j.jhep.2024.03.033"
"38704501","Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study","Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH.","Ann Surg Oncol. 2024 Aug;31(8):5340-5351. doi: 10.1245/s10434-024-15293-x. Epub 2024 May 4.","Zager JS","Ann Surg Oncol","2024","2024/05/04","PMC11249544","","10.1245/s10434-024-15293-x"
"38729567","A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD.","Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8.","Hamilton E","Ann Oncol","2024","2024/05/10","","","10.1016/j.annonc.2024.04.012"
"38789613","ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study","Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH.","Ann Surg Oncol. 2024 Aug;31(8):5220-5221. doi: 10.1245/s10434-024-15421-7.","Zager JS","Ann Surg Oncol","2024","2024/05/24","","","10.1245/s10434-024-15421-7"
"38834016","Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer","Chen C, Feng YS, Wang Z, Gupta M, Xu XS, Yan X.","Eur J Cancer. 2024 Aug;207:114147. doi: 10.1016/j.ejca.2024.114147. Epub 2024 May 31.","Chen C","Eur J Cancer","2024","2024/06/04","","","10.1016/j.ejca.2024.114147"
"38870979","Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","Li Z, Dang X, Huang D, Jin S, Li W, Shi J, Wang X, Zhang Y, Song Z, Zhang J, Zhuang W, Liu X, Jiang L, Meng X, Zhao M, Zhou J, Zhang L, Wang P, Luo H, Yang J, Cang S, Wang X, Zhang L, Lu S; D1553–102 Study Group.","Lancet Respir Med. 2024 Aug;12(8):589-598. doi: 10.1016/S2213-2600(24)00110-3. Epub 2024 Jun 10.","Li Z","Lancet Respir Med","2024","2024/06/13","","","10.1016/S2213-2600(24)00110-3"
"38924855","Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation","Michiel Zeeuw J, Wesdorp NJ, Ali M, Bakker AJJ, Voigt KR, Starmans MPA, Roor J, Kemna R, van Waesberghe JHTM, van den Bergh JE, Nota IMGC, Moos SI, van Dieren S, van Amerongen MJ, Bond MJG, Chapelle T, van Dam RM, Engelbrecht MRW, Gerhards MF, van Gulik TM, Hermans JJ, de Jong KP, Klaase JM, Kok NFM, Leclercq WKG, Liem MSL, van Lienden KP, Quintus Molenaar I, Patijn GA, Rijken AM, Ruers TM, de Wilt JHW, Verpalen IM, Stoker J, Grunhagen DJ, Swijnenburg RJ, Punt CJA, Huiskens J, Verhoef C, Kazemier G.","Eur J Cancer. 2024 Aug;207:114185. doi: 10.1016/j.ejca.2024.114185. Epub 2024 Jun 23.","Michiel Zeeuw J","Eur J Cancer","2024","2024/06/26","","","10.1016/j.ejca.2024.114185"
"38950555","Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial","Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT.","Lancet Oncol. 2024 Aug;25(8):1015-1024. doi: 10.1016/S1470-2045(24)00249-3. Epub 2024 Jun 28.","Tendler S","Lancet Oncol","2024","2024/07/01","","","10.1016/S1470-2045(24)00249-3"
"38969959","A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata","Anderson S, Cavaletti G, Hood LJ, Polydefkis M, Herrmann DN, Rance G, King B, McMichael AJ, Senna MM, Kim BS, Napatalung L, Wolk R, Zwillich SH, Schaefer G, Gong Y, Sisson M, Posner HB.","Pharmacol Res Perspect. 2024 Aug;12(4):e1204. doi: 10.1002/prp2.1204.","Anderson S","Pharmacol Res Perspect","2024","2024/07/05","PMC11226387","","10.1002/prp2.1204"
"39093871","Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: A phase II PRECAM experimental study","Wang F, Lai C, Lv Y, Zhang F, Shi L, Wang Y, Shen Y, Xu L, Hu P, Tang W, Xu D, Cao G, Shan L, Jia X, Chen Y, Larson DW, Wang D, Lao W, Gu H, Sun X, Huang X, Dai S.","Int J Surg. 2024 Aug 2. doi: 10.1097/JS9.0000000000001960. Online ahead of print.","Wang F","Int J Surg","2024","2024/08/02","","","10.1097/JS9.0000000000001960"
"39097413","Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)","Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, Voskoboynik M, Sanborn RE, Grewal JS, Narayan A, Patnaik A, Gainor JF, Sznol M, Enstrom A, Blanchfield L, LeBlanc H, Thomas H, Chisamore MJ, Peng SL, Naumovski A.","J Immunother Cancer. 2024 Aug 3;12(8):e009474. doi: 10.1136/jitc-2024-009474.","Davar D","J Immunother Cancer","2024","2024/08/03","","","10.1136/jitc-2024-009474"
"39128186","Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial","Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, Conca E, Capone I, Busico A, Perrone F, Tamborini E, Sabella G, Greco G, Greco FG, Tafuto S, Procopio G, Morano F, Niger M, Maccauro M, Milione M, de Braud F, Pietrantonio F, Pusceddu S.","Eur J Cancer. 2024 Aug 9;209:114276. doi: 10.1016/j.ejca.2024.114276. Online ahead of print.","Nasca V","Eur J Cancer","2024","2024/08/11","","","10.1016/j.ejca.2024.114276"
"38805668","Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma","Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK.","J Clin Oncol. 2024 Aug 10;42(23):2790-2799. doi: 10.1200/JCO.23.01462. Epub 2024 May 28.","Sangro B","J Clin Oncol","2024","2024/05/28","PMC11315407","","10.1200/JCO.23.01462"
"38680618","Co-relation of Portal Vein Tumour Thrombus Response With Survival Function Following Robotic Radiosurgery in Vascular Invasive Hepatocellular Carcinoma","Dutta D, Yarlagadda S, Kalavagunta S, Nair H, Sasidharan A, Nimmya SK, Kannan R, George S, Edappattu A, Haridas NK, Jose WM, Keechilat P, Valsan A, Koshy A, Gopalakrishna R, Sadasivan S, Gopalakrishnan U, Balakrishnan D, Sudheer OV, Surendran S.","J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101404. doi: 10.1016/j.jceh.2024.101404. Epub 2024 Mar 29.","Dutta D","J Clin Exp Hepatol","2024","2024/04/29","PMC11053332","","10.1016/j.jceh.2024.101404"
